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Summary
This thesis describes the results of dietetic led weight management for weight loss in three
different groups of subjects: overweight; overweight with angina; and those whose body
weight was close to the healthy upper BMI of 25 kg/rn'. It forms part of a growing
literature examining moderate weight loss as a success outcome in weight management.
The work in this thesis addresses an important general research question; whether the
effect of modest weight lossper se on established risk factors for lIID was similar across a
number of subject groups. The specific aims were to examine the effect of moderate
weight loss on the established IHD risk factors, fibrinogen, factor VII activity, plasma and
whole blood viscosity, PAI activity and t-PA antigen. The role of modest weight loss on
the adrenal hormone DHEAS was also studied.
The established indices of IHD risk for rheology and haemostasis: plasma and whole blood
viscosity, RCA, haematocrit, fibrinogen, factor VII activity and the fibrinolytic enzymes
PAI activity and t-PA antigen are known from epidemiological studies to reflect IIID risk,
and to be elevated in association with increased BMI. The serum DHEAS and plasma
total cholesterol, in particular the LDL and HDL cholesterol fractions were of interest and
also measured, although the available evidence suggested a more marginal influence on
rheological and haemostatic factors.
Conventional dietary management of obesity and overweight usually results in body weight
losses close to 5.0 kg over a three month period. However, the achievement of an "ideal
body weight" has often been set as the target for Success in those aiming to reduce their
body weight. This approach has been considered to be flawed given the accumulating
evidence that some benefits from moderate weight loss have been recognised with as little
as 5% body weight loss.
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The present studies examined the effects of moderate weight loss on risk factors for IHD
using a non invasive dietetic led approach. The dietary approach used for all studies was
an individualised energy deficit prescription within one to one consultations. The aim of
the intervention was to provide a comparable effect from weight loss in all subjects and
total compliance to the regimen a 6.0 to 7.0 kg weight loss should have resulted over 12
weeks. The use of a standard regimen permitted some group comparisons across the
different studies.
Otherwise healthy, but overweight subjects, mean BM! 34.9 (SD 6.1) kg/rrr', succeeded in
achieving a mean weight loss close to 5.0 kg (4.8%) over a twelve week period. Reported
dietary intakes from 7 dayWI diaries suggested that a diet composition in line with current
targets was reached. The actual weight loss seen was around 80% of that planned. Some
benefits in terms of IHD risk were shown with significant falls in the RCA, factor VII
activity and plasma cholesterol concentrations. No other significant changes were found.
Before and after intervention the biological measurements were within the established
reference ranges.
The benefits of weight loss were also examined in a group of overweight subjects with
established ischaemic disease, of mean BM! 30.8 (SD 4.5) kg/m', It was hypothesised that
those who were overweight with angina pectoris would show more adverse haemostatic
and rheological factors and show greater benefits in comparison with those who were also
overweight but free from cardiovascular disease. The weight loss in this group, 3.5 (SD
2.6) kg, 4.2%, was similar to the healthy overweight subjects with comparable effects on
established risk factors, a significant fall in RCA, factor VII activity and plasma total and
LDL cholesterol. The remaining IHD risk factors were unchanged after weight loss.
The final study examined whether weight loss in a group of subjects, whose mean BM!
was 25.3 (SD l.3) kg/m', close to the healthy range of 18.5-25 kglm2, would influence
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llID risk factors. This study was completed in a work site setting to reflect the different
population required. The weight loss achieved was close to 3.0 kg, representing a mean
4% weight loss. However, before and after intervention the biological measurements all
remained within their reference ranges, no significant changes were found in haemostatic
and rhelogical measures.
The conclusion of this thesis is that modest weight loss, (around 4%) which can be
achieved through well planned dietetic management, does produce important reductions in
llID risk. The weight loss achieved was similar in groups with BMI > 28 kg/m', with or
without llID, but less in absolute terms in individuals with baseline weights near the top of
the healthy (acceptable range). Reductions in factor VII activity and RCA were related to
the amount of weight loss, but the reductions were not greater in those with higher
baseline values and existing llID. The falls in factor VII activity and RCA were
accompanied by falls in other established llID risk factors, plasma lipid concentrations and
blood pressure.
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Chapter 1: Overweight and obesity
1.1 The increased health risks attached to overweight and obesity
Both cross-sectional and longitudinal studies have demonstrated strong and consistent
associations between indicators of overweight such as BM!, waist circumference or WHR,
and a range of conditions affecting most systems of the body.
Debate about the health hazards of overweight and the benefits of weight loss have been
dominated by the consideration of llID, although many other obesity related conditions
can contribute to the symptoms and distress suffered by the overweight. Early
epidemiological studies failed to show the influence of overweight when analysed with
multivariate statistical methods. These analyses removed many of the influences of
overweight, as they "controlled" for the influences of the diseases known to be related to
overweight such as hypertension, hyperlipidaemia and IGT. All these conditions are
regarded as being reversible consequences of overweight which are intensified by the
presence of a central fat distribution.
The most powerful analyses to demonstrate the effect of overweight on cardiovascular
disease have resulted from large longitudinal studies such as Whitehall, Intersalt, the
Boston Nurses, American Cancer Association and Framingham. The results of these
principal studies are similar, but there are some aspects of the evidence that prevent simple
conclusions being drawn. The crude relationships between BM! and mortality and
morbidity are not linear but follow a J-shaped distribution (Lew and Garfinkel, 1979). The
relative risks are greater when BM! is under 18.5 and are probably related to smoking. As
overweight develops above a BM! of 25 kg/m' the risks increase gradually and then more
markedly when BM! exceeds 30 kg/m'. This relationship has been interpreted as
indicating a lesser problem with coronary disease risk in the overweight. However, since
underweight people are less common (BM! < 20 kg/m2 in only 6% of the population) than
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those overweight (BMI > 25 kg/m2 in 53% of the population) (Bennett et al, 1995) the
contribution of overweight to coronary disease in absolute terms (Le. population
attributable risk) is much greater.
The incidence of IHD becomes more common with increasing age, but there is a clear
decrease in the IHD risk attached to overweight (Must et al. 1992), and the difference
between the sexes becomes less, mostly due to effects of the menopause in women
(Barrett-Conner et aI, 1984). As the development ofIHD takes place over a long period
of time the duration of overweight is likely to be important in determining the reversibility.
It is also possible that different mechanisms for lIm apply at different extremes of BMI.
Thus, smoking and with it thrombotic risks, may dominate the cardiac risk profile of the
underweight and in older people, while atheroma is likely to be more important as a
primary factor in the overweight and in younger people.
It must be remembered that in terms of symptoms and total medical burden, the main
health hazard of overweight is not IHD but a range of other related conditions which
contribute importantly to ill health and health service costs. When IIID risk attributable to
obesity is relatively small (e.g. in the elderly) these other problems dominate.
1.1.1 Hypertension
Studies have shown a higher risk of lIm with increases in arterial pressure (Kannel et al,
1987). A review of the Framingham study results revealed that overweight subjects had
significantly raised blood pressure (Stamler et al, 1978). The influence of age on blood
pressure was investigated by dividing the population into 20-39 year and 40-69 year age
groups. The prevalence of hypertension in the younger age group was twice that in those
of normal weight, and three times that in underweight, subjects. The prevalence of
elevated blood pressure in the older overweight age group was double that of older normal
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weight subjects. Those who were 125% or more above ideal body weight had double the
prevalence of hypertension, defined as diastolic blood pressure above 95 mmHg or the use
of anti-hypertensive therapy. These findings concur with another UK study (Elliott and
Marmot, 1984). The Scottish Heart Health study results suggested that gender, age,
alcohol consumption and BM! were all influential in a multiple regression model of factors
influencing blood pressure (Smith et aI, 1988). The second working party of the British
Hypertension Association concluded that strong correlations existed between BM! and
blood pressure and between raised BM! and the development of hypertension (Sever et aI,
1993). The small influence of gender showed that men have higher blood pressure than
women at all ages (Gregory et aI, 1990). The mean values for systolic blood pressure
were 125 vs. 118 mmHg and for diastolic pressure 77 vs. 73 mmHg for men and women
respectively. The 52 communities of the Intersalt study found a direct positive correlation
between BMI and blood pressure. Hypertension was defined as a systolic blood pressure
greater than 140 and a diastolic greater than 90 mmHg or a controlled blood pressure with
the use of regular anti hypertensive medication. Among all measured characteristics
except age, body weight had the strongest relationship with blood pressure (Intersalt
Research group, 1988). The Intersalt results showed significant correlations with both
median systolic and diastolic blood pressure and BMI. Alcohol consumption and
potassium but not sodium excretion elevated blood pressure.
In order to ensure accurate measurement of blood pressure in the overweight or those with
a large upper arm circumference (30 cm or greater) a large sized measurement cuff should
always be used (Wittenberg et aI, 1994). The size of a small cuff is 23 x 12 cm and a large
cuff is 34 x 15 cm. The use of a small cuff in those with an arm circumference of 30 cm or
more has been shown to overestimate systolic blood pressure by between 6 - 9 mmHg.
Similar findings concerning the overestimation of blood pressure when measured using an
incorrectly sized cuff in the overweight was also found by Iyriboz et aI, 1994. Both
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studies concluded that the use of a large cuff in all subjects would result in more accurate
blood pressure measurements and remove the majority of the overestimation. These
findings suggest that the results of other studies which have examined the relationship
between blood pressure and body composition may have been affected if incorrectly sized
blood pressure measurement cuffs were used.
The influence of overweight in children on lIm risk factors including blood pressure was
investigated in the Bogalusa Heart Study (Aristimuno et aI, 1984). Paired comparisons
showed that obese and very obese children had significantly higher systolic blood pressure
than normal weight children. These respective differences were 110 vs. 98 mmHg systolic
and 68 vs. 63 mmHg diastolic after a six year tracking period. Hypertension has also been
described in approximately 1-2 % of adolescents, of which the obese account for 50% of
all cases of adolescent hypertension (Rames et aI, 1978).
It has been suggested that hypertension treatment should begin at diastolic blood pressure
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of above 90 - 100 mmHg in those aged up to 65 years and of above 105-115 mmHg in
older subjects (Bannan et al, 1980, Sever et al, 1993). However, drug treatment of
hypertension brings risks of serious side effects including heart failure (beta-blockers),
postural hypotension and hypokalaemia (diuretics), as well as other lifestyle effects on
feeling of well-being, which must be set against the benefits of blood pressure reduction
ofS-l0 mm Hg.
1.1.2 Impaired glucose tolerance
Strong positive relationships between insulin resistance, IGT, NIDDM and BMI have been
found (Barret-Connor 1989, Zimmet et aI, 1991). However, additional influences such as
genetic traits which interact with BM! have also been suggested and are illustrated by
cross sectional studies in Pima Indians (Knowler et ai, 1981).
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Weight gain was examined as a risk factor for the development ofNIDDM in nurses aged
30-55 years as part of the Boston Nurses study of 114, 281 nurses (Colditz et al, 1995).
After adjustment for age, BMI remained the dominant predictor for NIDDM and a higher
BMI was related with an increased risk of developing NIDDM. Perhaps surprisingly,
women of average BMI (24 kg/m') showed an elevated risk of NIDDM when compared
with thinner women (BMI 22 kg/m'). The study also compared women with stable body
weight to those reporting weight loss or gain. A l.9 and 2.7 increase in risk of developing
NIDDM was associated with weight gains of between 5.0-7.9 kg and 8.0-10.9 kg
respectively. In contrast, a weight loss of 5.0 kg reduced the risk of NIDDM by 50%.
The Whitehall study of male civil servants examined the relationship between lIID, fasting
blood glucose concentrations and mortality after five years of follow-up (Fuller et aI,
1979). For those above the 98th percentile for fasting blood sugar distribution (> 110
mg/dL) a doubling of mortality was observed which was independent of raised blood
pressure and overweight (Fuller et aI, 1979). Another study of Pima Indians found that
within this rather unusual population obesity itself was not an independent predictor of
progression from IGT to NIDDM when insulin and glucose concentrations were
controlled for (Saad et aI, 1988). However, 83% of the Pima Indians with IGT were
overweight (classified as a BMI > 27 kg/m') with an incidence ofNIDDM 2.9 times that
of their normal weight counterparts. In desert based Aborigines BMI was independently
related to insulin response after glucose loading (O'Dea et aI, 1988).
1.1.3 Raised serum lipids
Two studies found increased body weight associated with increased plasma lipids in both
sexes (Kannel et al, 1971, Carlson and Bottiger, 1981). Some plasma lipids such as
cholesterol were themselves found to be associated with increased IHD risk (Van Itallie,
1985, Denke et al, 1994). In young (20-44 years) and older women (45-59 years), raised
total and LDL cholesterol and triglyceride concentrations and lowered HDL cholesterol
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concentrations were associated with excess body weight. This pattern seen in post-
menopausal women was also shown in men (Denke et aI, 1993) and children where raised
triglyceride concentrations have been noted in the obese and very obese (Arishmino et aI,
1984).
As part of an eight year study of nearly 116, 000 women, mild to moderate overweight
was found to increase the llID risk in middle-aged women grouped according to BMI
between 23-25, and 25-29 kg/nr' (Manson et aI, 1990). The increased BMIs were
paralleled by elevations in llID risk and these relationships were strengthened with
increases in plasma cholesterol, NIDDM and hypertension.
The most characteristic lipid disturbance in obesity is elevated triglycerides and low HDL
cholesterol (Bjomtorp, 1990). Total cholesterol is also frequently elevated in the
overweight (Gregory et aI, 1990). Decreased HDL concentrations have been observed
with increased BMI and associated with increased risk of MI (Glueck et aI, 1980, Lipid
Research Clinics, 1980, Haffuer et aI, 1985). Elevated LDL lipoprotein cholesterol
concentrations in obesity are common, but they probably reflect background lipid profiles
in the general population, and not a specific effect of overweight (Barrett-Connor, 1985).
The Prospective Cardiovascular Munster study illustrated the relationships between BMI
and plasma lipoproteins (Assman and Schulte, 1992). Elevated plasma triglycerides,
coupled with an increased ratio of hepatic lipase to lipoprotein lipase in the overweight,
lead to an excess of the small dense LDL (LDL3) particles which are readily oxidised and
highly atherogenic (Sattar et al, 1997).
Plasma triglycerides are an established independent risk factor for heart disease risk
(Hokanson and Austin, 1995). The increased atherogenic combination of raised
triglyceride and lowered HDL concentrations have been described in the overweight (BMI
> 25 kg/m"). The relationship between overweight and the increased risk of coronary
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disease was considered in 1985 at the consensus development conference. Obesity was
identified as a major influence in raising plasma lipids and in turn weight reduction was
identified as being advantageous in normalising plasma lipids and lipoproteins for
overweight individuals (Burton et al, 1985).
1.1.4 Haemostatic and rheological factors and overweight
Raised concentrations of the plasma protein fibrinogen have been shown to be associated
with increased llID risk and it becomes elevated in response to increased BMI, smoking,
stress and family history of nm (Ernst, 1991, Ernst and Resch, 1993). Strong
relationships between obesity and raised fibrinogen concentrations, coagulation factor VII
activity (Folsom et al, 1991) and PAl activity have been described (Meade et al, 1986,
Meade et al, 1993). Measures of blood flow and RCA are higher in the overweight than
normal weight subjects (poggi et al, 1994). These findings suggest an elevated thrombosis
risk in the overweight and possible mechanisms for this increased risk are an impairment in
fibrinolytic response and an elevation in the coagulation indicators. The role of overweight
and weight loss with respect to each rheological and fibrinolytic factor will be considered
in greater depth in chapter 3.
1.1.5 Endocrine/metabolic diseases and dehydroepiandosterone sulphate
Obesity has been characterised by abnormal steroid secretion and a reduced SHBG
(Kopelman et al, 1980). Reduced SHBG concentrations have been inversely correlated to
hyperinsulinaemia and insulin resistance and to the presence of increased upper body fat
(Weaver et al, 1990). The hyperinsulinaemia of obesity usually overcomes the insulin
resistance. However, the increased plasma insulin concentrations may enhance renal
retention of sodium and possibly cause hypertension as an undesirable secondary effect
(Bray, 1989).
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Rogers and Mitchell (1952) reported on the incidence of ovarian dysfunction in obesity.
They reported that 43% of women with abnormal menses were obese, compared with only
13% of the control group of non obese women. The two most common menstrual
disorders were secondary amenorrhea and dysfunction and uterine bleeding. A larger
study, of 26,000 overweight women taking part in a slimming study, examined the
incidence of abnormal menstruation. The incidence of menstrual disorders was directly
associated with the degree of obesity (Hartz et ai, 1979). The presence of hirsutism was
related to the duration of the obesity which indicated hyperandrogenism as a correlate of
obesity. The presence of PCOS has been strongly related to obesity and characterised by a
chronic ovarian hypersecretion of androgens (Friedman and Kim, 1985, Yen, 1976).
Adrenal functions are altered in obesity, as the secretion rate of adrenal hormones is
proportional to body weight (Jackson and Mowat, 1970). The increased cortisol
production rate in obese humans has been reproduced in those made obese by overfeeding.
A shortened plasma half life has been shown in association with the increased metabolism
of cortisol in obesity (Migeon et ai, 1963).
The C19 steroid DHEAS and the other principal steroids in this group are androstenedione
and androst - 5- ene 3~, 17(3-diol, are both produced by the adrenal glands. Lowered
concentrations of these steroids are seen in obesity, particularly with an abdominal fat
distribution (Tchemof et ai, 1996). DHEAS holds a particular interest to those studying
obesity, as it has been postulated as the possible link between hyperinsulinaemia and
obesity. It is also thought to affect platelet activity and thus blood coagulation (Nestler et
ai, 1992). Recent evidence suggests that DHEAS exerts multiple anti-atherogenic effects
and that hyperinsulinaemia may reduce serum DHEAS by decreasing production and
enhancing clearance. Lower DHEAS is found in those with elevated coronary risk and the
overweight (Barrett-Conner et ai, 1986, Nestler et ai, 1989, 1992). All of these
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alterations in the production rate of adrenal hormones have been inter-linked with
increased plasma insulin concentrations and insulin resistance.
Obesity has also been associated with a number of cancers. The American Cancer Society
followed men and women aged over 30 for 13 years. The study included 336, 442 men
and 419, 000 women free of cancer, heart disease, stroke and having only altered body
weight by a maximum of 4.5 kg in the preceding 12 months. The results of the study
clearly indicated that obesity was associated with infertility and cancers of the breast,
endometrium and ovary in women, and an increase in the incidence of prostrate cancer in
men (Garfinkel, 1985). The effect of overweight on increasing androgen and oestrogen
metabolism may have underlying effects on the development of these conditions
(Longscope et al, 1986). The influence of overweight on the risk of death from cancer
was confirmed by the results of a large study by Manson et al (1985). The study found
that mortality among women with BMIs of 32 kg/m" or greater was 2.1 times the relative
risk of death of women with BMIs below 19.0 kg/m'.
1.1.6 Smoking
Cigarette smoking has been strongly associated with all forms of coronary disease in both
sexes (Doll and Peto, 1976, Mann et al. 1976). On average, middle aged smokers have
about double the risk of a major coronary event, and this is compounded with increasing
overweight (pooling Project Research Group, 1978). The classic parallel curves of BMI
against mortality, which have been represented for both smokers and non smokers, show
that the progressive mortality increases with increasing overweight, an effect which is
present at every level of BMI (Lew and Garfinkel, 1979). It has been shown in the UK
population that smokers tend to be thinner than ex-smokers or those who have never
smoked (Gregory et ai, 1990). The role of smoking cessation in favouring weight gain
was shown in the MRFIT trial (Shimokata et al, 1989). The MRFIT data suggested that
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weight fluctuation may reflect unsuccessful attempts at smoking cessation. The health
outcomes which included heart disease, MI and death, may be a consequence of past and
current smoking habits. It has been suggested that nicotine may reduce food intake
(Shimokata et ai, 1989). The importance of remaining a non-smoker despite the regain of
body weight must be emphasised in health promotion and all settings.
1.1.7 Weight change, weight cycling, mortality and life expectancy
Periods of "famine and plenty" are well recognised to have occurred throughout the
evolution of man and something that humans have become adapted to. However, the
modem conditions of overeating and inactivity with episodic dietary restriction mean
weight cycling is a common occurrence with a baseline of obesity which tends to rise
throughout life. Current statistics on the number of adults trying to follow a weight
reducing diet are alarming. Figures for the UK suggest up to 35% of adults are engaged in
some form of slimming behaviour at anyone time (Kent and Bowyer, 1992) and in the
United States up to 40% of adult women and 20% of adult men (Williamson et ai, 1992).
Given that a larger proportion of the UK population are becoming more overweight, this
evidence warns that large numbers of adults are, repeatedly in adult life, within cycles of
slimmingand weight regain.
Retrospective studies suggest that potential hazards exist from "weight cycling" (i.e.
reported fluctuations in adult weight) with increases in llID risk and BMI. The evidence
supporting these claims is fairly consistent, but probably confounded. In the Western
Electric study of self-reported weight change 5% of the study group were considered as
"weight changers" (a gain and a loss of 10% body weight) within a 10 year period (Hamm
et ai, 1989). The 98 men considered to be weight changers showed a significant 50%
higher mortality from nm and cancer than the remaining group. In contrast, Wing et ai,
(1992) found no effect of "weight cycling" on total body fat, fat distribution or REE, and
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challenged the hypotheses that weight changes are related to metabolic changes or disease
activity. Larger studies such as the NHANES study or the MRFIT trial also have data on
body weights. Weights are again self reported and are without detail concerning the
reasons underlying weight changes. Brownell and Rodin (1994), posed many as yet
unanswered questions concerning weight cycling and suggested an equal prevalence of
cycling in both males and females of both normal and increased body weight. They also
proposed that weight cycling may be associated with negative psychological and
behavioural influences on lifestyle, the principal factors being binge eating, depression and
life dissatisfaction.
A number of epidemiological and cohort studies with longitudinal survival data have been
used to assess the disease association of reported weight changes. The problem with this
approach remains that weight loss may have been the result of intentional slimming, or it
may have reflected the presence of a disease which would shorten survival. The reductions
in all the major risk factors for cardiovascular disease would suggest that weight loss
should ultimately lead to increased survival. Self reported weight loss, in a number of
large observational studies appears to have adverse effects on survival, even amongst the
overweight. Thus the NHANES study identified obesity as a risk factor for mortality but
found no benefit from reported weight loss for the whole population. Pamuk et al (1992)
followed the first NHANES study subjects (1971-1975) surviving to five years post-study
for the cohort aged between 45-74 years at admission. For those with a BMI between 26-
29 kg/rrr', weight loss increased their risk of death even after adjustment for age, race,
smoking habit, parity and pre-existing illness. Those subjects who lost 15% or more of
their maximum weight had twice the mortality of those who only reduced their body
weight by 5%. At BMIs greater than 29 kg/m' mortality was increased in proportion with
weight lost for women.
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Lee and Paffenbarger (1992) investigated the effect of body weight change on longevity in
a cohort of Harvard University alumni. Self reported weights and health and activity
questionnaires were completed at two periods, 11 years apart. The lowest mortality was
found in those maintaining a stable weight. Weight losses and gains were associated with
significantly increased mortality from all causes. Blair (1993) examined the effect of
weight changes on mortality in the MRFIT cohort of over 10,000 men of mean BMI 27.7
kg/m' over a 7 year period. Mortality once more was found to be lowest in those whose
weight remained stable, irrespective of smoking habit. The strongest associations were
seen with 1 SD of weight change and death in the two lowest tertiles of BMI. There was
no association with weight change in the heaviest tertile of the group. Andres et al (1993)
summarised the results of the principle studies examining the issue of weight loss and
mortality, and concluded that the highest mortality rates do occur in the adult who has
either gained or lost excessive amounts of body weight. The lowest mortality rates are
usually associated with modest weight gains. The prevention of severe overweight may be
more effective than weight loss in reducing mortality.
These data highlight interpretational difficulties with self reported weight loss which may
not have been intentional. Inadvertent weight loss usually indicates some sub-clinical
disease process. The evidence on intentional weight loss appears more convincing,
although it must be remembered that intentional weight loss may be a response to
symptoms or advice for existing disease. Williamson et al (1995) studied reported weight
loss in 28,000 healthy non smoking women and showed a reduction of >9.1 kg was
associated with a 25% reduction in all-cause, cardiovascular and cancer mortality.
However, in healthy women intentional weight loss less than 9.0 kg increased mortality.
They also studied 15,000 women with existing disease and showed that weight loss of9 kg
or less reduced mortality from IHD (-10%), diabetes, (-30 to -40%) and obesity related
cancers (-40 to -50%).
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The health influences of reported fluctuations in body weight are probably dominated by
the presence of disease - either as a cause of weight fluctuations or as a reason for
intentional weight loss, but which did not completely reverse the associated risks. Weight
loss in population studies is a product of many causes, many reflecting the presence of
disease. However, the evidence on intentional weight loss or slimming under advice
supports advocating moderate weight loss in both sexes of adult diabetic people.
Conventional diets, when used in NIDDM subjects, lead to increased survival even in
those with existing disease.
1.1.8 Fat distribution, overweight and health risks
An additional influence of obesity on the established risk factors for IHD remains the
regional fat distribution or body shape. This has been shown to be influential on plasma
lipid concentrations, blood pressure and glucose tolerance (Seidell et ai, 1991). The
presence of abdominal obesity, "an apple shape" carries greater overall risk than the
presence of gluteal-femoral obesity (pear shaped). Although the causal mechanisms are
not fully understood, those with abdominal rather than gluteal-femoral fat distribution are
more likely to have hypercholesterolaemia, hypertension and IGT (Depres et ai, 1990,
Seidell et al, 1991). The relationship of waist circumference with these risk factors has
been examined in some detail (Lean et ai, 1995), since waist circumference predicts both
total fat (Lean et ai, 1996) and intra-abdominal fat (Han et ai, 1997). The measurement of
waist circumference was evaluated as a simple method to determine overweight and
adverse fat distribution, to identify people with cardiovascular risk factors and a range of
other conditions (Han et ai, 1995, Han et ai, 1996, Lean et al, 1998). People with waist
circumference between 94-102 cm in men, 80-88 cm in women have increased
cardiovascular risks. Those with waist circumferences greater than 102 cm in men and 88
cm in women have approximately triple the cardiovascular risk factors of those whose
waist circumferences are below these limits.
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1.2 The potential benefits and hazards from weight loss
1.2.1 Cardiovascular risk factors
There is evidence for health benefits from weight loss on most major cardiovascular
disease risk factors, symptoms and possibly even on atheroma regression. Five principal
risk factors for IHD are influenced by overweight and obesity: (1) hypertension, (2) IGT
or NIDDM, (3) hyperlipidaemias (usually elevations in plasma triglyceride reduction in
HDL cholesterol and elevations of small dense LDL (LDL3), (4) altered haemostatic and
(5) rheological factors. Recent information also links overweight with increased LDL
oxidisability (van Gaal et ai, 1997) probably reflecting the increased proportion ofLDL3 in
the overweight (Sattar et ai, 1997). During weight loss all these factors are improved, and
there may be additional improvements if the individual is then able to take more physical
activity. A consensus in the literature has reached the conclusion that weight loss
significantlyreduces the global risks ofllID.
1.2.2 Blood pressure
Weight loss reduces blood pressure in thin and obese, normotensive and hypertensive
individuals. A retrospective analysis of blood pressure in military recruits to the Danish
Armed Forces demonstrated that those who lost weight for whatever reason showed
reductions in blood pressure (Sonneholm et ai, 1989).
Virtually all of the many studies reporting the effects of weight loss on blood pressure
show a marked and predictable reduction, even with the relatively low weight losses (2-5
kg) achieved by conventional dietary means. The effect of weight loss in upper arm
circumference can be predicted from published equations (James et ai, 1994). Each 1 cm
of arm circumference is equivalent to about 1.2 kg/m' in both men and women, or about 4
kg loss for a patient ofBMI 30 kg/m', The loss of arm circumference would reflect body
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weight loss and reduce blood pressure. However, the ability of investigators to measure
this difference would depend on the use of the correctly sized blood pressure cuff.
The degree of blood pressure reduction from conventional weight loss is similar to that
from widely used antihypertensive drugs. Possible interactions between anti-hypertensive
drug therapy and weight loss for blood pressure reduction were studied by Oberman et al
(1990) in hypertensive individualswith body weight of more than 110% ideal. Weight loss
of 4.5 kg led to blood pressure changes of20 mmHg systolic and of IS mmHg diastolic in
patients treated with either atenolol or chlorthalidone. The possible influences of
antihypertensive drugs on weight loss have also been studied (Davis et al. 1993). In an
atenolol treated group mean weight loss was 2.7 kg, chlorthalidone 6.9 kg and placebo 4.9
kg. Decreases in diastolic blood pressure were 2, 4 and 2 mmHg respectively. Long term
weight loss after 5 years monitoring reduced the rate of failure in blood pressure control
for those receiving placebo, low dose diuretic or ~ blockers by 23%. The results were
similar in each drug group. This study is a reminder that ~ blockers tend to impede weight
loss, and can cause weight gain. Weight reduction, sodium restriction and physical activity
training can supplement the effects of pharmacological treatment to lower blood pressure,
with the advantage that all have no side effects. For individuals who remain significantly
hypertensive despite weight loss, the addition of antihypertensive drug therapy will
continue to be effective.
Practically all dietary approaches to weight loss involve a lowering of sodium intake,
which will also contribute to blood pressure lowering. The meta-analyses of Law et al
(1991a and b) draw the very clear conclusion that a decrease in sodium intake of 50
mmol/day will reduce systolic blood pressure significantly, by about 5 mmHg in
normotensive or 7 mmHg in hypertensive individuals aged 50-59. Reductions in diastolic
blood pressure are approximately half these values. The separate effects of weight loss
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and sodium restriction on blood pressure have also been studied. A weight loss of 11 kg
produced a 20% decrease in both systolic and diastolic blood pressure in hypertensive
subjects (Reisin et ai, 1978). This was a fall from a mean initial blood pressure of 160/90
mmHg. These differences were maintained even when sodium intakes were kept constant
by encouraging the maintenance of usual salt intakes by the consumption of salty foods,
demonstrating the independent effect of weight loss. The long term effects on blood
pressure of weight and salt reduction programmes were compared using 12 month
programmes of weekly 1 monthly group sessions focused on weight reduction, salt
restriction or both (Rissanen et ai, 1985). Mean weight reductions of7.0 kg and 5.0 kg
were achieved in the weight reduction, and the weight reduction and salt restriction groups
respectively after three months. These weight losses were maintained at 12 months.
Negligible weight changes were observed in the salt restriction group. Systolic and
diastolic blood pressure significantlyfell in the weight loss groups. Systolic blood pressure
fell from 159 to 147 and 150 to 143 mmHg for the weight loss and the weight loss and
sodium restriction groups, respectively. Diastolic blood pressure fell from 101 to 94, and
98 to 93 mmHg respectively. The salt restriction only group showed no significant fall in
blood pressure, though 24 hour sodium excretion fell from 50 to 35 mmol.
The practicality of applying weight reduction or salt reduction programmes for
hypertension management was studied in the Trial of Antihypertensive Medication study
(Wassertheil-Smoller et al 1992). Nine diet / drug combinations in 878 mildly
hypertensive moderately obese participants were evaluated. The greatest changes in blood
pressure were observed in the weight reduction / chlorthiadone treated group. A weight
loss of 6.8 kg reduced blood pressure by 15 mmHg. In the weight reduction / atenolol
group 3.0 kg loss was accompanied by 14.8 mmHg fall in blood pressure. The diet /
placebo groups all exhibited a smaller decrease in blood pressure of 8.9 mmHg with a
weight loss of 4.4 kg. The weight reduction intervention lowered blood pressure more
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than the low sodium I high potassium diets. Additional comparisons were made to
determine whether diet therapy enhanced the impact of pharmacological therapy. Weight
reduction with chlorthalidone yielded a significantly lower diastolic blood pressure (an
additional fall of 4.3 mmHg). Weight reduction in combination with atenolol enhanced the
impact of diet therapy by 2.4 mmHg.
In summary, it is clear that weight loss of an order achievable in clinical practice of 5-10
kg will reduce normal blood pressure by a valuable amount. The expected reduction per
kg weight loss in normotensive overweight subjects is around 1.0 - 1.7 mmHg systolic and
0.8 - 1.0 mmHg diastolic, or 1.8 - 2.0 mmHg per 1% weight loss. Blood pressure
reduction to this degree will confer benefits in reduction of cardiovascular disease, in
particular stroke.
1.2.3. Glucose tolerance, insulin sensitivity and diabetes
In adults, an effect of age is to produce a decline in insulin sensitivity. The detailed
reasons are unknown, but overweight has a compounding action reducing insulin
sensitivity at any age. Those who are pre-disposed, probably for genetic reasons or
through acquired pancreatic disease, demonstrate an accelerated progression to reach the
diagnostic criteria for IGT and NIDDM, so this occurs at a younger age in the overweight.
The great majority of NIDDM patients are overweight, around 75% in most studies
(Hadden et aI, 1975, Holbrook, 1989, Lean et aI, 1990). Physical inactivity seems to be a
key factor influencing the development of diabetes (Colditz et ai, 1995). Physical activity
training improves insulin sensitivity separately from any effect of body weight (Koivisto
and Defronzo, 1984).
An underlying pre-disposition to IGT and NIDDM is identifiable from a number of
relatively simplemarkers including family history ofNIDDM in a first degree relative, IGT
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during pregnancy, high waist circumference, and southern Asian origins. The UK PDS
suggested that a minimum weight loss of around 18 kg is needed for newly presenting
patients to achieve normoglycaemia, defined as a fasting blood glucose below 6 mmollL
(UK PDS, 1990). However, lesser degrees of weight loss improve glucose tolerance
significantlyin people with diabetes, and also other risk factors such as elevated lipids and
blood pressure (Vessby et al, 1984). Another study in a primary care setting showed a
reduction in plasma glucose from 8.2 to 6.5 mmolll with a 3.2 kg (2%) reduction in body
weight (Bitzen et al. 1988).
Limited information from a retrospective survival analysis in NIDDM patients with BM!
above 25 kg/m' suggests that 15-20% weight loss in the first year after diagnosis could
reverse the elevated mortality risk of elderly NIDDM. An increase in life expectancy of
about 3-4 months was found in a group of NIDDM patients with a mean age of 64 at
diagnosis (Lean et al, 1990). Williamson et al, (1995) found that an intentional weight
loss of9 kg or more led to 30-40% reduction in diabetes-related mortality.
A special problem when studying NIDDM patients is that the altered metabolic state
improves rapidly with energy restriction, so the effects of treating newly diagnosed
compared with established NIDDM patients will be very different. This phenomenon
makes interpretation of results from studies using a VLCD inNIDDM difficult to interpret.
A VLCD was used to achieve 10.5 kg weight loss in 30 subjects over 40 days (Henry et
al, 1985). A sub-group of 12 subjects were further evaluated during 40 days re-feeding.
Blood glucose fell from 297 mg to 158 mg after 20 days and further to 138 mgIL at day
40, a total decrease of 40%. Re-feeding to maintain weight losses resulted in a secondary
80% increase in fasting blood glucose, though this remained markedly lower than before
weight loss (254 vs. 167 mgldL glucose).
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The improvement in diabetic control with weight loss can be very marked in newly
diagnosed patients who have symptomatic diabetes. For the majority ofNIDDM patients
weight loss is sufficient to remove symptoms. A 10%weight loss (8.2 kg) has been shown
to reduce fasting blood glucose from 12 to below 8 mmollL which represents the
diagnostic threshold for diabetes (Hadden et al. 1975). In a primary care setting, a
reduction in plasma glucose from 8.2 to 6.5 mmollL was shown with a 3.2 kg (2%)
reduction in body weight (Bitzen et al. 1988).
Once body weight is stabilised in the newly diagnosed diabetic patient, insulin sensitivity
continues to decline with age (UK PDS, 1995). Attempts to check this progress with
further dietary interventions have usually met with limited success in terms of weight loss
when conventional dietary interventions are used. The benefits have been shown to be
greatest in subjects categorised as having poorly controlled diabetes (Wing et al. 1990).
For patients whose body weight was greater than 120% ideal body weight, as little as
4.4% weight loss led to a significant 4.3% decrease in HbA1e and a 15% decrease in
fasting blood glucose.
In contrast, plasma glucose concentrations do not always improve after weight loss. A
study of newly diagnosed NIDDM patients followed each subject until they achieved a
weight loss of 9.1 kg (Watts et al. 1990). A total of 55 subjects (41%) showed
improvements in metabolic control (responders), but the remainder failed to demonstrate
benefits (non responders). Responders showed a 50% fall in blood glucose from 14.0 to
7.0 mmollL. The non responders had an increase in fasting blood glucose from 14.0 to
18.0 mmollL (22%). No predictive differences between these groups were seen in age,
body weight or initial fasting blood glucose. Although the plasma glucose response to
weight loss cannot be forecast by initial clinical parameters the success or failure of diet
therapy can be predicted from the plasma glucose level after a weight loss of 2.3 - 4.5 kg.
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The authors concluded that moderately obese patients with NIDDM who remain
hyperglycaemic after a weight loss of 2.3 - 4.5 kg are unlikely to improve with further
weight loss and should be considered swiftly for treatment with either oral hypoglycaemic
agents or insulin.
The impacts of diet restriction and of weight loss are separate on glycaemic control and
lipid changes. Active energy restriction appears to have a marked but transient effect on
blood glucose and insulin sensitivity. When active weight loss ceases, there is a tendency
for insulin sensitivity to return gradually towards its starting point, reaching a new point
defined by the new body weight. Diet composition also influences insulin sensitivity and
may be changed during weight management.
In practical terms, weight loss of the order 5-7 kg is usually fairly easily achieved in most
newly diagnosed patients, with conventional dietary advice in a routine clinical setting,
following advice administered by a dietitian. People with NIDDM are not more resistant
to weight loss for any metabolic reason, and initial weight loss may sometimes be better
maintained in NIDDM patients rather than those with simple obesity. Body weight
changes in NIDDM patients with BMI greater than 25 kg/m2 showed that patients whose
BM! was under 25 kg/m2 at diagnosis had on average gained 1.3 kg one year after
diagnosis, those with BM! 25-30 kg/m2 at diagnosis had lost 2.6 kg, and those with BMI
greater than 30 kg/m2 at diagnosis had lost 6.8 kg one year after diagnosis. These results
indicate that dietary intervention, at least in the first year after diagnosis of diabetes, is
relatively rewarding (UK PDS, 1995).
It has been established that avoiding weight gain in adults would have a major effect on
delaying or avoiding completely the development of IGT and NIDDM. The opportunity
exists for targeting advice concerning both diet and exercise, at those identified with a
predisposition for IGT or NIDDM through family history of NIDDM, IGT in pregnancy,
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high waist circumference or WHR, or origins in South Asia. Weight loss of 5% body
weight leads to clinically important improvements in diabetic control. Loss of 10-20%
body weight in overweight NIDDM patients can normalise metabolic control and possibly
also increase life expectancy. Long term follow up results do not support the routine use
ofVLCD because interventions to ensure weight maintenance are not well developed.
Obesity and NIDDM are both associated with insulin resistance (Olefsky and Kolterman,
1981) a less than expected biological response to the hormone usually characterised by
hypercholesterolaemia (Bonadonna and De Fronzo, 1991). Hyperinsulinaemia has been
shown to be a vascular risk factor in healthy normoglycaemic normotensive individuals,
related to the presence of obesity (Winocour et ai, 1991). Obesity is frequently
accompanied by hyperinsulinaemia both in the fasting situation and after a glucose
challenge (Olesfsky and Kolterman 1981). Enhanced VLDL synthesis, an atherogenic
plasma lipid profile and hypertriglyceridaemia are all associated with elevated plasma
insulin concentrations (De Fronzo and Ferraninni, 1991). In obese subjects and in those
with NIDDM, weight loss has been shown to improve insulin sensitivity (Henry et ai,
1986). The decreased insulin sensitivity in those with N1DDM and its exacerbation in the
obese NIDDM indicate why weight reduction is one the most effective treatments for
these NIDDM patients (Campbell and Carlson, 1993).
1.2.4 Blood lipids
The effects of weight reduction on blood lipids and lipoproteins were examined in a meta-
analysis of both hyperlipidaemic and normolipidaemic subjects (Dattilo and Kris-Etherton,
1992). Results from 70 studies within the meta-analysis indicated that weight reduction
was associated with a decrease in plasma cholesterol of -0.79 mmollL per kg weight loss.
The change in LDL cholesterol concentrations was -0.39 mmol/L/kg, HDL cholesterol
concentrations was +0.14 mmolll/kg and triglyceride concentrations -0.66 mmol/L/kg.
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These results, although derived from studies of different duration, are convincing that
weight reduction through dieting is a viable approach to correct plasma lipids in
overweight individuals (Weinsier, 1992).
The benefits of weight loss on plasma lipids of obese women (BMI 36.2 kg/m') were
examined by Anderson et al (1995). An eight week slimming period resulted in an 11%
decrease in body weight and a fall in plasma cholesterol concentrations and triglyceride
concentrations of 23% and 16% respectively. Weeks 8 to 24 produced another 4.7 kg
weight loss representing an overall reduction in body weight reduction of 16.5%. During
the later phase of the study, cholesterol concentrations increased by 5.2%, LDL
cholesterol concentrations by 4.5% and triglyceride concentrations by 5.1%. These
findings suggest that improvements in plasma lipids after weight loss can be divided into
two periods, the effects of energy restriction and weight loss. In most studies with
duration under 3 months, subjects are still actively losing weight, and in a state of negative
energy balance at the end of the study. When study duration is longer, most subjects will
have stopped losing weight and become weight stable and some may be regaining weight.
During acute energy restriction, all blood lipids fall. When weight destabilises they tend to
rise again towards the pre-weight loss value. Plasma HDL cholesterol tends to rise to a
higher value than pre-weight loss over several weeks after weight destabilisation.
The effect of longer term weight fluctuations on plasma cholesterol concentrations can be
examined using data from the Framingham study. This has suggested that there are small
benefits for plasma cholesterol as well as blood glucose concentrations in subjects whose
body weight fell over a 10 year period (Higgins et ai, 1988). Over a 30 year period the
Framingham study (Garrison et ai, 1985) suggested some long term improvement in
plasma cholesterol concentrations with weight loss. In addition, some of the spontaneous
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weight loss may possibly be linked with a cholesterol lowering effect from underlying
disease within the population (Higgins et ai, 1993).
1.2.5 Weight loss at different levels of body mass index and waist to hip ratio
A few studies of weight loss have categorised the fat distribution of subjects by WHR
(Lean et ai, 1995). Cut offvalues ofWHR, above which health risks increase appreciably,
(a WHR > 0.95 in men and> 0.80 in women), have emerged from prospective studies.
Metabolic risk factors particularly serum concentrations of triglycerides and HDL
cholesterol improve most with weight loss in subjects with WHR above these values (den
Besten et ai, 1988, Sonnichsen et al, 1992, Wing et ai, 1992, Kanaley et ai, 1993,
Houmard et al. 1994). The beneficial effect of reduction in waist circumference on
cardiovascular risk factors has been shown (Han et ai, 1997). A waist reduction of 5 cm
led to a close to 10% improvement in at least one of the risk factors for cardiovascular
disease, these included total and LDL cholesterol concentrations, triglyceride
concentrations or systolic blood pressure. Waist circumference can thus act as an indicator
of obesity and the need for weight management, and also as a monitor of change in weight
and risk.
1.2.6 Cardiovascular symptoms: angina
Angina is the most reliably diagnosed symptom of IHD, provided standard criteria are
used. Epidemiological evidence from the Rochester Coronary Heart Disease Project has
shown women at the 75th percentile for BM! had a 50% increased risk of suffering from
angina when compared with women at the 25th percentile (Beard et ai, 1992). The work
ofOrnish et al (1990) in patients with known and stable angina suggested a low fat diet of
close to 10% energy from fat, together with a number of other interventions can reduce
angina frequency by 91% after a one year dietary education programme. The intervention
group lost 10.0 kg weight (from 91.0 to 81.0 kg) over a 12 month period and had a 17%
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reduction in total serum cholesterol together with evidence of atheroma regression. Over
this period of weight reduction another improvement was an increase in frequency of
physical activity (33%). Interpretation of these findings was complicated since the control
group, who had no improvements in angina, were very much lighter than the intervention
group. It has recently been reported that close to 40% of obese angina patients do not
have significant coronary artery disease, so benefit from weight loss might be expected
without invoking atheroma regression (Bahadori et al, 1996). It seems likely that
moderate intentional weight loss will improve the frequency of anginal pain, though further
studies are required.
1.2.7 The endocrine system particularly dehydroepiandosterone sulphate
A very wide range of endocrine changes are associated with overweight, and many have
been shown to undergo some degree of reversal following weight loss. In particular the
reduced SHBG in PCOS shows a tendency towards normalisation which was associated
with improved insulin sensitivity (Friedman and Kim, 1985, Kopelman et aI, 1981).
Improvements in endocrine and ovarian function in obese women with PCOS have been
demonstrated: 13 of 24 women with mean weight 91.5 kg reduced their body weight by
5% or more, and 11 of these achieved normal menstruation patterns (Kiddy et al 1992).
Those reducing body weight by less than 5% showed no improvements.
The impact of intentional weight loss on a wide range of diseases have been studied
(Williamson et al, 1995). The findings showed a striking reduction in incidence of the
hormone related cancers: prostate in men, uterus and breast in women. A weight loss of
1-19 lb. decreased fully adjusted mortality by close to 55%, and a loss of greater than 20
lb. reduced fully adjusted mortality by 40%. Decreased aromatase activity after weight
loss, reducing oestrogen in women and testosterone in men is the likely mechanism (Wade
et al, 1981).
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Caloric restriction has been established as being beneficial in extending life-span and
retarding ageing in laboratory animals (pahlavani et aI, 1994). More recently, DHEAS has
been proposed as a bio-marker of ageing and of caloric restriction (Lane et aI, 1997). In
this primate study, reduced caloric restriction slowed down the decline in DHEAS with
age. These findings are the first evidence that nutritional intervention has the ability to alter
aspects of ageing in a long lived species.
Male survivors of M! have been shown to have reduced serum DHEAS in comparison
with healthy matched controls (Slowinska-Srzednicka et al, 1989, Mitchell et al, 1994). In
women however, a prospective study failed to find any relationship between DHEAS
concentrations and llID (Orentreich et aI, 1984). In males high serum DHEAS
concentrations have been related to central fat distribution and inversely with BM! and
plasma insulin levels (Herranz et al, 1995). A significant inverse correlation was found
between BM! and DHEAS in a study of pre-menopausal women of high mean BM! (41.8
SD 10.3) (De Pergola et al, 1995), although age has been established as the principal
influence on plasma DHEAS (Gray et aI, 1991).
Experimentally induced hyperinsulinaemia lowers serum DHEAS concentrations (Nestler
et al, 1989) and weight loss decreases plasma insulin concentrations (UK PDS, 1995). A
reduction in weight may therefore be expected to result in a decrease in insulin and thereby
an increase in DHEAS, and so contribute to the ultimate reduction in llID risk.
Substantial weight loss of an order seldom achieved in routine clinical practice (13.0 SD
4.0 kg) in healthy pre-menopausal women and men significantly increased DHEAS
concentrations (Leenan et al, 1994). This study, published while the present thesis was in
progress, used a 4.2 MJ (1000 kcal) per day dietary plan in overweight pre-menopausal
women and men aged below 51 years (Leenen et al, 1994). These subjects BM! range
was 28-38 kg/m
2
and a 14% weight loss (12-13 kg) resulted in acute increases in DHEAS
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concentrations (32% and 36% for men and women respectively). Corresponding 35% and
45% reductions in plasma insulin concentrations in men and women were also reported.
Another study of weight loss in hyper-insulinaemic pre-menopausal hirsute women
achieved 5.8% weight loss in using a conventional dietary approach of 1500 kcal daily
(Crave et ai, 1995). The effect of weight loss increased serum DHEAS concentrations by
15-20% and decreased insulin by 15-20%. However, this potentially beneficial effect has
not been investigated in older subjects who have lower circulating DHEAS concentrations
(Gray et ai, 1991, Haffner et ai, 1994).
1.2.8 Potential health hazards of weight loss
The sequence of adverse developments during starvation were described classically by
Keys et al (1950), and included depression, apathy, inactivity and cognitive impairment. A
number of physical changes also occur during enforced weight reduction. Changes in the
skin and hair loss are common, particularly with extreme dietary regimens such as VLCD.
Starvation regimens have been largely dismissed as potentially dangerous, and have
received little attention in the recent literature. Starvation entailing a daily energy deficit
of 2500-2700 kcal alone will achieve a weight loss of about 3-4 kg per week. Tissue
composition lost in starvation represents about 50% lean muscle and 50% adipose tissue,
and thus presents difficulties through alteration in body composition (Garrow, 1988).
Starvation runs increased risks of unexpected death even before body weight reaches a
minimal healthy weight (Garnett et ai, 1969). The extreme psychological effects of
starvation were recorded by Keys et al (1950). Underlying heart disease exacerbated by
the loss of heart muscle was the most likely causes of sudden death with the use of
starvation diets (Garnett et ai, 1969) or the development of ventricular arrhythmia
secondary to the elevation of free fatty acids characteristic in starvation situations (Garrow
et ai, 1989, Drott and Lundholm, 1992).
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Everhart (1993) recently produced a comprehensive review of the evidence regarding the
development of gallstones. After weight loss through dietary intervention the development
of gallstones increased up to 22%. Above 24% weight loss following diet there was a
three fold increase in gallstone development. With weight loss greater than 45%, 60%
patients developed either gallstones or gallbladder sludge (Shiffman et ai, 1991).
Kaufman et al (1990) discussed in the light of three clinical cases, each of whom were
described as being at risk of seizure by electroencephalography, the possible link between
weight reduction and seizures, principally with respect to the use of VLCD regimes. The
weight loss preceding the incidence of seizure was 5%. Caution must be advised in the use
of VLCD in individuals with histories of seizures.
Obesity and overweight increase bone mass as it is responsive to changes in body mass. It
has been demonstrated that bone mass falls with weight loss; as overweight subjects
returned to their pre-diet weight, the bone mass followed these patterns (Compston et ai,
1992). Another study suggested that weight regain was not accompanied by a complete
restoration of bone mass (Avenell et ai, 1994). This may put those who "weight cycle" at
an increased risk of osteoporosis.
A number of potential hazards have been associated with weight loss, but they are
relatively uncommon, and likely to be out-weighed by benefits, or to account for a general
impairment of quality of life.
1.2.9 Psychological and "quality of life" effects
Weight gain is the result of relative overeating in response to a highly complex system of
psychological and social pressures, and reversing this process without resolving the
psycho-social issues introduces stress. Brownell and Rodin (1994) proposed that the
process of weight cycling, may be associated with negative psychological and behavioural
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influences on lifestyle. The principal factors which have been identified include binge
eating, depression and life dissatisfaction. No consistent findings relating weight cycling
behaviour, which indicated a group of subjects who regularly challenged their overweight,
and psychological characteristics have emerged. A greater number of psychopathologies
are apparent in the overweight in comparison with those who were weight stable (Foreyt
et al, 1995). Two recent reviews, the National Task Force on the Prevention and
Treatment of Obesity (1994) and Rebuffe-Scrive et al (1994) supported these findings.
A recent review of this area (Wadden and Stunkard, 1992) has suggested the existence of
complex emotional disturbances in those who are overweight and obese. The effect of
parental psychological characteristics on eating behaviour and dietary compliance in
overweight children has been considered (Favaro and Santonasto, 1995). Their study of
49 couples with children suffering from obesity found that the characteristics of the mother
were more important than those of the father in cases of obesity and weight loss. The
mothers who had a more serious psychiatric syrnptomology and a more disturbed
personality were associated with more severe obesity in their children. Weight loss was
lower in children with mothers who showed neurotic tendencies.
Recent assessments of indicators of quality of life in those who are either obese or
morbidly obese have suggested that these people have (or portray themselves as having) as
poor a quality of life as others diagnosed with terminal cancer (Sullivan et ai, 1993). In
addition, it has been recognised that emotional and psychological problems specific to
obese persons do exist but they are now seen as consequences of the prejudice and
discrimination which are directed at the obese and the overweight. The benefits of weight
loss with regard to psychological measures are now required to be considered in greater
depth.
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1.2.10 Benefits of weight maintenance at body mass index below 25 kg/m
1
By recent convention a BM! range 18.5-25 kg/m" has become considered acceptable for
good health based on mortality data (WHO, 1996). It has been reported that those
individuals whose BM! are within the upper part of the "healthy range" showed a greater
incidence of diabetes and llID than those with BM! 21-22 and a 5 times increased risk has
been reported (Colditz et ai, 1995, Willett et ai, 1995, Williamson et ai, 1995). The
lowest risk ofNIDDM is in people with BM! <21 kglm2 (Chan et ai, 1994).
The ideal BM! which has indicated minimum risks to health was shown to be 20-21 kg/m'
(Lew and Garfinkel, 1979, Willett et ai, 1995). This has been principally derived from the
J-shaped curve which described the relationship of body weight and mortality (Folsom et
ai, 1993). A recent quantitative analysis has succeeded in combining all principal studies
that have investigated body weight and mortality, suggesting that the BM! associated with
increased mortality risk is below 23 kg/nr' and above 28 kg/m' (Troiano et ai, 1996). A
limitation of this analysis is the failure to consider the risk of specific diseases, such as llID
and diabetes. Data from the Boston Nurses study (Manson et ai, 1990) examined the risk
of coronary heart disease with obesity. From BM! <21 kg/m', with a relative risk of 1.0
this rises to l.3 at BM! 21-23, 1.3 BM! 23-25 and 1.8, BM! 25-29 kg/m', These data,
where cigarette smoking was controlled for, reflect the importance of obesity as a
determinant for coronary heart disease risk.
With increasing age and using data for entire populations it has been suggested that older
people who gain small amounts of body weight have showed benefits as measured by
improved mortality risk whilst the opposite situation been associated with an increased
mortality risk (Lew and Garfinkel, 1979). However, these data reflect the influences of
sectors within entire populations who are unwell. It has been reported that in healthy
people a decreased mortality was associated with a lower body weight, and an increased
mortality was associated with a slightly higher body weight or BM! (Lissner et ai, 1991).
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A study of weight loss in males whose mean BM! was 24.6 (SD 1.8) kg/m2 achieved
losses of 7.4 kg improved fibrinolytic factors (Velthuis et ai, 1995). These data have
suggested benefits from the maintenance and achievement of a BM! of between 22-23
kg/rrr'.
1.3 Conclusions
The health consequences from being overweight affect almost every system of the body.
Weight loss as a result of intentional slimming results in predictable reduction in risks for
ischaemic and coronary diseases. Benefits and health improvements are seen from a wide
range of other specific weight related conditions as well as more "minor" symptoms
including excess sweating and dyspepsia/indigestion.
A wide range less frequently studied physical disorders have been associated with being
overweight and obese. The relative scarcity of reports on these conditions in relation to
body weight change may reflect both the difficulty in measurements and possibly the
considerable time period required to trace physical changes in these systems. Some
common physical symptoms associated with obesity such as breathlessness, dyspepsia and
profuse sweating are rarely described other than anecdotally, but often represent the
earliest and most predictable benefit to patients.
Overall, good clinical evidence supports anecdotal reports in justifying weight loss to
improve health and reduce health costs. The evidence with particular reference to
thrombosis risk and indices of clotting are based on the results of slimming studies, the
majority of which have used either surgery or very low calorie diets. One of the main aims
of the work presented in this thesis was to examine further the effect of weight loss,
achieved using a moderate daily energy deficit (600 kcal / 2510 kJ) on these measures. It
is hoped to extend our understanding of the value, or limitations, of moderate weight loss
achievable from routine dietetic intervention.
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Chapter 2: The results of different treatments in the management of
overweight and obesity and the assessment of dietary intake.
2.1 Dietetic approaches to weight loss
The management of obesity by the health care professions has developed along separate
lines for the main health professional groups potentially involved, who are dietitians,
doctors, nurses, physiotherapists and psychologists. Dietitians are professionals who
address nutrition related diseases primarily on a clinical basis. Within hospital services
they offer both inpatient and outpatient services in most general hospitals and in the
community and see the majority of internal referrals usually with little or no input from
specialist health professionals. Physician-led obesity clinics exist in only five UK National
Health Service centres, with only a few surgeons performing surgery in cases of morbid
obesity, usually gastroplications (COMA, 1994, SIGN, 1996). However, these latter
approaches represent the fringes of clinical circumstance, and the most usual scenario in
the first instance is a dietary approach. Practice nurses offer weight management advice to
many overweight clients, although this appears to be on an ad hoc basis (Hoppe and
Ogden, 1996). Other relevant health professionals, e.g. physiotherapists, clinical
psychologists rarely have a major input into current obesity and overweight management.
The target for success, or "good compliance" with slimming regimens in the past has
usually been the achievement of a BMI within the healthy range i.e. weight normalisation
(below 25 kg/rrr') (Bjomtorp, 1992). For this reason the medical interpretation of more
limited weight loss has tended to be negative. In the context of a general population
whose weight increases steadily between the ages of 18 and 60, simply arresting or
slowing weight gain should be considered a therapeutic success, and the health benefits
will be large if this is done at an early stage particularly in younger patients. When weight
loss is sought for medical reasons, the criterion for success should be of the order 5-10%
31
body weight and ideally maintained for at least 12 months (SIGN, 1996). The
achievement of moderate weight loss (5-10%) body weight is known to have beneficial
effects in a number of chronic diseases (Goldstein, 1993). The results of weight
management approaches are increasingly being evaluated in line with these reasonable
targets.
2.1.1 Dietary methods: conventional weight reducing diets
The use of a reduced energy regimen for self directed slimming, without guidance from
either lay or professional people has been estimated to be effective in achieving a 10%
decrease in overweight in only 10% of the population attempting to lose weight (Nezu and
Perri, 1992). It is against data of this nature, with considerable interpretational limitations,
that the success of weight loss programs must be judged.
Most conventional dietetic approaches providing published evidence use one-to-one
interviews, but groups are used by commercial organisations. Conventional dietary
restriction is usually considered to be based on foods, not on the use of nutritional
supplements (Garrow and Webster, 1992) and provide a minimum of 800 kcall 3347 kJ
per day. For many years the 1000 kcal (4.2 MJ) diet was used as standard dietary advice,
but compliance was recognised to be poor. Pearson et al (1991) report that this type of
regimen has a less than 40% success rate. The success criteria in this case were defined as
the achievement of a 50% reduction of the overweight, as defined by the subjects personal
target weight (pearson et ai, 1991).
Weight loss on a 1200 kcal regimen was found to be a third of that predicted for subjects if
they complied completely for 3 months (Frost et ai, 1991). The value of moving away
from more severe energy restriction was endorsed by Frost et ai, (1991) who confirmed
that a greater energy restriction does not lead to a greater weight loss in free living
32
subjects. The Lean and James (1986) formula together with a daily energy deficit close to
500 kcal below estimated energy expenditure was used to create individual diet
prescriptions. A mean prescription of 1700 kcal/day over three months produced a 5.0 kg
weight loss, compared to a 3.0 kg loss achieved with a standard 1100 kcal/day approach.
These results contrast with predicted weight losses of 6.0 kg and 13.2 kg respectively
which were calculated assuming a 100% compliance with prescription by all subjects.
In 1992, Dwyer surveyed the current scientific literature for the regimens for weight
reduction in most common use, and found those providing limits of 1200 kcal daily for
women and 1800 kcal per day for men were most frequently used. These regimens
demand a deficit ranging between 500-1000 kcal/d below estimated energy requirements,
and given adequate compliance, can reduce body weight by 0.5-1.0 kg per week. Dyer
(1994) described the use of conventional weight reducing regimes as being potentially
destructive, given their failure to incorporate long term support for adjustments in food
choice, eating behaviour and lifestyles. The majority of weight loss treatments in medical
clinics consist of referral to a local dietetic clinic, rather than use of more innovative team
based approaches (Young, 1992). As the sample populations, intervention, attrition,
duration and outcome measures vary widely in dietary interventions, a formal meta-
analysis was not attempted.
Few clinical audits of the assessment and management of body weight are available in the
scientific literature. A review of the outpatient management of obesity by junior medical
practitioners indicated that the most obese subjects were categorised easily. However,
children who were obese and those patients with additional cardiovascular risk factors
were less likely to be reported as being obese and be given dietary advice (Denen, 1993).
Other audits of weight management are even more general in nature and report the
difficulty in measuring the effects of intervention in these settings. An exception was a
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cross sectional survey of a specialist obesity clinic (pacy et aI, 1987). The most common
reason for seeking weight loss among all subjects was to improve their appearance,
although other physical symptoms including shortness of breath, and pain in weight bearing
joints were ranked second in importance. The results in terms of weight loss were
described by treatment duration, 1-3 months, 4-6 months, 7-12 months and greater than
this period. The treatment methods were dietary advice alone, with 17 subjects (11%)
being given jaw wiring. The losses were 5.0 (SD 6.2), 12.4 (SD 11.0), 12.4 (SD 10.2) and
12.0 (SD 5.2) kg respectively. These very encouraging results are likely to have been
improved by the inclusion of the jaw wired subjects.
The mean weight loss that was most often achieved in the majority of studies was close to
5.0 kg, with a typical study duration of 12 weeks. It is likely that a 12 week study
duration is moat usually chosen because maximum weight loss is achieved in this period
(Nezu and Perri, 1992). However, a common failing in almost all conventional approaches
for weight loss has been to leave weight maintenance to chance, so that regain is usual and
most often almost complete.
2.1.2 Attrition Rates
Attrition or dropout rates vary in the various dietary interventions, given their different
source populations, though most are around 20% (Tauberlassen et aI, 1990). A reluctance
of many researchers to report attrition rates, by excluding those who did not complete the
study from their final analyses has the effect of reporting exaggerated weight losses
(assuming that unaccounted drop outs fail to lose weight). Pratt (1989) evaluated the
various reasons for attrition from dietary studies, and found the individual's perception of
the personal value of the programme, together with self reinforcement and commitment
were the most influential factors.
34
2.1.3 Effect of macronutrient diet composition on weight reduction
There are consistent findings from metabolic studies and epidemiological observations, for
favouring high carbohydrate / low fat diets to assist weight loss and prevent regain (James
et aI, 1990). However, experimental evidence is not so persuasive for weight loss.
A 12 week randomised trial compared two sets of dietary advice designed for weight
reduction. Each provided 1200 kcal/day, but was either low in carbohydrate
(approximately 32% energy) or high in carbohydrate (approximately 58% energy) (Baron
et aI, 1989). Weight loss was 5.0 kg in the low carbohydrate and 3.7 kg in the high
carbohydrate diet groups with no significant differences in the lipoprotein patterns between
groups. Another study comparing two diets of different composition in free living subjects
was conducted using 1200 kcal/day diets for 110 women with mean body weight of 84.0
kg (Lean et al. 1997). Weight loss was 5.2 kg over 3 months, with no significant
difference on diets providing either 35% or 58% energy from carbohydrate. Similar
weight losses were achieved using low or high carbohydrate diets in obese persons in a
metabolic ward setting randomly assigned to diets with either 15% energy from
carbohydrate and 53% energy from fat or 45% carbohydrate and 26% energy from fat
(Golay et aI, 1996). The weight loss in response to these diets was 8.9 or 7.5 kg
respectively. The results of this study showed that energy intake not nutrient composition
determined weight loss in response to low energy diets over a short time period, in this
case 6 weeks of hospitalisation.
Several dietary intervention studies, exchanging low fat and high fat diet compositions
have been investigated without specific weight loss advice. On average, weight loss of 1-3
kg was seen. This may be of significance for preventing long term gain.
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2.1.4 Behavioural modifications: the principles in weight reduction
Behaviour modification has been described as a process which first identifies unproductive
habits, which are then replaced with adaptive behaviour patterns (Beales and Kopelman,
1994). The behaviour therapist seeks to support a process of change in behaviours
associated with weight gain, with reappraisal after a defined period (Blundell, 1984).
Rewards or penalties can be used (Jeffery et ai, 1983).
A strengthening of behavioural modification strategies can be achieved with the use of
contingency contracting which employs legally styled, enforceable, agreements negotiated
between therapist and client, usually over a defined period (Wing and Greeno, 1994). An
element of this approach can be seen in the use of commercially organised slimming
programmes, when a commitment to continue in a particular programme is given.
Behaviour therapy in body weight management addresses two main aims: 1) a reduction in
the food energy consumed, 2) an increase in physical activity and thus total energy
expenditure. In practice, a mixed approach of dietary advice and eating behaviour therapy
are most often used (Wing and Greeno, 1994). Thus food intake and eating patterns may
be monitored and assessed to identify eating behaviour cues before introducing control
methods. Self-monitoring has been considered vital to the success of these approaches as
the subjects then contribute to and define their own programme of care with which they
feel most comfortable. Wing (1993) proposed that a change in peoples own individual
environmental prompts for eating activity was required. Wing suggests that it helps people
to develop a better insight into their own actions, and even perhaps clarify their particular
reasons for being and remaining overweight. Cognitive approaches are often used in
parallel with behavioural methods, to combat barriers to weight loss which exist within the
patients' framework of beliefs. The administration of behaviour therapy can be either
through group teaching or individual counselling. The success of each method being very
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dependent on the individual preferences of patients (Perri and Nezu, 1992).
Wadden (1993) reviewed the results of treatments which included behavioural therapy for
weight reduction in the years 1974-1978 and 1984-1990 (table 2.1). Sixty five randomised
weight reduction studies were published in four behavioural journals over these periods
were reviewed. Weight loss for the 1988-1990 period was 8.5 kg in 21.3 weeks, whilst in
1974-1978 a 3.8 kg weight loss was achieved over a mean period of 8.4 weeks, and
attrition rate was about 20% in all cases. In 1990 compared to 1974, subjects were more
overweight and were studied over longer periods. The rates of weight loss with
treatments designated as principally behavioural are generally a little greater than with diet
therapy alone.
The need to treat obesity as a chronic disease and to offer a continuous ongoing
programme of care with the need to consider the differing individual needs of patients and
changes over time has been stressed (perri et al, 1993). A range of professional therapists
have been proposed to be present in care teams to incorporate many components such as
exercise, social support and coping strategies and post-treatment patient therapist contact.
Perri et al (1993) showed that in overweight subjects a maximum initial weight loss of9.0
kg was achieved after 9 months, and 5.0 kg loss remained 27 months post-treatment. A
more standard behavioural approach without a care team or flexibility in the components
achieved 7.0 kg weight loss after 9 months, and only 1.0 kg weight loss was maintained 27
months later. Perri et al (1988) found that after 18 months follow-up behaviour therapy
alone had decreased body weight by 3.0 kg and 33% of this was maintained. Other more
comprehensive approaches which included long term behaviour follow up, a social
influence programme, and aerobic exercise resulted in 12.0 kg loss and 82% of the weight
lost of this was maintained over 24 months. A number of studies have achieved weight
losses 10-15 kg over 12 months, with about 30% regain at 2 years, 60% regain at 5 years,
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(Jeffrey et ai, 1983, Wolfe 1983, Kramer et ai, 1989, Graham et ai, 1992).
2.1.5 Physical activity strategies in the treatment of obesity
The established health benefits of physical activity include reduced blood pressure (Kostis
et ai, 1992) improved lipids (especially HDL cholesterol and triglyceride concentrations)
and increased insulin sensitivity (Siscovick et ai, 1985) and have been discussed in brief in
the behaviour modification section. The potential mechanisms linking exercise with weight
include enhanced resting metabolic rate, preservation of lean tissue during weight loss,
increased total daily energy expenditure and post-exercise oxygen consumption (Hill et ai,
1994). The influences of physical activity on hunger and satiety are conflicting, with both
increases and decreases being reported (Bray et ai, 1990). A J-shaped relationship with
appetite, involving a paradoxical increase in appetite with complete inactivity has been
suggested.
When physical activity or exercise alone is used in the treatment of obesity, weight losses
are modest and average 2-3 kg (King and Tribble, 1991). However, evidence does exist
that exercise alone can produce much larger reductions in weight when exercise is of
sufficient frequency, intensity and duration (Gwinup, 1975). There appears to be a dose
response relationship between level of exercise and degree of weight lost (Gwinup, 1975).
One study which compared the effects of dieting versus exercise on weight loss and
lipoproteins, in a one year randomised controlled trial, found that both intervention groups
lost significant weight compared to controls. Dieters lost an average of 7.2 kg after 12
months compared to exercisers who lost an average of 4.0 kg (Wood et ai, 1988).
A combination of diet and exercise generally produces greater weight losses than diet
alone (Pavlou et ai, 1989a, b, Kempen et ai, 1995, Skender et ai, 1996) although this is
not always observed (Grilo, 1994). One study which randomised dieters to an exercise or
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no exercise group found that the exercise group lost an average of 10.8 kg during the 12
week intervention period compared to the diet only group who lost an average of 8.1 kg.
Perhaps more importantly, subjects in the exercise group adhered to the prescribed diet
better than the no exercise group (Racette et ai, 1995).
One encouraging finding in the study of exercise in the treatment of obesity is the effect on
weight maintenance. During one study, subjects who had participated in a 12 month
randomised controlled trial of the effects of weight loss through exercise or diet were
randomly assigned to either a weight maintenance treatment or an assessment only control
group (King et ai, 1989). The maintenance strategy involved regular mailed information
packs and telephone contacts. The initial amount of weight lost that was regained in
intervention was different for exercisers compared to dieters when compared with control
groups. Although dieters had lost more weight than exercisers after 12 months, dieters
regained 42% of weight lost compared to exercisers who only regained 17.4% of weight
lost. Similar findings occurred in the study by Skender et al (1996) who also followed
subjects for 2 years. After 12 months, dieters had lost an average of6.8 kg, exercisers 2.9
kg and the diet plus exercise group 8.9 kg. At 2 years, dieters had reached a weight 0.9 kg
above baseline, the diet plus exercise group 2.2 kg below baseline and the exercise only
group 2.7 kg below baseline, only 0.2 kg greater than that at one year. However, this
meant that the total weight change at 2 years was not significantly different between either
group.
An 18 month follow up data of a study which randomly assigned subjects to different
dietary interventions and to exercise or no exercise, showed no difference in weight
regained between the different dietary regimens. However, comparisons between
exercisers and non-exercisers showed a significant difference in the maintenance of weight
loss. All non exercise groups regained nearly all of the weight lost during the 8 week
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treatment period compared to the exercisers who maintained most of the weight lost
(Pavlouetal,1989b).
Two of the few studies to follow subjects who had taken part in commercial weight loss
programmes both found that maintenance of weight lost was associated with frequency of
exercise (Holden et aI, 1992, Grodstein et aI, 1996).
The combination of physical activity and diet limits the amount of lean tissue lost (Skender
et aI, 1996), maintains reductions in plasma cholesterol (Svedsen et aI, 1994) and limits
weight regain (Garrow and Summerbell, 1995). Analysis of physical activity schemes
within these publications have consistently shown the benefits of physical activity on both
psychological and physical well being. Advice to increase regular appropriate physical
activity should be incorporated in all weight management programmes. Reviews of the
literature indicate that physical activity increases additional short term weight losses by
around 1-2 kg when used in combination with a conventional reduced energy regimen
(Brownell and Jeffery, 1987, Wood et aI, 1991).
2.1.6 Financial incentives
Within the area of behavioural therapy for overweight, financial incentives have frequently
been used to achieve agreed targets. Commercial organisations often relate their perceived
success to the personal financial commitment made by clients.
Phillips and Philbin (1992) used a 12 week competitive behavioural programme (Brownell
et aI, 1984) which comprised a personal pledge of $10 and allocation to one of two
slimmingteams. After weight reducing advice the team to achieve the greatest weight loss
kept the money. Over 12 weeks this achieved a weight loss of 3.5 vs. 3.0 kg per person in
the winning and losing teams respectively. Other advice concerning nutritional principles
was given in a learn and lunch format, offering food and nutritional advice.
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A range of financial commitments ($30, $150, and $300) were investigated by Jeffery et al
(1983) in a study of obese middle-aged men, allocated to be treated on a group or
individual basis and with a 12 month follow up period. After 15 weeks, weight loss was
14.6 kg for individuals with highest financial commitment, 1l.3 kg for the middle group
and 10.6 kg for those with the lowest financial commitment (table 2.2).
Thus greater financial commitment and group therapy both favoured greater weight loss at
15weeks, but at one year all the three groups differed by only 2.0 kg body weight.
In conclusion, it is evident that behavioural approaches to slimming can only operate via
changes in energy expenditure or energy intake. No single package of behavioural
interventions exist, but the application of the basic general principles of behavioural
techniques seem to offer hope for greater weight reduction and better maintenance than
simple dietary advice. The cost implications may also be favourable as a mixture of lay
and professional leaders may feature in the use of behavioural treatments. The wide range
of successes from behavioural treatments points to differences between individual skills,
and also depend heavily on the response of relatively small subjects groups recruited in
different parts of the developed world, all components which are hard to evaluate. Since
studies of behavioural therapy often do not specify the exact methods used in detail it is
seldom clear how much dietary advice is incorporated in behavioural strategies.
Conversely, many studies of dietary advice have failed to describe simple behavioural tips
which are usually included in good dietetic practice.
Many health professionals are unfamiliar with the terminology of behavioural therapy, and
lack confidence in its use. The 5 core components or stages are self monitoring, stimulus
control, modifying the topography of eating, adjunctive behaviour strategies and cognitive
restructuring (perri et al, 1992). It is appropriate for all weight loss programmes to
include some behavioural measures and for all health professionals to be trained in simple
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behavioural modification techniques (chapter 5, table 5.1).
2.1.7 Starvation regimens
These have been largely dismissed as potentially dangerous, and have received little
attention in the recent literature. Total starvation entailing a daily energy deficit of 2500-
2700 kcal will potentially achieve a weight loss of about 3-4 kg per week. The
composition of tissue lost in starvation represents about 50% lean muscle and 50% adipose
tissue initially (Garrow, 1988). Starvation leads to increased risks of death, even before
body weight reaches a minimalhealthy weight (Garnett et aI, 1969). This can be related to
underlying heart disease exacerbated by the loss of heart muscle by starvation (Garnett et
aI, 1969) or to ventricular arrhythmia, secondary to elevated free fatty acids (Garrow,
1988, Drott and Lundholm, 1992). The other psychological and physical effects of
starvation were documented in detail (Keys, 1950). Healthy subjects who starve
voluntarily die after 6-7 weeks, when fat stores have been expended (Keys et aI, 1950).
2.1.8 Very low calorie diet regimens
The VLCD regimens are usually in the form of liquid drinks but which often allow a daily
meal based on food. The term is used when energy provision from the entire regimen is
less than 800 kcal per day (Royal College of Physicians, 1983, Committee on Medical
Aspects of Food Policy, 1987, National Task Force on Obesity Prevention and Treatment,
1993).
The use of VLCD was extensively reviewed by the United States Task Force on Obesity
treatment (National Task Force on the Prevention and Treatment of obesity, 1993). The
committee concluded that supervision by a physician and the selection of patients with
BM! of >30 kg/m' should provide appropriate and adequate safeguards to VLCD use.
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The recommended VLCD diet composition includes 1g protein per kg ideal body weight
per day to minimise muscle breakdown. Cholelithiasis has been shown as the most
frequent clinical complication associated with the use of VLCD. Yang et al (1992)
reported a 10% incidence of clinicallyrecognisable symptoms of gallstones in 16 weeks of
VLCD therapy. Potential dangers wijh VLCD are increased if there is underlying heart
disease present, and through prolonged use. A 12-20 week period is acceptable (National
Task Force on Obesity Prevention and Treatment, 1993).
Mean weight losses with VLCD range from 1.5-2.5 kg per week, so that their use over 12-
16 weeks should produce close to a 20.0 kg weight loss. This compares with an average
weight loss of 0.5-0.6 kg per week using a conventional 1200 kcal diet, leading to a
weight loss of 6-8 kg over the same time. Basal metabolic rate is suppressed by a mean of
15% on VLCD (Bray, 1969, Apfelbaum, 1971, Garrow and Webster, 1989) tending to
slow the speed of weight loss.
In practice, VLCD compliance is rarely complete with patients tending to revert to their
usual diet and life style using VLCDs intermittently. Acceptability ofVLCD regimens has
been investigated in comparison with a similar energy provision to that achieved using
food from either fish and fowl to supply dietary protein (Wadden et al, 1985). No
differences in actual weight loss were seen between the two groups although the "food"
based diet was rated as being more acceptable by the subjects.
The use of VLCD regimens in many short term weight reducing studies, but fewer
consider their long term use (Hymans et al; 1993). Either an intermittent 500/1200 kcal
regimen, or a constant 1200 kcal daily regime for 20 weeks in two overweight patient
groups achieved weight losses of 9.5 or 8.0 kg respectively (Foster et al, 1992). Using
estimates of energy requirements the expected weight losses would have been 27.5 and
22.0 kg, respectively, so both values suggested shortfalls in dietary compliance. Actual
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weight losses were 34% and 36% of those estimated for each group if patients had
followed advice completely. The authors concluded that there were no benefits in weight
loss associated with VLCD use.
2.1.9 Maintenance of weight loss after very low calorie diet
Maintenance of weight loss continues to be of crucial concern for all types of weight
control programmes including VLCD. Flynn and Walsh (1993) enrolled overweight but
otherwise healthy patients on a VLCD regimen for a period of 26 weeks. After this period
the weight loss achieved was 10% body weight for 90% of the study population, and this
was maintained by 33% of subjects in a 30 month follow up. The initial mean weight loss
was 21.4 kg at 26 weeks, and the maintained mean weight loss was 6.S kg at 30 months.
The entire programme was completed by 44% of subjects completed, the others having all
withdrawn before the completion of the follow up period.
Weight maintenance following VLCD in NIDDM patients was examined by Wing et al
(1994). There was greater weight loss with VLCD when compared with conventional
hypocaloric diet (14.5 kg vs. 10.5 kg) at 50 weeks. These differences were due to
differences in weight loss after the first 12 weeks of dietary treatment. Interestingly, the
authors did not consider these weight losses important enough to justify the use of a
VLCD regimen over a conventional reduced energy dietary regimen. Actual weight losses
are comparable with the use ofVLCD, whatever the duration of the study. Caprio-Shovic
et al (1993) examined the effectiveness of a 16 week VLCD programme and rigorously
followed up the recruits. Weight loss was 15.0 kg (15% body weight) for men and 15.0
kg (9% body weight) for women at 16 weeks, but at 1.S years baseline weights were
regained by two thirds of the remaining of subjects.
A structured programme was tested which combined a VLCD (12 weeks / 2500 kJ) with a
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period of relaxing the dietary regime to 5000 kJ for 6 weeks and finally a period of weight
maintenance on a step 1 national cholesterol education programme diet for 7 further weeks
(Osterman et ai, 1992). At 25 weeks, weight loss was 25.0 kg, providing evidence for
improved compliance on this structured programme, though the long term weight
maintenance post-programme was not evaluated. Reviews of the long term maintenance
of weight loss after VLCD concluded that after one year post-slimming 75% of dieters
regain most of weight lost (Andersen et ai, 1988, Safer et ai, 1991). After 2 years this
figure rose to 85-90% (Sikand et ai, 1988, Wadden et ai, 1989). A study of VLCD
followed by Dexfenfluramine showed the value of medication, in the maintenance of
weight loss. After eight weeks VLCD, the patients then continued on a diet providing
75% of estimated energy requirements. They were randomised to receive either the
medication or placebo. Those patients who received placebo showed a mean weight
regain of2.9 kg, whereas those receiving the medication reduced weight by 5.8 kg (Finer,
1992).
2.1.10 Milk diet
A milk based regimen was pioneered by Garrow as an alternative to the more expensive
commercial VLCD. A typical milk diet is based on 3 pints of whole milk providing 59g
protein and close to 50% energy from fat, with appropriate multivitamin therapy, ferrous
sulphate supplements and an inert bulk laxative if necessary (Garrow, 1981, Garrow et ai,
1988). Weight losses on the milk regimen containing 1170 kcal per day are comparable
with those achieved with proprietary VLCD. A study designed to compare a commercially
available VLCD (Cambridge diet), and the milk diet resulted in similar weight losses of
1.5-2.0 kg per week over 8 weeks (Garrow and Webster, 1989). The same limitations
probably exist with the milk as with the commercial VLCD in terms of long term weight
maintenance, but its low cost and universal availabilitymake this approach preferable.
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2.11 Conclusions
There are a range of different clinical approaches towards the achievement of weight loss.
The outcome of the majority of these interventions are moderate weight losses, which have
been acknowledged to lead to health benefits. The use of the VLCD regimes are proven
to achieve good weight losses over the short term, but their value in long term weight
maintenance depends on effective weight maintenance strategies. The moderate energy
deficit approach has been shown to lead to a weight loss of close to 5.0 kg over 12 weeks,
and this approach could offer promise for weight maintenance over the longer term. The
value of this approach may lie with an emphasis on eating conventional foods, and
introducing regular meal patterns. The effect of diet composition on weight loss is
minimal, although the consumption of a high carbohydrate diet in the longer term should
be advocated to reduce risk of long term chronic disease. Physical activity in addition to
dietary intervention can offer opportunities for improved maintenance of weight loss,
though physical activity programmes alone result in minimalweight losses.
2.2 Physical interventions
2.2.1 External mandibulo-maxillary fixation
External mandibulo-maxillary fixation, jaw or tooth wiring, for obesity is not currently
offered by any major UK centres, probably due to the lack of evidence to prove that
weight loss is maintained. Jaw-wired subjects are only able to consume liquids (Garrow,
1988). Jaw wiring together with a milk diet has resulted in remarkable weight loss of36.0
kg over 9 months and 42.0 kg over 11 months in obese patients of BM! above 40 kg/m"
(Harding, 1980). The published results of jaw-wiring indicate profound weight loss.
Where this therapy is practical and acceptable, renewed efforts to maintain weight loss
might make jaw-wiring worthy of re-appraisal, and to reduce surgical risks prior to
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gastroplication surgery, it would seem justified. Limitations to the use of jaw-wiring are a
lack of teeth, or the loosening of teeth. A period of unwiring can resolve the loosening of
teeth.
2.2.2 Waist cords
In an attempt to prevent weight regain after wire removal, use of a waist cord has been
studied (Garrow, 1981). The inextensible waist cord was developed for use after
considerable weight reduction (e.g. with jaw-wiring) to prevent weight regain. In one
study, (Garrow et ai, 1986), 14 subjects from 36 whose jaws were wired were given a
waist cord. In the 14 subjects mean weight loss immediately after jaw-wiring was 43.0 kg
over 11 months and the weight regain was only 10.0 kg at one year (Garrow and Webster,
1986). The waist cord has also been studied to maintain weight loss between periods of
intermittent protein sparing fast treatment (Simpson et ai, 1986). Subjects with a waist
cord lost an additional 5.0 kg weight over 11 months follow up compared with those
without a waist cord who regained 7.0 kg weight over the same period.
The acceptability of the waist cord differs widely between patients, perhaps limiting long
term use in some patients (Jung and Chong, 1991). For practical reasons the waist cord
can only be used when there is an identifiablewaist, excluding most patients with BM! >30
kg/m'. The BMI of Garrow's subjects was 46.0 kglm2 before wiring, and 29.8 after wiring
when the waist cord was first used. A waist cord has been shown to be a cheap and
effective aid to restrict weight regain.
2.2.3 Gastrointestinal surgery
There is a long and varied history of surgical attempts to cure obesity. In practice a
multidisciplinary team is required including a surgeon/physician, nutritionist/dietitian and
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clinical psychologist. Pre-operation psychological assessment is usually advised, and post-
operative respiratory problems may make availability of intensive care ventilatory facilities
desirable (Beales and Kopelman, 1994).
The most widely used stomach surgery is the vertical banded gastroplications (pories et ai,
1992a). Weight loss after gastric restriction surgery has been reviewed by Halverston
(1985). The average loss is 4.5 kg per month for the first 6 months, which has been
associated with improvements in the major accompanying diseases of overweight. Final
weight loss following surgery is usually around 50% of the excess above ideal body
weight, but is determined by the diameter of pouch outlet (Kral, 1992). The regain
following weight loss is much less than with other interventions with a failure rate at
around 10% (Pories et ai, 1992b). There are potential nutritional, emotional and
psychiatric complications, though the greatest benefits are for patients with greatest health
risks, and peri-operative mortality may be as low as 0.1% (Deitel et ai, 1992, National
Institutes for Health, 1992).
For those grossly overweight people who suffer some of the many health complications of
their obesity, surgery may be life saving, and this applies particularly to sleep apnoea
syndrome (Dyer 1994, Loube et ai, 1994). NIDDM has been described as a surgical
disease (pories et ai, 1992a) as post-surgical weight loss succeeded in resolving NIDDM.
A total of 80% of the 163 subjects with IGT achieved normoglycaemia. The impact on
health and quality of life of gastroplication is currently under review from the Swedish
Obesity Study. Early evidence suggests improved outcomes compared to conventional
dieting approaches (Sjostrom, 1994) although it might be argued that the control group
does not represent best conservative practice.
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2.2.4 Intra-gastric balloon
Initial impressive weight losses over the initial three month period of up to 21.0 kg have
been shown using the intra-gastric balloon (McFarland et al. 1987, Ramhandany and
Baird, 1988). All studies showed regain of the weight lost, due to the ability of the
stomach to expand. Potential dangers in the use of balloons include rupture and intestinal
blockage (Garrow, 1988). The evidence does not support the use of an intra-gastric
balloon in obesity treatment.
2.2.5 Liposuction
The use of cosmetic surgery to remove adipose tissue deposits known as liposuction or
liposculpture has not been used widely except in the field of cosmetic surgery (Fischer,
1991). The practical use of this therapy is difficult to assess and it has side effects,
including the relocation of adipose tissue deposits to their original sites and to some new
ones leading to further deformations of body shape (Coleman, 1991). Current evidence
suggests that this surgery is of no value in long term clinical management of obesity and
overweight unless the psychological motivations for overeating are resolved (Coleman,
1991). A role for cosmetic surgery may be to remove the folds of skin resulting from
excessive weight loss e.g. after surgery.
2.2.6 Conclusion
A conventional weight reducing diet remains the most valuable intervention in the
treatment of overweight given the considerations of both safety and nutritional adequacy
and efficacy, and usually results in around 4 -5 kg weight loss. Do-it-yourself dieting is
only successful for 10% of slimmers. The results for the use of VLCD (or the cheaper
milk diet) suggest they can be valuable in inducing short term weight loss of 10-15 kg.
Medical supervision is required, together with a minimum BM! of30 kg/m', and long term
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management in these cases. The use of jaw-wiring, waist cords and surgery provide a
variety of alternative treatments available to the clinician. With careful selection
procedures and an established multidisciplinaryteam for peri-operative care and long term
supervision, gastroplication may be the most useful therapy in those patients with high
health risks associated with their obesity, and for whom less drastic interventions have
proved unsuccessful.
2.3 Anti-obesity medication
There are a number of anti-obesity medications, either under development, or available for
prescription by physicians. The main classes of medication available, or under
development for weight management operate through appetite suppression (or satiety
promotion), inducing malabsorption (anti-nutrients) or by thermogenesis to increase
energy expenditure. The use of anorectic medications have received particular criticism
for their poor long term effectiveness (Garrow, 1991). The older amphetamine-like drugs
can lead to dependence, and have been abused in the past. Case reports have linked some
centrally active appetite suppressants including dexfenfluramine with the very rare
condition primary pulmonary hypertension and dexfenfluramine has recently been
withdrawn from use in the UK.
2.3.1 Malabsorption
Lipase inhibition induces a partial malabsorption of dietary fat by the inhibition of
triglyceride hydrolysis. The chemically synthesised hydrogenated derivative of lipostatin
(tetrahydrolipostatin) is a potent inhibitor of gastric, pancreatic and carboxylester lipase
(Hadvary et al 1988). Drent et al (1993) found that the 12 week use of
tetrahydrolipostatin (Orlistat) together with a hypocaloric diet (500 kcal daily energy
deficit) achieved a weight loss of 4.3 kg compared to 2.1 kg in people receiving diet alone.
Beales and Kopelman (1994) have suggested that the principles by which the medication
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operates are sound, although there are possible risks, possibly correctable, of fat soluble
vitamins A, D, E and K depletion. Predictable side effects from malabsorption, altered
bowel habit, and also bacterial overgrowth of the small bowel have led to around a 10%
patient withdrawal from therapy. Alpha glucosidase inhibitors such as acarbose, delay
digestion of starch and sucrose. These drugs reduce blood glucose, but do not produce
weight loss.
2.3.2 Appetite Adjusters
These medications have been divided into groups by Silverstone (1992). Those acting via
catecholamine pathways, those acting via serotoninergic pathways (5-hydroxtryptophan,
SHT), serotonin precursors and other agents such as opiate receptor blockers.
2.3.3 Dexfenfluramine
The only serotoninergic drug licensed for use in obesity treatment in the UK was
dexfenfluramine, which has very recently been withdrawn from use. The medication
reduced the subjective levels of hunger and food intake (Silverstone and Goodhall, 1992),
and large clinical trials showed an average weight loss of 3.0 kg more than placebo after
12 months of treatment (Guy-Grand, 1992). Stunkard et al (1980) compared the use of
dexfenfluramine with a behaviour programme, or a behavioural programme alone for one
year. The behaviour modification alone achieved a weight loss of 10.0 kg, the use of
behaviour therapy and Dexfenfluramine achieved a weight loss of 15.0 kg respectively. In
a one year follow-up a third of all weight lost was regained despite the continued use of
behavioural therapy.
A recent Scottish study (Manning et ai, 1995) showed the best outcome in the treatment
of overweight NIDDM was with dexfenfluramine for three months followed by
conventional diet therapy. However, after a year of treatment this difference, compared
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with other available therapies, was lost. Another study compared dexfenfluramine with
dietary advice to encourage compliance with healthy eating principles (Mathus- Vliegen et
aI, 1993). Over a 6 and 12 month intervention weight loss was 10.0 and 11.0 kg for
placebo and dexfenfluramine treated groups respectively over the one year study period
suggesting no benefit of medication above the influence of dietary counselling.
2.3.4 Sibutramine
Sibutramine is a serotonin and noradrenaline uptake inhibitor which was launched in USA
and Brazil in 1998. A study of depressed patients who were not actively seeking to reduce
their body weight, found that in 8 weeks a weight loss of 2.1 kg was achieved (Kelly et aI,
1995). The result of a double blind placebo controlled trial found that when given with
dietary advice, the same dose (30 mg /day) achieved a weight loss of 6.1 kg over 12
weeks, while the placebo group lost 0.9 kg (Bray et aI, 1995). Side effects of sibutramine
were recognised including a dry mouth, dizziness and headaches. Pulse and blood pressure
are elevated by sibutramine, although this is usually counteracted by weight loss. A recent
study in France found that 24 week treatment with sibutramine reduced weight by 6.5 kg
in the treatment group and 3.1 kg in the placebo group. Fifty seven percent of treatment
compared with 25% of placebo subjects lost at least 5% of body weight. The study also
found beneficial effects on plasma glucose and insulin. Further long term studies of the
continued effectiveness of sibutramine are in progress.
2.3.5 Fluoxetine
This antidepressant operates in a very similar manner as the dexfenfluramine and
fenfluramine as a seratonin reuptake inhibitor but it does not have a licence for weight loss.
Effectiveness has been demonstrated in use with diabetic patients (O'Kane et aI, 1993)
where a 4.3 versus 0.8 kg weight loss was achieved for treatment versus placebo group
and hence an overall drug effect of3.5 kg weight loss. In addition, Potter Van Loon et al
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(1992) found an increase in insulin action in NIDDM subjects taking Fluoxetine, aside
from any effect on reducing body weight. A long term trial of Fluoxetine (Darga et al.
1991) reported the results after one year, with a 41% and 27% dropout rate for the drug
and placebo group respectively. Weight loss was 8.5 kg and 4.5 kg respectively for the
treatment and control groups. Connelly et al (1995) used dietary management of obesity
in a double blind study of the effectiveness of fluoxetine. Weight loss in the drug treated
group loss was 3.9 kg and 1.3 kg in the placebo, over 12 weeks in obese elderly NIDDM
patients. The drug was also evaluated in terms of achieving weight loss against placebo
(Sayler et al. 1994). The drug showed improvements of 10% against placebo for systolic
blood pressure reduction, an 8% improvement in BM! and a 10% improvement in total
cholesterol and fasting blood glucose. An uncontrolled weight maintenance study was
designed for the evaluation of fluoxetine (Goldstein et al. 1993). Over an eight week
period a weight loss of3.6 kg was achieved.
2.3.6 Phentermine
This anorectic appetite suppressing drug has been widely used with overweight patients.
Its effectiveness was found to be unrelated to dietary habit, body weight and age in a
randomised controlled study (Munro et al. 1968). Over 16 weeks weight loss was 4.0 kg
with placebo and 7.0 kg with drug, a drug effect of 3.0 kg. The use of phentermine was
extensively evaluated together with fenfluramine (Weintraub et al. 1992a, 1992b).
Although the results were difficult to interpret due to the complex experimental design, the
studies spanning a 4 year period do suggest a value in the long term use of anorectic
agents with few side effects. Over stage one, a period of 3 months, weight loss was 10.0
kg, and overall weight loss for the whole study was 50.0 kg. However, the study used a
range of dosages and combinations of the two medications, and this may account for the
programme's success (Weintraub et ai, 1992a, 1992b).
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2.3.7 Conclusion
The range of drugs for weight management reflect both the lack of an ideal medication and
the strength of mechanisms maintaining and governing appetite and body weight. Most
available drugs, used alongside conventional diet advice, produce an average weight loss
of 2.0-5.0 kg (5% body weight), better than placebo over a 3 month period, and this is
maintained for as long as the diet is followed and the drug is taken. In routine practice
drugs are introduced as therapeutic trials so the "non-responders" can be identified and the
medication withdrawn. In "responders" weight loss of 8-12 kg should be expected. There
is a wide range of efficacy between individuals and the reasons for this variation are
unknown, however some individuals can achieve remarkable responses. Side effects
reported in well documented controlled trials may be less problematic than might be
imagined from anecdotal reports. Evidence on drugs which can be taken effectively for
long periods are urgently required, since the main role of a drug in weight management is
probably to prevent long term weight gain, rather than to induce massive weight loss in
patients who already have become obese.
2.4 Weight reducing diet therapies in specific diseases
2.4.1 Non insulin dependent diabetes mellitus
Most NIDDM patients are overweight and the disease can be completely controlled by
weight loss in many cases (Nutrition Sub-Committee of the British Diabetic Association,
1992). The recommendations for diet composition for other aspects of diabetes
management are entirely compatible with weight loss (Nutrition Sub-Committee of the
British Diabetic Association, 1992). The aims and methods of dietary interventions in
overweight NIDDM patients are similar to that offered to other overweight people as a
population, but given the much greater health risks in those with NIDDM, a greater
motivation to achieve acceptable weights might be anticipated.
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2.4.2 Weight loss in newly diagnosed non insulin dependent diabetes mellitus
The UK PDS examined the effects of dietary management on newly diagnosed NIDDM
diabetics (UK PDS, 1990). A weight loss of 18.0 kg was required to normalise blood
glucose to 6 mmolll or below, and this was achieved by 16% of patients. In a primary care
setting a weight loss of 3.2 kg, achieved using nurses competent with the principles of
dietetics, resulted in significant falls in blood glucose (Bitzen et ai, 1988). In 1990, newly
diagnosed NIDDM patients in a routine clinic setting (Lean et ai, 1990), those with BMI
25-30 kglm210st 2.6 kg, those with BM! >30 kglm210st 6.8 kg at one year. Weight loss in
the first year of treatment was found to improve the prognosis of NIDDM. Expected
survival time for their group of diabetics was 8 years at a median age of presentation of 64
years. The value of group treatment for weight reduction in newly diagnosed NIDDM
patients has been examined (Heller et ai, 1988). Group treatment achieved greater weight
loss at 6.0 kg compared to 3.5 kg from individual dietetic advice at three months, 7.2 kg
versus 2 kg at 6 months and 5.5 versus 3.0 kg at one year. A cost benefit was reported
from group therapy as a result of the more efficient and effective use of the resources of
the health professionals, nurse, doctor and dietitian.
2.4.3 Weight loss in established non insulin dependent diabetes mellitus
A recent study investigated 4 widely used weight reduction strategies in NIDDM patients
attending routine diabetic clinics (Manning et ai, 1995). The study closely reflected the
clinical situation, recruiting subjects who had failed in earlier dietetic treatments to reduce
body weight adequately. A control group was followed with no intervention offered
beyond routine care. The three active interventions were standard dietetic intervention,
behavioural group therapy and dexfenfluramine for 3 months followed by a mixture of
home and clinic visits over one year. For all treatments at 3 months a 1-2 kg weight loss
was achieved and this was maintained for one year. Home visits showed no additional
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benefits. This study demonstrated the difficulty in achieving weight reduction in
established NIDDM patients. The weight losses achieved were rather less than those
achieved in overweight non diabetic subject groups. Similar results were demonstrated in
a comparison of conventional dietary intervention with a more intensive intervention which
included group behaviour therapy (Blank et aI, 1994). Weight loss was 2.2 kg at 3
months and 1.3 kg at 24 months. No significant differences were seen between
conventional and intensive interventions.
The effect of a VLCD on metabolic control and cardiovascular risk factors in the treatment
of obese NIDDM diabetics was evaluated (Uusitupa et aI, 1990). A 3 month VLCD
resulted in a 14.0 kg weight loss, and fasting blood glucose fell from 12.3 to 10.5 mmol/l.
No effects were seen on serum cholesterol or triglyceride concentrations, however systolic
and diastolic BP were significantly reduced. A recent review of the benefits of using
VLCD in overweight NIDDM patients concluded that as weight loss improved the medical
problems associated with NIDDM the use of VLCD regimens may have a place in long
term treatment. Even short term VLCD for weight control could offer value (Henry and
Gumbiner, 1991).
2.4.4 Heart disease and hyperlipidaemia
The results for the majority of treatments for hyperlipidaemia are shown in table 2.3 which
is devoted to hyperlipidaemia and weight loss. The results in terms of weight loss are
comparable with the results of weight management in other overweight subjects. The
range of different interventions used in this subject group are comparable with those
described for diabetes. It is usually assumed that a medical diagnosis, and feedback of
medical information will increase the motivation for weight loss. A study of nurse-
delivered dietary advice in a primary care setting in addition to information concerning the
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plasma cholesterol concentration was not found to have any motivational effect
(Robertson et al, 1992). The attitudes of patients towards adherence to a multiple
restriction cardiac diet was examined by Barnes and Terry (1991). The researchers found
that simple messages and concrete examples of diet advice were regarded as being of
value.
The effects of weight reduction on blood lipids and lipoproteins were examined in a meta-
analysis (Dattilo and Kris-Etherton, 1992) which included studies in both hyperlipidaemic
and normolipidaemic subjects. Results from 70 analysed studies indicated that weight
reduction was associated with a decrease in plasma cholesterol concentrations of 0.79
mmollL per kg weight loss. The fall in LDL cholesterol concentrations was 0.39
mmollLlkg, HDL cholesterol concentrations was 0.14 mmollLlkg and triglyceride
concentrations 0.66 mmollLlkg. These results, although derived from studies which
differed in duration, are convincing that weight reduction through dieting is a valuable
approach to reduce plasma lipids in overweight individuals (Weinsier, 1992).
The benefits of weight loss on plasma lipids of obese women (BM! 36.2 kg/m') were
examined in a 24 week study (Anderson et al, 1995). The first 8 week slimming period
resulted in an 11% decrease in body weight and a fall in plasma cholesterol and triglyceride
of 23% and 16% respectively. Weeks 8 to 24 produced another 4.7 kg weight loss
representing an overall reduction in body weight reduction of 16.5%. During the later
phase of the study, cholesterol and triglyceride increased both by 5.2% and LDL by 4.5%.
These findings suggest that improvements in plasma lipids after weight loss can be divided
into two periods, the effects of energy restriction and weight loss, or weight stability.
2.4.5 Conclusions
The dietary principles which are recommended for NIDDM and hyperlipidaemia are
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compatible with those advocated for the general population (COMA, 1991). An additional
reduction in energy intake will achieve weight loss in both. The case for using VLCD or
surgery is stronger in the conditions where risks to health are greater and where long term
medical follow-up is already required. Efficacy of dietary approaches in newly diagnosed
diabetic patients is improved in comparison with simple obesity. In NIDDM patients
weight losses of between 6.0-10.0 kg are more likely to be maintained for a year (table
2.4). Overweight hyperlipidaemic patients appear to lose weight at the same rate as
patients with simple obesity. Benefits on blood pressure are also seen in these patients
(table 2.5)
2.5 Settings and sources of advice
2.5.1 Group versus individual therapy
The value of a group approach has been described as offering a cost effective environment
for effective weight management (Bitzen et ai, 1988). Whilst the group environment is
undoubtedly unsuitable for some shy or reluctant socialisers, for those agreeable to this
approach, it allows additional harnessing of structure and support not accessible to the
subject undergoing individual one-to-one dietary counselling.
The Harrow slimming club uses an approach similar to that used by commercial
organisations, with frequent meetings as a group, usually in the evenings. However, it is
run under the National Health Service, by State Registered Dietitians and although clients
were fee paying, it is non profit making (Bush et ai, 1988). The programme of 10 session
runs over 10 weeks, with individual weighing, dietary advice and education. An identical
dietary approach based on a 5000 kJI1200 kcal dietary prescription was used for all-
comers. An audit of the club showed a weight loss of 5.4 kg for those who attended 8 of
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the 10 sessions. This was reduced to 3.8 kg in those attending around seven sessions.
Another group approach to weight management is the Finnish Primary Health Care
programme (Hakala et al, 1993). This Finnish study used a 1200 kcal diet group, and a
control group who were followed up, but offered no advice. After the six week weight
reduction course, which included behavioural advice, follow-up meetings were arranged at
monthly and twice monthly intervals. Men reduced their weight by 10.9 kg at one year,
and women 5.4 kg over the same time period. After a lengthy 7 year follow-up, men has
maintained weight losses of8.7 kg and women 3.5 kg.
Advantages for group therapy in comparison with conventional one-to-one therapy in
newly diagnosed diabetic patients have been described (Heller et aI, 1988). No
improvement in diabetic control in established overweight patients was found by Blonk et
al (1994) following group treatment. The impressive results of Jeffery et al. (1983)
favoured group therapy (table 2.2).
Group therapy offers obvious and important benefits for decreasing cost and improving
professional resource management (Chenoweth, 1990). Good weight losses of 11.3% of
starting weight over 6 months were seen in this setting and described (Ashwell and Garrow
1975). Several studies have made direct comparisons between group therapy and
conventional one to one counselling for weight loss, with contrasting results.
In the treatment of overweight patients who had recently survived MI weight reducing
advice was compared in the individual and group situation. Patients were allocated to
receive weight reducing nutritional advice on a group or individual basis. The use of either
individual dietetic intervention, group advice, or a diet sheet directly handed to patients
was compared (Wright et aI, 1981). No significant differences were seen with weight
losses of8.1, 7.5 and 8.9 kg respectively after 6 months.
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The "Pawtucket Weigh In" was a randomised controlled heart health programme designed
to reduce obesity by offering either individual advice or group treatment. In the pilot study
the 10 week program achieved a weight loss of3.5 kg in the group education and 3.9 kg in
the individual advice group (Lasater et ai, 1991). Group or individual treatments in
severely overweight subjects were compared by subjects being randomly allocated to
group counselling, 2 weeks weight reduction in a rehabilitation centre and then group
sessions for 2 years, or individual follow up by a physician, also for 2 years (Hakala et ai,
1993). Mean starting BM! was 43.5 kg/m' in women and 42.2 kg/m' in men. With
individual counselling weight losses were 8.0 and 17.0 kg after 3 months, 3.0 and 13.0 kg
at 5 years in women and men respectively. The group counselling team achieved 15.5 and
15.0 kg losses at 3 months and then 2.1 and 3.0 kg losses at 5 years for women and men,
respectively. The Australian "Gutbuster waist loss" programme was a group programme
designed for men who were recruited to a 6 week course, and then followed for a year.
The programme involved advice on exercise, dietary fat, and alcohol intake. Average
waist losses of 4% were achieved and lifestyle advice led to lowered fat and alcohol
intakes. A more advanced programme which included 6 additional fortnightly sessions
falls in waist circumference were 10% (Egger et ai, 1996). These programmes highlight
the value of weight management group programmes in men.
2.5.2 Commercial slimming groups
Commercial slimming organisations have, to date, failed to publish the findings of their
work, though the findings from non commercially run groups are reported in the literature.
The commercial clubs themselves suggest that their treatments, together with a measure of
financial commitment, are effective, but attrition rates are a major problem (Hymens et ai,
1993). The compliance with commercial slimming organisations varies from 10 to 50
weeks (Garb and Stunkard, 1974, Volkamar et ai, 1981). The findings that a 9.3 kg
60
weight loss (11.3% of starting weight) over 6 months in a slimming organisation are
impressive, though these figures are based on self reported body weights provided by
willing, successful subjects (Ashwell and Garrow, 1975). The American TOPS (take off
pounds sensibly) programme reported a similar degree of success (Kahn and Williamson,
1991). Weight loss was found to be related to the length of attendance, and to the initial
degree of overweight (Garb and Stunkard (1974). Between 25-30% of TOPS members
lost more than 20 lb. in their survey.
2.5.3 Family/partner
A familybased slimmingprogramme was compared to a diet sheet, or dietary advice given
on an individual basis in overweight subjects, or a non commercial slimming group
approach (Cousins et ai, 1992). The entire family slimming group achieved losses of 4-5
kg, in comparison to those allocated to individual treatment, which was either individual
advice or a diet sheet. Those who received the group treatment in both the diet sheet and
individual advice groups lost 1-2 kg over the one year study period.
The value of a partnership of "buddy system" in weight loss interventions where a
commitment or partnership between people is made has been examined. In practice, the
"buddy" or supporter may be a friend or relation of a subject who themselves do not
require weight management. A weight loss programme in a work-site found no effect of
partnership compared with slimming alone on final weight loss (Zandee and Oberman,
1996). The meta-analysis of Black et al (1990) examined weight loss programmes of
couples, versus subject alone analyses. They supported the inclusion of couples In
programmes up to the first 12 weeks of slimming,but not beyond that period.
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2.5.4 Self-help groups
Self help management of obesity was the approach examined by Garb and Stunkard
(1974). A nation-wide self help group was examined to measure weight loss achievements
and also attrition rates. The greater the degree of overweight, the more likely the subjects
were to remain in the study, and the more likely to achieve weight loss. Attrition rates
were 47% after one and 70% after two years. Mean losses for groups were 14 (SD 16) lb.
and 30% of subjects lost more than 20 lb. whilst 6% lost more than 40 lb.
The use of church-based behavioural therapy programs in religious communities to whom
the church provides a central meeting point has also shown benefits. The Baltimore
church high blood pressure programme offered 8 diet counselling and exercise sessions in
an 8 week programme. Team incentives, nutrition education and counselling sessions for
black women were evaluated (Kumanyika et al, 1992). Weight loss was 3.0 kg after the
programme and a 6 month follow up suggested that this weight loss was maintained or
exceeded by 65% of subjects.
2.5.5 Workplace
Health awareness amongst employers has led to successful work place programmes for
weight loss (Brownell, 1986). However, a need to provide single sex programmes because
of the different physical requirements of men and women and the fact that women in
general tended to have less manual employment was highlighted by Teufal (1992). The
needs of the individual work-site were also examined with group therapy being combined
with financial intervention (philips and Philbin 1992). Twenty eight Texan police
employees of mean body weight 96 kg, 146% of ideal body weight were recruited to join a
12 month study. This comprised nutrition counselling, seminar attendance on eating
behaviour and monitoring of body weight and blood lipid levels (Briley et aI, 1992).
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Plasma cholesterol but not triglycerides showed significant decreases with a weight loss of
2.5 kg over 52 weeks (a decrease in 2.4% in body weight). Re-entry was offered to
programme to consolidate achieved benefits. The effectiveness of work-site wellness
programmes was examined by Erfurt et al (1991). Their review defined effective
programmes as those that had achieved and maintained a 3 lb. weight loss at 3 years.
Another criteria of effectiveness they proposed was the recruitment of at least 72% of the
population of overweight employees to any weight management programme (Erfurt et ai,
1991). The effectiveness of contingency contracting towards weight loss in a work-site
setting was considered by Zandee and Oermann (1996). They compared weight loss using
contingency contracting alone, with a partner or no contracting. Weight loss was close to
7.0 kg for all groups over a 10 week period however improvement was shown with
contracting.
A recent article review examined work-site based weight management studies (Hennrikus
and Jeffery, 1996). They found that the majority of weight management studies were
mostly of an uncontrolled design. However, a unique feature of these studies was that
they reached a median of39% of the overweight populations in their respective work-sites,
and achieved good weight losses over the short term of 1-2 lb. per week. However, the
literature failed to demonstrate long term reductions in site wide obesity and overweight or
other improvements in health and productivity benefits.
2.5.6 Conclusion
Group therapy for obesity provides an appealing setting to some subjects but is an
uncomfortable situation for others. Most studies have shown greater benefits using groups
rather than individual treatments. Group therapy is more widely used in otherwise healthy
overweight subjects rather than in those with a particular diagnosis such as established
NIDDM, heart disease or hyperlipidaemia. Group therapy represents a much more
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effective use of professional time and resources, although greater commitment from
patients is usually required.
The setting that weight management treatment is given is crucial in determining the
outcome. The target population, the setting and in turn the flexibility and frequency of the
follow-up are all important. A wide range of settings and a variety of programmes
described are all valuable in providing a range of weight management programmes. The
work-site setting has not been fully exploited and may offer longer term opportunities for
weight management and dietary intervention studies.
2.6 Overall conclusion
A wide range of treatments for overweight have been tested, and the majority can achieve
a modest (5-10%) weight loss, sufficient to improve clinical outcomes for NIDDM, plasma
lipids, hypertension and other risk factors for IHD. This weight loss is usually achieved
over 12 weeks, after which it is difficult to achieve further loss. Greater weight loss may
be possible for patients with major diseases, e.g. diabetes on diagnosis which can be
improved or controlled by weight loss or dietary modification.
Greater weight loss in the region of 10.0-15.0 kg, can be achieved using VLCD or milk
diets over 20 weeks, offering advantages when preparing for surgery and can be used to
form the start of a structured programme. Weight regain is usual without long-term
professional or counsellor contact, so weight management programmes should include
provision for a long term maintenance programme. Simple behavioural and cognitive
approaches offer advantages for long term weight maintenance which are currently under-
utilised, largely through ignorance. Exercise has a value, though this appears to be
important in the maintenance of weight loss, and has only small effects on weight loss.
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Group treatment leads to greater weight loss than individual treatment in most settings,
and has major resource advantages. Group approaches should be adopted as the principal
method for weight management. Family based weight management for overweight and
adolescent children, focusing on behavioural methods and physical activity, principally to
check weight gain, should be given priority.
2.6.1 Important unanswered research question
A dietary intervention incorporating an energy deficit approach to weight loss would
achieve losses close to the theoretical 0.5 kg per week in obese volunteers, those with a
diagnosis of coronary disease, and those with a close to healthy BM!, but a desire to lose
weight.
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Table 2-1 Wadden's summary analysis of sixty five studies of weight loss which included
behavioural modification
Variable 1974 1978 1984 1985-87 1988-90
studies (n) IS 17 IS 13 S
Sample size (n) S3.l S4.0 71.3 71.6 21.2
Initial wt (kg) 73.4 87.3 88.7 87.2 91.9
Initial overweight /% 49.4 48.6 48.l 56.2 59.8
Weeks of study 8.4 10.S 13.2 15.6 21.3
Wt loss (kg/study) 3.8 4.2 6.9 8.4 8.S
Loss per week (kg/wk) O.S 0.4 O.S 0.5 0.4
Attrition % 11.4 12.9 10.6 13.8 21.8
Follow up (weeks) IS.S 30.3 S8.4 48.3 S3
Weight loss on follow up 4.0 4.l 4.4 S.3 S.6
From Wadden (1993)
Table 1 provides a summary of randomised trials in which moderate weight reduction was
combined with behaviour modification. All values are means, hence the majority of values
are given to one decimal place.
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Table 2-2 Weight losses following financial commitment
Financial commitment Weight loss (kg)
(individual approach)
Weight loss (kg)
(group approach)
15 weeks 52 weeks 52 weeks
High
Middle
Low
14.6
11.3
10.6
6.3
7.4
5.4
14.4
15.4
12.6
From Jeffery et al (1983)
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Chapter 3: Review of haemostasis, rheology, fibrinolysis and
haemorheology. The relationship of ischaemic heart disease
risk, overweight, weight loss and changes in dietary
composition
3.1 Factor VII
Factor VIT a single chain glycoprotein is synthesised in the liver (Radcliffe and
Nemerson, 1975). It exists in plasma at low concentrations (0.13-1 mg/L) (Bajaj and
Mann, 1973). Almost all of factor VIT is present as the inactive zymogen (99%) and
activation is achieved through the actions of serine proteases. These hydrolyse factor VU
into a two chain form, increasing the activity 85 fold. The conversion of factor VU to
factor VITa involves the cleavage of an arginine bond resulting in a light chain and a
heavy chain containing the active site linked by two disulphide bonds. In contrast with
other zymogens of other serine proteases, factor VU possesses significant catalytic
activity and coagulation can be initiated by the association of factor VU with membrane
bound tissue factor (Rao et al, 1986). The activation of factor VIT,factor XUa, IXa and
thrombin all activate factor VITand factor IX.
3.1.1 The role of factor VII in the intrinsic and extrinsic coagulation cascade
Factor VU is a key component in the promotion of the coagulation cascade. There are
two systems operative in humans both of which activate the coagulation cascade, the
intrinsic or the extrinsic systems (Bloom et al, 1994) (figure 3.1).
The extrinsic pathway of blood coagulation is thought to be the main pathway for the
initiation of thrombin and fibrin formation. After injury to the endothelial lining of the
blood vessel wall, sub-endothelial fibres become exposed initiating the platelet
component of haemostasis. On adherence to the collagen fibrils, platelets are changed
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and allow platelet products such as thromboxane to be released. This promotes of
vasoconstriction resulting in an impaired blood flow. A complex number of interactions
then take place which consolidate the platelet plug, allowing the process of repair to
proceed.
Tissue factor, a membrane-bound protein also becomes exposed to blood after
endothelial damage. Coagulation factor VII becomes bound to tissue factor in the
presence of free calcium ions and the complex becomes highly active. Activated factor
VII, or factor Vll, has a high affinity for factor X which itself becomes activated (Xa).
The peptide is attached to the endothelial and platelet surfaces. Activated factor X is an
endo-peptidase enzyme which has the effect of activating prothrombin to thrombin.
Factor V is another essential co-factor and is present in both platelets and plasma. This
becomes bound to the factor VIIa,Xa, Ca2+ complex, and is then activated by thrombin or
VXa This can then convert more prothrombin to thrombin.
The intrinsic, or contact system which initiates blood coagulation involves the action of
factor XU. Specific steps in the cascade are not fully understood nor is the precise
mechanism for the initiation of contact activation. There is some overlap with the
extrinsic pathway. The start of the intrinsic system is with the Hageman factor (XII),
prekallikrein (also known as Fletcher factor) and high molecular weight kininogen
(HMWK) which react together. This results in the generation of XIla which is then able
to activate factor XI, to factor XIa. Factor XIa then activates factor IX, which can also be
activated by the enzyme complex of IXa, thrombin modified factor VID, negatively
charged phospholipid and Ca2+. Factor IX can also be activated by the factor Vila, tissue
factor complex. As with the extrinsic system, factor VU complex activates prothrombin
to thrombin, before fibrinogen is converted to fibrin.
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3.1.2 Factor VII and factor VII activity as risk factors for ischaemic heart disease.
Factor VU activity has been measured within large epidemiological studies that have
sought, among their other aims, to prospectively examine any relationships between risk
factors for llID and coronary events. The factor VU activity (also known as factor VUc)
has been the form of factor VU most widely measured and described and as such the
remainder of this chapter will focus on it. In 1980, the Northwick Park Heart study
showed that coagulation factor VU was a predictor of fatal llID but no association was
observed with non fatal events (Meade et al, 1980). The Northwick Park Heart study
also showed that the strongest association of factor vn activity with fatal llID events
occurred soon after measurement (Meade et al, 1980). However, factor VU activity was
still associated with fatalllID events over the study's 16 year follow up period (Ruddock
and Meade, 1994).
Results from the six year follow up of the Prospective Cardiovascular Munster study of
19,698 subjects, demonstrated a similar though less marked distinction between the
factor VU activity in those who suffered either fatal or non fatal events (Heinrich et al,
1994). Factor VU activity in the 23 subjects who suffered fatal coronary events tended to
be higher than the concentrations in those who suffered non fatal events (p=0.06), though
no differences were seen between men who suffered llID events and those who remained
well.
The Northwick Park Heart study and the Prospective Cardiovascular Munster study are
very similar in their findings concerning the relationship between factor VU activity and
fatal events. It has been proposed that the factor VU activity at the time of
thrombogenesis initiation is important for the determination of the size and stability of
the thrombus, through the fibrin deposition and the platelet aggregating property of
thrombin (Meade et al, 1993).
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Considerable debate surrounds the different assays for factor VII activity (Miller et al,
1994, Meade et al, 1991, ECAT, 1993). An international comparison of the different
factor VII activity assay methods was carried out by Miller et al (1994). The assay used
for the Northwick Park Heart study was reported to have a greater sensitivity than either
the Prospective Cardiovascular Munster study assay or that used in the Atherosclerosis in
Communities study (Wu et al, 1990). These findings have important implications for the
comparison of results between studies, particularly the Northwick Park Heart study and
Prospective Cardiovascular Munster study results.
3.1.3 Major influences on factor VII activity
Positive relationships have been shown between factor VII activity and a number of
other risk factors such as fibrinogen, smoking habit, total cholesterol and blood pressure.
These positive associations were reported by the Gothenburg Heart Study (Rosengren et
al. 1990), Framingham study (Kannel et al, 1987), the Caerphilly and Speedwell studies
(Yarnell et al, 1991) and the Prospective Cardiovascular Munster study (Balleisen et al,
1987).
Another prospective multicentre study, the Progetto Lombardo Atero-Trombosi study
(Cortellaro et al, 1992) examined the association of haemostatic variables, including
factor VU activity, with conventional risk factors and atherothrombotic events in four
groups of patients with pre-existing vascular disease. From the entire cohort, sub-groups
were identified including survivors of MI, angina pectoris patients, those suffering
transient ischaemic attacks, and those with PVD. In the MI and PVD groups raised
plasma factor VII activity was positively associated with risk of coronary events.
The importance of the factor VII genotype has recently been discussed in relation to risks
of coronary events (Humphries et al, 1994). An estimated 20% of the UK population
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have the polymorphic factor VII genotype which favours a lower plasma factor VU
activity, and thus a reduced likelihood of experiencing thrombotic ischaemic events.
The Atherosclerosis in Communities study of 12 000 men and women aged 45-64 years
(Folsom et al, 1991) reported that factor VII activity was elevated in women compared
with men. An increase in factor VII activity of 4% per decade was seen only in women.
Increases in body size, triglycerides, LDL and HDL cholesterol concentrations were all
accompanied by higher factor VU activity in all subjects.
The relationship between factor VU concentrations and coronary artery disease severity
was examined in patients with similar degree of atheroma, some of whom had survived a
prior MI (Broadhurst et al, 1990). Those who had suffered prior infarction had
significantly higher concentrations of factor VU activity.
Seasonal influences affect factor VU activity (Woodhouse et al. 1994), and the elevation
of factor VU activity in older people throughout the winter months has been related to
their increased risk of cardiovascular death in this period. The influence of habitual
alcohol intake is unclear. Alcohol intake has been shown to have no significant effect on
factor VU activity in the Scottish Heart Health study (Lee et al, 1995), but was
negatively related with factor VU activity in the Atherosclerosis in Communities study
(Folsom et al, 1991).
3.1.4 Relationship between factor VII activity and plasma lipids
The Northwick Park Heart study was important as it identified the strong associations
between factor VU activity and the incidence of coronary artery disease (Meade et al,
1980, 1986). Raised plasma cholesterol concentrations were also related to the
development of llID, but the associations were stronger for factor VII activity and llID.
A positive correlation was observed between factor VU activity and both plasma
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triglyceride and cholesterol concentrations. Epidemiological studies have also found
similar relationships (Prospective Cardiovascular Munster study, Atherosclerosis in
Communities study, MONICA, Caerphilly). The strongest associations in Northwick
Park Heart study were seen with triglyceride rich chylomicron and VLDL (Mitropoulos
et al, 1989). Plasma factor VII activity is determined largely by the circulating
concentrations of factor vn antigen (a measure of total factor VII protein) which is also
associated with plasma lipids. A cause and effect relationship has been seen between
factor VII activity when lipid lowering is achieved, by using either diet or medication
(Simpson et at, 1983,Wilkes et al. 1992).
A study of 3,000 patients with angiographically determined angina pectoris reported that
factor VII activity and plasminogen increased in parallel with concentrations of
cholesterol and triglycerides (BeAT, 1993). The role of dietary manipulation on factor
vn activity and plasma lipids will be considered later.
3.1.5 Factor VII activity, body mass index and physical activity
The results from the Northwick Park Heart study have been very important in identifying
the positive link between factor vn activity and body weight (Meade et al, 1986).
Changes in factor vn activity were correlated with weight changes after the study
population had undergone repeated measures (Meade, 1987). The Atherosclerosis in
Communities study also related increased factor VII activity with increased BMI
(Folsom et ai, 1991).
A positive association was found between BMI with factor VU activity. The difference
in factor VII activity between subject groups of mean BMI of 23 kglm2 and those of
mean BMI > 30 kg/m
2
was close to 10% (Balliesen et al, 1987). Clinical studies have
confirmed these epidemiological findings (Yang et al, 1993, Avellone et al, 1994, Poggi
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et al, 1994). However, the relationship of increasing factor VU activity with BMI was
not seen in subjects with angina (ECAT, 1993). The reasons for this are unclear,
although the positive relationships between plasma cholesterol and triglyceride observed
in the other studies were still present.
The role of central obesity on factor VU activity, as measured by an elevated WHR has
been investigated (Licata et al. 1995). Nineteen overweight subjects, with a raised WHR
> 0.81 for women, > 0.92 for men and mean BMI of 36.3 kg/m' and 20 lean subjects
(mean WHR 0.75) mean BMI 23.3 kg/m' were examined. Factor VU activity was
elevated in the obese group with the elevated WHR compared with the lean group. The
differences between the two values for factor VU activity were significant 79 SD (11%)
and 105 SD (18%) (Licata et ai, 1995).
Physical activity as a regular part of lifestyle has shown important effects on factor VU
activity. The higher the frequency of reported physical activity the lower the factor VU
activity (Connelly et al. 1992). The beneficial effect of regular moderate physical
activity on factor VU activity was also noted in the Caerphilly prospective study (Elwood
et ai, 1993). In both cases the factor VU activity measurements were not made
immediately after physical activity and thus did not reflect acute changes. This was
important as immediately post physical activity an acute increase in fibrinolysis and
coagulation has been observed (Schobersberger et al, 1996).
3.1.6 Weight loss and factor VII activity
Some dietary intervention studies have examined the impact of weight loss on factor VU
activity using a number of different approaches. They have all shown an elevation in
factor VU activity with increased BMI. Folsom et al, (1993) used an energy restricted
diet to achieve weight loss in overweight men and women of mean BMI 31 kg/m', After
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a 6 month period a weight loss of 9.5 kg was accompanied by an 11% fall in factor VU
activity.
Weight loss achieved using a short term VLCD approach has shown more acute effects
on factor VU activity. A 4.3% weight loss over a 7 day intervention period lowered
factor VU activity by 26% in subjects whose starting BM! was 32.7 kg/m' (Slabber et al,
1992). Longer term use (3 month) of a VLCD in 52 subjects whose mean BM! was 35
kg/m2 in women and 40 kg/m' in men, improved mean body weight by 17% and factor
VU activity by 23% (palareti et al, 1994). However, not all studies of weight loss have
significantly altered factor VU activity. The use ofVLCD in 20 women with polycystic
ovary disease whose mean BM! was 34 kg/m2 achieved an 8.0 kg weight loss and factor
VU activity was unchanged (Andersen et al, 1995). A 3.5 kg weight loss at 1 month and
4. 2 kg was achieved loss over a 3 month period, using a dietary intervention of 1000-
1200 kcal daily in 135 subjects (Baron et al, 1989). Factor VU activity decreased at 1
month, but rose back to baseline levels at 3 months. These results suggest weight loss
alone does not explain the relationship between obesity and factor VU activity (table
3.1).
3.1.7 Factor VII activity and physical activity intervention for weight loss
A combined physical activity and smoking cessation intervention was used in young men
and achieved a weight loss of close to 4.0 kg, with a significant fall in factor VU activity
(Gris et al, 1990). The results were not adjusted for the effect of smoking. In contrast,
no improvement in factor VU activity was seen after an intervention to improve the
frequency of physical activity and lower dietary fat intake in a study of healthy middle
aged men (Rankinen et al, 1994a). The authors concluded that any benefit from physical
activity is likely, at best, to reflect a temporary change in coagulation measures.
However, the subjects within the latter study remained weight stable, and the benefit of
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physical activity may have been effective through weight loss (Oris et al. 1990,
Rankinen et al, 1994a).
3.1.8 Factor VII activity and surgical intervention for weight loss
Surgical means to achieve weight loss result in much greater weight loss than dietary
interventions (Pories et al, 1992). A 50.0 kg weight loss was achieved by subjects of
mean weight 154 (SD 27) kg after a 6 month period, a further 14.0 kg weight loss was
achieved after 12 months. Factor VU activity was decreased by 20% at 6 months, from
113 to 90% but increased to 99% at 12 months despite the continued weight loss
(primrose et al, 1992). These studies point to an effect of acute energy restriction to
reduce factor VU activity, independent of sustained effects from weight loss.
3.1.9 Factor VII activity and dietary fat composition
Factor VU activity is increased by hyperlipidaemia and by consumption of a high fat diet.
It has been well established that diets that are high in saturated fatty acids raise total
plasma cholesterol (Hegsted et al, 1965, Keys et al, 1965) and are associated with
increased llID risk (Schonfeld et ai, 1982). The increased intake of saturated fatty acids
has also been shown to elevate factor VU activity. A randomised cross over study
compared 2 controlled iso-energetic diets which provided either 20% or 50% of energy
from fat on the effect on factor vn activity (Bladberg et al, 1994). The two diets were
served on consecutive days to 17 young volunteers of mean BM! 21.8 kg/m2 and factor
VU activity was measured at 1.5 hour intervals postprandially throughout the day. The
high fat diet elevated factor VU activity by 6 to 15%when compared to the low fat diet.
The effect of a low fat high fibre diet on factor vn activity was examined in a longer
study (Marckmann et al, 1992). Young healthy men were randomised to receive either a
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low fat, high fibre diet for 8 months or a "control" diet which was the usual Danish diet
and provided close to 40% energy from fat. However, while remaining weight stable the
factor VU activity in the group following a low fat diet (26% energy from fat) decreased
by 5-10% during the first two and fmal months of the study. In the intervening months
factor VU activity displayed considerable variation across the study.
Miller et al, (1986) examined the effect of a diet providing 13% or 62% energy from fat
on factor VU activity. Sixty two middle aged men were allocated to receive each weight
maintenance diet in turn using a crossover design and both factor VII activity and total
factor VU antigen were measured. Each diet was followed for 3 weeks after which the
plasma factor VU activity was 16% higher on the high fat diet, though total factor VII
antigen concentrations were unchanged. Plasma cholesterol was significantly decreased
and triglyceride increased after the high carbohydrate low fat intervention. To examine a
more acute effect of dietary fat on factor VII activity Miller and colleagues (1986)
examined individual day to day fluctuations in both dietary fat intake and factor VII
activity. The values for factor VII activity were examined as standard deviations about
individual mean values measured across the duration of the study. This representation of
the findings demonstrated a strong positive association between factor VII activity and
total dietary fat consumption.
A larger study also examined the influence of dietary fat intake on plasma lipids and
factor VU activity (Miller et al, 1989). The results indicated that dietary fat and plasma
triglyceride concentrations were both independently and positively related with factor
VII activity. For the highest and lowest dietary fat intakes factor VII activity differed by
13%. This difference was comparable to the that seen between factor VII activity in
those who suffered MI in the Northwick Park Heart study and those who remained well
(Meade, 1987).
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The influence of fat type on total factor vn antigen has also been investigated. Five
healthy adults were asked to consume either a high fat diet, high in unsaturated fat (63%
total energy from fat, and of that 68% from unsaturated fatty acids) or a high saturated
fat diet (62% total energy from fat, and of that 85% from saturated fatty acids) or a low
fat diet which provided 15% energy from fat (Mitropoulos et al, 1994). The diets were
each fed for 4 weeks using a crossover design and included a 12 week washout period
between diets. Factor vn activity was raised by 13.1% following the high saturated fat
diet and by 6.5% after the unsaturated high fat diet and the results from both
interventions were compared to the factor vn activity after following the low fat dietary
regimen. Plasma stearic acid was particularly strongly associated with factor VII
activity, suggesting an in vivo role for saturated fatty acids in increasing the coagulability
of blood. Interestingly, factor VII antigen was significantly increased only after the
consumption of the high saturated fat diet, suggesting a role for unsaturated fatty acids in
reducing total factor vn protein.
A long term cholesterol-lowering diet was implemented in premenopausal women
(Brace et al, 1994). The subjects were advised to consume sufficient energy in order for
them to maintain their body weight. Dietary energy from fat was decreased to 30% from
36% and the change was maintained for 20 weeks. An 11% improvement in factor VII
activity was observed over the study period though no change was observed in total
factor vn antigen. These findings suggest a benefit from a diet low in both saturated and
total fat on llID risk.
The habitual consumption of a high fat diet has been established as leading to elevated
total factor VII activity and antigen (Marckmann et al, 1990). An increase in factor VII
antigen was shown in habitual consumers of a high compared with low fat diets (Miller
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et al, 1994). A diet which provided less than 28g day -1 Im-2 per day fat was deftned as
low fat while a diet providing >39.9 g day -1 Im-2 high fat.
3.1.10 The influence of polyunsaturated to saturated fat ratio and specific fatty
acids on factor VII activity
The effect of different PIS ratios on factor VII activity was examined using a low (0.3)
and a high PIS ratio diet (3.0). The usual UK diet has a PIS ratio close to 0.7 (Gregory et
al. 1990). The study subjects were each given experimental dietary advice in line with
their usual dietary energy intake. Each diet was followed for 7 days including a 7 day
washout period between the diets. No changes were seen in factor VII activity, or in
total factor VII antigen (Miller et ai, 1989). Two diets with widely differing PIS ratios
0.28 or 0.89 have been compared (Marckmann, et aI1990). Each diet was consumed by
healthy non obese volunteers for a period of2 weeks, both provided 32% from fat. Both
dietary regimens signiftcantly lowered factor VII activity by 11% and 14% respectively
compared with the usual dietary intakes comprising 40% energy from fat. No effect
from fat type on factor VII activity and antigen was observed. Lipid proftles were
improved with a signiftcant fall in triglyceride concentrations on both regimens, however
plasma cholesterol concentrations fell only in the group consuming the high PIS ratio
diet.
Early work by Hegsted (1965) examined the cholesterolaemic effects of different fatty
acids. Stearic acid, a signiftcant contributor to saturated fatty acid intake, was found not
to affect total plasma cholesterol. However, other fatty acids rich in foods such as lauric,
palmitic and mystic acids were hypercholesterolaemic (Hegsted et al, 1965). The role of
specific fatty acids on factor VII activity has also been considered. Early studies have
indicated effects of various fatty acids on thrombogenesis, as well as elevating plasma
lipoproteins. Saturated fatty acids have been reported to shorten thrombus time though
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actual thrombogenicity was lowered with decreasing carbon chain length (Hegsted et aI,
1965).
The effects of high intakes of specific saturated fatty acids on factor vn activity have
been considered (Tholstrup et al, 1994a) using carefully prepared diets rich in stearic,
palmitic, mystic and lauric acids. Slim, healthy, young male subjects were randomised
to one of 3 experimental diets within a controlled metabolic feeding study. One diet
provided 42% stearic acid, one 43% palmitic acid, and a third 10% mystic acid and 30%
lauric acid. For all diets the total percentage energy from fat was 40%, with 90% of the
total fat energy provided from the test fats. The diet high in stearic acid lowered factor
VU activity by 13% over a 3 week intervention. Factor VU activity was unaffected by
the two other diets. Another study by the same authors compared the effect of mystic
and palmitic saturated fatty acids on factor VU activity (Tholstrup et al, 1994b). The
study design required that each fat was given in a synthetic form in order to provide 40%
energy from total fat, and 41% of the total fat from either palmitic or mystic acids. Both
of the saturated fatty acids significantly raised factor VU activity by 2% and 4%
respectively, with no differences in their cholesterolaemic effects. A more recent study
(Tholstrup et al, 1996) examined the short term effects (over 24 hours) of a high fat meal
containing either stearic or mystric acid. Stearic but not mystric acid tended to cause
some increase in factor VU coagulant activity. These results are at odds with another
study which suggested that mystic acid was mainly responsible for the
hypercholesterolaemic effects of saturated fatty acids (Hayes et al, 1991).
3.1.11 The role of the consumption of fish and omega three fatty acids on factor VII
activity
Cross-cultural (Armstrong et aI, 1975) and prospective studies (Kromhout et al, 1985,
Shekelle et al, 1985, Norell et aI, 1986, Burr et al, 1989) have suggested an inverse
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relationship between fish intake and llID. One of the possible theories to explain this
relationship has been "hypercoagulability" as measured by increased plasma factor VU
activity and fibrinogen concentrations. Others theories have included the effects of fish
intake on the fibrinolytic system, improvements in the lipid profile, or decreased platelet
aggregation.
The influence of fish intake and dietary n-3 fatty acid intake on factor vn activity were
examined in the Atherosclerosis in Communities study (Shahar et al, 1993). The three
principle n-3 fatty acids within the diet are EPA, DHA and DPA. Usual intakes were
estimated using a FFQ method. No significant associations were seen between either of
the fatty acids and factor VU activity, or between the dietary polyunsaturated fatty acids
derived from the intake of fish and other seafood and factor VU activity. Muller et al
(1989) examined the effect of supplementing the diet of 40 healthy volunteers with
mackerel (intervention) and meat paste (control) for a 6 week period. Factor vn antigen
or VU activity were unaffected by dietary supplementation.
3.1.12 Conclusion
Total fat intakes influence strongly both factor vn activity and protein. The long term
consumption of a diet high in saturated fatty acids has been associated with increases in
both factor vn activity and factor VU protein, though in the short term factor vn activity
is principally affected. The role of polyunsaturated fatty acids on factor vn is
conflicting and some studies have reported a beneficial effect on factor VU activity. In
addition, specific saturated fatty acids, such as stearic, have been shown to have varying
effects on both factor VU activity and factor vn antigen. However, the reduction of total
dietary fat intake results in a significant improvement in factor VU activity and total
plasma cholesterol and triglyceride concentrations. The effect of manipulating dietary
96
fat composition appears much less influential. Weight reduction has at least as great an
effect as lowering dietary fat intakes. However, in the majority of intervention studies
weight loss has been achieved by changes in dietary composition and energy intake and
moderate physical activity. Though it is the intervention as a whole which must be seen
to have influenced these coagulation measures as it is impossible to separate the
influences of both change in diet composition and decrease in energy intake.
3.2 The fibrinolytic system in haemostasis
The coagulation of blood is a carefully controlled and reversible process which prevents
the loss of blood from injured vessels. The fibrinolytic system is the back up or fail safe
system which becomes initiated when fibrin is being formed (Kay, 1988). The
fibrinolytic system (figure 3.2) comprises three major protease enzymes, plasmin, t-PA
and u-PA and the rapid inactivator PAl. The three fibrinolytic enzymes are homologous
and the inactive zymogens exist as single chains whilst their active forms have two
carbon chains held together by disulphide bonds.
Plasminogen is a single chain glycoprotein with a plasma concentration of 1.5-2.0 umol/l
and a half life of approximately two days. Plasminogen becomes adsorbed onto either
fibrinogen or fibrin molecules at their lysine binding sites. Only fibrin molecules
possess a specific binding site for t-PA. The plasminogen bound to fibrinogen then
becomes unavailable for t-PA activation and very little plasminogen activation occurs
(Hoylaerts et ai, 1982).
The plasma concentrations of t-PA are produced almost entirely by the vascular
endothelial cells, whilst the less abundant endothelially produced activator u-PA is
present in urine, tears, saliva and plasma (Bachman, 1994). Unlike t-PA, u-PA does not
97
have a specific fibrin binding site and can activate plasminogen in its absence. It is
likely that u-PAis valuable in maintaining clear ducts and tubules, such as in the kidney,
and limiting the amount of insoluble fibrin which remains in the circulation and tissues
(Kay, 1988). Innormal plasma, the concentration oft-PA is 70 pmol/l with a halflife of
5 minutes (Booth et al, 1990). About 15% of total t-PA is in the active form and the
remainder exists complexed together with PAl. An acute rise in t-PA concentrations
results from a number of stimuli such as physical activity, venous occlusion and
catecholamines (Prowse and MacGregor, 1988).
PAl is a rapid inactivator of both t-PA and u-PA and is present in the plasma with a half
life of 7 minutes (Booth et al, 1990). The presence of the inhibitor PAl was first
confirmed using immunohistochemical techniques and is now known as PAl-I, as
another inhibitor PAI-2 has been detected (Chmielewska and Wiman, 1986). Almost
90% of the PAI-l in the blood is present within platelets whilst the remainder is present
within endothelial and liver tissues (Sprengers and Kluft, 1987). Inthe tissues almost all
the PAI-l is active compared with only 3% - 5% in platelets (Booth et al, 1990). PAI-l
is released from platelets by thrombin, which increases platelet aggregation, limits
plasmin formation and favours fibrin deposition. The normal plasma concentrations of
PAI-l are 20 - 100 pmol/I.
The fibrinolytic activity of plasma varies throughout the body, depending on the site and
the response from different stimuli but in general, fibrinolytic activity is greatest in the
arterial system. Altered fibrinolysis has been observed during pregnancy, where high
levels of PAl -1 and PAI-2 are measured in the neonate. Increased PAI-l concentrations
are also observed following trauma and surgery. Reduced fibrinolytic activity has been
noted in obese subjects, those on prolonged bed rest and in women using the oral
contraceptive agent. Post surgically the reduction in fibrinolysis probably represents the
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exhaustion of fibrinolytic components following their activation in response to thrombus
formation.
Tests to measure fibrinolytic potential after stimuli such as physical activity or venous
occlusion have been developed. Only a small increase in t-PA is required to completely
overwhelm the low levels of PAI-l normally present (Prowse and MacGregor, 1988).
Using the venous occlusion test it has been shown that some people who are termed
"non-responders" have elevated PAI-l activity (Nilsson et al, 1985). The inhibition of
released t-PA in this situation results in increased PAl-I. PAI-l behaves as an acute
phase reactant (Juhan-Vague et al, 1985, Kluft et al, 1985) and is raised in a number of
pathological conditions including diabetes and llID (Juhan-Vague et al, 1984, 1988).
However, impaired fibrinolysis is usually a result of either a decrease in t-PA synthesis
or an inactivation of t-PA and to a lesser extent u-PA (Kay, 1988). The analysis of
different components of the fibrinolytic system such as PAI-l and t-PA are relatively
recent. They supersede more crude earlier measures of overall fibrinolytic activity such
as clot lysis time or euglobulin lysis measured by a fibrin plate method (Meade et al,
1980, Wilhelmsen et al, 1984). Epidemiological studies such as Northwick Park Heart
study and the Gothenburg study have continued using these methods to ensure long term
follow-up data from their populations remains comparable. Some studies report the
antigen or activity of both t-PA and PAl-I, and others report overall clot lysis time.
Table 3.3 includes the results of studies of weight loss and the fibrinolytic system.
3.2.1 Fibrinolytic system and ischaemic heart disease risk
Several cross-sectional studies have shown an association between increased fibrinolytic
activity and nm but they cannot establish which comes first (Chakrabarti et al, 1968,
Hamsten et al, 1986, Francis et al, 1988, Jannson et al, 1993). Early reports from the
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Northwick Park Heart study suggest an association between impaired fibrinolytic activity
and increased llID incidence, albeit not as strong as that for fibrinogen and factor VII
activity. This is perhaps due to the few incidents recorded in younger men (Meade et al.
1980, 1986). Longer term follow-up of the Northwick Park Heart study reports a strong
and independent relationship between low fibrinolytic activity and IHD incidence, whilst
still supporting the other positive relationships between fibrinogen and factor VII activity
(Meade et al. 1993). In the Gothenburg study, euglobulin lysis time was used to
establish global fibrinolytic capacity and this was found not to be related to llID
incidence at baseline (Wilhelmsen et al. 1984). In contrast, another study which
examined euglobulin lysis time in survivors of acute MI found a reduced lysis in those
who suffered reinfarction (pedersen et al. 1993).
Raised PAl activity has been found in those with diabetes (Juhan-Vague et al. 1989a)
hypertension (Landin et al. 1990) and angina pectoris (Yudkin et al. 1987, Juhan-Vague
et al, 1989b) which are sub groups of the population all known to be at increased risk of
llID. The European Concerted Action on Thrombosis study reported an association
between decreased fibrinolytic activity due to high levels of PAI-1 and increased
coronary stenoses (ECAT, 1993). In atherosclerotic patients, fibrinolytic activity is
probably decreased due to an increase in PAI-1 and therefore a decrease in t-PA (Collen
and Juhan-Vague, 1988). PAI-l has been reported to be a risk factor for recurrent MI
(Hamsten et al. 1987). A recent review concluded that raised PAI-1 concentrations and
hypertriglyceridaemia may predispose diabetics to coronary thrombosis and an increased
incidence of atherosclerosis and nm (Rocha and Paramo, 1994).
Circulating t-PA in the fibrinolytic system has generally been thought to offer protection
against llID. However, the findings of a recent study in those with angina have indicated
that a greater t-PA mass was associated with a greater risk of mortality. These
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contrasting observations probably reflect the increased t-PA concentrations due to the
raised concentrations of t-PA / PAI-l complexes which was seen in subjects with
increased total concentrations of inhibitors (Jansson et al, 1991, 1993). In a random
healthy population, raised insulin concentrations have been associated with lowered t-PA
and raised PAI-I concentrations (Eliasson et al, 1994a). This relationship has previously
been proposed as the missing link between insulin resistance and atherothrombosis
(Juhan-Vague et al, 1991). A positive relationship between llID risk factors has been
reported with factor vn activity, fibrinogen and PAI-l activity being positively related to
each other and to the sex hormones testosterone and oestrodiol (Yang et al, 1992).
3.2.2 Other influences on the fibrinolytic system
Dyslipidaemias have been associated with alterations in factor VII activity (see section
on lipid and coagulation and haemostasis) and PAI-l activity (Zitoun et al, 1996).
Smoking has been associated with increased PAl activity, BM! and plasma triglyceride
concentrations (Oudenhoven et al, 1994). Regular physical activity improves
fibrinolysis, though this has also been associated with reductions in body weight (Gris et
ai, 1990).
3.2.3 The fibrinolytic system and body weight
Concentrations of PAI-1 correlate closely with BM! (Vague et al, 1986, Sundell et al,
1989) and are greatest in those with a central fat distribution measured by WHR (Vague
et al, 1989). The role of fat distribution was also examined in obese and lean middle
aged women with either a high or low WHR. Raised WHR was associated with raised
PAI-I, and negatively related to insulin sensitivity (Landin et al, 1990). Both euglobulin
lysis time and PAI-1 were positively correlated with BM! (Urano et al, 1993). The
European Concerted Action on Thrombosis study demonstrated an increase in PAI-l
activity with increased BM! in angina subjects (ECAT, 1993),
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The long term effect of major weight loss on the concentrations of fibrinolytic factors t-
PA and PAI-1 was examined in 45 subjects 14-20 years postjejuno-ileal bypass surgery.
The PAI-1 and t-PA concentrations in post surgical patients (mean BM! 30.2) were
compared with those in other 10 obese subjects (mean BM! 44.0). The PAI-1 and t-PA
antigen concentrations were raised in the obese subjects compared with the post surgical
groups by 74% and 40% respectively (Sylvan et al, 1992).
3.2.4 The fibrinolytic system and weight loss
Weight loss in overweight subjects improves fibrinolytic capacity by decreasing PAI-l
activity (Andersen et al, 1988). A physical activity regimen for men aged 20-30 years
with mean BM! of 26.5 achieved a 5% weight loss and a 42% reduction in PAI-l
activity. These changes were the result of exercise as dietary advice was not included in
the study (Gris et al, 1990). A moderately restricted energy regimen in males (mean
BM! 24.6 kg/m2) showed benefits on both PAI-1 and t-PA antigen, and PAl activity
CVelthuis-te-Wierik et al, 1995). Other studies of the effects of body weight reduction
on t-PA antigen and PAI-l activity have been inconclusive (Palareti et al, 1994).
3.2.5 The fibrinolytic system and diet composition
The fibrinolytic system could theoretically be influenced by nutritional factors in a
number of ways, either by the dietary components which affect circulating constituents
of the system, or by becoming adsorbed onto the vascular endothelium (Ogston, 1985).
The reported studies have concentrated on changes of diet composition and examined the
effects on the fibrinolytic factors. The effect of different fat loads (saturated fat, n-6
polyunsaturated fats) on fibrinolytic activity has also been examined (Salomaa et al,
1993). Increased PAI-l activity and antigen were associated with total and VLDL
triglycerides during fasting and during post prandial lipaemia, though no effect of fat
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type was observed. These results concur with findings from other similar studies
(Heinrich et al, 1990, Tholstrup et al, 1994a, b, Rankinen et al, 1994a, b). A moderate
reduction in dietary fat intake (from 35 to 30% energy) was not associated with any
significant changes in the components of the fibrinolytic system (Marckmann et al,
1992). However, an 8 month study of a low fat diet (26% energy from fat) was
associated with a 50% improvement in fibrinolytic capacity measured by increased t-PA.
The beneficial effects of a high carbohydrate dietary intake were shown in a study of the
relationship between habitual diet and cardio-respiratory fitness (Rankinen et al, 1994).
Positive relationships between PAI-l and t-PA antigens and dietary fat intake, in contrast
with negative relationships with increased carbohydrate intake were found.
The effect of fruit and vegetable consumption were examined using a FFQ in a cross
section of healthy subjects (Nilsson et al, 1990). The highest tertile of fruit consumption
was associated with lowered PAI-1 activity in comparison with the 2 lower tertiles. The
concentrations oft-PA antigen were unchanged across groups showing improvements in
the fibrinolytic system. Although dietary fat composition does not significantly improve
the fibrinolytic system, moderate alcohol intake was beneficial and increased t-PA
antigen concentrations (Lee et al, 1995).
A 6 month supplementation study (a daily supplement of 4 g 0>-3 fatty acids) in
hypertriglyceridaemic post coronary bypass patients examined their effect on fibrinolysis
(Eritsland et al. 1994). An increase in PAI-1 activity was the only significant change
which concurs with the fmdings of a previous study (Hellsten et al, 1993). A crossover
study compared the effects of a fish supplemented diet (210 g fatty fish daily) with a diet
in which the fish was replaced by an equivalent amount of lean meat. Fish increased
PAl-I, PAI-1 antigen and reduced t-PA activity and increased t-PA antigen, whereas
with the meat diet they remained unchanged (Marckmann et al, 1991).
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3.2.6 Conclusion
The fibrinolytic system and components have been established as risk factors for UID,
and are also affected by a number of chronic diseases. For overweight subjects, a
reduction in body weight is associated with increased fibrinolytic activity. The effect of
dietary changes, particularly the reduction in fat intake, and also increases in fruit,
vegetables and fish consumption have been associated with increased fibrinolytic
activity. There is sufficient evidence that large weight losses improve fibrinolytic
activity, although the effect of moderate weight loss remains unclear. The effect of
moderate weight loss on t-PA antigen and PAl activity in overweight subjects requires
further study.
3.3 The haemostatic and fibrinolytic systems and plasma lipids
3.3.1 Relationship between plasma lipids and coagulation factors
The association between raised plasma lipids, most frequently triglyceride, and risk
factors for llID have been well established (Meade et ai, 1980). However, the exact
nature of the relationships between the haemostatic factors and llID risk are less clear.
The presence of a positive relationship between plasma factor vn activity and
triglyceride in middle aged subjects has been reported (Miller et ai, 1986, Mitropoulos et
ai, 1989, Mitropoulos, 1994). A recent large survey of cardiovascular risk factors
confirmed these relationships in an elderly population (Cushman et al, 1996). Raised
triglyceride concentrations have been shown to be associated with increased body size
and LDL cholesterol concentrations (Folsom et al, 1993). Other researchers have
identified a positive relationship between triglyceride concentrations and factor VU
activity (Mitropoulos et ai, 1989). The liver, the source of the majority of the
haemostatic factors and lipids, may mediate any links, although scant evidence exists of
a causal relationship between the coagulation and lipid systems. This relationship is
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thought to have become influential on the incidence of MI when the presence of
atheromatous plaques or sites of vascular injury were present in addition to elevations in
factor VII activity (Krauss et al, 1991). The hepatic synthesis of both the coagulation
factors including factor VII activity, and the lipid fractions could be related. The
relationship between factors noted here has been known to be open to confounding by
factors including age and cigarette smoking.
3.3.2 Relationship between plasma lipids and plasma fibrinogen concentrations
Plasma fibrinogen concentrations and LDL cholesterol fractions have been positively
associated (Wilhelmsen et al, 1984, Balleisen et al, 1985, Lee et al, 1990). Although,
once more there are no fmdings to support this relationship as being causal. Weaker
associations than for fibrinogen concentrations have been seen between LDL cholesterol
and factor VII activity (Balleisen et aI, 1985, Miller et al, 1986, Baron et a/1989). Falls
in factor VII activity, but not fibrinogen concentrations, have been associated with
weight loss (Folsom et al, 1993) and therefore any direct link between LDL cholesterol
and fibrinogen appears unlikely.
3.3.3 Relationship between plasma lipids and fibrinolytic factors
The significant correlations between the changes in LDL cholesterol and the fibrinolytic
factors are interesting although they must be interpreted with care, as the causality of
these relationships cannot be identified. The LDL cholesterol fraction has been well
established as the most atherogenic major cholesterol fraction (Pyorala et al, 1994).
Raised LDL and lowered HDL concentrations have been associated with increased risk
of MI (Castelli, 1996). The concentration of LDL cholesterol has been shown to
increase with advancing age particularly in post-menopausal women (Hallberg et al,
1967). Obesity and overweight are also well established factors in raising LDL and other
lipid fractions (Dattilo and Kris-Etherton, 1992). Plasma triglyceride concentrations
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have also been related with increased plasma PAl activity (Tikkanen, 1996). The
development of atherosclerosis has been described as the route by which the LDL
promotes llID (Castelli, 1996). The LDL cholesterol fraction has been proposed as the
lipid fraction related most closely with haemostatic factors (Lowe, 1996 personnel
communication).
The relationship between PAl activity, risk factors for llID and the metabolic syndrome
have been supported by research findings (Eliasson et al, 1994a). PAl activity has been
correlated with low HDL concentrations, hyperglycaemia and hyperinsulinaemia.
Concentrations of PAl have been shown to decrease with falls in insulin concentrations
(Vague et al, 1986) and in WHR (Landin et al, 1990). Falls in PAl activity have also
been associated with weight loss (Folsom et al, 1993). No relationship was found
between the changes in HDL or total cholesterol or triglycerides with PAl, in contrast to
the fmdings of a larger study (Eliasson et al, 1994b). The small range in the triglyceride
concentrations already discussed may partly explain the non significant relationship
between triglycerides and PAI. Thus, the mechanism by which weight loss results in the
lowering of both LDL cholesterol and PAl activity are unlikely to be shared, and the
relationships not causal. The relationship between t-PA and PAl activity has been
described as very close, possibly as they are usually found complexed together in vivo
(Pearson et al, 1997). The measurement of t-PA antigen has been associated with
reduced fibrinolysis (Thompson et al, 1985). The majority of points which have been
considered for PAl activity remain relevant to t-PA antigen.
3.3.4 The use of hormone replacement therapy and lipid lowering therapy to
examine inter relationships between lipids, fibrinolytic and haemostatic
systems
The use of exogenous hormones as part of HRT treatments in post-menopausal women
has provided some insight into the relationship between the haemostatic and lipid
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systems. The use of synthetic oestrogen and progesterone therapy has been associated,
in some cases, with increased liver synthesis of the haemostatic factors, factor VU and
plasma fibrinogen concentrations and plasma triglyceride (Alkjaersig et al, 1980). The
area has recently been reviewed (Tikkanen, 1996) and it was concluded that exogenous
HRT therapy has separate effects on the haemostatic and lipid systems. However, no
effects on LDL cholesterol or total cholesterol concentrations were seen. The use of
lipid lowering therapy was another setting where the relationship between the lipid and
haemostatic system has been considered. Simvastatin, (20 or 40 mg / daily), was given
to hypercholesterolaemic subjects using a randomised controlled double blinded study
design (Mitropoulos et al, 1997). Haemostatic measurements were made following 2
years of lipid lowering therapy. There were significant falls in LDL and total cholesterol
and triglyceride in those receiving medication compared with control subjects.
However, PAI-1 increased significantly on lipid lowering therapy, whilst factor VU
antigen fell significantly. The general failure of simvastatin therapy, which lowered
plasma lipids, to affect haemostatic and rheological factors suggests the relationship
between the haemostatic and lipid pathways to lHD may not be closely linked. In
contrast, fibric acid derivatives, such as bezafibrate, lower fibrinogen by close to 20%
and also lower plasma triglycerides and cholesterol concentrations (Almer et al, 1988).
In this latter case, it was suggested once more that it was impossible to separate the
effects on fibrinogen from those on plasma lipids. However, early results from a still
ongoing bezafibrate study suggest that the changes in fibrinogen are only weakly
correlated with those changes in plasma cholesterol concentrations (Meade, 1995) .
3.3.5 Conclusion
Alterations in the fibrinolytic and coegulatlon systems often coexist alongside an altered
lipid system. Raised triglycerides are seen alongside altered concentrations of
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fibrinolytic and coagulation factors. Both components have been established as risk
factors for ll-ID, and also are raised in a number of chronic diseases. Plasma LDL
cholesterol concentrations are particularly associated with altered concentrations of
fibrinolytic and coagulation factors, changes which are shown in both overweight and
high risk coronary risk subjects. The reduction of body weight results in improvements
in both these areas, although no evidence concerning whether these relationships may, or
may not, be causal exists. The relationship between moderate weight loss on lipid and
haemostatic pathways may be used to clarify the overlaps between these important
physiological systems.
3.4 Haemorheology
Rheology is the branch of physics concerned with the flow and change of shape of
matter, especially the viscosity of liquids. The branch of rheology study known as
haemorheology concerns the influence of blood cellular and plasmatic components on
the circulation (Dintenfass, 1971). The flow of blood is remarkable. At its minimum it
has a viscosity of only 1.8 times that of water even though close to half of the volume is
composed of cells (Dintenfass, 1971). The processes of cellular concentration,
aggregation, deformation and hence viscosity are all components ofhaemorheology.
Blood rheology with emphasis on the relationship between viscosity and flow in arterial
disease was reviewed using laminar flow principles to describe the flow in a tubular
blood vessel (Lowe, 1986). Laminar flow exists when parallel "layers" of blood have
different velocities relative to each other (figure 3.1). Each layer undergoes shearing
when passing over another. The outer layers have a low velocity and high shear rate
compared with the high velocity and low shear rate of the inner layers. The frictional
resistance to blood flow (its viscosity) due to molecular interactions falls with increases
in temperature. Viscosity in laminar flow is the ratio of shear stress (the applied force
per unit area) to shear rate (the velocity gradient between adjacent layers) (Lowe, 1986).
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Thus, the greater the viscosity of the liquid, the greater the shear stress required to
maintain the shear and flow rates. Viscosity and flow rate have been represented as:
Viscosity (mPa.s) = Shear stress (mPa)
Shear rate (S-l)
Flow rate a.= pressure gradient x tube radius
tube length x fluid viscosity (Lowe, 1986)
Flow in a tube depends on both driving pressure and a resistance factor which is affected
by the tube length, radius and the intrinsic blood viscosity. Erythrocyte defomability and
plasma viscosity are the main determinants of blood viscosity when measured at high
shear rates (Dintenfass, 1971). In vitro viscosity measurements can be made at a variety
of shear pressures which can mimic the in vivo situation when shear stresses are lowered
in the larger compared with the smaller vessels (Lowe, 1987, Schmid-Schonbein, 1981).
A variety of different shear rates can be applied. The measurement of whole blood
viscosity at high shear rates (over 300 S-l) at 370 C becomes an asymptotic value, where
viscosity measurements reach a plateau and further rises in shear rate were no longer
influential (Lowe et al, 1996) (personal communication). The measurement of viscosity
in a viscometer has limited in vivo application given the many different sizes and types
of vessels through which blood flows (Schmid-Schonbein, 1981). The additional and
complementary measurements of haematocrit, plasma viscosity and RCA allow a fuller
interpretation of viscosity measurements.
3.4.1 Blood viscosity
The haematocrit or packed cell volume has been identified as the principal determinant
of viscosity although the presence of plasma proteins and erythrocyte defomability are
important. Within perfused capillaries erythrocytes deform and adopt a cigar shape, and
travel more rapidly than plasma to lower the apparent haematocrit. The RCA due to
109
rouleaux and associated networks provide blood's structural framework and strength of
the RCA may increase the viscosity of the blood.
The shear stresses throughout the human circulation vary widely. They are low in
arteries under conditions of normal arterial pressure (2.0 Pa), higher in the arterioles and
highest in the smallest nutritive capillaries (10 Pa) (Lowe, 1988). Blood that has flowed
from the arterioles to the post capillary venules (0.2-0.5 Pa) is subjected to increasing
shear stresses in the larger veins and back to the heart. However, in all normal blood
vessels the shear stresses are such that the blood becomes a low viscosity fluid (1.2-4.0
rnPas) (Schmid-Schonbein, 1982).
The hyperviscosity syndromes of paraproteinaemias and polycythaemias have allowed
some insight into the clinical significance of blood viscosity. Retinal circulation times
show close relationships with increased viscosity, circulation times are improved when
viscosity is lowered (Luxenberg and Mausolf, 1970). Other diseases which influence
viscosity are trauma, inflammation, malignancy, obesity, diabetes, vascular disease,
hyperlipidaemia, and arthritis (Chien et al, 1986, Lowe, 1987, 1988, Ehrly, 1991). The
development of peripheral arterial disease and venous and arterial thrombosis are
favoured by raised viscosity, increased RCA and haematocrit (Lowe, 1988). The
stagnation of blood flow in a diseased vessel allows the activated coagulation factors to
remain in situ and favours thrombin generation (Lowe, 1988). Poorly perfused tissues
with low shear rate conditions favour locally increased viscosity and increased risk of
rheological obstruction. Viscosity increases with age by a maximum of 10%.
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3.4.2 Plasma viscosity
Plasma is the liquid part of the human blood in which erythrocytes, leucocytes and
platelets are suspended. Blood flow in the smallest vessels is more influenced by plasma
viscosity, in contrast with whole blood viscosity where haematocrit is the principal
determinant of the flow of blood in the larger vessels (Harkness, 1981, Schmid-
Schonbein 1981). The sizes and shapes of plasma proteins determine their influence on
plasma viscosity. The small cigar shaped protein albumin contributes only 30% of the
difference in viscosity between plasma and water. In contrast, the larger proteins such as
fibrinogen, LDL cholesterol and immunoglobulins have shown greater influences on
plasma viscosity (Lowe, 1987). Fibrinogen accounts for 22% of the difference in
viscosity between plasma and water, despite only making up 4% of the total protein
weight (Lowe, 1988).
3.4.3 Influence of whole blood and plasma viscosity on ischaemic heart disease risk
The conventional risk factors for llID namely the plasma concentrations of cholesterol
and triglyceride, overweight, male gender, high sodium intake and increasing age all
increase with both whole blood and plasma viscosity (Chien, 1986, Lowe, 1986 , Lowe
et al. 1986, 1988, de Simone et al, 1990,). Women have lower blood viscosity than men
though this gender difference becomes reduced after the menopause (Lowe et al, 1988,
Small et ai, 1989). Premenopausal women using oral contraceptive agents have elevated
blood, but not plasma, viscosity compared with those who do not use oral contraceptive
agents. The effect is sufficient to remove the sex differences in blood viscosity.
Smokers have reversible increases in blood viscosity due to increases in haematocrit and
plasma viscosity (Lowe et al, 1980, 1988, 1992). The reversible increase in plasma
viscosity has been partly explained by increased plasma fibrinogen concentrations in
smokers (Lowe et al, 1991). Increased blood viscosity has been observed in those with
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peripheral arterial disease when compared with healthy control subjects (Lowe et al,
1986, Ciuffetti et al, 1989). Plasma viscosity was used as a comparison between areas of
low (Augsberg, Germany) and high (Glasgow, Scotland) incidence ofllID (Koenig et al.
1994). The higher incidence ofllID events was associated with higher blood viscosities.
3.4.4 Effect of body weight on whole blood and plasma viscosity
The relationship of overweight and obesity with raised whole blood viscosity is seen at
every shear rate and is attributed to the positive relationship between viscosity and
haematocrit and plasma viscosity (de Simone et al, 1990). A similar pattern was seen by
Koenig et al (1987) where increased plasma viscosity was observed with increasing age
and overweight. Overweight accompanied by a central fat distribution has been shown
to raise whole blood viscosity in comparison with overweight without a central fat
distribution (Wysocki et al, 1991). The majority of studies that have identified
elevations in plasma fibrinogen concentrations have also reported an increase in blood
and plasma viscosity.
3.4.5 Effect of weight loss on whole blood and plasma viscosity
A number of clinical studies have examined whether raised plasma and whole blood
viscosities are raised with increased BM! and are reversible after intentional weight loss.
These studies are summarised (table 3.3 and 3.4). They range in duration from 15 days
to 12months and use a variety of dietary methods from a VLCD to a 1300 kcal regimen.
The consensus fmding was that weight loss did not significantly lower fibrinogen (Ernst
et al, 1993). However, RCA, an influential factor governing whole blood viscosity has
been shown to be significantly lowered after weight loss (Ernst and Matrai, 1987, Poggi
et al, 1994). Both moderate amounts of weight loss (approximately 5% body weight)
and increased weight loss (15% body weight) has been shown to either lower (Parenti et
al, 1988, Fanari et al. 1993, Poggi et al, 1994) or have no effect on plasma viscosity
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(Craveri et al, 1990, Tozzi et al, 1994). This discrepancy may be the result of studying
subjects with different BMI.
3.4.6 Conclusions
The effect of intentional weight loss on whole blood viscosity has been examined in the
same studies as plasma viscosity (table 3.4). Whole blood viscosity was shown to be
either unchanged (Parenti et al, 1988, Ernst, 1989, Craveri et al, 1990, Fanari et al,
1993) or lowered with weight loss (Ernst and Matrai, 1987, Tozzi et ai, 1994). There are
no published studies which have examined the effect of changes in dietary composition
alone on blood or plasma viscosities.
3.5 Red Cell Aggregation
3.5.1 The physiological role of red cell aggregation
The aggregation of red blood cells, RCA, is a reversible process caused by
macromolecules present in the plasma, such as fibrinogen and globulins, bridging
between one cell and another (Lowe, 1987). The physiological relevance of this process
is complex and at present remains incompletely understood.
Conditions of low blood flow favour RCA, enabling the erythrocytes to form linear
aggregates or rouleaux. The rouleaux then form elastic networks (Fahraeus, 1929).
Fibrinogen becomes adsorbed onto the red cells and favours bridging between cells. In
static blood, a stress known as the yield stress is required to disrupt the elastic networks
and to re-initiate blood flow.
The RCA is overcome and the cells become entirely dispersed at a minimum shear rate
of 50s·
1
• In the large vessels RCA favours erthyrocyte migration to the vessel walls with
the effects of increasing blood fluidity and improving oxygen transport. In low flow
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conditions RCA favours the formation of local obstacles to vessel perfusion. Increases
in fibrinogen concentrations greatly increase both RCA and whole blood viscosity
especially when measured at low shear rates.
3.5.2 Red cell aggregation in overweight, diabetes, angina pectoris and
hypertension
The RCA measured in overweight subjects, free of any associated pathological
conditions, was significantly increased in comparison with that found in slim control
subjects (Le Devehat et al, 1992). Increased plasma viscosity and fibrinogen
concentrations have both been associated with an elevated RCA. Raised fibrinogen
concentrations were proposed as a partial explanation for this increase seen in the
overweight (Le Devehat et ai, 1992). The presence of IHD and angina pectoris result in
elevated RCA when compared with measurements made in healthy subjects (Rainer et
ai, 1987).
Diabetes has been associated with increased in RCA and plasma and whole blood
viscosities. These rheological alterations favour reduced blood flow, and promote
thrombosis. The elevated blood viscosity seen at low shear rates is probably due to
elevated plasma proteins, in particular plasma fibrinogen concentrations which are
frequently raised in diabetes (Barnes et al, 1988). Increased RCA has been reported in
both IDDM and NIDDM diabetes (MacRury, 1990, MacRury et al, 1992). The raised
RCA was positively correlated with the plasma concentrations of triglycerides and
VLDL, and inversely correlated with HDL cholesterol. Smoking habit and BM! were
both positively related to RCA. These findings led to the conclusion that RCA was a
possible mechanism by which some cardiovascular risk factors promote disease
(MacRury et ai, 1992). A higher RCA has been shown in hypertensive patients and has
been positively correlated with diastolic pressure (Rampling et al, 1989).
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3.5.3 Relationsh'ip between red cell aggregation and plasma lipids
The effect of lipoprotein sub-fractions on RCA has been investigated (Simon et al,
1995). These researchers examined the aggregability of erythrocytes in the presence of
fibrinogen, with either the HDL or the LDL cholesterol sub-fractions. The HDL sub-
fraction known to be protective against llID, was negatively correlated with RCA,
though the presence of LDL, known to increase llID risk, interacted with erythrocytes
and enhanced fibrinogen induced RCA. These findings suggest raised plasma LDL
cholesterol, and lower plasma HDL cholesterol and may favour increased llID risk by
enhancing RCA.
3.5.4 Red cell aggregation, body mass index and weight loss
The relationship between RCA and overweight has been established. Increased values of
RCA have been reported in the overweight when compared with healthy weight control
subjects (Le Devehat et aI1992). The effect of simple overweight, IGT, and NIDDM on
RCA was also examined (Caimi et al, 1991). The overweight subjects (BM! 35.5 kg/m')
had a lower RCA when compared to the IGT group (BM! 34.4 kg/rrr') and the highest
RCA was measured in the NIDDM group (BM! 38.8 kg/m'), The improvement in RCA
with intentional weight loss was shown in two studies (table 3.5) (Ernst and Matrai,
1987, Poggi et ai, 1992) which used low energy regimens. Both showed the beneficial
effects of large (10-15% body weight) weight losses on RCA after 3 months
intervention. The effect of changes in dietary composition on RCA, or the effect of
dietary supplementation are unknown.
3.5.5 Conclusions
RCA has been shown to be influenced both by the presence of obesity and overweight
and by the presence of metabolic disease. Preliminary data have suggested that weight
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loss may be of benefit to lower RCA. A wide variety of measurements of RCA can be
made, which makes the available data difficult to compare. Further studies are required
to clarify the role of dietary modification and weight loss on RCA.
3.6 Haematocrit
The haematocrit of blood is also known as the packed cell volume. This is the ratio of
the volume occupied by cells, especially the red cells, to the total volume of blood,
expressed as a percentage. A linear increase in haematocrit over the range 35-55%,
which includes most human values, is accompanied by a linear increase in blood
viscosity (Chien, 1975, Lowe, 1987). Increased haematocrit has been related to the
increased shear dependence of blood viscosity. The greatest influence of haematocrit
was seen at the lower shear rates (Lowe, 1987, Stuart and Nash, 1990). However,
erythrocyte deformability, in response to flow forces, facilitates cells of 7-8 J..Ul1 diameter
to flow through vessels with diameters of 3-5 urn (Schmid-Schonbein, 1981). The
erythrocyte deformability is increased with increased shear stress, haematocrit and
plasma viscosity. This partly compensates for the increased blood viscosity arising from
increases in haematocrit or plasma viscosity under high shear conditions. In two random
Scottish population samples (Lowe et al, 1988, 1992) blood viscosity was lower in
women than in men. This was especially evident in pre-menopausal women and was
largely due to their lower haematocrit. These gender differences were almost entirely
removed in post-menopausal women. These studies (Lowe et al, 1988, 1992) also
reported a correlation coefficient of 0.7 between blood viscosity and haematocrit. They
concluded that around 50% of the community variation inblood viscosity was accounted
for by variations in haematocrit, and 40% of the variation was due to changes in
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erythrocyte deformabilty. The presence of peripheral arterial disease has also been
significantly associated with increased haematocrit (Lowe et al, 1992).
3.6.1 Haematocrit and ischaemic heart disease risk
Patients with polycythaemic disease also have elevated haematocrit and elevated llID
risk compared to healthy subjects (Chievitz and Thiede, 1962). It is likely that this
reflects the influence of haematocrit on blood. Smoking has also been associated with
raised haematocrit (Lowe et al, 1992, Wannamethee et aI, 1994). The influence of
physical activity habit and physical fitness as measured by forced vital capacity on
haematocrit are small (Sorlei et aI, 1981, Carter et aI, 1983). A number of
epidemiological studies have examined the relationship between haematocrit and llID
events. The majority have reported inconclusive results, though they did report a
positive association between increased haematocrit and an increased risk of MI (Sorlei et
aI, 1981, Carter et al, 1983, Campbell et aI, 1985). In the majority of studies, a linear
relationship between haematocrit and outcome of MI has been assumed, although this
has been challenged recently (Knottnerus et al, 1988, Wannamethee et aI, 1994). Their
results have indicated that a haematocrit of 46% or greater is associated with increased
risk of MI (Knottnerus et al, 1988, Wannamethee et al, 1994). These independent
effects of haematocrit on coronary risk remained, even after adjustment for the principal
llID risk factors.
3.6.2 Effect of increased body mass index and weight loss on haematocrit
A positive relationship between raised haematocrit and BM! was shown in the Glasgow
MONICA study (Lowe et aI, 1992), by a study in healthy employed adults (de Simone et
al, 1990) and in a population of Hawaii-resident Japanese migrants (Carter et al. 1983).
No difference in haematocrit was seen between healthy and obese subjects (Poggi et al.
117
1994) but when males and females were grouped separately, males showed a
significantly raised haematocrit. In contrast, no significant differences in haematocrit
were reported by other studies which compared overweight with slim control subjects
(Rillearts et al, 1989, Craveri et al. 1990, Le Devehat et al. 1992). Haematocrit was
increased by 3% in obese subjects with a central body fat distribution and a similar BM!
in comparison to obese without a central fat distribution, (Wysocki et al. 1991). Only 2
slimming studies that examined haematocrit (Ernst and Matrai, 1987, Poggi et al. 1994)
achieved a significant fall in haematocrit after weight loss 15% weight loss in obese
subjects after a three month intervention. The remaining studies reporting no change in
haematocrit (Parenti et al. 1988, Craveri et al. 1990, Fanari et al. 1993, Tozzi et al.
1994) (table 3.6). No studies within the literature have reported that alterations in
dietary composition have influenced haematocrit.
3.6.3 Conclusion
Risks of lliD are increased with increased rheological indices. The flow and viscosity of
blood and plasma are significantly influenced by the presence of disease including llID,
diabetes, hypertension, angina pectoris and overweight. Available evidence suggests that
weight loss in the overweight can be beneficial in lowering the measurements of blood
flow and related indices. The majority of studies have been concerned with VLCD and
surgical approaches. The influence of changes in dietary composition on haemorheology
have yet to be established.
3.7 Fibrinogen and coagulation
3.7.1 Physiological role of fibrinogen in coagulation
Fibrinogen is a large plasma protein (340 KD) and is found in the form of a dimer, each
half of which comprises three non identical peptide chains, (a, P and y). It is synthesised
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in the parenchymal cells of the liver, and its concentration in normal plasma is between
2-4 gIL with a half life of approximately 3 days (Poller et at, 1990). It is held together
by disulphide bonds and includes small amounts of carbohydrates although their role in
the function of fibrinogen are largely unknown (Kay, 1988).
Although the catabolism of fibrinogen is not fully understood it appears that the
formation of fibrin from fibrinogen plays only a minor role. Fibrinogen is converted to
fibrin in a 3 stage process. First, cleavage of 4 small peptides (2 fibrinopeptides A and 2
fibrinopeptides B) from the fibrinogen molecule by the proteolytic enzyme, thrombin.
The release of the A peptide occurs more quickly than that of B peptides which are
essential for fibrin monomer polymerisation in the formation of fibrin. Fibrin monomer
is fibrinogen from which the peptides A and B have all been cleaved. The second stage
is polymerisation of the fibrin monomer and the third stage involves the cross linking of
soluble fibrin. The process requires factor Xlll (thrombin stabilising factor) which is
activated by thrombin and covalently links the polymer. Insolubility is conferred by the
formation of disulphide bridges which are promoted by factor Xllla (activated factor
Xill).
3.7.2 Role of fibrinogen in ischaemic heart disease risk
Fibrinogen is involved both in blood clotting and in the determination of plasma and
blood viscosities (Kay, 1988). A number of epidemiological studies which examined the
role of fibrinogen and coronary disease have revealed links between plasma fibrinogen
and the risk of lliD and stroke (for review see Ernst, 1990). The Northwick Park Heart
study of 1510 men aged 40-64 years showed the first independent associations between
fibrinogen and other clotting factors and coronary events. These associations were
stronger than the associations between plasma cholesterol and coronary events (Meade et
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al. 1986). The authors attributed a great deal of the increased fibrinogen concentrations
to smoking, but concluded that a "hypercoagulable state" was at least as predictive of
coronary events as total cholesterol. Another method by which an increase in fibrinogen
was seen to increase llID risk was by leading to rises in whole blood and plasma
viscosity (Yarnell et ai, 1991). These findings were from the Caerphilly and Speedwell
study.
The Gothenburg prospective study followed a population of 792 men aged 54 years for
13.5 years. Ninety two cases of MI and 37 strokes occurred. Smoking, fibrinogen and
cholesterol concentrations were once more identified as key risk factors for MI
(Wilhelmson et al. 1984). The Framingham study results also confirmed the dose
dependent relationship between smoking and fibrinogen (Kannel et al. 1987). Data from
the Scottish MONICA study (Lowe et al. 1988) showed fibrinogen was increased in both
male and female smokers. Blood viscosity, directly influenced by fibrinogen
concentrations was strongly correlated with the principal risk factors for llID. The
results from these prospective studies showed strong and independent associations
between high plasma fibrinogen concentrations and first episodes and incident coronary
disease. All found elevated fibrinogen indirectly reflected the effect of established risk
factors for llID. A high plasma fibrinogen concentration was suggested as being
thrombogenic (Ernst, 1991).
Fibrinogen concentrations have been reported as being increased in patients suffering
from llID, stroke and PVD when compared to subjects who were disease free (Ogston
and Ogston, 1966). Plasma fibrinogen concentrations were increased with the number of
affected coronary arteries, and were elevated in those diagnosed with angina pectoris
(Rainer et al. 1987). Other accepted cardiovascular risk factors, smoking, hypertension,
hyperlipidaemia and diabetes mellitus all elevate plasma fibrinogen concentrations.
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A prospective study investigated fibrinogen concentrations in 120 patients with MI, and
followed them to measure both the rate of re-infarction and fibrinogen concentration
(Fulton et ai, 1976). Re-infarction only occurred in cases where the initial fibrinogen
level was elevated at above 750 mg ei.', which suggested lower plasma fibrinogen
concentrations are tolerable and do not need a threshold.
3.7.3 Other influences on fibrinogen concentration
The factors which influence plasma fibrinogen are many and have been summarised
(figure 3.4) Fibrinogen concentrations are positively correlated with age (Meade, 1981,
Balliesen et ai, 1985) and plasma viscosity (Ernst et ai, 1986).
As previously stated, smoking has often described as the most influential factor in
increased plasma fibrinogen (Belch et ai, 1984, Balliesen et ai, 1985) and these changes
are known to be reversible on smoking cessation (Ernst et ai, 1986, Meade et ai, 1987).
Essential hypertension is characterised by elevations in plasma fibrinogen
concentrations, which is absent in those remaining normotensive (Fletcher et ai, 1981).
Elevated plasma lipids, and in particular in type IT hyperlipoproteinaemia, are
accompanied by increased plasma fibrinogen concentrations (Lowe et ai, 1979, 1982).
However, in healthy men a positive relationship has also been observed between plasma
cholesterol and plasma fibrinogen concentrations (Meade et ai, 1977). Diabetes
frequently is accompanied by raised plasma fibrinogen concentrations (Barnes et ai,
1988). Considerable available evidence has supported the suggestion that increased
plasma fibrinogen concentrations were present in both IDDM and NIDDM diabetes
(Ostermann and Van de Loo, 1986). Diabetic vascular disease in has been associated
with increased plasma fibrinogen concentration, above that in those diabetics free of
vascular complications (Lowe et ai, 1980).
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The effect of symptomatic and asymptomatic peripheral arterial disease on plasma
fibrinogen concentrations and other risk factors was examined as part of the Edinburgh
Artery Study (Fowkes et ai, 1991, Lowe et al, 1993). A recent summary of all of the
principal case control studies that have been completed in this area shows that all report
significantly raised fibrinogen concentrations in those with peripheral arterial
disease(Fowkes,1995). The relationship between high plasma fibrinogen concentrations
and peripheral arterial disease is stronger in men than in women (Fowkes et al, 1994)
which has suggested that differences in fibrinogen concentration could account for some
of the sex differences observed in disease susceptibility. Although the role of smoking
in increasing peripheral arterial disease has been related to fibrinogen concentrations, an
interaction was found between smoking, plasma fibrinogen and risk of peripheral arterial
disease. This indicated the likelihood of more than one mechanism of developing
peripheral arterial disease (Lowe et ai, 1993).
Fibrinogen concentrations are known to be higher in women than men at all ages (Lee et
ai, 1990). The use of an oestrogen containing oral contraceptive agents, pregnancy, post
menopausal state are all associated with increased plasma fibrinogen concentrations in
women (Lowe et al, 1982, Lee et ai, 1993).
Environmental factors account for less than 20% of the inter individual variability in
fibrinogen concentrations in population samples. However, it has been estimated that
the total genetic contribution to plasma fibrinogen concentrations can vary from 30-50%
(Humphries, 1994).
Acute infections such as that which occur in dental disease can result in elevated plasma
fibrinogen concentrations (Kweider et ai, 1993). The findings from epidemiological
studies have suggested that stress increases plasma fibrinogen concentrations (Meade,
1981, Rosengren et al, 1990). However, no evidence is available from the effect of
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relaxation programmes, designed to alleviate stress, on plasma fibrinogen
concentrations.
A seasonal variation in plasma fibrinogen concentrations has been established, with an
increase in winter compared with summer, a finding which is also true for factor VII
activity. It has been proposed that the increase ofO.13 gIL increase in plasma fibrinogen
concentrations in winter can be related to the 15% elevation in llID observed in this
period (Woodhouse et ai, 1994).
3.7.4 Influence of exercise on plasma fibrinogen concentrations
The influence of exercise on plasma fibrinogen has been examined within several
epidemiological studies. The Whitehall study (Morris et ai, 1990), the Gothenburg study
(Rosengren et ai, 1990) and the Northwick Park Heart study (Connelly et al. 1992) all
showed an inverse relationship between physical activity and fibrinogen. In the Scottish
Heart Health study individuals who were inactive in leisure time or at work had
significantly higher fibrinogen concentrations, compared with the more physically active
participants (Lee et al, 1990). When individuals with a history of either no, mild or
strenuous exercise were compared, strenuous exercise was associated with lower
fibrinogen concentrations even after age, smoking habits, alcohol consumption, BM! and
occupation were accounted for (Connelly et ai, 1992). The authors of the most
comprehensive cross-sectional study, the Atherosclerosis in Communities study (Folsom
et al, 1991), recorded reported exercise habit in units. Each unit was that which fulfilled
the equivalent of 20 minutes vigorous exercise and was described as one unit of
"sporting index". The authors extrapolated this information on exercise habit, to
propose that one unit of sporting index would reduce plasma fibrinogen concentrations
by 0.3 to 0.4 gIL for members of the general population, The effect was proposed as
being effective as long as exercise habit is maintained.
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Clinical research fmdings support the role of aerobic exercise in significantly reducing
fibrinogen concentrations. Fifty five men, 12 months post coronary artery surgery, were
randomised to 1 of 3 groups, a no exercise, regular aerobic exercise or regular power
exercise (non aerobic) for a 6 month exercise intervention (Worsomu et al, 1992). Each
session lasted for 12-60 minutes and was repeated 3 times weekly. Only the aerobic
exercise was associated with a significant decrease in plasma fibrinogen concentrations.
In healthy volunteers, fibrinogen concentrations were significantly decreased after a 9
week endurance exercise programme (Ernst et 01, 1986). These workers concluded that
regular endurance exercise decreased plasma fibrinogen concentrations by 0.4 gIL (Ernst
and Resch 1995). The Northwick Park Heart study data indicated a change of 0.1 gIL in
fibrinogen concentrations was related to a 15% fall in llID risk (Meade et 01, 1986).
From these 2 studies it was possible to speculate that the potential effect of exercise,
taken regularly and in the quantities described, on fibrinogen may be as great as a 60%
reduction in llID risk.
3.7.5 Plasma fibrinogen concentrations and body weight
The association between fibrinogen and the variables reflecting body weight have been
demonstrated in several cross sectional studies, and been described as a close
relationship (Ernst, 1993). In the Scottish Heart Health study (Lee et al, 1990) BM! and
plasma fibrinogen concentrations were very closely correlated. In the Prospective
Cardiovascular Munster study the Broca index, (ideal body weight: body length (cm) _
100= ideal weight in kg) was also significantly correlated with fibrinogen concentrations
(Balliesen et al, 1985). The Northwick Park Heart study showed a close relationship
between skinfold thickness and plasma fibrinogen concentrations (Meade, 1981).
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Plasma fibrinogen concentrations have been shown to be the major influence on plasma
viscosity (Lowe et ai, 1988) which has been shown to be significantly increased in
overweight women (Ernst and Matrai, 1987). This is in agreement with data reported by
the Atherosclerosis in Communities study (Folsom et al, 1991). Raised plasma
fibrinogen concentrations were reported only in those subjects whose body weight was
increased from that recorded at study baseline (Meade et al, 1987). The magnitude of
this difference was measured as a change of 0.1gIL in fibrinogen per unit change in BMI.
When related to llID risk, this change in fibrinogen indicates a possible 15% reduction
(Wosomu et al, 1992). The change was at least comparable with the potentially
beneficial effects of exercise. A number of clinical studies also support the elevation of
fibrinogen concentrations in overweight adults and children. Elevations in plasma
fibrinogen in overweight children (Cacciari et ai, 1988) and overweight adults have been
reported (Ferlito et ai, 1990, Le Devehat et al, 1992). The plasma fibrinogen
concentrations of healthy weight overweight and obese subjects were compared (BMI
22.4, SO 0.8 kglm2, BMI 28.8, SO 0.4 kglm2, BMI 36.2, SO 2.5 kg/m') (Avellone et ai,
1994). The overweight and obese group had 45% and 68% higher fibrinogen
concentration than the healthy weight group.
3.7.6 Weight loss and plasma fibrinogen concentration
A number of clinical studies have examined whether the established increase in
fibrinogen concentrations associated with increased BMI are reversible after weight loss.
The studies are summarised (table 3.7). Only three of the dietary studies in adults have
achieved a significant decrease in plasma fibrinogen concentrations (Hughes et al, 1984,
Parenti et al, 1988, Kuyl et ai, 1992) and one study in children (Fanari et al, 1993).
Although the results of these studies are not consistent, the implication of the majority
was that fibrinogen concentrations were lowered when body weight became normal in
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previously obese individuals. Gastric bypass surgery and protein sparing fast (close to
400 kcal daily) were both used in a study of overweight diabetic patients (Hughes et al,
1984). Six subjects who received surgery achieved weight losses of 27% (117.0 to 86.0
kg). These losses were accompanied by a 13% fall in fibrinogen concentrations, from
3.8 to 3.3 gIL. The effects of weight loss in the six fasted subjects were similar, a 20%
fall in body weight reduced plasma fibrinogen concentrations by close to 12%.
No correlation was observed between duration of the diet or the calorie intake. The
surgical study reported the effects of a weight loss far in excess of anything achieved by
conventional dietary interventions and was accompanied by a significant fall in
fibrinogen (Primrose et al, 1992). No studies have specifically examined the effect of
moderate weight loss on plasma fibrinogen concentrations.
3.7.7 Plasma fibrinogen concentrations and diet composition
Animal studies have suggested that high fatty acid concentrations stimulate fibrinogen
production (Pickart et al, 1976). In humans, fibrinogen concentrations have been
resistant to dietary manipulation, although fish oils have some beneficial effects
(Hostmark et al, 1988, Meade, 1992). The reduction in fibrinogen concentrations
appears to be dose dependent, a 2g daily dose of fish oils reducing fibrinogen by a mean
0.55g!L after a 20 week treatment period. The reductions were greatest with the higher
baseline fibrinogen concentrations (Radack et al, 1989).
Fehily et al (1982) suggested that the influence of dietary composition on plasma
fibrinogen was in the region of 5%, with cereal fibre intake showing an inverse
relationship with plasma fibrinogen. The results of a smaller cross sectional study of
Finnish men were in agreement. No relationship was observed between habitual dietary
intake, measured by 7 day WI and fibrinogen concentrations (Rankinen et al, 1994). A
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vegetarian diet has been reported as having no effect on fibrinogen concentrations (Ernst
et aI, 1986) although this finding has been contradicted by a 3 week study in which
fibrinogen concentrations fell after a 3 week vegetarian diet in healthy weight subjects.
However, in this later study fasted subjects had significantly reduced body weight (mean
weight loss 6.0 kg). This change suggested weight loss rather than dietary change may
have been influential (Hostmark et aI, 1993). Polyunsaturated or monounsaturated fatty
acid rich diets and their effects on plasma fibrinogen have also been studied. A 23 day
diet which provided 16% energy from monounsaturated fatty acids showed no effect on
fibrinogen in weight stable subjects (Heinrich et aI, 1990). The influence of dietary
composition on plasma fibrinogen composition appears small, only the fish oils showing
any important influence.
3.7.8 Plasma fibrinogen concentrations and alcohol consumption
A negative relationship between self reported alcohol consumption and fibrinogen
concentrations has recently been observed in both men and women (Lee et al, 1995).
This fmding supports the earlier findings of the Northwick Park Heart study (Meade et
aI, 1979) and the Scottish Heart Health study (Lee et aI, 1990). A literature review
confirmed that greater alcohol intakes were associated with lower plasma fibrinogen
concentrations (Folsom, 1995).
3.7.9 Conclusions
Plasma fibrinogen concentrations are well established as a good index of llID risk. They
are raised in the overweight. Smoking has been established as the lifestyle factor most
influential on plasma fibrinogen concentrations. Body weight losses in the overweight
have significantly effected fibrinogen concentrations in only two studies in adults, one of
which was using a VLCD approach. A number of studies have examined the effects of
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changes in dietary composition on fibrinogen concentrations. Only the addition of fish
oils to the diet proved effective in reducing fibrinogen concentrations.
3.8 General conclusions on haemostatic and rheological risk factors for
ischaemic heart disease in relation to obesity
The haemostatic and rheological risk factors for llID are known to be affected by the
presence of diseases of particular relevance to this review, obesity, hyperlipidaemia and
NIDDM. Epidemiological and limited clinical fmdings show a positive relationship
between rheological factors, RCA and blood viscosity, coagulation factors, factor VII
activity and fibrinogen and fibinolytic factors, PAl and t-PA with overweight and
obesity. Their relationships with dietary composition, in particular habitual increased
dietary fat intakes, are less strong than with raised body weight.
3.8.1 Important unanswered research questions
Moderate weight loss following a dietary intervention to lower total energy intake and
change dietary composition in line with current dietary targets (600 kcal/day energy
deficit) would improve haemostatic and rheological risk factors for llID.
Weight loss per se achieved by "healthy" overweight subjects, overweight subjects with
angina and those close to healthy BM! would be equally effective in improving
haemostatic and rheological risk factors for llID.
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Figure 3-3 Laminar flow characteristics of blood
minimum velocity, maximum shear
.-
maximum velocity, minimum shear
Figure 3-4 Fibrinogen: determinants and pathways
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Chapter 4 Methodological and statistical considerations for the work in
this thesis
4.1 Introduction
The studies in this thesis evaluate dietary intervention to achieve "moderate weight loss",
close to the theoretical 0.5 kg per week over 12 weeks, in three different groups of
volunteers, using a standard individualised 600 kcal per day energy deficit approach. The
volunteers varied in their body weight and health status, and comprised three groups. 1)
uncomplicated overweight; 2) overweight with clinical evidence of llID; 3) healthy
weight, close to a BMI of 25 kg/nr'. The studies considered whether modest weight loss
would differ between these groups, in particular, whether those subjects with llID would
show greater changes than the disease free subjects after dietary intervention, in terms of
IHD risk factor measurements. The effects of the weight loss per se on llID risk was also
considered, adjusting for the three subject groups on the risk factors measured. It was
accepted that the dietary intervention for weight loss would include effects from changes
in dietary composition as well as changes in body weight. In free living subjects the
separation of these two influences is impossible, and attempts at dietary assessment are
invariably seriously confounded by under-reporting.
The key llID risk factors chosen to investigate the effect of a dietary intervention to
reduce body weight were haemostasis, rheology and plasma lipids. The specific
measurements were RCA, whole blood and plasma viscosities, fibrinogen, factor VII
activity, PAl activity, t-PA antigen and lipids.
Four research questions were addressed in this thesis after research in volunteers:
1. Does a dietary intervention incorporating an individualised energy deficit approach to
weight loss (600 kcal per day) achieve body weight losses of close to 0.5 kg per week?
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2. How does dietary intervention to lower total energy intake and change dietary
composition in line with current dietary targets affect haemostatic and rheological risk
factors for IHD?
3. How does modest weight loss, following a dietary intervention to lower total energy
intake and change dietary composition in line with current dietary targets, affect
plasma lipid concentrations?
4. Does the effectiveness in achieving intentional weight loss and changes IHD risk
factors differ between the those with a diagnosed disease, the overweight and those
close to healthy weight?
The planning of a study to examine the effects of weight loss on biological measurements
requires careful consideration as to the most appropriate study design. Inadequate
experimental conditions lead to inconclusive, unrepresentative results and the conduct of
such research on patients or volunteers is unethical. Any effects that may weaken the
interpretation of the results should be minimised at the design stage. The principal factors
that confound measurements and analysis in medical research as a whole are those that
give rise to errors and biases. These should be minimised by optimising recruitment,
study design and measurement methods, and then by ensuring that the study has adequate
power. Major influences on experimental design and analysis will be considered in
relation to the studies within the present thesis.
4.2 Variance and error
Variance describes the distribution of results measurements in a sample or population. As
a generalisation, distributions which are normal (Le. symmetrical about the mean) are
easier to handle statistically, describing variance in terms of standard deviation or
standard error of the mean. Variance in non-normal distribution can be characterised
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from median and inter-quartile range, or after normalisation by a procedure such as
logging. Variance comprises the biological variation, which is the inherent differences
between subjects, and error (Pocock, 1990). Biological variation can be minimised at the
protocol design stage by the selection of as homogenous a sample as possible in terms of
subject characteristics. This requires the use of closely defined inclusion and exclusion
criteria for each study, and usually includes setting eligible age ranges. The selection of a
specific sample group, and the reduction in biological variation, must be balanced against
the need for validity in generalising the results to a given population. Practical issues like
ease of recruitment often force issues like combining sexes in a single study, even though
variance will be increased.
Error can either be random (chance) or systematic (bias). Random error leads to a wrong
result due to chance, unknown and unpredictable sources of variation, and is equally
likely to distort the sample in either direction. One source of random error is
measurement error, although all measurements include a component of error. This can be
estimated when the same measurement is repeated on a number of occasions. Improving
the precision, reliability and consistency of any procedure reduces measurement error. In
practice, the precision of measurements can be improved in a number of ways. These
include ensuring the minimum number of trained investigators make measurements,
frequent inclusions of standards in assays, calibrations of any machinery used and
routinely carrying out all measurements in duplicate. Accuracy and precision differ in
their meaning in a research setting. A very precise measurement is one that has nearly the
same value each time it is measured. Precise measurements reflect the real or correct
value for a given item. The more precise a measurement the greater the statistical power
for a study at a given sample size. An error such as an incorrect dilution of a solution may
make the measurement inaccurate, but it could still be precise.
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Bias is an error effect that causes results either to depart systematically from the true
values, or to fail to mirror the distribution in the normal population (Coggan, 1985). Bias
can have the effect of either concealing a true relationship or introducing a spurious one.
The application of results from a non-representative group of subjects to a wider
population is an important source of bias. If the results from any study are to be
applicable to a wider population, then the subjects recruited ought to be representative of
that population. Bias can also result from the effects of seasonal variation as seasonality
is known to influence a number of biological measurements. With regard to the lliD risk
factor measurements any seasonality effects can be minimised most commonly by
ensuring subject recruitment extends across all seasons.
Regression towards the mean can occur in clinical trials which are dependent on repeated
measures of a variable which is also an entry or selection requirement. It is likely that the
measurements in the highest and lowest part of the distribution within a given population
will include a high proportion where biological variability and measurement error have
played a part. A repeated measurement will be nearer the mean on purely statistical
grounds Le. high results from the first measurement will tend to be lowered when
measured for a second time, whilst low results will tend to be higher. The large multiple
risk factor intervention trial "MRFIT" examined the value of health promoting
interventions, particularly diet, in samples selected on the basis of their high plasma
cholesterol concentrations. Regression towards the mean led to confounded trial results
(MRFIT, 1982). This effect depends mainly on random error, but there may also be
biological influences, so it will be particularly true for diseases or dietary intakes that
follow a cyclical pattern including body weight and plasma lipids. To minimise
regression towards the mean in a clinical trial care must be taken when selecting subjects
who are characterised by high or low values for any measurement (e.g. plasma cholesterol
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concentrations or blood pressure). A simple solution is to make more than one
measurement of the variable of concern, and disregard the first, defining one. For studies
of weight loss, weight measurement is so accurate that a systematic tendency for the
overweight to lose weight is more likely to be biological. Table 4.1 lists some potential
sources of random error and of bias which may be met in studies of weight loss. The
design of any studies of weight loss should consider possible sources of variation and
error, including the selection and measurements of subjects, and statistical approaches
used for data analysis. Many can be addressed by clear inclusion and exclusion criteria
for subjects, by ensuring that the principals of good clinical practice are adhered to, and by
incorporating statistical expertise.
4.3 Controls
Control subjects are required in clinical studies to be able to estimate, and correct for, the
influence of confounding factors (e.g. age, social circumstances, secular influences not
specific consequences of the intervention under study) that occur amongst subjects
participating in a clinical trial.
"Study effects" are effects related to changes in lifestyle, dietary and behavioural patterns,
which tend to occur simply as a result of participating in a research study. This is
especially relevant to studies of weight loss because subjects volunteer with the
expectation and intention of weight loss. They tend to modify diet and exercise
irrespective of the planned treatment, and often lose weight even if not specifically
requested to.
The differences between any measurements made in treatment and control groups can be
considered to be the effects of the treatment. The use of a crossover design is a more
efficient method with respect to sample size and power, with the subjects participating in
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these studies being randomly allocated to the order in which they underwent each
treatment period. A washout interval may be required between each of the periods to
remove any carry over effects. The use of parallel controls may be preferable because
they remove any need for washout periods, but obese subjects are often less willing to
comply with non-intervention arms. The duration of treatment necessary for weight loss
trials (a minimum of 3-4 months) usually precludes crossover designs.
4.4 Design of studies with weight loss as an outcome of treatment
Designing studies that examine the treatments for, and effects from, weight loss involve
some rather unusual and complicated considerations. All studies that examine the
effectiveness of a treatment in achieving weight loss must include a control or comparison
group. However, for such studies whether of drugs, diet, lifestyle or other treatments the
inclusion of a control group is problematic. It is not possible to have "placebo" lifestyle
change for obese subjects recruited to a slimming study or a blind allocation, such as
would be mandatory for a drug trial. Overweight recruits who receive no treatment and
are described as a "control group" or "usual or routine treatment", may confuse the
analysis because such subjects recruited as volunteers for weight loss inevitably do make
extra changes. Comparison between different styles of management e.g. intensive versus
usual, or between different behavioural or dietary approaches may be scientifically
valuable, but results may not relate well to those in routine practice.
4.5 Design of studies with weight loss as a treatment
If the aim of a study is to achieve weight loss and then examine the effects of weight loss
on a given biological measure (rather than evaluating the efficacy of a treatment in
achieving weight loss) the issue of statistical control becomes complicated.
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Firstly, as body weight is an unstable continuous variable it is impossible to offer "control
subjects" "placebo" advice to remain weight stable. All participants in an ethical
slimming study using a design with a dietary treatment and control will have been given
information on the study aims and requirements. Thus outside of drug trials, participants
will be aware as to which treatment they have been allocated to. Recruitment into a study
using overweight as a selection criterion can result in weight loss even without specific
advice, and control overweight subjects who receive no advice will frequently change
weight (upwards or downwards), either intentionally or under secular influences (Blonk et
al, 1994, Svedsen et al, 1994).
Interventions designed to produce weight loss do not, and cannot, introduce a fixed effect,
but a range of individual responses, with some participants even gaining in body weight.
This situation is very different to a trial where a fixed dose of medication allocated to all
treatment subjects would have a more predictable effect, and the placebo no
pharmacological effect. Weight loss as a "treatment" cannot be administered as "a preset
dose" and therefore is never identical, such that a range of weight losses and gains occur
in all groups. Treatment effectiveness can be assessed in terms of the number of subjects
who achieve pre-determined degrees of weight loss e.g. 10%, and the main factor is
usually acceptability or compliance. The division of subjects into "successes" and
"failures" in terms of weight loss may have value in certain circumstances, but the cut-off
between Success and failure require careful definition, ideally at the design stage to avoid
introducing bias from post hoc categorisation.
In a randomised controlled trial which is testing the effect of a particular "treatment"
against a dummy or "placebo" treatment, the only difference between the two groups
should be the treatment, with all other elements remaining the same. In the case of trials
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of medication efficacy each group will include subjects whose compliance is poor. In
dietary studies, there will be a range in the ability of subjects to comply with the advice,
so some subjects in treatment and control groups may show rises and falls in outcome
measures.
As an alternative to conventional placebo controlled trials employing two-sample
treatment comparisons, the effects of variable weight loss on metabolic variables may be
more appropriately analysed by correlation analysis, as a measure of linear association,
and regression analysis to allow for the adjustment for interacting factors. This single
sample approach is the most economical and more ecologically valid incorporating the
range of weight losses and their consequences across a chosen population. In the context
of the present studies where weight loss was a treatment and not an outcome, and where a
range of weight changes (from + 2.0 kg to -10.0 kg) were present, the best use of the data
was considered to be the application of correlation analysis between changes in weight
and outcome measures. However, the study power estimation was based on the more
conventional paired student's t-test.
An alternative approach to a "no treatment group" for comparison or reference is to relate
measurements in subjects to data in historical controls considered to be have been
exposed to the same secular and other influences. This may provide information about a
given study sample compared with a larger representative one. This approach was chosen
in chapter 6 and 7 with a subset from the Glasgow MONICA study population.
Relationships for the subset of the MONICA population were shown between two
physiological measurements of interest and BM! (Hankey et ai, 1997). The same
comparisons were made in the population of study participants, where the relationships
between the measurements and BM! were also described. This comparison provided
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information on the differences between the angina study subjects and a subset from the
MONICA population at baseline. It also gave an indication of the expected influence of
weight change on these specific measurements.
4.6 Subject selection
In practice, recruitment to clinical trials is always limited to willing subjects who are
available to participate. The limited access a researcher has to subjects may lead to
volunteer bias, with only those who are eager, health conscious and motivated,
participating in and completing the experiment. Payments of expenses to volunteers may
attract people who otherwise would not volunteer to participate in clinical studies so
increasing numbers and the representative the sample were. On the other hand, paying
fees as incentives could attract unsuitable participants, introduce unwanted effects,
particularly to self-completed measurements. There is always a trade-off between the
needs to obtain a representative sample, the need to reduce sources of variance and bias,
and securing participants who will complete a study. Reducing uniformity could lead to
other difficulties, as a dietary intervention could be effective in one sector but not another.
An obvious issue is whether to study men, women, or both sexes together. Obesity is
often more frequent in women, who are more likely to volunteer, but cardiac risk factors
are worse and weight loss often better in men.
Recruiting participants to weight loss studies who have participated in many other
attempts to reduce weight is another consideration which may introduce bias. The
recruitment of subjects to a slimming study who have already intentionally begun to
reduce their body weight immediately prior to participating would also introduce bias.
This is likely as the participants may have already reached a plateau from where further
weight loss may be problematic.
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The use of a random selection procedure for recruitment to provide a representative
sample of overweight individuals from the population would not have been a useful
approach for the present studies. The requirements from study participants were onerous,
and thus only certain subjects would have been prepared to participate in the study, at
least much beyond attendance at a number of outpatient appointments. It is more
reasonable to aim for a sample representative of those who seek help for weight loss.
For the present thesis, the recruitment of subjects used poster advertisements in and
around Glasgow Royal Infirmary, (chapter 6), a press release (chapter 7), and e-mail
(chapter 8) for each of the different studies. The selection of subjects was principally
based on BMI, and being in good or stable health. Although it was impossible to recruit
subjects who had not previously been engaged in slimming, the subjects had to report
being weight stable within 3.0 kg over the previous three months to be eligible to
participate.
4.7 Sample size and power calculations
After defming the smallest treatment effect which would be of clinical value, the required
power must be decided, and then the size of any study can be calculated. The power of a
study is the probability of detecting a clinically important difference, assuming it exists,
and of excluding a difference where there is none (Gore and Altman, 1982, Rees, 1994).
Statistical power to detect or exclude any treatment effects is defined by the variance and
sample size. To decide on a sample size, it is therefore to know (or estimate) the
treatment effect expected, the population variance for the main outcome measure and
level of significance. Consideration should also be given to the ability to generalise
results of any research. An increased range of subject selection criteria leads to an
increase in variance, and the study numbers have to increase in order to maintain power.
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Intervention studies with inadequate sample sizes are unethical wastes of patients or
volunteers time. Too large a sample is as unethical as too small a sample, as additional
subjects would be researched unnecessarily and resources wasted. Frequently, the data
required to calculate study power are unavailable, especially if the planned research is the
first study in a given area. In this case, a number of assumptions are made usually based
on experience in related fields.
An appropriate equation for the calculation of power is:
n= ci x !(a,p)
(1l2- Illi
(Pocock, 1990)
where 0' = standard deviation of the difference of response, 112 and III are measurements at
time 1 and 2. !(a,p)is a statistical function derived from the normal distribution which
depends on the chosen power (Le. P) and significance level for the study (Le. a). a is
commonly called the type I error, and is the probability of detecting a significant
difference when there is none. This factor represents the risk of a false positive result. p
is commonly called the type II error, and this factor represents the risk of a false negative
result, failing to detect a difference when there is one. The values selected in this thesis
were a =0.05, and p=O.1. This equation assumes a normal distribution of data, and a
paired student's t-test comparison of means. Power becomes reduced when non-
parametric comparisons are needed, which within this thesis was rare.
The study design, whether a parallel or single stranded study, affects the power of a study.
The power of a single stranded study employing paired student's t-tests is substantially
increased versus the two sample parallel study, as the biological variation is usually
reduced with only one sample of subjects, each acting as his or her own control. Study
numbers required are approximately halved. The following power calculations were
carried out for the present studies, and the results used to decide on the required sample
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size. The calculations used the results from any relevant studies that had examined the
effects of weight loss on the principal end points, the haemostatic and rheological
measures and DHEAS. Itwas considered unnecessary to carry out power estimations for
plasma lipids, since these routine assays were included to provide additional information
to interpret the results for the principal study measures.
Red cell aggregation
The RCA measurement is only used in research studies, and the size of the minimum
clinically important difference or change is poorly defined. However, mean difference in
RCA of -0.8 AU and standard deviation of the difference 1.2 AU after an intervention to
reduce body weight have been estimated from experience (Lowe, 1996).
Baseline RCA 3.7, post-intervention value 4.5.
(1.2)2
(3.7 -4.5i
The present studies were therefore powered sufficiently to exclude clinically relevant
x 10.5 = 24 subjects
effects on RCA.
Factor VII activity
A change in factor VII activity which is considered clinically important is between 5-10%
(Meade et aI, 1991). A dietary intervention study which examined the effect of weight
loss on plasma factor VII activity (Baron et al, 1988) after a mean weight loss of 4.2 kg
found a change of -8% and standard deviation of the change of 12%.
Therefore, assuming a baseline factor VII activity 108%, post-intervention value 100%.
Sample size required: (-12) 2 x
(100 -108)2
10.5 = 25 subjects
The present studies were powered sufficiently to exclude clinically relevant effects on
factor VII.
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Plasma viscosity
A difference in plasma viscosity of 0.04 mPas can represent the difference between those
who remain free of disease, and those with llID (Koenig et al, 1994). After weight loss a
mean change in plasma viscosity of -0.04 mPas (standard deviation 0.09 mPas) resulted
(Poggi et ai, 1994). Since the present studies used a modest energy deficit approach, it is
estimated that the change in plasma viscosity would be only -0.04 mPas.
Baseline plasma viscosity 1.39 post-intervention value 1.37
(0.09) 2 x 10.5
(1.34 - 1.39)2
= 34 subjects
The present study was powered sufficiently powered to exclude clinically relevant effects
on plasma viscosity.
Whole blood viscosity
A clinically important difference in whole blood viscosity is 0.15 mPas, identified as
separating subjects who experienced cardiovascular events from subjects who remained
well (Lowe et al, 1997). No data exist on weight loss, but a difference of -0.2 and
standard deviation of the difference 0.3 mPas in whole blood viscosity was seen between
the measurements for an obese group of subjects (BM! 36 kg/m') and those of healthy
BM! (BM! 22 kglm2) (Rillaerts et ai, 1989). Since the present study expected weight loss
was <6.0 kg, a treatment effect of -0.1 SD 0.3 mPas was proposed.
Whole blood viscosity in obese subjects 5.2, those of healthy BM! 5.0.
(0.3)2
(5.1 - s.2i
x 10.5 = 95 subjects
The present studies were expected to be under-powered for WBV.
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Haematocrit
A clinically important difference in haematocrit has been shown as 1.0% representing an
increased risk of IHD (Lowe et aI, 1997). The difference between haematocrit values in
obese and healthy weight subjects was 0.5% with a standard deviation of the difference
0.9% (Rillaerts et al, 1989). Therefore the estimated treatment effect in the present
studies at 0.25 SD 0.9%.
(0.9) 2 X 10.5
(41.6 - 41.9i
= 94 subjects
The present studies were under powered with respect to haematocrit.
Fibrinogen
A difference in plasma fibrinogen of 0.25gIL is considered biologically important (Meade
et aI, 1986). The mean change in plasma fibrinogen after a mean weight loss of 16.5 kg
was -0.2 gIL and the standard deviation of this change was 0.7 gIL (Ditschuneit et al,
1995). No CV was given for this assay.
Baseline fibrinogen 3.3, post-intervention value 3.1.
(0.7) 2
(3.1 -3.3)2
The present studies were under powered with respect to plasma fibrinogen concentrations.
x 10.5 = 129 subjects
Plasminogen activator inhibitor activity
A clinically important difference of 1.3 U/mL has been shown to divide those who have
suffered a MI from those who remain well (ECAT, 1993). After dietary intervention for
weight loss (8.0 kg) a mean difference in PAl activity was -2.9 U/mL with a standard
deviation of2.9 IU/mL (Velthuis-te Wierik et al, 1995). Baseline PAl activity was 13.2
U/mL with the post-intervention value 10.3 IU/mL. Assuming a 4.0 kg weight loss in the
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present studies, half of this reduction (-1.5 U/mL) is assumed.
(2.9) 2 x 10.5
(11.7 -13.2i
The present studies were just sufficiently powered to exclude clinically relevant effects on
= 39 subjects
plasma PAl activity.
Tissue plasminogen activator antigen
Differences in t-PA antigen of 1.6 ug/ml, have been found to be of clinical significance,
and have reflected the difference between those who remain free of disease, and those
with IHD (Jansson et al, 1994). After 8.0 kg weight loss, a mean difference in t-PA
antigen of -3.1 and standard deviation 2.9 ill/mL resulted (Velthuis-te Wierik et aI, 1995).
Assuming a 4.0 kg weight loss in the present studies, half of this reduction (-1.6 U/mL) is
assumed.
(2.9)2
(4.8 -6.3i
The present studies were just sufficiently powered to exclude clinically relevant effects on
x 10.5 = 40 subjects
plasma t-PA antigen.
Dehydroepiandosterone sulphate
The sample size that was required to complete the studies examining the effects from
weight loss on DHEAS was chosen depending on the minimum clinically important
difference. This was estimated as close to 1.5 mollL (Wallace, personal communication,
1996). The fmal power analysis was based on the results from Leenen et al (1994) who
achieved a weight loss of 13.5 kg.
Mean difference in DHEAS concentrations (Leenen et al, 1994) 1.9 SD 3.3 umol/L.
Baseline DHEAS concentrations 5.3, post-intervention value 7.3 umol/L, 5.9 umol/L
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based on a 4.0 kg weight loss.
(3.3)2
(5.9-5.3i
x 10.5 = 318 subjects
The present studies were under powered with respect to DHEAS concentrations.
4.8 Application of statistical principles to the studies within this thesis
The studies in this thesis have all examined the effects of weight loss on established risk
factors for llID. These data also include the effects of a standard dietetic approach to
weight loss. For the reasons already described, a single stranded study design was chosen
which simply compared the measurements before and after weight loss.
Bias due to seasonal variation in plasma cholesterol and its fractions, factor VU activity,
fibrinogen, and body weight was minimised with recruitment taking place throughout the
year. Body weight measurements made in at different times of day, or days of the week
are a possible sources of bias. This problem was minimised by ensuring as similar
conditions as possible for weight measurements. The major sources of bias and error
likely to be encountered in studies of weight loss are summarised in table 4.1.
The evaluation of the range of values and any patterns and relationships were examined
using the statistical techniques of correlation and linear regression analyses. Data are
presented as the mean and standard deviation for data that showed a normal distribution
or as the median and inter-quartile ranges where data showed a skewed distribution. The
effects of treatments, in different study groups, were examined for using the students t-
test, where data were normally distributed, or the one sample Wilcoxon for skewed data.
The statistical methods employed in this thesis were completed with the aid of Minitab
statistical software (Version 10, Minitab Inc., Philadelphia, USA), and the specific
statistical methods are described in each chapter.
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Figure 4-1 Possible sources of error and bias in studies of weight loss
Possible sources of error Possible sources of bias
• Few entry criteria for participants • Over restricting entry criteria
• Poor weighing scales, not regularly
calibrated
• Poor training of investigators
making measurements
• Failing to complete laboratory
analyses in duplicate
• Pre-menstrual fluid accumulation
(gender)
• Changes in clothing between
measures
• Combining sexes
• Statistical power may be insufficent
to confirm negative conclusions
• Failure to represent confidence
intervals may fail to illustrate the
range of the data
• Completing weight measures at different of
the day, or day of the week
• Seasonal variation in measurement of body
weight and biochemical measures
• Regression to the mean of weight-related
measurements in groups selected as
overweight
• Recruiting participants who have already
participated in weight loss studies
• Recruiting participants who have already
recently achieved intentional weight loss
• Subdividing subjects retrospectively on a
weight loss basis to examine metabolic
variable
• To short study duration, effects of acute
negative energy balance and of weight loss
superimposed
• Passage of time in long term studies
• Poor matching for age, or unusual age
distribution
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Chapter 5Methods
5.1. Statement of personal involvement and extent of collaboration
The overall plan and design of studies was completed by the author in collaboration with
Professor Lean. The recruitment and consultation with all volunteers were arranged and
completed by the author, as were all measurements of dietary intake and resting energy
expenditure. The physical measurements including ABPI and sample collection,
preparation and storage were also all completed by the author.
Of the biological assays: serum DHEAS were completed by the author as were the
majority of measurements of RCA and haematocrit. The remaining assays: insulin, factor
VU activity, fibrinogen, PAl activity, t-PA antigen, total and HDL cholesterol, triglyceride
and plasma and whole blood viscosity measurements were performed by the staff of the
Coagulation Laboratory and the Department of Pathological Biochemistry Glasgow,
Royal Infirmary. The intra and inter-assay CV's for the samples collected in the studies
of this thesis were unavailable. This was because the analyses were made by staff within
other departments who included the samples from these studies within their larger batch
assays. Some coefficients of variation for each assay are given, but these are the values
recorded by the laboratory staff at the time when the majority of samples were analysed.
Data entry, checking and cleaning, as well as statistical analyses were carried out by the
author, with guidance from Dr James Currall.
5.2.Anthropometric and physical measurements
5.2.1. Subjects and recruitment
Subjects were recruited for each of the dietary studies using a variety of approaches.
Specific methodologies and subjects will be detailed in the relevant chapter.
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5.2.2. Height, body weight and body mass index
Body weight was measured in duplicate using calibrated scales (Seca, Germany) to the
nearest 100 g in light clothing and without shoes. Height was measured to the nearest 0.5
cm with subjects standing with their back to the stadiometer. The head was adjusted so
that the Frankfort plane was horizontal (WHO, 1987). The subjects were all asked to
breathe in deeply and reach up to a maximal height with their legs stretched, but feet flat
on the ground (plate 5.1). The calculation ofBM! weight (kg) / height (m2) was made as
an index of body weight, as it shows a reasonable correlation with body fatness as
measured by densitometry (WHO, 1995, Han et al, 1996). The BM! has been used to
classify obesity and a number of arbitrary cut offs have been established (WHO, 1995). A
BM! below 18.5 kg/m' was considered to reflect under weight whereas a BM! between 20
- 25 kglm2 was considered to reflect a healthy body weight. A BM! between 25 - 30
kglm2 was defined as overweight and a BM! greater than 30 kg/m' was defined as obese.
5.2.3 Waist and hip circumferences
Waist circumference was measured mid way between the lower rib margin and iliac crest
using a steel tape (Holtain Ltd, Dyfed, Wales). The hip circumference was measured at
the level of the great trochanters with the measuring tape being held horizontal (WHO,
1989). Both measurements were made whilst individuals were standing with their legs
slightly apart in line with their pelvis. All measurements were made in duplicate and a
mean value established. If differences of greater than 5 mm were found for duplicate
measurements, both measurements were repeated until a difference of 5 mm or below was
found. The waist circumference was also used ~o estimate the percentage body fat (Lean
et ai, 1995).
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5.2.4 Skin-fold thickness
Equations have been derived from which skin-fold thickness measured at pre-determined
sites can be used to predict total body fat as determined by densitometry. Two main
assumptions are associated with this method, firstly that subcutaneous fat is a constant
proportion of body fat, and secondly that the chosen measurement sites also have a
constant relationship to total body fat. The measurements were made at the 4 standard
sites (triceps, biceps, subscapular and suprailiac) with skin-fold callipers (Holtain Ltd,
Dyfed, Wales). The equations were designed for use in adults were used to derive values
for total body fat (Durnin and Womersley, 1974). The measurements at each site were
carried out using standard guidelines (WHO, 1989). For all sites the measurements were
made in duplicate and the mean value taken. Each measurement was read to the nearest
mm about 4 seconds after the pressure on the skinfold was fully applied from the calliper
(Becque et ai, 1986).
a) Triceps skin-fold
The triceps skin-fold measurement was made according to the standard methods of the
World Health Organisation (WHO, 1987). The right arm was bent at right angles, and the
length from the tip of the acromion process on the scapular to the olecranon process of the
ulna was measured and the mid point marked. With the arm hanging limply by the side,
the skin-fold at the mid-point level on the back of the arm was picked up between the
thumb and forefmger of the left hand. The calliper was placed on the skin-fold just below
the fmgers. The fmgers were then removed, and the first reading taken.
b) Biceps skin-fold
As for the triceps, but the measurement was made over the biceps muscle on the front of
the arm.
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c) Subscapular skin-fold
About 2.5 cm in and below the angle of the scapula towards the mid-line and at an angle
of approximately 45° to the spine along the natural line of skin cleavage.
d) Suprailliac skin-fold
Midway between the anterior supenor iliac crest and the lowest point of the ribs,
horizontal to the floor, or just above the iliac crest in the mid-axillary line.
5.2.3 Ankle Brachial Pressure Index
The ABPI is the standard method for identifying peripheral vascular disease (PVD). It is
the ratio between the ankle pressure and the pressure measured in the branchial artery.
The ABPI correlates with the severity of ischaemia (Yao et al, 1969, Yao, 1973). This
measurement was used in the study of angina patients to determine the presence or
absence of PVD, a possible influence on coagulation and haemostatic measures (chapter
9). Subjects were rested supine for at least 5 minutes before the measurement was made.
The branchial, anterior tibial and posterior tibial artery systolic blood pressures were
measured after occlusion of the vein using a standard sphygmomanometer and cuff.
The anterior tibial and posterior tibial artery systolic blood pressures were measured using
a Sonicaid Blood Velocimeter (Bognor Regis, UK) using an 8 MHz doppler probe as the
blood pressure cuff was deflated and the pulse returned. The ABPI was calculated in both
lower limbs using the highest tibial artery pressure divided by the branchial artery
pressure. The limb with the lowest ABPI was used for the assessment of ischaemia in any
individual subject.
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5.3 Estimation and measurement of resting energy expenditure
5.3.1 Prediction equations for basal metabolic rate
A number of prediction equations have been devised for use in healthy subjects and the
equations most commonly used in the UK are the Schofield equations (Schofield et al,
1985). Twelve equations by sex and age were derived to allow the calculation of BMR
from weight for infants, children and adults. These equations were derived from indirect
calorimetry measurements carried out in 1500 healthy adults aged below 60 years, and are
most accurately used in comparable populations (Livesey and Elia, 1988). The use of the
Schofield equations was less appropriate in our older population of subjects with angina.
The predicted BMR was used in all studies except for that of angina patients.
Schofield equations to calculate BMR
Adults aged 18 - 30 years: Men: BMR = 0.063 (Wt) + 2.896
Women: BMR = 0.062 (Wt) + 2.036
Adults aged 30 - 60 years: Men: BMR = 0.048 (Wt) + 3.653
Women: BMR = 0.034 (Wt) + 3.538
5.3.2 Indirect calorimetry using ventilated hood method
The REE was measured in all subjects in the angina study because of their age range and
poor health invalidated the predictive equations (chapter 7). The principles of indirect
calorimetry measured using a ventilated hood method are based on measurements of
respiratory gas exchange, the consumption of oxygen and the production of carbon
dioxide (McLean and Tobin, 1990). These values were then used to calculate energy
expenditure. The ventilated hood method (plate 5.2) has been compares favourably with
159
whole body calorimetery measurements of energy expenditure (Murgatroyd et al, 1993).
The measurement of REE is the energy expenditure required to maintain physiological
equilibrium whilst at rest in the fasted state. In ideal conditions it is measured as subjects
are lying supine having just wakened, and before they have under taken any activities for
the day.
Expired air was measured using the ventilated hood method, in this case the Deltatrac
metabolic monitor (Merilainen, 1987) whilst the subjects laid at rest. The hood was
ventilated with air at atmospheric pressure at a rate of 40 Uminute. The subject only
inspired a small fraction of the air. The expired air was drawn over a 4 litre mixing
chamber within the instrument and the sample passed through differential paramagnetic
oxygen and infrared carbon dioxide sensors. The oxygen consumption and carbon
dioxide production were then calculated from the ventilation rate and the differentials in
gas concentration between the inspired and expired air. The instrument under micro-
processor control provides minute-by-minute data on oxygen consumption, carbon
dioxide production and energy expenditure. The REE was measured when the subject
was awake, lying supine and having fasted and only consumed water for a minimum
fasting period of 8 hours. Gas calibration was carried out before each measurement, using
standard gas (95% oxygen and 5% carbon dioxide) and the barometric pressure
measurement was adjusted to measured atmospheric pressure daily.
5.3.3 Factors affecting measurement of resting energy expenditure
The measurements of REE should be completed under conditions as strictly controlled
and constant as possible. In practice, these factors include room temperature, time of day
and resting time prior to measurement. The chosen measurement duration was 20
minutes, as beyond that time it was discovered that subjects found it difficult to remain
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wakened. In order to allow for an acclimatising period when the subjects were adjusting
to the environment beneath the hood, the initial 5 minutes of measurements were always
discarded. During the measurements, care was taken to ensure subjects did not sleep and
record artificially lowered REE values.
5.3.4 Dietary prescription methodology
Dietary intervention used an individual dietary prescription based on the Schofield
equation (Schofield et al. 1985) to estimate BMR for the 2 healthy subject groups. This
equation incorporated body weight, sex and age in its predictions. For the subjects with
angina, REE was measured and was considered to be the equivalent ofBMR. None of the
subjects engaged in regular physical exercise so an activity factor of BMR x 1.3 was used
to estimate daily energy requirements (COMA, 1991). A 600 kcal (2510 kJ) daily energy
deficit was applied and the resulting dietary prescription was adjusted to the nearest 100
kcal with a minimum daily prescription of 1200 kcal (5021 kJ).
The prescribed dietary composition was designed to provide greater than 50% energy
from carbohydrate, less than 35% energy from fat and under 20% from protein (COMA,
1991). Total fat energy targets were divided into approximately 10% energy from each of
monounsaturated, polyunsaturated and saturated fatty acids respectively. Advice was
given to restrict or avoid alcohol consumption.
5.4 Detailed dietary and behavioural advice
An eating plan employing standardised principles was devised and used for all three
studies (appendix 3). The plan was based on an exchange system for three groups of
foods "bread", "meat" and "fruit". The "bread" exchanges included foods rich in starchy
carbohydrate such as bread, cereals, rice, pasta and potatoes. The "meat" exchanges
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included lean meats, fish, eggs and cheese. The subjects were encouraged to increase
their consumption towards the dietary compositional targets (COMA, 1991). The "fruit"
exchanges were rich in carbohydrate which provided the main source of simple sugars,
although some jam or marmalade was permitted in order to ensure the palatability of
bread.
The portion sizes for each of the exchanges from each of the groups were described in
household measures. The sizes were calculated using the guide to average portions
(MAFF, 1993). A number of modifications had to be introduced in order to allow the
overall eating plan to reach the dietary targets and the portion sizes are given (appendix
3).
Individual energy prescriptions from a minimum of 1200 to a maximum 2400 kcal daily
were calculated in increments of 100 kcal per day using various combinations of these
exchanges. For each of the exchange groups mean energy provision and macronutrient
composition were calculated. The calculations were completed with the assumption that
the subjects would chose to eat a range of different combinations of the foods in the
exchange groups, and as such, their dietary intake would be as close as possible to the
targets.
A minimum of 45 minutes were allowed for each of the dietetic consultations when the
eating plan was given to each subject. A number of simple pieces of behavioural advice
were included within each consultation (table 5.1). These were devised for the present
studies, as the literature in this area has failed to detail the most effective components of
behavioural treatments. In review consultations, subjects described their current dietary
patterns before receiving their new eating plan. If subjects were failing to reach particular
dietary targets within their present dietary intake their particular barriers to making these
162
changes were discussed together. Practical suggestions to incorporate the recommended
lifestyle changes were considered.
5.4.1 Seven day weighed inventory
All studies reported within this thesis used the same method of dietary intake assessment,
with only the duration of recording differing between studies. For the study of overweight
but otherwise healthy subjects a 4 day WI diary was used, governed by the prior
commitment of these particular subjects to a study of diet and medication. In the study of
overweight subjects with angina, and healthy subjects whose BM! was close to 25 kg/rrr',
7 day WI diaries were used (Bingham et aI, 1994). At least 30 minutes were taken to
describe to the subjects how to make these recordings correctly. Subjects were advised to
weigh (plate 5.3) and record each item of food or drink as it was consumed (plate 5.4).
The food was weighed in the form in which it was to be eaten (Le. after cleaning and
cooking) and any left-overs were also recorded.
When possible, individual components or combined dishes should have been weighed.
For example, the individual components of a sandwich such as the bread, spread, and
filling should be weighed and recorded individually. For component dishes such as a
casserole, the subject was usually asked to weigh the item whole, and to record detailed
information about the quantities of ingredients used. A method, recipe and cooking time
were requested as well as the number of portions served in order that its composition
could be calculated later. Meals eaten outside the home and difficult to weigh were
accorded standard portion weights or household measures were used (MAFF, 1993).
The subjects were asked to weigh everything that they consumed during the recording
period, but in practice certain food items such as confectionery, crisps, commercially
produced biscuits and cakes, drinks in public houses would be consumed in standard
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weight portions and the subjects were advised of this. These items and their portion sizes
were described. A number of food photographs which had previously been validated
were included in each food diary (Edington et ai, 1988). These were used to estimate
portion sizes of commonly eaten foods which were difficult to estimate in terms of
household measures, e.g. rice, potatoes, chips. When incomplete descriptions of foods
were reported, or unaccounted gaps in the record appeared where food should have been
consumed, dietary recall approaches were used to try to obtain any missing information
and complete the record.
The 4 day WI diary included 2 consecutive weekend days and 2 weekdays. In order to
make the best comparison with 7 day WI method, the 2 week day nutrient values were
divided by 2 and multiplied by S. These new totals were added to the sum of the 2
weekend day values. Division of the fmal totals by 7 provided a mean nutrient total with
a reduced bias toward weekend food intakes. Food scales (Selectronic 2200, Salter, UK,
plate S.3) accurate to 2g were used to maximise the accuracy of dietary recording (Black,
1986). All subjects were asked to demonstrate use of scales, advised to use metric
measurements and shown an example day from a completed food diary. All subjects were
asked to complete food diaries at baseline, and week 12 (plate S.4).
5.4.2 Dietary analysis
Dietary analysis was carried out using the Compeat 4.0 dietary analysis system,
(Lifesystems, London) based on current food tables (Royal Society of Chemistry, 1991).
Weights used for foods were estimated from either household measures or from
packaging information. The chosen weight was recorded in the food intake diary being
analysed. The accuracy of data entry and overall quality control was ensured by using a
cross checking process. For each day from a food diary, a summary sheet with the totals
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for all foods consumed was compiled. These totals were compared to the values for food
intakes for each day within the dietary analysis programme. Any differences between
each method were checked and any inaccuracies found were corrected. This method
allowed the checking and entry of data to be completed by the same person.
5.4.3 Sample collection, handling and storage
Careful blood collection, sample handling and storage are essential for the accurate
measurement of the variables reported in these studies. The reliability of these results
ultimately reflected the care taken with these procedures. The withdrawal of blood is
known to result in immediate changes in some of the haemostatic factors (Thomson,
1992) activating some, such as tissue factors and platelet release factors, whilst
inactivating other factors such as t-PA and factor VU activity. To reduce the possibility of
the pre-analytical phase affecting the results, protocols were generated based on the
recommendations of ECAT (Thomson, 1992) and adherence to these protocols was
strictly observed. The venepuncture procedures for the blood samples used for the work
reported in this thesis thus used a standard procedure and were all carried out by the
author. To minimise the acute effects eating or any diurnal variations in all studies, blood
was sampled between the hours of 9-11 am following a 5 minute supine rest. Blood for
viscosity and lipid measurements was anticoagulated with EDT A and used to generate
plasma for viscosity after centrifugation for 15 minutes at 3000g. Aliquots of plasma
were stored at 4 0 C for later analysis. A maximum storage time of 6 months was allowed
for all samples (Thomson, 1992).
Blood was added to tubes containing 0.109 mM trisodium citrate with a final ratio of 9
volumes of blood to 1 volume of citrate. These tubes were pre-cooled on crushed ice in
order that the blood sample was cooled rapidly and the components were known to
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deteriorate at higher temperatures were preserved. The tubes were then centrifuged within
an hour at 2000g for 20 minutes in a refrigerated centrifuge at 4°C to produce platelet
poor plasma. After the careful removal from the cells with a disposable Pasteur pipette
the middle layer of the plasma was aliquoted and snap frozen at -70°C.
5.5 Haemorhology:
5.5.1 Red cell aggregation
Measurement of RCA was performed in whole blood anticoagulated with EDTA (1.5
mg/ml). A photometric technique using an automated MAl aggregometer (Myrenne
GMBH, Roetgen, Germany) was employed (Schmid-Shonbe et al, 1982, plate 5.5).
An aliquot of 25 ul of well mixed blood was placed on the aggregometer cone which
contacted a glass slide on closing the machine. The sample was subjected to a 10 second
period of high shear (around 600s·1) to disrupt any red cell aggregates. The change in
light transmission over a 5 second period of stasis was then measured. The greater the
RCA, the greater the transmission through the sample, and the higher the numerical value
obtained in AU from the aggregometer. These measurements were carried out at ambient
temperature (20 - 25°C) and at native haematocrit, as the standardising of haematocrit at
45% has been shown to have no effect on RCA in the majority of clinical situations
(MacRury, 1990). The mean of the duplicate readings was taken and the procedure was
repeated if there was a difference of more than 0.3 units between the readings, until
consistent readings were obtained.
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5.5.2 Haematocrit
Haematocrit was measured by the Hawksley microhaematocrit method (Hawksley and
Sons, Lancing, Sussex, UK) in accordance with the current international
recommendations (International Committee for Standardisation in Haematology, 1986).
Whole blood anticoagulated with EDTA was well mixed, and duplicate samples were
drawn up into glass capillary tubes of I mm in diameter which were then sealed at one
end. The tubes were then placed in the Hawksley microhaematocrit centrifuge and spun
at 13000 g for 5 minutes. The haematocrit was then read as a percentage of the sample
which was packed cells, without any correction for plasma trapping. An average reading
of the 2 samples was taken.
5.5.3 Whole blood viscosity
Whole blood viscosity was measured at 370 C and at high shear rates (over 300 s") with a
Coulter Harkness semi-automatic capillary viscometer (Coulter Electronics, Luton, UK,
plate 5.6). The instrument had a constant pressure head, which drew the sample through
the capillary tube, with a CV close to 1% (Harkness, 1971).
The time taken for the blood to flow through the capillary tube was recorded
electronically as the meniscus moved between 2 electrodes and the movement activated
an electronic timer. The velocity of flow was determined by measuring the time for the
mercury meniscus, which moved in a capillary tube parallel with the sample, to pass
between the electrodes. This activated a electronic timer. The viscometer was calibrated
daily with the standard viscosity solutions and the temperature of measurement checked.
The inter-assay CV was <5% and the intra-assay CV was <2%.
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5.5.4 Plasma viscosity
Plasma viscosity were measured at high shear rates (over 300 S·l) at 370 C in a Coulter
Harkness capillary viscometer (Coulter Electronics, Luton, UK, plate 5.6). The principles
for plasma viscosity measurements were very similar to those described in whole blood
viscosity measures. A 0.5 ml plasma sample was used for each measurement, and the
procedures and sample preparation were in accordance with the International Committee
for Standardisation in Haematology (1984). All measurements were made in duplicate
and a mean value reported. The inter-assay CV for <5.0% and the intra-assay CV was
<2.0%.
5.6 Coagulation measurements
5.6.1 Fibrinogen
Clottable fibrinogen was measured by the dilute thrombin clotting time method of Clauss
(1957). This was carried out on a Coag-A-Mate X2 automated coagulometer (Organon
Teknika, Cambridge, UK) using reagents and standards from the manufacturer. The
international fibrinogen standard (Gaffney and Wong, 1992) was also used to check the
manufacturers standard which was found to be satisfactory. An in-house plasma pool
from 20 healthy donors was used as the internal quality control which was aliquotted and
stored at -70 °c and used in each assay. Using the fibrinogen concentrations of the normal
pool over 10 assays the CV for inter-assay variability was found to be 5.1%. The intra-
assay variability was 3.2%, calculated from fibrinogen concentrations measured on the
pooled plasma run 5 times in the same assay.
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5.6.2 Factor VII activity
Factor vn activity was measured using a one stage clotting assay with human factor vn
deficient plasma (Sigma Chemical Co., Poole, Dorset, UK) and rabbit thromboplastin.
This was carried out on a Coag-A-Mate X2 automated coagulometer (Organon Teknika,
Cambridge, UK) using reagents and standards from the manufacturer and the results were
recorded as a percentage of a reference plasma pool. The inter-assay CV for <8.0% and
the intra-assay CV was <5.0%.
5.7 Fibrinolytic measurements
5.7.1 Tissue plasminogen antigen
Plasma levels of t-PA were measured with a commercially available enzyme linked
immunsorbent assay (ELISA) from Biopool AB, Umea, Sweden (Tintelize #101120).
The assay quantifies human single chain and two chain t-PA antigen. No cross reaction
with urokinase was observed. Maximal sensitivity of the assay, reported by the
manufacturer, was 1.5 ng/ml.
In this assay some interference may occur from plasma levels of other antibodies such as
anti-goat antibodies and rheumatoid factor. In order to exclude false positives, each
sample is added to 2 wells, one containing normal goat IgG, and the other containing goat
anti-human t-PA IgG. The difference in assay response between these two wells is highly
t-PA specific. After initial binding of the sample "to the pre-coated well, the second
antibody which is conjugated to bound peroxidase is added to the wells. This will bind to
free antigenic determinants on the t-PA molecules present. Unbound conjugate becomes
washed away after a further incubation period, and the remaining peroxidase was then
measured by the addition of the substrate orthophenylenediamine dichloride. The colour
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development was proportional to the amount of t-PA bound to the well and the optical
density was determined using an automatic MR700 microplate reader (Dynex, West
Sussex, UK) at 492 nm. The results were compared to standard curve established using
known amounts oft-PA.
Inter-assay CV was determined using a normal pool measured on 10 occasions and this
was found to be 9.8%. Intra-assay CV calculated on 5 single assays was 9.0%. The assay
was checked by testing the plasma from 6 healthy volunteers known to have a wide range
of t-PA concentrations. These measurements were used to calculate the CVs and the
duplicates were found to be very similar.
5.7.2 Plasminogen activator inhibitor
Plasma PAl activity concentrations were determined by a commercially available
chromogenic substrate assay (Coatest PAl; Chromogenix, Epsom, UK). The assay
involved the addition of a fixed amount of single-chain t-PA in excess to undiluted
plasma, where most of it rapidly forms an inactive complex with the fast inhibitor PAl-I.
The single chain t-PA was used in the assay as PAI-2 another inhibitor oft-PA found in
plasma inhibits this single chain form very poorly. The residual t-PA then activated
plasminogen to plasmin in the presence of a stimulator. The amount of plasmin formed
was directly proportional to the PAl activity in the plasma sample (this was most often
PAl-I). Plasmin levels are then determined by measuring the amidolytic activity of
plasmin on a chromogenic substrate (S-2403) which releases p-nitroaniline,
concentrations which are determined using an automatic microplate reader (MR700 from
Dynex, West Sussex, UK) at 405 nm. The adsorbance of the sample was then compared
with the standard curve generated on each test run, and a value for the concentration of
PAl activity obtained. This is expressed in AU, one unit being defined as the amount
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which inhibits one ID of t-PAlml under the test conditions (Chmeilewska and Wiman,
1986, Gram et al, 1993).
The kit had a reported sensitivity of S AU Iml, and remained unaffected by the normal
concentrations of alpha-2-antiplasmin. The pool or "control plasma" was produced by
combining normal plasma from 20 healthy volunteers, 10 men and 10 women aged
between 2S and 4S years, and freezing aliquots rapidly at -70 °C. The laboratory policy
has since become to express the results as a percentage of the "normal pool" rather than as
AU Iml. The value obtained for the normal pool was used to calculate the PAl activity
values for the samples on that plate. Assay of the normal pool in each set of assays also
gave information about the CV of the assay. The inter-assay CV performed on a normal
pool on 10 occasions was found to be 8.1% and the intra-assay CV was 7.0%.
5.8 Endocrine measurements
5.8.1 Dehydroepiandosterone sulphate concentrations
Serum for DHEAS measurements was collected by centrifugation of clotted blood at
3000g for 20 minutes at room temperature. Aliquots were pipetted into glass tubes,
capped and stored at _700 C for later analysis. Total serum concentrations of DHEAS
were determined using a radioimmunoassay kit (ICN Biomedicals). The assay had a
working range ofO.3 - 17.8 umol/l DHEAS. Inter- and intra-assay CV's were IS% and
10% respectively. EDTA anticoagulated blood (10 ml) was used for lipoprotein and
triglyceride analyses.
5.8.2 Insulin concentrations
Blood for insulin measurements was drawn from the anticubital vein with a minimum of
stasis using a sterile butterfly needle and plastic syringe and anti-coagulated with lithium
heparin. It was placed immediately on ice before centrifugation at 3000g for 20 minutes
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at 40 C and frozen at -700 C. Insulin measurements were carried out using an "in house"
immunradiometric assay with inter- and intra-assay CV's of 10% and 6%, respectively
and a sensitivity of 0.5 mUll.
5.9 Lipid measurements
Triglycerides and total cholesterol were measured on an automated analysis system
(Boehringer Mannheim, Lewes, Sussex.). HDL cholesterol was measured using ~-
quantification and ultracentrifugation with the removal of low density lipoprotein
cholesterol (LDL) by precipitation with heparin and manganese chloride. The Friedwald
equation (Freidwald, 1972) was used to calculate LDL cholesterol. For total, HDL
cholesterol and triglyceride measurements the inter-assay CV's were <5% and the inter-
assay CV were <2%.
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Table 5.1 Simple behaviour and eating guidelines
1. Regular meals
2. Fruit with each meal (3 daily)
3. Vegetables with both main meals
4. No butter or margarine
5. Eat only sitting down, off a plate, with a knife, fork and spoon
6. No eating in front of the television
7. 20 minutes daily exercise
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Plate 5-2 Delta trac metabolic monitor
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Plate 5- 3 Food scales
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Chapter 6 The effects of moderate weight loss on haemostatic
and rheological factors and plasma lipids in overweight
subjects
6.1 Introduction and hypotheses
The introductory literature review chapters have described the considerable evidence
which has supported overweight as being an important risk factor for llID mortality.
Elevations in blood pressure, blood lipids and insulin all encourage atheroma, and
contribute to an increased tendency towards thrombosis in the overweight. Overweight
individuals have elevated plasma coagulation factor vn activity, fibrinogen
concentrations and impaired fibrinolysis with an increased PAl activity (Meade et al.
1986, Vague et al. 1986, Lee et al. 1990). Raised rheological indices of blood flow,
haematocrit, whole blood and plasma viscosity and RCA have been shown to be related to
llID, stroke and peripheral disease (Lowe et al. 1990, 1991).
Clinical studies have shown altered coagulation and fibrinolytic measurements in the
overweight (Landin et al. 1990, Poggi et al. I994). These indices of coagulation and
fibrinolysis can be improved with weight loss (Slabber et al. 1992, Ernst et al. 1993,
Palareti et al. 1994). These studies used VLCD regimens, where effects from acute,
severe energy restriction were likely to confound effects of weight loss per se (Henry and
Gumbiner, 1991) and whose results are unlikely to persist in the long-term. The present
study used currently recommended dietary advice (COMA, 1991) and a moderate daily
energy restriction to investigate the effects of dietary intervention and weight loss on
haemostatic and rheological variables.
This study aimed to investigate the effect of a dietary intervention to reduce body weight
on RCA, factor vn activity, PAl activity, t-PA antigen, fibrinogen, whole blood viscosity
and plasma viscosities and lipids.
179
There were three hypotheses to be tested in this study of subjects who were overweight
but otherwise free of known disease:
1) if a dietary intervention incorporating an energy deficit approach to weight loss (600
kcal per day) would be achieve losses of close to the theoretical 0.5 kg per week in obese
volunteers?
2) if weight loss following a dietary intervention to lower total energy intake and change
dietary composition in line with current dietary targets, would improve haemostatic and
rheological risk factors for IHD?
3) if weight loss following a dietary intervention to lower total energy intake and change
dietary composition in line with current dietary targets, would be effective in improving
plasma lipid concentrations?
6.2 Methods
6.2.1. Study design and statistical approaches
A 12week study duration was chosen, to coincide with the period when maximum weight
losses are achieved by most subjects using dietary methods (Cowburn et al, 1997). The
experimental design, a single stranded study with biological measurements at baseline and
week 12, was used in accordance with the methodological principles described in chapter
4. Power calculations to determine sample sizes are given in chapter 4.
In order to provide additional information about the study subjects, their results were
compared with existing data from a West of Scotland population recruited from the Third
North Glasgow MONICA survey (WHO, 1989b). This random sample was from the
parent population of the study participants. Analysis of RCA and factor VU activity and
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anthropometric measurements for the MONICA subset were made using the same
methodology employed for the measurements of study subjects. The males and females
from the subsets of the MONICA population were selected using criteria very similar to
those used for the present study. These included being in good health, not following a
special diet, never ever having been given a doctor's diagnosis of stroke, angina, or MI
and having no ECG abnormality. A total of 521 males and 562 females fulfilled these
criteria. Values were obtained for both RCA and BMI from 368 males and 261 females.
Both factor VII activity and BMI results were obtained for and 431 males and 409
females.
A regression line was fitted for BMI, for both RCA and factor vn activity against BMI,
and the 95% confidence intervals for the mean values were calculated by sex group.
6.2.2 SUbject recruitment
Fifty-eight overweight subjects (49 women and 9 men) were recruited both from a local
weight management clinic and from local advertisements. Recruitment was carried out
throughout a whole year to minimise any seasonal influences. Twenty one subjects who
were also participating in a double blind placebo controlled trial of the lipase inhibitor
Orlistat (Roche Products Ltd, Welwyn Garden City) a weight reducing agent (Drent and
van de Veen, 1993). These subjects received the same dietary intervention as other study
participants who were not involved in the lipase inhibitor study. The degree of weight
loss achieved by the "orlistat" group", and changes in haemostatic and rheological
parameters were not different, so they were analysed alongside the other subjects as a
single group. All participants with any significant cardiovascular abnormalities or
diabetes (WHO, 1985) were excluded. All subjects were free of any medication known to
influence haemostatic measures, such as oral contraceptives or diuretics (Lowe et al,
1980). All subjects described at least a period of slimming in the preceding 2 year period
181
before commencing the study, although no one had reduced their weight by greater than
3.0 kg within the 3 month period prior to recruitment. Ethical approval for the study was
obtained from the Glasgow Royal Infirmary Joint Ethics Committee and signed informed
consent was obtained from all study participants.
6.2.3. Physical measurements
Subjects attended as outpatients on 5 occasions over the 12 week study period.
Anthropometric measurements of body weight, body fat distribution and percentage body
fat estimated using skin-fold calliper recordings, were made.
6.2.4. Dietary intervention and monitoring
Dietary intervention used an individual dietary prescription based on the Schofield
equation to predict BMR (Schofield et al, 1985). The dietary intake of each of the
subjects was monitored by the completion of 4 day WI diaries during study week 1 and
week 12, both recorded after dietary intervention.
6.2.5. Venesection and laboratory methods
Venesection was performed at baseline and after (week 12) dietary intervention. Whole
blood and plasma viscosity, haematocrit and RCA were measured, as were fibrinogen,
factor vn activity, PAl activity and t-PA. Plasma triglyceride, total and HDL cholesterol
were measured, and LDL cholesterol was estimated using the Friedwald equation
(Frieldwald, 1972).
6.3 Results
Thirteen subjects, 11 women and 2 men, failed to complete the study, and were excluded
from all the analyses. The reasons included illness (2), and a lack of satisfaction with the
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weight loss they achieved (4) and an inability to keep study appointments (7). There was
no reason to think that these drop-outs introduced bias. The characteristics of the 45
subjects (36 women and 9 men) who completed the study are shown as one group and
according to gender (table 6.1-6.3). The range of baseline body weight in the women
subjects was 61.5-120.8 kg, and in the men was 86.6-153.2 kg. The mean weight loss of
4.5 (SD 2.9) kg represented a weekly weight loss of 0.38 kg, 76% of the target value, with
no gender differences (p=0.18). Those subjects receiving Orlistat or placebo in addition
to dietary advice showed reductions in BMI of -1.95 vs. -1.59 kg/m2 respectively (p=0.75)
and were not significantly different from the dietary advice only group.
Mean dietary energy prescription was 6729 (SD 1648) kJ/day: range 5439-11715 kJ/day
(1608 SD 394) kcal/day, range 1300-2800 kcal/day). Recorded dietary intakes were 86%
and 85% oftotal daily energy prescription for the whole group after dietary intervention at
weeks 1 and week 12 respectively. Dietary analysis showed the reported intake of
macronutrients differed from the diet prescription, with an elevated percentage energy
from protein and a reduced percentage energy from carbohydrate. No significant
differences were found between dietary records for either total macronutrients or the
percentage energies for the whole group, or for either sex (table 6.4-6.6).
The haemostatic and fibrinolytic measurements are shown (table 6.7-6.9). Red cell
aggregation was significantly reduced by 13.6% after intervention (P=0.022) in all
SUbjects,inwomen (p=0.01) but not in men (p=0.73) (table 6.3). At baseline RCA was
not associated with BMI, WHR, although it was at week 12 (table 6.10-11). However the
changes inRCA were significantly associated with changes in WHR, but not BMI (table
6.12).
Mean factor VU activity was significantly reduced by 6% in all subjects (p=0.008), in
women (p=0.0043) but not men (p=0.27). The relationships for factor VU activity against
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BMI for the MONICA subset are shown (figure 6.2). The 95% confidence intervals
represent the anticipated limits for the mean factor VU activity at individual fixed BMIs.
For the study population the baseline and post-intervention values for factor VU activity
are shown as the base and tips of arrows respectively. Factor VU activity at baseline was
not significantly associated with anthropometric measures, but post-intervention was
associated with WHR, although no relationships were seen with changes in the measures
(table 6.10-6.12).
Amongst women (p=0.015) there were reductions in t-PA antigen concentrations of 22%
after dietary intervention. The evidence was weaker in all subjects (p=0.06), in men
(p=0.09).
Plasma cholesterol was reduced in all subjects by 7% (p=0.013) women (p=O.025) and,
but not men (p=0.25). LDL cholesterol concentration was significantly reduced only in
women (p=O.034). However, HDL cholesterol and triglyceride concentrations remained
unchanged. Relationships between plasma lipid measurements, haemostatic and
rheological risk factors are shown (table 6.14-6.16). At baseline significant relationships
were shown between plasma viscosity and total and LDL cholesterol, these relationships
were not shown after weight loss or between differences. Whole blood viscosity was
significantly related to triglyceride concentrations at baseline. The concentrations of t-PA
antigen were significantly related to plasma total cholesterol concentrations at baseline
and week 12, although no relationships were seen with the changes after weight loss (table
6.14-6.16). Changes in PAl activity were significantly related with changes in total
cholesterol concentrations (p=0.061).
Use of Pearson's correlation analysis revealed a significant relationship between the
changes post-intervention in BMI and in factor VU activity (r=0.395, p=O.OI) (figure 6.1).
No significant relationships were found between changes in haemostatic and rheological
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measures and serum lipid concentrations, or between changes in PAl activity, t-PA
antigen, plasma and whole blood viscosity, haematocrit, fibrinogen and WHR or BMI
(table 6.12).
The mean BMI for MONICA "healthy" men was 25.7 and the 25 and 95% percentiles
were 23.0 and 28.0 kg/m2 respectively. For "healthy" women these values were 25.7,
22.3 and 27.8 kg/rrr', The mean value for RCA for the subset of MONICA men was 3.8,
with 3.0 and 4.6 the 25% and 95% percentiles. The equivalent women's values were 3.9,
3.1 and 4.7. For men the mean factor VII activity was 104.3 IU/dL and the 25% and 95%
percentiles were 90.0 and 119.5. In women these values for factor VII activity were
109.3, 92.0 and 127.0 IU/dL. For the MONICA population figure 6.2 shows the
anticipated limits for the mean RCA at individual fixed BMIs. For the study sample the
baseline and post-intervention values for mean RCA against BMI are shown as lines.
6.4 Discussion
The principal aim of this study was to study the effect of weight loss on haemostatic and
rheological risk factors for ll-ID. However, the first hypothesis for the present study
concerned the effectiveness of energy deficit approach to weight loss in reducing body
weight, the approach used to achieve weight loss. The mean weight losses of 5.9 kg in
males and 4.1 kg in females after 12 weeks in this study are comparable with those
achieved by the majority of other workers using conventional dietary approaches
(Wadden, 1993). The results of Frost et al (1991), the only other published study to
examine the energy deficit approach to weight loss in clinical practice, resulted in similar
weight losses to this study. Inmales, the energy deficit approach resulted in weight losses
almost identical to the 6.0 kg predicted by calculation. Mean weight losses for females
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were 70% of the target. These differences could reflect an effect of gender in dietary
compliance.
These short term results (12 weeks) support the use of the 600 kcal energy deficit
approach to weight loss favoured in the SIGN guidelines (SIGN, 1996), in overweight but
otherwise healthy subjects.
Reported nutrient intakes at baseline (after dietary change was advised) and week 12 were
not significantly changed. These findings may be partly be explained by under reporting,
a recognised feature in the reported dietary intakes completed by those who are
overweight (Bingham, 1987). The results could suggest that the value of using weighed
food records lies more with influences on improved dietary compliance, rather than
providing accurate or meaningful information on food intakes. However, this assertion
cannot be answered by the present findings,
The second hypothesis for this study concerned the effects of weight loss on haemostatic
and rheological risk factors for llID. Significant improvements in 2 measures of llID
risk: RCA and factor VII activity were found after moderate weight loss. For both RCA
and factor VII activity the relationships between the study population and the
representative MONICA subset were made with BMI. The subset was selected using the
inclusion criteria for the current study population which were then applied to its' parent
population, which was both random and representative of the West of Scotland. For men,
the mean values for the study sample sat exactly on the MONICA data for both RCA and
factor vn activity. Yet, for women, the study sample had lower factor VII activity and
RCA in relation to BM! compared with the MONICA data, and no obvious explanation
for this fmding was apparent.
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The MONICA comparison has provided information about the relationships between
factor VII activity and BMI and RCA and BMI. The 95% confidence intervals only
provide a guide as to what is anticipated about the relationships between mean RCA,
mean factor VII activity and mean BMI because the confidence intervals are valid for the
individual, rather than the mean BMI (Woodward, personal communication 1996). The
finding that the baseline values for study subjects (represented by the point of the lines),
were closer to the regression line than the week 12 values, with the exception of RCA in
men, was unexpected. However, this probably reflected the acute effect of weight loss,
although only a moderate energy deficit was applied. The effect of the change in dietary
composition, to a lower percentage energy from fat may have also been influential.
Nevertheless, the failure of any significant correlations between the haemostatic and
rheological risk factors, or the changes are in agreement with these findings,
The lower RCA in the overweight women (figure 6.2) compared with a subset of the
Third north Glasgow MONICA survey population was surprising, with no obvious
explanation. Other studies of RCA values in overweight NIDDM, (MacRury et al, 1993)
adults and children (Ernst et ai, 1986, Wysocki et ai, 1991, Poggi et al, 1994) have found
RCA to be raised. In contrast, the trend towards increased RCA in the study population of
males after weight loss when compared with the MONICA subset was unexpected. The
13% reduction in RCA achieved in the entire study group can be compared with similar
findings in studies of healthy overweight subjects (Poggi et al, 1994). The association
between reduced abdominal fat distribution and RCA could suggest a mechanism related
to insulin resistance. However, other workers have found no clear evidence of a
relationship between changes in haemorheological and WHR values (Poggi et al, 1994).
Elevated whole blood and plasma viscosities have been shown in overweight subjects
compared with those within the range of 20-25 kg/m' BM! (Ernst et ai, 1986) and in
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overweight subjects with an elevated WHR compared with those with an acceptable ratio.
A WHR of >0.8 for women, >1.0 for men has been shown to reflect low llID risk
(Cacciari et al, 1988). Raised plasma and whole blood viscosities have been reported in
studies of the overweight (Ernst and Matrai, 1987, Fanari et al, 1993, Poggi et al, 1994).
Poggi et al (1994) showed a significant reduction in plasma viscosity in subjects
achieving a weight loss of 15.0 kg from a starting BMI exceeding 30 kg/rrr'. Plasma
viscosity in their study was 5% higher than in the present study (poggi et al, 1994),
however the values measured in this study were comparable with a representative West of
Scotland population (WHO, 1987). An 11% weight loss in adolescents with BMI greater
than 30 kg/m' reduced plasma viscosity significantly (Fanari et al, 1993) and in adults a
17 % weight loss from a BMI of 42.6 kg/m' significantly reduced plasma viscosity
(Cacciari et al, 1988). The presence of elevated WHR influenced blood rheology,
particularly whole blood viscosity, and haematocrit (Fanari et ai, 1993), but not plasma
viscosity. Blood viscosity showed significant reductions with a 17% weight loss when
differences were corrected to a 45% haematocrit before measurement at a low shear rate
(Fanari et al, 1993). No significant correlations were seen with BMI or WHR, excepting
plasma viscosity, which suggested that these relationships were weak.
The amount of weight loss and the starting BMI appear to be key factors in achieving
significant reductions in plasma and whole blood viscosities (Fanari et al, 1993). It seems
likely that the subjects in this present study were both slimmer at baseline than those in
others (parenti et al, 1988) and also failed to lose sufficient weight to alter either plasma
or blood viscosities.
An elevated haematocrit is associated with increased blood viscosity and has been shown
as a significant risk factor for non fatal MI and coronary disease (Carter et al, 1983). The
subjects' mean haematocrit was not elevated when compared with the non obese
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population, and it remained unchanged after weight loss. These findings are in agreement
with the results of some studies (Parenti et al, 1988, Fanari et al, 1993) but at variance
with others (Poggi et al, 1994).
Plasma fibrinogen concentration is another important determinant of plasma viscosity
(Koenig et al, 1994). However, the significant decrease in RCA was not, however, due to
any decrease in plasma fibrinogen concentrations. These results are in agreement with
those of other studies which suggest that the influence of both dietary intervention and
weight loss to reduce plasma fibrinogen concentrations are small (Fehily et al, 1982, Ernst
et al, 1986, Parenti et ai, 1988, Ernst et al, 1989, Slabber et al, 1992, Palareti et al, 1994).
Existing studies which have reported both the effects of weight loss and dietary change on
plasma fibrinogen concentrations have been equivocal (Fehily et al. 1982, Ernst, 1993)
and they have suggested that the influence of dietary intake on plasma fibrinogen was very
small, accounting for around 5% of total variance. Interestingly, fibrinogen
concentrations were significantly associated with BM! at baseline, which was in
agreement with the evidence that increased body weight and increased plasma fibrinogen
are associated (Ernst, 1991).
The influence of factor VII activity as an indicator of increased coronary risk has been
demonstrated by epidemiological studies (Meade et al, 1986, Lee et al, 1990, Heinrich et
al, 1994) and linked with increased body weight and dietary fat intake (Folsom et al,
1993). The 10% reduction in factor VII activity achieved in the present study is close to
the results of others (Folsom et al, 1993, Palareti 1994). Similar differences in factor VII
activity were demonstrated between groups of those at high and low heart disease risk
within two large epidemiological surveys (Meade et al, 1986, Lee et ai, 1990). In
contrast, the results of a similar study which achieved weight loss using a 1200 kcal diet
in contrast to that used in the present study, although factor VII activity remained
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unchanged (Baron et al, 1989). A possible explanation for these results may be the effects
of dietary composition, as half of the study population were consuming a diet with a
percentage energy from fat of close to 50% after dietary intervention.
The influence of dietary fat intake on factor VU activity has also been considered (Miller
et al, 1986). A significant association has been found between total dietary fat intake and
factor VU activity. A significant decrease was seen in factor VU activity with reductions
in dietary fat intake (31% energy from fat) without weight loss. A similar dietary
intervention (32% energy from fat) with two different fat compositions, a low or high
polyunsaturated to saturated fat ratio also significantly lowered factor VU activity
(Marckmann et al, 1992). The present study did not find a relationship between dietary
fat intake and factor VU activity at baseline, or between differences in these variables
post-intervention.
The two components of the fibrinolytic system PAl activity and t-PA antigen measured in
the present study are related to overweight and to increased llID risk (Carlson et al, 1981,
Vague et al, 1986, Landin et al, 1990). An elevated PAl activity has been associated with
obesity and with raised WHR (Vague et al, 1986, Wysocki et al, 1991). Significant
reductions in PAI-l activity and t-PA antigen have been shown after weight losses (Vague
et al, 1986, Landin et al, 1990, Mehrabian et ai, 1990) double that observed in the present
study (mean weight loss 10.0 kg). Once more the reason for the reduction in t-PA antigen
in Women subjects in the present study was probably the result of sufficient weight loss
being achieved. Two other studies of weight loss, one using surgery (Sylvan et al, 1992)
and the other using dietary intervention (Folsom et ai, 1992) showed significant falls in t-
PA antigen, 60% and 24% respectively. The actual weight losses were only available for
the latter study (8.0 kg). The results of this present study found a 21% fall in t-PA antigen
in women which is in line with these other findings.
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The findings of the present study, that BMI was significantly correlated with factor VII
activity at baseline, week 12, and with the differences in BMI after weight loss were in
agreement with the majority of the literature. The relationships for PAl activity were in
agreement with those for factor VII activity. These relationships are also encouraging as
to what the effect of increased weight loss could possibly have been. Of the findings from
the present study, these relationships between the changes in factor VII activity, PAl
activity and BMI, WHR, fibrinogen with BM! and RCA with WHR were the only
significant ones. Greater weight losses may have strengthed some of the other
relationships. However, these relationships have supported other published results.
The third hypothesis for this study ''that the dietary intervention used would be effective
in lowering plasma lipids", was also proven. The degree of reduction in plasma
cholesterol following weight loss is 1.3% per kg weight loss, in agreement with the
majority of the literature (Dattilo and Kris-Etherton, 1992). However, the stability of
HDL cholesterol and triglyceride found in this study following weight loss are in contrast
with the majority of publications (Goldstein, 1992), and these results reflect the modest
weight losses in the present study. The effects of dietary change and weight loss on
plasma HDL cholesterol in the scientific literature are somewhat confused. The
influences on plasma HDL cholesterol in this study are probably twofold. Firstly, the
effect of reducing dietary fat intake would be to elevate the HDL cholesterol
concentration, whilst the acute effect of weight loss would lower HDL (Leenen et al,
1994). These two opposing effects probably led to HDL cholesterol concentrations
remaining unchanged. The few relationships between the lipids and haemostatic and
rheological factors at baseline, week 12 and with weight loss, are probably a reflection of
all factors remaining within the laboratory reference ranges and the limited weight loss
observed.
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6.5 Conclusion
The results of this study of dietary intervention for weight loss in healthy but overweight
subjects suggest that moderate weight loss significantly improves two coagulation and
rheological indices linked with increased llID risk, (factor VU activity and RCA), and
plasma cholesterol concentrations. Some less pronounced benefits on fibrinolytic
measures were also seen. The 600 kcal energy deficit dietary approach to weight loss has
been shown to be at least as effective as other more complex or invasive methods.
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Table 6-1 Characteristics of women who completed the study at baseline and week
twelve
Baseline Week 12 Difference p
Age (years) 44.3 (10.5)
Weight (kg) 87.6 (12.6) 83.5 (13.2) -4.1 (2.9) 0.00001
BMI (kg/m2) 34.1 (5.2) 32.4 (5.4) -l.7 (1.1) 0.00001
Waist to hip ratio 0.97 (0.1) 0.97 (0.1) 0.0 (0.1) 0.20
Total cholesterol (mmolll) 5.6 (0.9) 5.2 (0.95) -0.4 (0.6) 0.025
LDL cholesterol (mmolll) 3.6 (0.9) 3.4 (0.9) -0.2 (0.5) 0.034
HDL cholesterol (mmolll) 1.4 (0.3) 1.3 (0.4) -0.1 (0.2) 0.22
Trigll:ceride ~mmollll 1.2 (0.4) 1.3 (0.5) +0.1 (0.3) 0.36 -
Data mean (SD), n=36
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Table 6-2 Characteristics of men who completed the study at baseline and week
twelve
Baseline Week 12 Difference p
Age (years) 40.8 (9.8)
Weight (kg) 116.8 (2404) 110.9 (23.6) -5.9 (3.3) 0.0007
BMI (kglm2) 38.5 (804) 36.5 (8.0) -2.0 (0.9) 0.0003
Waist to hip ratio 1.1 (0.1) 1.0 (0.1) -0.1 (0.1) 0.0045
Total cholesterol (mmol/l) 6.5 (1.1) 5.9 (0.8) -0.6 (1.2) 0.25
LDL cholesterol (mmol/l) 404 (1.3) 4.0 (0.9) -004 (1.6) 0.54
HDL cholesterol (mmol/l) 1.2 (0.9) 1.0 (0.2) -0.2 (0.9) 0.60
Triglyceride (mmol/l) 1.8 (0.7) 1.8 (0.6) 0.0 (0.6) 0.96
Data mean (SD), n=9
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Table 6-3 Characteristics of all subjects who completed the study at baseline and
week twelve
Baseline Week 12 Difference p
Age (years) 43.6 (10.4)
Weight (kg) 93.5 (19.3) 88.9 (19.1) -4.5 (2.9) 0.00001
BMI(kg/m2) 34.9 (6.1) 33.2 (6.1) -1.7 (1.1) 0.00001
Waist to hip ratio 0.99 (0.1) 0.98 (0.1) -0.1 (0.1) 0.020
Total cholesterol (mmolll) 5.8 (1.1) 5.4 (0.9) -0.4 (0.8) 0.016
LDL cholesterol (mmolll) 3.8 (1.1) 3.6 (0.9) -0.2 (0.9) 0.11
HDL cholesterol (mmolll) 1.3 (0.5) 1.2 (0.4) -0.1 (0.5) 0.34
Trigl~ceride {mmolll~ 1.4 (O.6} 1.4 ~0.62 0.0 (0.42 0.55
Data mean (SD), n=45
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Table 6-7 Haemostatic and fibrinolytic measurements at baseline and week twelve
for women
Baseline Week 12 Difference p
Whole blood viscosity (mPas) 2.9 (0.3) 2.9 (0.3) 0.0 (0.3) 0.73
Haematocrit (°/0) 43 (4) 43 (4) 0(3) 1.00
Plasma viscosity (mPas) 1.31 (0.07) 1.29 (0.08) -0.02 (0.07) 0.23
Red cell aggregation (AU) 4.4 (1.2) 3.8 (1.1) -0.6 (1.2) 0.010
Fibrinogen (gil) 3.3 (0.9) 3.2 (0.63) -0.1 (0.7) 0.44
Factor VII activity (IU/dL) 115 (22) 108 (22) -7 (18) 0.017
PAl activity (°/0 pool) 147 (62) 137 (63) -10 (54) 0.29
t-PA antigen (flg/mL) 9.2 (5.1) 7.2 (3.1) -1.9 (3.5) 0.03
Data as mean (SD), n=36
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Table 6-8 Haemostatic and fibrinolytic measurements at baseline and week
twelve for men
Baseline Week 12 Difference p
Whole blood viscosity (mPas) 3.5 (0.3) 3.4 ( 0.3) -0.1 (0.2) ----0.92
Haematocrit (%) 44 (2) 45 (3) +1 (4) o.ia
Plasma viscosity (mPas) 1.36 (0.04) 1.33 (0.03) -0.03 (0.06) 0.29
Red cell aggregation (AU) 4.7 (2.0) 4.8 (1.5) +0.1 (1.8) 0.8S
Fibrinogen (gil) 2.9 (0.7) 3.5 (0.8) +0.6 (0.7) 0.06
Factor VII activity (IU/dL) 114 (10) 107 (10) -7(11) 0.14-
PAl activity (% pool) 194 (58) 178 (74) -16 (85) 0.61
t-PA antigen ~~g/mL} 9.8 (2.4) 11.1 (0.9) +1.3 (2.1) 0.16.__
Data as mean (SD), n=9
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Table 6-9 Haemostatic and fibrinolytic measurements at baseline and week twelve
for all subjects
Baseline Week 12 Difference p
Whole blood viscosity 3.05 (0.38) 3.04 (0.39) -0.01 (0.40) 0.82
(mPas)
Haematocrit (%) 43 (4) 43 (3) 0(4) 0.45
Plasma viscosity (mPas) 1.32 (0.06) 1.30 (0.08) -0.02 (0.07) 0.48
Red cell aggregation (AU) 4.4 (1.3) 4.0 (1.2) -0.4 (1.4) 0.04
Fibrinogen (gil) 3.2 (0.8) 3.4 (0.7) +0.2 (0.7) 0.11
Factor VII activity (lU/dL) 114 (21) 107 (20) -7 (17) 0.006
PAl activity (% pool) 157 (62) 150 (69) -7 (59) 0.23
t-PA antigen {~g/mL} 8.7 (4.5) 8.3 (3.1) -0.4 (3.4) 0.12 -
Data as mean (SD), n=45
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Table 6-10 Relationships between body mass index and waist to hip ratio
with haemostatic and rheological factors at baseline
t-PA antigen (ug/ml.)
BMI kg/ml WHR
r= 0.111 r= 0.168
p= 0.474 p= 0.282
r= -0.123 r= -0.125
p= 0.431 p= 0.431
r= 0.369 r= 0.381
p= 0.016 p= 0.014
r= 0.245 r=0.171
p= 0.110 p= 0.274
r= 0.471 r= 0.221
p= 0.002 p= 0.170
r= 0.020 r= -0.253
p= 0.902 p= 0.111
r= 0,410 r= 0.347
p= 0.006 p= 0.026
r= 0.252 r= -0.072
p= 0.150 p= 0.685
Haemostatic factors
Whole blood viscosity (mPas)
Haematocrit (%)
Plasma viscosity (mPas)
Red cell aggregation (AU)
Fibrinogen (gIL)
Factor VII activity (IU/dL)
PAl activity (% pool)
n=45
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Table 6-11 Relationships between body mass index and waist to hip ratio with
haemostatic and rheological factors at week twelve
t-PA antigen (ug/ml»)
BMI kg/m1 WHR
r= 0.262 r= 0.184
p= 0.102 p= 0.299
r= 0.044 r= 0.072
p= 0.783 p= 0.683
r= 0.209 r= 0.142
p= 0.207 p= 00430
r= 00400 r= 0.683
p= 0.009 p= 0.835
r= 00460 r=0.175
p= 0.175 p= 0.323
r= 0.021 r= 00419
p= 0.892 p= 0.009
r= 0.508 r= 0.508
p= 0.001 p= 0.014
r= 0.207 r= 0.207
p= 0.290 p= 0.182
Haemostatic factors
Whole blood viscosity (mPas)
Haematocrit (%)
Plasma viscosity (mPas)
Red cell aggregation (AU)
Fibrinogen (gil)
Factor VII activity (IU/dL)
PAl activity (% pool)
n=45
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Table 6-12 Relationships between changes in body mass index and waist to hip
ratio with changes in haemostatic and rheological risk factors for all subjects
Change in haemostatic factors Change in Change in
BMI kglm2 WHR
r= -0.13 r= -0.01
p= 0.421 p=0.946
r= 0.11 r= -0.16
p= 0.491 p=0.373
r= -0.20 r= 0.10
p=0.244 p=0.614
r= -0.09 r= 0.34
p= 0.551 p= 0.057
r=0.01 r=-0.04
p=0.946 p= 0.841
r= 0.39 r= -0.18
p=0.014 p= 0.337
r= 0.43 r= -0.30
p= 0.005 p= 0.101
r= 0.21 r= -0.15
p=0.305 p= 0.509
Change inwhole blood viscosity (mPas)
Change in haematocrit (%)
Change in plasma viscosity (mPas)
Change in red cell aggregation (AU)
Change in fibrinogen (gil)
Change in factor VII activity (lU/dL)
Change in PAl activity (% pool)
Change in t-PA antigen ij1gImL)
n=45
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Table 6-13 Relationships between haemostatic and rheological factors and plasma
lipids at baseline
Haemostatic factors ~ Cholesterol LDL
(mmoUL) cholesterol
(mmoUL)
HDL
cholesterol
(mmoUL)
Triglycerid
e
(mmoUL)
Whole blood viscosity (mPas) r = 0.106
p = 0.577
r = 0.166
p=0.409
r= 0.279
p=O.142
r= 0.427
P = 0.021
lIaematocrit(OI'o) r= 0.054 r= 0.102 r=-O.I44 r= 0.250
p = 0.775 p = 0.614 p=0.457 p = 0.457
Plasma viscosity (mPas) r = 0.418 r= 0.454 r= -0.214 r= 0.384
p=0.027 p=0.023 p=0.285 p=0.285
Fibrinogen (gIL) r= 0.040 r= -0.023 r= 0.083 r= 0.020
p=0.843 P = 0.913 p=0.686 p= 0.686
Factor VII activity (lU/dL) r=0.099 r=-0.015 r= 0.019 r = 0.181
p=0.610 p=0.944 p=0.922 p = 0.922
PAl activity (% pool) r= 0.356 r= 0.228 r= -0.037 r= 0.354
p=0.063 p=0.273 p=0.856 P = 0.856
t-PA antigen {JlgImL) r=0.448 r= 0.270 r=0.07 r= 0.288
p=0.037 p=0.263 p=0.758 P = 0.758
n=45
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Table 6-14 Relationships between haemostatic and rheological factors and plasma
lipids at week twelve
Haemostatic factors Cholesterol LDL HDL Triglycerid
(mmol/L) cholesterol cholesterol e (mmel/L)
(mmol/L) (mmol/L)
Whole blood viscosity (mPas) r=0.066 r= -0.123 r= -0.296 r = 0.218
p=0.279 P =0.568 p=0.143 p=0.284
Haematocrit(oAD) r= 0.112 r = 0.106 r = -0.150 r = 0.337
p =0.571 p = 0.615 p=0.359 p=0.085
Plasma viscosity (mPas) r= 0.450 r=0.448 r= -0.224 r=0.327
p = 0.021 p=0.032 p=O.318 p = 0.111
Fibrinogen (gIL) r = 0.119 r= 0.089 r=-0.183 r=0.294
p = 0.563 p=0.694 p =0.450 p = 0.153
Factor VII activity (lU/dL) r=0.338 r = 0.145 r= 0.305 r= 0.131
p=0.068 p = 0.471 p=0.287 p = 0.497
PAl activity (% pool) r= 0.225 r= 0.140 r= -0.056 r= 0.347
p=0.250 p = 0.505 p=0.956 p = 0.076
t-PA antigen WglmL) r= 0.490 r= 0.574 r = -0.401 r= 0.572
p=0.024 p = 0.010 p=0.378 p=0.007
n=45
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Table 6-15 Relationships between changes in haemostatic and rheological factors
and plasma lipids
Change in haemostatic factors Change in Change in Change in Change
cholesterol LDL HDL Triglyceride
mmollL cholesterol cholesterol mmollL
mmollL mmollL
Whole blood viscosity (mPas) r=-0.238 r= 0.154 r= -0.180 r= -0.002
p=O.242 p=0.484 p= 0.390 p=0.994
-------
lIaematocrit(~) r=0.021 r= -0.016 r= -0.189 r= -0.424
p=0.917 p=0.942 p= 0.356 p= 0.031
Plasma viscosity (mPas) r=0.262 r= -0.336 r= -0.212 r= -0.191
p=0.228 p= 0.148 p=0.331 p=0.394
Red cell aggregation (AU) r= 0.259 r= -269 r= -0.194 r= -0.064
p= 0.183 p= 0.194 p= 0.616 p= 0.750
---_.- ...Change in fibrinogen (gil) r= -0.028 r= 0.012 r=0.111 r= 0.191
p=0.896 p=0.957 p=0.652 p= 0.372
Factor VII activity (lU/dL) r= 0.098 r= 0.015 r= 0.200 r= -0.072
p=0.620 p=0.942 p= 0.316 p=0.721
PAl activity (~ pool) r= 0.373 r= -0.226 r= 0.224 r= 0.083
p= 0.061 p= 0.300 p= 0.281 p=0.693
t-PA antigen {J.tgImL) r= 0.141 r= 0.091 r= 0.230 r= 0.065
p= 0.576 p=0.737 p=0.374 p=0.798
n=45
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Figure 6-1 Relationship between changes in factor VII activity and BMI
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Figure 4-2 Fitted regression lines of red cell aggregation and factor VII activity
against body mass index for the MONICA subsets of men and women
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Chapter 7 The effects of moderate weight loss on haemostatic and
rheological factors and plasma lipids in overweight subjects with angina
pectoris
7.1 Introduction and hypotheses
A number of clinical studies support the epidemiological observations that haemostatic
and fibrinolytic measurements are altered in the overweight (Le Devehat et al, 1992). In
addition, some of these haemostatic and fibrinolytic factors have shown greater alterations
in those with known llID and angina (Aznar et al, 1988). The present study used
recommended dietary composition (COMA, 1991) and a moderate daily energy restriction
to investigate the effects of weight loss in angina subjects.
The main aim of this study was to investigate the effect of moderate weight loss on
haemostatic and rheological factors in older overweight subjects with established ilID, in
this case angina pectoris, who might show greater changes than healthy subjects. The
effects of weight loss on plasma lipid concentrations and the frequency of anginal pain
were also examined.
A link between plasma lipid concentrations and haemostatic and rheological factors has
been observed (Miller et al, 1986). The hypothesis that improvements in plasma lipid
concentrations are associated with improvements in haemostatic and rheological factors
has been proposed (Mitropoulos et al, 1991). The present study examined relationships
between the triglyceride and total, HDL and LDL cholesterol concentrations at baseline
and between changes in the measurements after dietary intervention for weight loss.
There were four hypotheses to be tested in this study of overweight subjects diagnosed
with angina pectoris. It was hypothesised that the effects of dietary intervention on the
principal outcome measures may be increased in subjects with established ilID.
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1) A dietary intervention incorporating an energy deficit approach to weight loss (600 kcal
per day) would be effective in achieving losses of body weight close to 0.5 kg per week in
subjects with angina.
2) Weight loss after a dietary intervention to lower total energy intake and change dietary
composition in line with current dietary targets would improve haemostatic and
rheological risk factors for llID in overweight subjects with angina.
3) Weight loss after a dietary intervention to lower total energy intake and change dietary
composition in line with current dietary targets would improve plasma lipids in
overweight subjects with angina.
4) Dietary intervention and weight loss would reduce anginal symptoms.
7.2 Methods
7.2.1 Study design and statistical approaches
A single stranded design was used for the study. This method was chosen according to
the principles described in chapter 5. The same power analyses calculated for the
previous study (chapter 4) was used to determine the required sample size of 48 based on
factor VII as the principle outcome measure. Parametric statistical methods were applied
as the differences between the haemostatic, rheological and lipid measurements were
normally distributed, when determined by a distribution plot. The relationships between
the changes in haemostatic and rheological measurements and plasma lipids were
examined using Pearson's correlation analyses.
7.2.2 Subject recruitment
Fifty-four overweight subjects with angina (31 men, 23 women) with a BM! > 26 kg/m2
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who had been given a medical diagnosis of angina pectoris but who had not had dietetic
advice were recruited. Several West of Scotland newspapers included the recruitment
appeal as feature stories (appendix 4). All respondents made telephone contact with the
department and were posted an initial screening questionnaire which requested them to
provide personal details including their age, anthropometric measurements and medical
history. Angina was confirmed with a positive modified Rose questionnaire completed
when the subjects attended the Department of Human Nutrition (Rose, 1962). All
subjects described at least one period of unsuccessful slimming in the preceding 2 year
period before commencing the study, though no one had reduced their weight by greater
than 3.0 kg during the 3 month period prior to recruitment. Ethical approval for the study
was obtained from the Glasgow Royal Infirmary Joint Ethics Committee and signed
informed consent was obtained from all participants.
Coagulation and haemostatic measures from study subjects were compared with existing
data from a representative West of Scotland population: the North Glasgow Third
MONICA survey database (WHO, 1987). For men and women a representative subset of
the MONICA population was selected on the criteria of having a diagnosis of angina
given by a doctor, no history of stroke, a positive Rose questionnaire, no Q\QS interval on
the ECG and no history of MI. A total of 77 men and 74 women fulfilled these criteria.
Values were available for both RCA and BMI for 52 men and 41 women and for factor
vn activity and BMI for 60 men and 51 women.
7.2.3 Physical measurements
Each subject attended the University of Glasgow Department of Human Nutrition on 5
occasions over a 12 week study period. Body weight, waist and hip circumferences were
measured and BMI, body fat composition and WHR were calculated.
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Inorder to characterise health of the subjects, 2 further measures were made. Any cardiac
changes reflecting coronary disease which may have also been present in addition to the
angina, were examined using an ECG (Cardiofax V, Nihon Kohdon). In addition, the
presence or absence of PVD was assessed using the brachial and ankle systolic blood
pressures. The pressure measurements were made using an ultra-sonic flow detector and
ABP! was calculated (Yao et al, 1969). The ABP! measurement reflects long term
vascular disease and does not change acutely over a short period such as 12 weeks. For
these reasons the measurement was only made at baseline (Yao, 1973). Subjects reported
medication use and anginal frequency at baseline and study week 12. The subjects
reported the frequency of anginal pain alongside the food intake information in the 7 day
WI diaries.
7.2.4 Dietary intervention and monitoring
Dietary intervention used an individualised dietary prescription based on the indirect
measurement of REE, because prediction equations for BMR are only valid for healthy
subjects, This was measured using an indirect ventilated hood calorimeter (Delta-trac)
which was calibrated at 4 weekly intervals by alcohol burning (Merilainen et al 1987).
The predicted BMR was also calculated using the Schofield equation (Schofield et ai,
1986) and the two methods were compared. This methodology has been described in
greater detail in chapter 5.
Dietary intake was monitored by the subjects completion of 7 day WI food diaries during
the week before dietary intervention, (baseline), and at week 5, 7 and 12 of the
intervention period. The first (week 0) and last (week 12) monitoring periods were
considered the most important and only their values and the differences between the two
measurements are given in the results. The final recording day on each occasion was the
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day before the last study visit. The dietary records were completed using the standardised
methodology already described (chapter 5).
7.2.5 Venesection and laboratory methods
Venesection was performed at baseline, (pre-intervention) and week 12 (post-
intervention). The measurements made included haemostatic and rheological factors,
factor vn activity, fibrinogen, PAl activity, t-PA antigen, plasma viscosity, RCA,
haematocrit and plasma lipids. The lipid measurements comprised total and HDL
cholesterol and triglyceride. The LDL cholesterol concentration was calculated using the
Friedwald equation (Friedwald, 1972). The measurements were all carried out according
to the established methods described earlier (chapter 5).
7.3 Results
The characteristics of the subjects who completed the study are described (table 7.1-7.3).
The prescribed medications for these subjects relevant to their cardiovascular disease were
glyceryl trinitrate spray (27), aspirin (20), diuretics (12), ~ blocking agents (29) and lipid
lowering medications (1). There was no change in any prescribed medications after the
dietary intervention was complete.
There were no significant differences between the sexes for age (p=0.76) however the
mean BM! in men was greater than that in women 30.9 (SD 4.5) kg/m' (range 25.6 to
40.9) vs. 27.8 (SD 2.5) kglm2 (range 25.0 to 32.7) (p=0.04). Mean weight change over
the 12 study weeks was similar in men and women at 3.5 kg (table 7.1-7.3). The
frequency of anginal pain in all subjects between baseline and week 5 was unchanged, but
was significantly reduced below baseline at weeks 7 and 12 (table 7.4, figure 7.1).
Mean energy prescription was 6217 (SD 1498), range 4184-1172 kJ, and 1485 (SD 358),
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range 1000-2670 kcal, per day for all subjects. For men this was 6941 (SD 1292), range
5020-10460 kJ, and 1658 (SD 309), range 1199-2500 kcal, and for women 5322 (SD
1292), range 4184-7949 kJ, and 1271 (SD 309), range 1000-1899 kcal. The
measurements made with the Delta-trac metabolic monitor are shown (table 7.3).
Comparison of the estimated BMR calculated using the Schofield equations 6703 (SD
1025) kJ and 1602 (SD 245) kcal, and the measured values, 6113 (SD 1058) kJ and 1461
(SD 253) kcal showed the estimated values significantly exceeded the actual values
(p=0.0062). This comparison illustrated the value of measuring REE in subjects who did
not match the criteria of healthy subjects aged below sixty years of age, from whom the
equations were derived.
Recorded dietary intakes were 106% of total daily energy prescription for all subjects at
week twelve, and 105% and 107% for men and women respectively. Dietary analysis
showed elevated protein and decreased carbohydrate in comparison with the dietary
prescription (table 7.5-7.7). After dietary intervention, reported dietary intakes fell
significantly for energy and percentage energy provided by fat and alcohol, and dietary
protein and carbohydrate increased (except for alcohol in men and women) for both sexes
(table 7.5-7.7).
The biochemical measurements are reported at baseline and week 12 together with the
differences for all subjects. Factor VII activity at baseline was higher in women than men,
130 (SD 20) vs. 114 (SD 26) IU/dL (p=O.04) but no sex difference was observed in the
other measures (table 7.1-7.3).
Of all the haemostatic and fibrinolytic indices measured, significant changes were only
observed in RCA and factor VII activity (table 7.1 - 7.3). The RCA and factor VII values
were compared with a subset of the North Glasgow Third MONICA survey population.
These plots show men and women separately because there was an effect of sex on factor
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vn activity (p=0.0002) and a sex by BMI interaction on RCA (p=0.02) in the MONICA
data. This showed baseline values well below the regression line for all measures
excepting factor vn activity in men. RCA and factor vn activity in the present study
showed similar falls with 4.2% weight loss (figure 7.2). No significant changes were
found in the other rheological or fibrinolytic measurements. There was some suggestion
of a trend towards reductions in PAl activity in men with weight loss (p=0.09).
Waist circumferences were significantly reduced in all subjects (p=0.0005), in men
(p=0.0007), but not women alone (p=0.11). A significant correlation was found between
the changes in factor VII activity and changes in BMI for all subjects and in the group of
men (table 7.8-7.10). Changes in HDL cholesterol were significantly related with changes
in waist in all subjects and men and in WHR for all subjects (table 7.8-7.10). No other
significant relationships were found between changes in body weight or alterations in
waist circumference and changes in biochemical measures throughout the course of the
study.
To examine whether a normal or altered ECG measurement or the presence of PVD
would influence haemostatic and rheological factors the study sample was divided
according to ECG or ABP! measurements. ABP! measurements were only made at
baseline, as the measurement reflects long term changes in the peripheral vasculature
which take place over years, not weeks (Yao, 1973). Eleven subjects (2 women) showed
signs of occlusive PVD with ABP! below 0.9. No differences in plasma measures could
be related to ABP!. There was no effect of lowered ABP! measurements on baseline
measures or changes in biochemical measures.
Twenty-seven subjects had a normal ECG (14 women), whereas 13 subjects (4 women)
showed sinus bradycardia and 9 (4 women) showed significant signs of myocardial
ischaemia. There were no differences in biochemical measures according to ECG at
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baseline, or in the changes in biological measures after intervention. The exception was
factor VU activity. The group with a normal ECG showed a significant fall in mean factor
VU activity 121 {SD 21} to 115 {SD 19} IU/dL, mean difference 6 {SD 16} IU/dL
(p=O.037) but this fall was not observed in the other two groups after dietary intervention.
Plasma cholesterol was reduced by 6% in all subjects (p=O.OOOl), in men (p=O.019), and
in women (p=O.Oll), HDL cholesterol was unaffected by body weight change. The LDL
cholesterol fraction was significantly lowered in all subjects (p=O.008), in men (p=O.010)
and women (p=O.021) {table 7.1-7.3}.
At baseline, HDL cholesterol was significantly correlated with factor VU activity in the
group of men and in all subjects {table 7.12 -7.13}. Factor VU activity was also related
to total cholesterol concentrations at baseline in women and all subjects {table 7.11, 7.13}.
For women baseline t-PA antigen was significantly correlated with total and LDL
cholesterol concentrations {table 7.11}. For men, triglyceride concentration was
correlated with PAl activity {table 7.12}. For all subjects factor VU activity was
significantly correlated with total and HDL cholesterol concentrations {table 7.13}.
After intervention, some significant relationships between the changes in the LDL
cholesterol fraction and in the haemostatic and fibrinolytic factors were seen (table 7.14-
7.16). For all subjects there were no significant correlations between changes in total
cholesterol, HDL cholesterol and triglyceride concentrations and the fibrinolytic indices t-
PA antigen and PAl activity and the coagulation indices, fibrinogen and factor VU
activity. However, significant relationships between changes in LDL cholesterol and
haemostatic factors were found in all subjects. Figure 7.3 shows the correlation between
changes in PAl activity and LDL cholesterol (p=O.002). Figure 7.4 shows a similar
relationship between changes in t-PA antigen and LDL cholesterol (p=O.OIO). Significant
correlations were found between the changes LDL cholesterol concentrations and factor
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VII activity (p=0.07) (figure 7.5) and between changes in fibrinogen and LDL cholesterol
concentrations (p=0.033) (figure 7.6). Figures 7.3 - 7.6 show that a number of potential
outlying values can be observed, a re-analysis with the removal of apparent outliers
showed no effects on the significance of any final relationships. These analyses suggest a
number of relationships between changes in haemostatic and rheological measures and
changes in plasma lipids.
7.4 Discussion
This study has demonstrated improvements, from quite modest weight losses, in four
indices related to llID risk. These were RCA, factor VII activity, plasma total and LDL
cholesterol concentrations and the frequency of anginal pain.
However, the first hypothesis for this study concerned the approach used to achieve
weight loss. This was that a dietary intervention incorporating an energy deficit approach
to weight loss would be effective in achieving weight losses of close to 0.5 kg per week in
subjects with llID. The 3.5 kg (4%) weight loss was only 58% of what should have been
achieved with 100% compliance to the dietary advice. A comparison with the weight loss
achieved by other workers after a 3 month study, suggests it is a little below the average
4.5 kg achieved using similar approaches (Goldstein, 1992, Wadden, 1993). It has been
proposed that increasing age may decrease the effectiveness with which dietary changes
can be adopted (Seidell, 1996, Schaefer et al, 1997). This hypothesis may provide a
partial explanation as to why these older subjects lost less weight than their younger
counterparts given the same dietary intervention (chapter 6). However, research findings
either supporting or refuting a negative relationship between increasing age and decreased
intentional weight loss are scarce. The lack of evidence may be related to the majority of
studies comprising of small and usually unrepresentative volunteer populations
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(Williamson et al, 1992).
The condition of angina may lead patients to become less active in order to reduce the
number of acute anginal episodes. This change may favour gradual weight gain, or
oppose weight loss. However, moderate physical activity should usually be recommended
for angina patients to strengthen their heart muscles, and possibly encourage re-
vascularisation of the myocardium. Although the subjects with angina who completed
this study were not inactive, they anecdotally reported that they had become less active
than prior to the onset and diagnosis of angina pectoris.
The extent of compliance with dietary advice directly effects the amount of weight loss
achieved. It has been shown that the presence of a medical diagnosis often leads to
improved compliance with any treatment programme particularly a diagnosis of llID
(Barnes and Terry, 1991). The subjects in the present study were not newly diagnosed
with angina although all had all volunteered to participate in this dietary study. This
perhaps indicated a personal interest or concern, which could have already led to their
achieving as much weight loss as possible, alone. The reported dietary intakes completed
by all study participants at baseline showed a lower fat intake than estimated to be usually
consumed by the Scottish population (Gregory et al, 1990). Once more this finding may
indicate a greater personal interest in this group.
Improved nutritional intakes, such as the lower fat intake may reflect selective under-
reporting of food intakes. A recent a Finnish study has examined the effect of under
reporting on the macronutrient composition of a group. The presence or absence of
subjects known to be under-reporting their dietary intakes within different statistical
analyses failed to significantly affect the percentage energy values for macro-nutrients
(Hirvonen et al, 1997). These results are particularly encouraging for the validity of the
present fmdings.
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The second hypothesis was whether weight loss after a dietary intervention would
improve haemostatic and rheological risk factors for llID. The improvement in RCA
after weight loss is in agreement with studies ofNIDDM subjects (MacRury et al, 1993)
and healthy adults given a VLCD (Poggi et al, 1994). The stability of plasma viscosity
following weight loss is also in accord with previous studies (Fanari et al. 1993) and
suggests that substantial weight losses are required to change this measure. The acute
effects ofa VLCD and weight loss have both been seen to reduce plasma viscosity (6.9 %
higher at baseline than in our study) (Poggi et al, 1994). An 11% weight loss in
adolescents with BM! greater than 30 kg/m2 significantly reduced plasma viscosity
(Fanari et al, 1993). Our fmdings of an unchanged haematocrit following dietary
intervention and weight loss concur with the majority of studies (Le Devehat et al, 1992,
Palareti et al, 1994) but are at variance with others (Poggi et al, 1994). It seems likely
that much greater weight loss would be necessary to achieve significant changes.
Additionally, the mean haematocrit for both men and women were not elevated but
remained within the laboratory reference ranges at baseline and study week 12. It was
unfortunate that in the present study equipment limitations meant that only RCA measures
on women could be made.
In order to examine the relationships between BM! and RCA in a larger West of Scotland
population, a comparison with a representative subset from the MONICA population was
made. For men and women the mean values for RCA were below the regression line for
the MONICA data.
As described in chapter 6, the 95% confidence intervals only provide a guide as to what is
anticipated about the relationships between mean RCA and mean BM! in the MONICA
comparison because the intervals are valid for the individual rather than the mean BMI.
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The reasons why the study population had a lower RCA than the MONICA population
could include an effect of a small sample size and reflect the sample including men and
women with low mean RCA. A possible role for laboratory influences exists, although
identical equipment was used to measure RCA in this study to that reported in chapter 6,
where the mean values for RCA in chapter 6 were much higher. In addition, the subset of
the MONICA population with angina were much smaller than the subset compared with
the study sample for chapter 6.
Other studies have suggested only a small influence from a combination of changed
dietary composition and weight loss on plasma fibrinogen concentrations but they have all
lacked power (Le Devehat et aI, 1992, Palareti et aI, 1994). The influence of dietary
composition on plasma fibrinogen concentrations has been shown to be small (Fehily et
aI, 1982). Although the power of the present study was low with respect to plasma
fibrinogen concentrations, the values for the study population allowed the sample to be
classified according to the quintile of cardiovascular risk. The present study population
had mean plasma fibrinogen concentrations in the highest quintile of cardiovascular risk,
3.25 gIL and above (Lowe et aI, 1987, Fowkes et al, 1994), a finding which was in
agreement with the presence ofllID.
Factor vn activity has been linked with increased body weight and dietary fat intake and
the significant decrease in factor vn activity achieved in this study concurs with others
(Marckmann et al, 1991, Palareti et aI, 1994). In contrast, other workers using a 1200
kcal weight reducing diet in overweight subjects failed to achieve a significant change in
factor vn activity despite a similar weight loss (Baron et aI, 1989). This fall in factor VII
activity was less than that observed in a previous study with healthy overweight subjects
(Hankey et aI, 1997, chapter 6) whose factor vn activity was 5% lower than that of the
angina subjects in this present study. This may suggest dietary modifications and weight
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loss in those with llID are less effective in reducing llID risk factors than in those in good
health.
The observed effects on factor VII activity in this present study and that reported in
chapter 6, are most likely to reflect actual weight loss, and not the effects of starvation
seen in VLCD studies (Palareti et ai, 1994). Factor VII activity has been related to a high
fat diet, and the study sample reported consuming a fat intake 5% below the figure shown
for the Scottish population by the Survey of British Adults (Gregory et ai, 1990). Thus,
the effects of dietary intervention in the angina subjects may not have led to marked
changes in dietary composition. The lack of effect of altered ECG on factor VII activity
was also surprising, as it was the group with the normal ECG who showed the
improvement in plasma factor VII activity. It may have been expected that the presence
of ischaemia (shown on ECG trace) would have been related with increased factor VII
activity (Meade et ai, 1991).
Once more a comparison was made between the mean factor VII activity of the study
sample and with the values in a subset of the MONICA population. This provided
information about what could be anticipated about the relationship between mean factor
VII activity and mean BMI. The reasons why men had a mean factor VII activity above
the MONICA subset with angina, and females were below, is open to speculation. It
could be that the smaller MONICA subset with angina was not as representative as the
larger subset included in chapter 6. Most importantly the data suggest that the study
sample were at lower llID risk than the MONICA subset, and this may confirm the theory
that they had, prior to enrolling in the study, already been trying to improve the
composition of their diets and control their body weight.
A number of studies have succeeded in lowering PAl activity and t-PA antigen following
large weight losses in subjects whose fibrinolytic activity was impaired (Landin et ai,
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1990, Folsom et al, 1993, Palareti et al, 1994). The PAl activity at baseline of the llID
subjects was 9% below the values for the overweight but healthy subjects (Hankey et al,
1997, chapter 6) which suggested that fibrinolytic activity was not raised. The stability of
the fibrinolytic variables may also reflect insufficient weight loss, and confirm the
stability of the subjects' angina.
The third hypothesis, that a reduction in plasma cholesterol and its fractions would
improve with moderate weight loss was proven according to the findings of this study.
The value of weight loss in improving plasma lipid concentrations has been shown
previously (Wolf and Grundy, 1983, Folsom et al, 1993, Svedsen et al, 1995). However,
the reductions in plasma lipids achieved in this study are encouraging for the value of
moderate weight loss. The significant fall in plasma LDL concentrations was of particular
interest, given LDL cholesterol concentrations of greater than 4.14 mmollL are an
independent risk factor for coronary artery disease (Expert Panel, 1988). The falls in LDL
cholesterol of 4% in women, 8% in men and 6.5% overall are comparable with free living
dietary modification studies (Hjerman et al, 1981). Recently, the main determinants of
LDL have been identified as baseline LDL concentrations and age (Schaefer et al 1997),
both of which were raised in this study. In contrast, the stability of the unchanged HDL
cholesterol and triglyceride concentrations support the fmding that the weight loss
achieved was insufficient to affect these measures (Goldstein, 1992), or in the case of
triglyceride, that the plasma concentrations were already low. The stability of HDL may
reflect two contrasting effects, a fall in body weight and a decrease in dietary fat intake
(Leenen et al, 1994).
The expected positive relationship between factor vn activity and triglyceride was not
found in this study (Miller et al, 1986, Mitropoulos et al, 1989, Mitropoulos, 1994) nor
was any relationship between the changes in other haemostatic factors and triglyceride
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concentrations. The explanation probably lies in the very low mean triglyceride
concentrations in the angina subjects (1.7 mmollL), well below the upper reference range
of 2.3 mmollL. This observation possibly indicates previous dietary improvement in
these subjects. Raised triglyceride concentrations are usually associated with increased
body size and low HDL cholesterol concentrations (Seidell et ai, 1992). Other workers
have identified a positive relationship between triglyceride concentrations and factor VII
activity (Mitropoulos et al, 1989). However, this subject group had wider ranging
triglyceride concentrations, the mean 2.0 (SD l.6) and range of 0.4 - 10.1 mmol/L far
wider than in the present study (0.6 - 4.45 mmol/L).
The positive relationships between the changes in LDL cholesterol after weight loss and
plasma fibrinogen concentrations, factor VII activity, PAl activity and t-PA antigen
provide more evidence to support the many benefits from moderate weight loss on IHD
risk factors.
The fmding that weight loss and dietary change improve both haemostatic factors and
plasma lipids after weight loss has been reported in a middle aged population (Folsom et
ai, 1992). These fmdings could not prove whether the improvements were causally
linked. One possible explanation for the relationship between the benefits of moderate
weight loss and dietary change could be simultaneous improvement in both the LDL
cholesterol concentrations and the levels of haemostatic factors. However, the hepatic
synthesis of haemostatic factors, particularly factor vn activity, and the lipid fractions
may be related (Mitropoulos, 1994). The relationship between factors noted here has been
known to be open to confounding by factors including age and cigarette smoking (Krauss
et ai, 1991).
The fourth hypothesis concerned the effect of dietary intervention for weight loss on the
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symptoms of anginal disease. The fmding of an improvement in anginal pain frequency
with weight loss is in accordance with clinical impressions. Surprisingly, there are no
reports of evidence from controlled trials for angina reduction with weight loss. It has
recently been reported that close to 40% of obese "angina patients" are in fact free from
significant ischaemic disease (Bahadori et al, 1995). In addition, it has been reported that
the perception of angina deteriorates with advancing age (Umachandran et al, 1991), and
the present study population were in the age group identified as least able to recognise
anginal symptoms (Umachandran et al, 1991).
After 5 weeks of dietary intervention it was surprising that no change in the reported
frequency of anginal pain was seen, despite the achievement of significant weight loss.
However, the significant fall in the frequency of anginal pain at week twelve was most
encouraging. Perhaps a minimum of 12 weeks of dietary intervention is required before
dietary changes can significantly influence the frequency of anginal pain.
7.5 Conclusions
A 4% weight loss as part of a dietary intervention to change both the composition and
quantity in overweight subjects with angina improves some, but not all, risk factors for
IHD, the principal hypothesis of this study. The results also suggest that the changes after
12 weeks dietary intervention and moderate weight loss may be further increased with
greater weight loss. This may lead to more valuable benefits on rheological and
fibrinolytic measures. The improvements in plasma lipids, haemostatic and rheological
measurements and plasma lipids support the broad benefits of moderate weight loss in
those who are overweight with lliD.
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Table 7-1 Characteristics and plasma biochemistry at baseline and week twelve for
women
Baseline Week 12 Difference p
Age (years) 61.2 (5.7)
Weight (kg) 76.2 (8.2) 72.7 (8.1 ) -3.5 (2.6) 0.00001
BMI (kg/m1) 27.5 (2.7) 26.3 (2.8) -1.2 (0.9) 0.00001
,
Body fat(%) 40.5 (1.9) 38.9 (1.9) -1.6 (1.6) 0.0001
Waist circumference (cm) 106.3 (9,4) 104.3 (10.8) -2.0 (5.8) 0.11
Waist to hip ratio 0.99 (0.06) 1.00 (0.08) +0.01 (0.07) 0,48
Systolic blood pressure (mm Hg) 143 (16) 141 (17) -2 (19) 0.61
Diastolic blood pressure (mm Hg) 89 (12) 86 (11) -3 (15) 0.39
ABPI 0.9 (0.2)
Plasma insulin (mUlL) 13.1 (7.6) 14.2 (11.6) +1.1 (7.7) 0.54
Total cholesterol (mmollL) 6.7 (1.2) 6.4 (0.9) -0.3 (0.6) 0.011
HDL cholesterol (mmollL) 1.4 (OJ) 1.3 (OJ) -0.1 (0.1 ) 0.11
LDL cholesterol (mmollL) 5.6 (1.1) 5.4 (0.9) -0.2 (0.5) 0.021
Triglyceride (mmollL) 1.7 (0.8) 1.6 (0.6) -0.1 (0.6) 0.68
Haematocrit (%) 43 (6) 44 (5) +1 (5) 0.67
Plasma viscosity (mPas) IJ3 (0.07) 1.30 (0.07) -0.03 (0.07) 0.17
Red cell aggregation (AU) 3.8 (1.6) 2.8 (0.5) -1.0 (1.3) 0.019
Fibrinogen (gIL) 3.5 (0.8) 3.4 (0.7) -0.1 (0.8) 0.40
Factor VII activity(IU/dL) 130 (20) 121 (16) -9 (22) 0.08
PAl activity (% pool) 124 (62) 125 (57) + 1 (41) 0.88
t-PA antigen (ug/ml.) 10,4 (2.8) 9.9 (2.8) -0.5 (2.0) 0.11
Data as mean (SO), n=22
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Table 7-2 Characteristics and plasma biochemistry at baseline and week twelve for
men
Baseline Week 12 Difference p
Age (years) 59.5 (7.1)
Weight (kg) 85.9 (12.4) 82.4 (11.9) -3.5 (2.6) 0.00001
BMI (kg/m2) 30.8 (4.5) 29.5 (4.3) -1.3 (0.9) 0.00001
Body fat (%) 30.1 (3.7) 28.6 (4.7) -1.5 (5.9) 0.22
Waist circumference (cm) 101.9 (8.9) 99.6 (9.2) -2.3 (3.3) 0.0007
Waist to hip ratio 1.00 (0.05) 0.98 (0.06) -0.02 (0.04 ) 0.0038
Systolic blood pressure (mm Hg) 144 (15) 143 (16) -1 (15) 0.70
Diastolic blood pressure (mm 83 (6) 85 (23) +2.0 (23) 0.58
Hg)
ABPI 1.00 (0.23)
Plasma insulin (mUlL) 12.9 (8.7) 9.7 (5.1) -3.2 (7.4) 0.047
Total cholesterol (mmol/L) 5.9 (0.8) 5.5 (0.9) -0.4 (0.8) 0.0019
HDL cholesterol (mmol/L) 1.2 (OJ) 1.1 (0.3) -0.1 (0.1) 0.48
LDL cholesterol (mmol/L) 4.9 (0.8) 4.5 (0.8) -0.4 (0.7) 0.010
Triglyceride (mmol/L) 1.8 (0.9) 1.7 (1.3) -0.1 (0.6) 0.34
Haematocrit (%) 47 (5) 46 (4) -1 (6) 0.62
Plasma viscosity (mPas) 1.27 (0.07) 1.28 (0.08) +0.01 (0.09) 0.74
Red cell aggregation (AU) ... ... ... ...
Fibrinogen (gIL) 3.4 (1.1) 3.5 (0.8) +0.1 (0.8) 0.51
Factor VII activity(lU/dL) 114 (26) 111 (21) -3 (19) 0.53
PAl activity (% pool) 135 (79) 117 (65) -18 (66) 0.094
t-PA antigen(~g/mL) 11.2 (3.5) 11.3 (3.9) +0.1 (3.4) 0.77
Data mean (SD), n=27, ...missing values
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Table 7-3 Characteristics and plasma biochemistry at baseline and week twelve for
all subjects
Baseline Week 12 Difference p
Age (years) 60.3 (6.5)
Weight (kg) 81.6 (11.7) 78.1 (11.3) -3.5 (2.6) 0.0001
BMI (kg/m2) 29.3 (4.3) 28.1 (4.0) -1.2 (0.9) 0.0001
Body fat (%) 33.9 (5.9) 33.2 (6.3) -0.7 (4.0) 0.087
Waist circumference (cm) 103.9 (9.3) 101.6 (10.2) -2.3 (4.5) 0.0005
Waist to hip ratio 1.00 (0.06) 0.99 (0.07) -0.01 (0.06) 0040
Systolic blood pressure (mm Hg) 144 (16) 142 (17) -2 (17) 0.99
Diastolic blood pressure 86 (10) 85 (18) -1 (19) 0.14
(mmHg)
ABPI 0.96 (0.22)
Plasma insulin (mUlL) 13.1 (8.1) 11.8 (8.9) -1.3 (7.8) 0.29
Total cholesterol (mmollL) 6.3 (1.1) 5.9 (1.0) -004 (0.7) 0.0001
HDL cholesterol (mmollL) 1.3 (0.3) 1.2 (0.3) -0.1 (0.6) 0.092
LDL cholesterol (mmollL) 4.6 (0.9) 4.3 (0.8) -0.3 (0.6) 0.008
Triglyceride (mmollL) 1.8 (0.8) 1.7 (1.0) -0.1 (0.6) 0.31
Haematocrit (0/0) 45.5 (SA) 45.0 (4.2) -0.5 (5.6) 0.32
Plasma viscosity (mPas) 1.30 (0.08) 1.29 (0.08) -0.01 (0.08) 0.33
Red cell aggregation (AU) * * '" '"
Fibrinogen (gIL) 304 (1.0) 3.6 (0.8) +0.2 (0.1) 0.15
Factor VII activity(lU/dL) 120 (14) 115 (20) -5 (20) 0.04
PAl activity (0/0 pool) 134 (75) 123 (59) -11 (57) 0.10
t-PA antigen (J..lg/mL) 10.9 (3.2) 10.6 (3.6) -0.3 (2.8) 0.21
n 49
Data as mean (SO)
* missing values
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Table 7-4 Angina frequency at baseline and weeks five, seven and twelve
Baseline WeekS p Week p Week 12 p
7
Angina frequency 3.2 3.4 0.28 1.6 0.027 1.4 0.009
(4.5) (10.6) (4.6) (2.5)
Frequency of use of 5.3 ... ... 4.3 0.17
glyceryl trinitrate (7.1) (3.2)
Data as mean (SD), p values show the differences between baseline and weeks 5, 7 and
12,
n=49, ... indicates failure to record glyceryl trinitrate and anginal pain measurements at
weeks 5 and 7
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Table 7-5 Measured resting energy expenditure and reported dietary intake before
and after weight loss in women
Baseline Dietary intake
REE Baseline Week 12 Change p
Energy kJ 6768 (1347) 6932 5611 -1033 0.003
(6159, 7870) (4562,6247) (-1887, +50)
Energy kcal 1618 (322) 1657 1341 -247 0.003
(1472, 1881 ) (1112, 1493) (-451, +12)
Fat % energy 34.9 31.2 -2.5 0.006
(29.8,38.6) (24.2, 35.3) (-6.6, -0.4)
Protein % energy 17.9 19.2 +1.5 0.015
(16.2,20.1) (17.9,20.6) (-0.5, +3.4)
Carbohydrate 46.2 48.0 +2.4 0.092
% energy
(42.3,49.3) (44.4, 51.6) (-56.7,
+14.9)
Alcohol % energy 1.1 0.3 -0.2 0.485
(0.0,2.8) (0.0,2.3) (-1.7, +0.6)
Data as median and inter-quartile range except for REE measure mean (SO), n= 22
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Table 7-6 Measured resting energy expenditure and reported dietary intake before
and after weight loss in men
Baseline Dietary intake
REE Baseline Week 12 Change p
EnergykJ 6506 8707 7201 -5665 0.0001
(1075) (7778, 10259) (5732, 8594) (-6518, -4527)
Energy kcal 1555 (257) 2081 1721 -1354 0.0001
(1864,2452) (1370,2054) (-1557, -108)
Fat % energy 32.2 29.9 -2.8 0.001
(29.5,35.4) (26.7,32.8) (-8.0, -0.2)
Protein % energy 16.9 19.4 +1.3 0.002
(14.7, 19.8) (17.1,20.8) (0.0, +4.1)
Carbohydrate % 44.4 46.5 +2.7 0.015
energy
(41.0,48.7) (43.3,53.5) (-1.5, +7.7)
Alcohol % energy 2.8 0.75 0.0 0.478
(0.2,6.6) (0.0,5.9) (-1.9, +0.5)
Data as median and inter-quartile range except for REE measure mean (SD), n=27
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Table 7-7 Measured resting energy expenditure and reported dietary intake before
and after weight loss in all subjects
Baseline Dietary intake
REE Baseline Week 12 Change p
Energy kJ 6106 (1057) 7929 6108 -1439 0.00001
(6564, 8865) (5213, 8075) (-2247, -88)
Energy kcal 1461 (253) 1895 1460 -344 0.0001
(1569,2119) (1246, 1930) (-537, -21)
Fat % energy 33.4 30.0 -2.7 0.00001
(29.5, 38.2) (25.9, 33.5) (-6.8, - 0.3)
Protein % 17.4 19.3 -0.7 0.00001
energy
(15.6, 19.9) (17.6,20.7) (-2.3, +0.8)
Carbohydrate 0/0 45.5 48.0 -1.3 0.004
energy
(40.9,48.9) (44.0,53.4) (-3.8, +2.3)
Alcohol % 1.4 0.2 -0.5 0.0019energy
(0.0,5.3) (0.0,3.9) (-2.7, +1.9)
Data as median and inter-quartile range except for REE measure mean (SD), n=49
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Table 7-8 Relationships between changes in body mass index, waist circumference
and waist hip ratio and changes in haemostatic and rheological risk factors
after weight loss for women
Change in haemostatic factors Change in Change in Change in
BMI (kg/m:!) waist (cm) WHR
Haematocrit (%1) r = 0.288 r = 0.198 r= 0.198
p = 0.247 P = 0.431 p = 0.431
_______ O __ o ___
Plasma viscosity (mPas) r = 0.025 r =0.059 r=0.112
p = 0.931 P = 0.841 p= 0.703
Red cell aggregation (AU) r = -0.202 r = 0.192 r = 0.192
p = 0.632 P = 0.649 P = 0.649
Fibrinogen (gIL) r = 0.016 r = -0.289 r = -0.289
p = 0.947 P = 0.216 P = 0.216
---Factor VII activity (IU/dL) r= 0.200 r = 0.081 r = 0.081
p = 0.427 p=0.74 P = 0.74
PAl activity (% pool) r = 0.123 r = 0.279 r = 0.279
P = 0.605 p= 0.234 P = 0.234
t-PA antigen (llg/mL) r = 0.016 r = -0.289 r = -0.291
P = 0.947 P = 0.216 p = 0.219
Cholesterol (mmollL) -.----.-~-...~-.~-..-r = 0.088 r= 0.162 r = 0.175
P = 0.713 P = 0.494 P = 0.460
HDL cholesterol (mmollL) r = 0.073 r= 0.261 r = 0.448
p = 0.813 P = 0.389 p = 0.124
LDL cholesterol (mmollL) --------.--.---~---..---.- ..--.r = 0.052 r= -0.045 r = 0.008
P =0.865 P =0.833 P = 0.980
Triglyceride (mmol/L) r -0.324 r = -0.171 r = -0.426
P =0.176 P = 0.485 P = 0.069
n=22
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Table 7-9 Relationships between changes in body mass index, waist circumference
and waist to hip ratio and changes in haemostatic and rheological risk factors
after weight loss for men
Change in haemostatic factors
Red cell aggregation (AU)
Change in Change in Change in
BMI waist (cm) WHR
(kg/ml)
r = -0.024 r = -0.005 r=O.l13
p = 0.913 P = 0.983 P = 0.598
r = 0.377 r=0.172 r = -0.101
P = 0.076 P = 0.645 P = 0.645
• • •
Haematocrit (%)
Plasma blood viscosity (mPas)
Fibrinogen (gIL) r= 0.235 r = 0.559 r = 0.123
P = 0.248 P = 0.003 p = 0.551
-Factor VII activity (IU/dL) r = 0.665 r = 0.012 r = 0.214
p = 0.0001 p = 0.953 p = 0.285
PAl activity (% pool) r = 0.073 r = -0.028 r = 0.073
p= 0.767 P = 0.767 p = 0.766
t-PA antigen (J-lg/mL) r= 0.288 r= 0.003 r = 0.109
P = 0.153 p = 0.596 P = 0.566
Cholesterol (mmollL) r = -0.105 r= 0.274 r = -0.229
p=0.609 p = 0.175 p = 0.260
HDL cholesterol (mmollL) --r=0.003 r = 0.532 r = 0.337
p = 0.991 p = 0.019 P = 0.158
LDL cholesterol (mmollL) r = 0.091 r = 0.328 r = -0.033
p = 0.710 p = 0.170 p = 0.894
Triglyceride (mmollL) r = 0.162 r = 0.048 r = -0.207
p = 0.430 p= 0.816 p= 0.309
n=27, • missing values
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Table 7-10 Relationships between changes in body mass index, waist circumference
and waist to hip ratio and changes in haemostatic and rheological risk factors
after weight loss for all subjects
Change in haemostatic factor
Red cell aggregation (AU)
Change in Change in Change in
BMI waist (cm) WHR
(kg/m2)
r = 0.243 r = 0.109 r = -0.035
p = 0.147 P = 0.522 P =0.836
r = 0.147 r = -0.105 r = 0.086
P = 0.352 P = 0.507 P = 0.589
... ... ...
Plasma blood viscosity (mPas)
Haematocrit (%)
Fibrinogen (gIL)
Cholesterol (mmol/L)
.~~~.~-.-- ---~-
r = 0.147 r = 0.082 r = -0.054
P = 0.328 P = 0.589 P = 0.724
r = 0.434 r= 0.104 r = -0.084
P = 0.006 p= 0.528 P = 0.611
r = 0.238 r=0.125 r= 0.226
p = 0.145 P = 0.448 P = 0.145
r=0.167 r=0.169 r= 0.134
p= 0.262 P = 0.256 P = 0.371
------
r = -0.022 r = 0.201 r= 0.024
p= 0.883 P = 0.180 P = 0.872
r = 0.008 r = 0.384 r = 0.348
p = 0.967 P = 0.030 p = 0.051
·------.-. __ .__ ._.w ____ .__ ..____ ... ___ .¥.___
r = 0.050 r = 0.143 r = -0.006
P =0.787 P = 0.435 P = 0.976
r - 0.231 r = -0.068 r = -0.286
P =0.126 P = 0.656 p= 0.057
Factor VII activity (IU/dL)
PAl activity (% pool)
t-PA antigen (J-lg/mL)
HDL cholesterol (mmol/L)
LDL cholesterol (mmol/L)
Triglyceride (mmol/L)
n=49
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Table 7-11 Relationships between lipid fractions and haemostatic factors at baseline
in women
t-PA ag PAl activity FYII activity Fibrinogen
(ug/mL) (0/0 pool) (IU/dL) (gIL)
Cholesterol (mmollL) r=O.558 r=O.131 r=O.587 r=O.168
p=O.OO9 p=O.570 p=O.OO8 p=OA54
HDL cholesterol r=O.438 r=-O.OO8 r=O.558 r=-O.186
(mmollL) p=O.135 p=O.979 p=O.074 p=O.542
LDL cholesterol r=O.586 r=-O.204 r=OA50 r=-O.274
(mmollL) p=O.035 p=O.504 p=O.165 p=O.365
Triglyceride (mmollL) r=O.272 r=O.356 r=O.253 r=-O.096
p=O.233 p=O.l13 p=O.296 p=O.296
n=22
Table 7-12 Relationships between lipid fractions and haemostatic factors at baseline
in men
t-PA ag PAl activity FYII Fibrinogen
(ug/mL) (% pool) activity (gIL)
(IU/dL)
Cholesterol (mmollL) r=O.056 r=O.073 r=O.275 r=-O.259
p=O.791 p=O.739 p=O.174 p=O.202
HDL cholesterol r=-O.276 r=-O.200 r=O.587 r=-O.349
(mmollL) p=O.254 p=OA27 p=O.OO8 p=O.143
LDL cholesterol r=O.179 r=-O.078 r=-O.lS7 r=-O.175
(mmollL) p=OA62 p=O.759 p=O.520 p=O.5S2
Triglyceride (mmollL) r=O.144
___ M_~~ ...
r=O.610 r=O.195 r=-O.169
p=OA08 p=O.OO2 p=O.339 p=OA08
n=27
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Table 7-13 Relationships between lipid fractions and haemostatic factors at baseline
in all subjects
t-PA ag PAl activity FYI I Fibrinogen
(ug/mL) (0/0 pool) activity (gIL)
~IU/dLl
Cholesterol (mmollL) r=0.229 r=0.064 r=0.468 r=-0.042
p=0.126 p=0.678 p=O.OOI p=0.7777
HDL cholesterol r=-0.082 r=-0.096 r=0.625 r=-0.120
(mmollL) p=0.654 p=0.608 p=O.OOOI p=0.512
---- -_._-_._-
LDL cholesterol r=0.236 r=-0.014 r=0.119 r=0.055
(mmollL) p=O.194 p=0.939 p=0.293 p=0.764
Triglyceride (mmollL) r=O.198 r=-0.513 r=0.182 r=-0.137
p=O.187 p=0.016 p=0.231 p=0.352
n=49
Table 7-14 Relationships between changes in haemostatic factors and changes in
plasma lipid fractions after weight loss for women
t-PA ag PAl activity FVII Fibrinogen
(uglmL) (% pool) activity (gIL)
~IU/dL}
Cholesterol (mmollL) r=0.558 r=0.089 r=0.586 r=0.168
p=0.009 p=0.710 p=O.Oll p=0.454
HDL cholesterol r=0.438 r=-0.097 r=0.558 r=O.186(mmollL) p=0.135 p=0.764 p=0.074 p=0.542----_._.
LDL cholesterol
'N __ " __ ' ___ ~"_' _____ "_~ ___ ~~. ___ ._. ____ •• ________ ••• __ •••••• _. ___ ••••• ,,_ •• __ •___ , __ •
r= 0.259 r= 0.298 r= 0.213 r= 0.526(mmollL) p= 0.393 p= 0.347 p= 0.530 p= 0.063
Triglyceride (mmol/L) r=0.272 r=0.349 r=0.257 r= 0.096
p=O.135 p=0.131 p=0.304 p=0.670
n=22
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Table 7-15 Relationships between changes in haemostatic factors and changes in
plasma lipid fractions after weight loss for men
t-PA ag PAl activity FYII Fibrinogen
(ug/mL) (% pool) activity (gIL)
(lU/dL)
Cholesterol (mmollL) r=0.056 r=0.073 r=0.275 r=-0.259
p=0.791 p=0.056 p=0.174 p=0.202
HDL cholesterol r=-0.276 r=-0.200 r=0.587 r=-0.349
(mmollL) p=0.254 p=0.427 p=0.008 p=0.143
LDL cholesterol r=0.510 r= 0.638 r= 0.366 r= 0.321
(mmollL) p= 0.026 p= 0.014 p= 0.123 p= 0.194
Triglyceride (mmollL) r=0.144 r=0.610 r=0.195 r=-0.169
p=0.492 p=0.002 p=0.339 p=0.408
n=27
Table 7-16 Relationships between changes in haemostatic factors and changes in
plasma lipid fractions after weight loss for all subjects
t-PA ag PAl activity FVII Fibrinogen
(ug/mL) (% pool) activity (gIL)
(lU/dL)
Cholesterol (mmol/L) r=0.166 r=0.238 r=0.223 r=0.147
p=0.264 p=0.144 p=0.150 p=0.330
HDL cholesterol r=0.159 r=0.343 r=0.159 r=0.342(mmollL) p=0.385 p=0.071 p=0.385 p=0.059
LDL cholesterol r= 0.451 r= 0.574 r= 0.345 r= 0.383(mmollL) p= 0.010 p= 0.002 p= 0.07 p= 0.037
Triglyceride (mmollL) r=0.093 r=-0.161 r=0.040 r=0.067
p=0.533 p=0.326 p=0.792 p=0.658
n=49
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Figure 7-1 (a) Angina frequency and (b) changes in body weight before during and
after intervention for all subjects
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Data are mean (SEM).
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Figure 7-2 Fitted regression lines of red cell aggregation (RCA) and
factor VII activity against body mass index (BMI) for the MONICA subsets
of men and women
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Figure 7-3 Relationship between changes in PAl activity and LDL cholesterol
after weight loss
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The relationship between changes in PAl activity and LDL cholesterol after weight
loss was reanalysed with a possible outlier (a) removed but this did not affect the
significance of the relationship (r=0.470 p=0.018).
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Figure 7-4 Relationship between changes in t-PA antigen and LDL cholesterol after
weight loss
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The relationship between changes in t-PA antigen and LDL cholesterol after
weight loss was reanalysed with a possible outlier (a) removed but this did not affect the
significance of the relationship (r=O.2S3 p=O.OI7).
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Figure 7-5 Relationship between changes in factor VII activity and LDL cholesterol
at week twelve
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Figure 7-6 Relationship between changes in fibrinogen and LDL cholesterol at week
twelve
2.5 - I
r=0.0383 I·
2.0 - I;::- p = 0.037 I11.5 - ! •
1.0 - • If 0.5 - • •• +
~ 0.0 -t---~---;-_'_.JI.Ii-~1i----.---.---
8 -0.5 - •• II.
lS
~ ~~- :
I
• I
21 I- .0 -~-----r------------~------------~I I I
~ 0 1
•
•
-1.5 - •
lDL change (mml/l)
n=29 (17 men, 11 women)
244
Chapter 8 The effect of moderate weight loss on haemostatic
and rheological factors and plasma lipids in subjects of body
mass index close to 25 kg/m1
8.1 Introduction and hypotheses
Risk of coronary death is known to be doubled at BMI 25 kg/m' compared to BMI 22
kg/m2 (Colditz et aI, 1995). The benefits of moderate weight loss have been established
in those whose BMI exceeds the "healthy weight" category (BMI > 25 kg/rrr'). Some of
the benefits of weight loss in terms of haemostatic and rheological factors have already
been described within this thesis, and other benefits of moderate weight loss have already
been established with reference to other recognised IHD risk factors (Goldstein, 1992).
Many people, especially women, who are not obese (BMI > 30 kg/m2) or even overweight
(BMI 25 - 30 kg/m') seek weight loss for other reasons. The medical value of reducing
body weight below a BMI of 25 kglm2 remains largely unproven, although the suggestion
has been made that moderate weight loss could offer health benefits (Chan et al, 1994).
The main aim of this study was to investigate the effect of moderate weight loss on
haemostatic and rheological factors and plasma lipids in healthy subjects with BMI close
to 25 kg/m2• Weight loss was targeted by using the same dietetic approach, a 600 kcal
(2510 kJ) daily energy deficit, already used for the two earlier studies, chapters 6 and 7.
The effectiveness of achieving weight loss in a group of subjects close to healthy weight
was also examined.
There were three hypotheses to be tested in this study of healthy weight subjects who had
expressed a desire to achieve weight loss.
1)A dietary intervention incorporating an energy deficit approach to weight loss (600 kcal
per day) would be effective in achieving losses of close to 0.5 kg per week. This
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approach would be effective in subjects (with an expressed desire to reduce body weight)
2whose BMI was close to 25 kg/m .
2) Weight loss after a dietary intervention to lower total energy intake and change dietary
composition in line with current dietary targets would improve haemostatic and
rheological risk factors for nm in subjects whose BM! was close to 25 kg/m2•
3) Weight loss after a dietary intervention to lower total energy intake and change dietary
composition in line with current dietary targets would be effective in improving plasma
lipid concentrations in subjects whose HMI was close to 25 kg/m'.
8.2 Methods
8.2.1. Study design and statistical approaches
A 12week study duration was chosen, to coincide with the period when maximum weight
loss using dietary methods was achieved, and to ensure comparisons could be made with
the results of the other studies in this thesis. The chosen experimental design was the
single stranded study, with the biological and physical measurements being made at
baseline and post-intervention (week 12). The study design was chosen following the
statistical principles already described (chapter 4), and the sample size with sufficient
power to determine the differences that the study was designed to seek, at 80% with a 5%
level of significance. The power analysis calculations are applicable to those given in
chapter 4.
Data for the differences in biological measurements before and after dietary intervention
were approximately normally distributed, as determined from a distribution plot, and thus
were analysed using a paired Student's t test. The differences between the two dietary
measurements showed a skewed distribution and were analysed using a paired Wilcoxon
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test. Pearson's correlation analysis was carried out to investigate any relationships
between changes in body weight or BMI, and changes in haematological, fibrinolytic and
plasma lipid measurements.
8.2.2 Subjects
In order to recruit "healthy" subjects for weight loss without clinical disease and a BMI
close to 25 kg/rrr' a different approach was required to the two earlier studies. In
particular, it was considered to be impractical both in terms of travel and time constraints
to expect subjects, likely to be in current employment, to attend study appointments in a
hospital setting. The use of financial incentives could have attracted inappropriate
subjects, or led to alterations in methods used by the subjects. The start of this study
coincided with the launch by the Health Education Board for Scotland for their "Healthy
Work-sites" initiative (HEBS, 1996), to draw attention to the work setting as a location
for health promotion. At the time the occupational health personnel were contacted, no
implementation of the Health Education Board for Scotland's initiative had taken place,
although those company employees whose responsibility was Health and Safety had been
informed of the aims. The use of the work-site allowed a new sector of the Scottish
population to be specifically targeted for health promotion. Eighteen work-sites
employing greater than 200 employees in the West Lothian area were identified from the
West Lothian Business Directory (West Lothian District Council, 1994). Either the
Occupational Health, Human Resource or Health and Safety leaders within each company
were personally contacted by a letter describing the aims and practical requirements of the
study. Four companies indicated that they were uninterested in hosting the study and 8
companies requested further information. No reply was received from the remaining 6
companies.
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The BP Oil refinery was the work-site chosen to host the study (plate 8.1). The staff of
the Occupational Health Department were delighted to host the study and their
Occupational Health Centre was large, with sufficient clinical space to accommodate the
study. The Occupational Health Leader regarded the study as another opportunity to
target the employee population with a health promotion initiative not yet addressed at the
refinery site. Other reasons for the choice of the refmery site included the large work
force (1200 people) and the existence of an individual electronic mail system with
individual and confidential mail boxes for each employee.
The BP work-force was 90% male of which 43% were shift workers. Initial recruitment
and advertising for the study used the work-site electronic mail system. A refinery-wide
message advertising the study and detailing selection criteria was sent to all employees.
The message requested healthy volunteers to take part in a study which offered them the
opportunity to find out about the composition of their present diet and to receive
specialised advice about how to adjust their diet in line with current dietary targets
(COMA, 1991, Scottish Office, 1996). Physical measurements of body composition and
plasma lipid concentrations were also offered. One hundred and ninety requests for
further information were received. A screening questionnaire was sent to all these
employees who had registered an interest in the study and each was to asked detail their
anthropometric information (body weight, height) and their recent medical history. A
guarantee concerning the confidentiality of this information was made. From the original
sample of 190 volunteers, 51 subjects were approached who fulfilled the principal
selection criteria. The criteria included a BM! between 22.5-28.5 kg/m2, being in good
health, and a desire to lose body weight. Those with any significant cardiovascular
abnormalities or diabetes (WHO, 1985) were excluded. All subjects were free of any
medication known to influence haemostatic measures, such as oral contraceptives or
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diuretics (Lowe et al, 1980). No subject had reduced their weight by greater than 3.0 kg
within the 3 month period prior to recruitment. Recruitment was carried out from May
through to September to minimise any seasonal influences. The 51 volunteers, 13 women
and 38 men, who fulfilled the inclusion criteria were recruited to the study. Subjects were
requested to attend the Occupational Health Centre on 3 occasions over the 12 week study
period (study week -1, baseline and week 12). In order to reinforce the requirements of
the study, a further 2 telephone contacts were planned at weeks 4 and 8. Any subjects
who expressed a preference to attend the Occupational Health Centre in person for these
contacts were offered this option.
Ethical approval for the study was obtained from the Forth Valley Health Board joint
ethics committee and signed informed consent was obtained from all study participants.
S.2.3 Physical measurements
Body weight, body fat distribution, waist and hip circumferences, waist to hip ratio and
percentage body fat were measured according to the methods of Lean et al (1995).
S.2.4 Dietary intervention and monitoring
Dietary intervention used an individual dietary prescription based on the Schofield
equation to predict BMR (Schofield et al, 1985). Dietary intake was monitored by the
completion of7 day WI food diaries during study week 1 and week 12 (Bingham, 1987).
Dietary analysis was carried out using the Compeat dietary analysis programme (Nutrition
Systems, London).
S.2.SVenesection and laboratory methods
Venesection was performed before (week 0) and after (week 12) dietary intervention.
Blood was centrifuged on site within 10 minutes of venepuncture. Plasma viscosity,
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haematocrit, fibrinogen and factor vn activity were measured. PAl activity and t-PA
antigen concentrations were measured as indices of the fibrinolytic system. Plasma
triglyceride, total cholesterol and HDL cholesterol were also measured and LDL
cholesterol estimated using established calculations (Friedwald et al, 1972).
8.3 Results
Of the 51 subjects recruited to the study, 13 subjects, 5 female and 8 male, failed to
complete the study, and were excluded from all analyses. The reasons were a lack of
motivation to fulfil the study requirements (6), a desire to remain weight stable (4) and
relocation from Grangemouth (3). The characteristics of the 38 subjects (31 male), who
completed the study are shown (table 8.1-8.3). For all subjects BMI range was 57.8-91.0
kg and 22.5-28.2 kg/nr', The weight loss and changes in BMI after intervention are
shown (table 8.1). No gender subdivisions were made due to the small number of females
completing the study. The results were analysed for the study population as one group.
The mean weight loss for the entire group was 3.3% which represented a weekly weight
loss ofO.2 (SD 0.2) kg (p<O.OOOI).The weekly weight loss was 40% of the target value.
At baseline the individual daily energy requirement was calculated for all subjects. The
Schofield equations were used to estimate the individual's resting metabolic rate and a
PAL of 1.4 was applied (COMA, 1991). The daily energy requirement was then
calculated. Median energy requirements were 10255, range 7753 - 11397 kJ, 2451, range
1853 - 2724 kcal. A one sample Wilcoxon test was used to compare the differences
between the values for energy requirements and reported energy intakes measured before
intervention. No significant differences were observed (p=0.29). Reported energy intakes
and dietary composition measured both at baseline and week 12 are shown (table 8.2).
After dietary intervention a significant fall in reported energy intake was observed
(P=O.OOOl). Total energy from fat and saturated fat also fell significantly after
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intervention. Percentage energy from polyunsaturated fat remained unchanged. These
changes were in accordance with the dietary advice given to the study participants. The
percentage dietary energy from carbohydrate was significantly increased, although that
from protein was increased post-intervention. Dietary energy from alcohol was
unchanged post-intervention.
Median dietary energy prescription for the group was 7531 kJ: range 4602 - 8368 kJ/day
(1800 kcallday, range 1100-2000 kcallday). Recorded dietary intakes were 115% of the
mean total daily energy prescription after dietary intervention at week 12.
The subjects' mean haemostatic and fibrinolytic measurements are shown (table 8.3). No
significant changes were seen in any of the haemostatic and rheological factors with
weight loss. The mean value for plasma viscosity at baseline of 1.24 m Pas was
significantly below the mean values for those healthy overweight subjects already studied,
(chapter 6) and not significantly changed by weight loss. Haematocrit was very close to
the current reference values in healthy subjects (45.7%) and was significantly reduced
with weight loss (p=0.04). Fibrinogen concentrations were unchanged with weight loss.
The mean values for fibrinogen concentrations in the earlier study of healthy overweight
subjects were closely comparable with those of the present study group (chapter 6).
Factor vn activity also remained unchanged with weight loss, although a positive
relationship between reductions in factor VII activity and weight loss was indicated
(figure 8.1). The fibrinolytic factor t-PA antigen showed no effects due to weight loss,
however PAI activity was lowered and the change was very close to the 5% significance
level.
Plasma total cholesterol and HDL cholesterol were reduced (p=0.037, 0.033) while
triglyceride and LDL cholesterol concentrations remained unchanged.
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At baseline, there were few significant relationships between plasma lipids and
haemostatic factors, the exceptions being plasma viscosity and t-PA antigen with total
cholesterol and LDL concentrations and triglyceride (table 8.5). After dietary intervention
total and LDL cholesterol concentrations were significantly correlated with fibrinogen and
t-PA antigen, as were HDL cholesterol concentrations with plasma viscosity and
haematocrit (table 8.5).
After intervention, some trends towards significant relationships between the changes in
BM! and t-PA antigen, factor VII activity and LDL cholesterol were seen (p=0.016, 0.058,
0.053) (table 8.6). However, no significant relationships between changes in waist
circumference, WHR, haemostatic, rheological factors or plasma lipids were found (table
8.4, table 8.7).
8.4 Discussion
The initial process of choosing a location from which to run the study was an encouraging
one as it has identified new settings and target groups for health promotion. The
enthusiastic responses received from the individual companies who responded to the
initial letter discussing the possibility of hosting the study suggested that the study was
carried out in an optimal climate. The reasons for this may have included influence of the
HEBS healthy work-site initiative. This targeted the staff responsible for the health of
employees to increase their use of health promotion in these work-site populations. The
positive responses from companies to the request to host the study suggested future
dietary intervention or health promotion initiatives may be well received.
The results of this study have shown a significant improvement in haematocrit but in none
of the other haemostatic and rheological risk factors for IHD. after a mean body weight
loss close to 3%. These fmdings are in contrast to the results from the two earlier studies
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(chapter 6 and 7) when factor vn activity and RCA were significantly reduced. The
baseline values for a number of the llID were lower than the other two groups. This will
be discussed fully in chapter 9. Aside from haematocrit, these findings do not support the
first hypothesis of the study, that moderate weight loss in those whose BMI was close to
the healthy range (BMI 25 kg/m2) would improve haemostatic, rheological and lipid risk
factors for llID. The findings were in keeping with the comparison of the laboratory
reference ranges for all the indices measured with the mean study values. For all of the
indices measured, none of the mean values for study subjects were outside the reference
ranges. In addition, it was unfortunate that due to practical limitations, it was not possible
to make RCA measurements in this study.
Although a number of patients failed to lose weight, when regression analysis was carried
out significant relationships between changes in BMI and factor vn activity were shown
(table 8.4). Other significant relationships with changes in BMI were t-PA antigen and
LDL cholesterol concentrations. These findings all suggested a greater weight loss could
have significantly effected the plasma indices examined. The scientific data available has
suggested that the reduction of body weight in the overweight could be valuable in the
improvement of the haemostatic and rheological risk factors for llID.
Inthe present study, the values for plasma viscosity were well below the cut-off of 1.33 m
Pas (1.25 mPas at baseline) which has been identified with low risk of stroke or coronary
disease (Lowe et aI, 1997). However, the amount of weight loss and the starting BM!
appear to be key factors in achieving significant reductions in plasma viscosity (Fanari et
al, 1993, Wadden, 1993). It seems likely that our subjects, slimmer at baseline than those
in other studies and in good health (Parenti et al, 1988) did not lose sufficient weight to
alter plasma viscosity, which was not elevated.
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Mean haematocrit fell significantly with weight loss, but was not elevated at baseline
when compared with the values in an obese population or a population with increased
llID risk (Lowe et al, 1997). Other studies of weight loss in the overweight have shown
that haematocrit remained unchanged with weight loss (Parenti et al, 1988, Fanari et al,
1993). Only the results of a large weight loss / VLCD programme were in agreement with
our study results of a significant fall in haematocrit with weight loss (Poggi et al, 1994).
The possible reasons why a mean weight loss of 3% was effective in reducing haematocrit
are unclear and require further study.
The failure of weight loss to reduce fibrinogen concentrations in this present study is in
agreement with the following studies, all of which lack power to make definitive
statements (Fehily et al, 1982, Ernst et al, 1986, Parenti et al, 1988, Ernst et al, 1989,
Slabber et al, 1992, Ernst, 1993, Palareti et al, 1994, Ditschuneit et al, 1995) and earlier
chapters of this thesis.
A fall in factor vn activity of close to 10 % appears to be the extent of change achieved in
the majority of studies of dietary change and weight loss (Folsom et al, 1993, Palareti
1994). In agreement with the fmdings of this present study, but in contrast with the
majority of the literature, are the findings of Baron et al (1989). They examined the effect
of intentional weight loss in factor vn activity. A mean weight loss of close to 4.0 kg
using a 1200 kcal diet was achieved after 12 weeks and factor vn activity remained
unchanged. This could have reflected a number of influences including the type of dietary
intervention offered, a 1200 kcal energy prescription was advised for all subjects, of
which half of the subjects were advised to consume 1200 kcal in the form of a high fat
diet (50% energy from fat), insufficient weight loss, or the effects of seasonal variation.
Seasonal variation has been identified as altering factor vn activity, which is known to
rise in winter along with plasma fibrinogen concentrations (Woodhouse et ai, 1994).
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Practical constraints governed when the recruitment for this present study commenced,
but it may have coincided with the greatest variation in factor vn, between autumn and
the onset of winter. However, the failure of weight loss to reduce factor vn activity was
probably due to two factors. Firstly, the insufficient weight loss, and a mean plasma
factor vn activity that was not elevated. These ideas are confirmed by the relationship
between reducing body weight and factor VII activity shown (figure 8.1). This suggests
that further weight loss may have strengthened the relationship.
As in any study which was aimed to achieve weight loss in a free living population, there
are changes in both energy intake and dietary composition. The influence of dietary fat
intake on factor vn activity has been shown to be significant (Miller et al, 1986). A
significant decrease was seen in factor vn activity with reductions in dietary fat intake
(31% energy from fat) without weight loss. A similar dietary intervention (32% energy
from fat) with two different fat compositions, a low or high PIS ratio also significantly
lowered factor vn activity (Marckmann et ai, 1992). The present study did not find a
relationship between dietary fat intake and factor vn activity at baseline, or between
changes in these variables after intervention. The plasma triglyceride concentration itself
has been identified as a possible mediator of the relationship between dietary fat intake
and factor vn activity (Miller et al, 1990). However, the subjects in this study had low
mean plasma triglyceride concentrations, with only a small range. In addition, they also
reported a percentage energy from dietary fat of 35%, close to 5% below the estimated
dietary fat intake of a sample of the Scottish population. These two factors, together with
factor vn activities, which were not elevated and with only a small range of values, may
explain the failure of a significant relationship to become apparent. Alternatively, it may
be that dietary intake assessment is not possible in these subjects.
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The fibrinolytic system enzyme PAl activity and t-PA antigen are related to overweight
and to increased IHD risk (Carlson et al, 1981, Vague et al, 1986, Landin et al, 1990).
Significant reductions in PAI-l activity and t-PA antigen have been shown after weight
loss at least three times greater than that observed in this present study (Vague et aI, 1986,
Landin et al, 1990, Mehrabian et al, 1990). It was encouraging that the relatively small
amount of weight loss achieved in this present study appeared to affect PAl activity,
although no influence on t-PA antigen was apparent. However, regression analysis
revealed a significant relationship between BMI change and t-PA antigen. This may be a
suggestion that greater weight losses could have resulted in a greater reduction in t-PA
concentrations. These results are in contrast to those of chapter 6, where t-PA antigen fell
significantly with weight loss in overweight women. Once more, the baseline values for
these subjects were very close to the reference range, which may explain why the weight
loss achieved was not influential.
The second hypothesis concerned the effects of dietary intervention and weight loss on
plasma lipids. The significant reduction in total and HDL cholesterol concentrations
following weight loss is in agreement with the majority of the literature (Dattilo and Kris-
Etherton, 1992, Goldstein, 1992). The mean plasma cholesterol concentrations in those
who reduced body weight were similar to the current European Atherosclerosis Society
recommendations of a plasma cholesterol of 5.2 mmollL, or below (European
Atherosclerosis Society, 1987).
The examination of relationships between the changes in haemostatic and rheological risk
factors and the changes in plasma lipids provided an opportunity to examine whether the
dietary intervention led to similar effects on the two areas of measurement. The
significant relationship of changes in PAl activity with total and LDL cholesterol was of
interest, and provided more evidence of the many benefits from moderate weight loss on
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llID risk factors. This evidence supports the finding of Folsom et al (1992) of a link
between haemostatic factors and plasma lipids after weight loss. However, no evidence
exists as to whether this relationship is causal, and further research is required in this area.
The final hypothesis examined the effects on body weight of a 600 kcal daily energy
deficit in a group of close to healthy weight subjects. The target weight loss was 0.5 kg
per week. The mean weight loss for the whole group was 0.2 kg per week, 40% of the
target value. Anecdotally expressed opinions from fellow dietetic professionals have
suggested that a structured approach towards weight loss, such as the 600 kcal energy
deficit, would be impractical and ineffective in a group of subjects with a close to healthy
BMI. Studies which have examined the effectiveness of weight reduction using this
approach in close to healthy weight subjects group are few.
Velthuis-te Wierik et al (1995) used a similar daily energy deficit approach to this present
study and achieved a far greater weight loss (7.0 kg over ten weeks) in men whose mean
BMI was 24.6 kglm2 at baseline. It is likely that their success was due largely to
differences in the design of the intervention and in the approach to energy prescription and
food provision. In order to calculate an appropriate energy prescription, their subjects
were asked to complete a 7 day WI food diary. The prescription was calculated to be only
80% of the individuals estimated energy requirements as measured by the completion of a
7 day WI. Significant under-reporting of food intakes, 13%, was identified using the
doubly labelled water method. Thus, subjects had a mean daily energy deficit of 33%
(close to 3810 kJ / 911 kcal) below requirements, which exceeded the daily 600 kcal
deficit used in this present study. The second reason why the mean weight loss achieved
was much closer to the target of 0.5-1.0 kg per week was the approach used in the
management of subjects (Velthuis-te Wierik et ai, 1995). Food comprising the complete
diet and which achieved each subjects' individual energy prescription was provided in the
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form of pre-prepared meals and snacks, so all the foods consumed for the ten week study
were effectively a gift to the subjects. Measured by weight lost, this approach resulted in
substantially improved dietary compliance. The mean weight loss of 2.6 kg after 12
weeks in this study was considerably below that achieved by the majority of other workers
using a conventional dietary approach in overweight and obese subjects (Wadden, 1993).
It was encouraging to fmd that no significant difference was found between the reported
energy intakes at baseline and the estimated energy requirements (using the
WHO/Schofield equations). This would suggest the group as a whole was not
significantly under-reporting food intake at baseline. However, under-reporting has been
well recognised as a feature of self reported dietary intakes completed by overweight and
close to normal weight subjects 01elthuis-te Wierik et al, 1995). The majority of the
significant changes between reported nutrient intakes at baseline (before dietary
intervention) and week 12were in agreement with the principle targets for dietary change.
These included a reduction in total and saturated fat and an increase in percentage energy
from carbohydrate (COMA, 1991). The exception remained the significant increase in the
percentage energy from dietary protein post-intervention, which exceeded its dietary
target. This most likely reflected the difficulty that subjects found in adjusting their
dietary protein intake within the context of a lowered energy intake. The failure of
subjects to achieve at least 50% dietary energy from carbohydrate whilst lowering their
energy intakes was probably related. Subjects often reduce the quantity of food consumed
to fulfil the requirement to lose body weight, but often fail to reduce the quantity of
protein in their diet. Personal dietetic experience suggests that subjects often fail to
reduce their protein intakes as the "protein rich" component this part of their meals are
often pre-portioned, e.g. chops, steak, fish fillets etc. This change requires considerable
planning to adjust to and subjects often fail to achieve reductions in their protein intakes.
258
The apparent reluctance of subjects to increase their consumption of bread and potatoes
exacerbated this problem, and probably led to the lower than optimal carbohydrate
consumption. Both of these findings are in agreement with the reported dietary intakes in
the two earlier studies. However, at present there is insufficient scientific evidence to
support these possible explanations.
8.5 Conclusions
Dietary intervention and moderate weight loss of 2.6 kg in subjects of near normal weight
achieved significant reductions in haematocrit and total cholesterol concentrations. In
contrast, the failure of the weight loss to influence the haemostatic and rheological
indices, particularly factor VU activity, linked with increased IHD risk was not
unexpected. The haemostatic and rheological risk factors for IHD were within their
laboratory reference ranges at baseline, i.e. the values associated with a minimal incidence
of chronic disease. However, the significant relationships shown by correlation analyses,
suggest strongly that a greater amount of weight loss may have shown significant falls in a
number of IHD measures. These relationships suggest weight loss of between to 5-10%
body weight may be of value in reducing IHD risk. The present results also suggest that
moderate weight loss can be advocated to improve cholesterol concentrations, haematocrit
and possibly PAl activity, all established risk factors for mD. Weight losses in this
subject similar to the present group of can be recommended following this study.
Furthermore other subjects with a close to healthy BMI, but the presence of greater llIn
risk, e.g. diabetes, would be even more likely to show greater benefits, and possibly
reductions in IHD risk following moderate weight loss.
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Table 8-1 Characteristics of all subjects who completed the study at baseline and
week twelve
Baseline Week 12 Difference p
Age 41.6 (8.5)
Weight (kg) 77.9 (8.1) 75.3 (7.7) -2.6 (2.6) 0.00001
BMI (kg/m2) 25.3 (1.4) 24.4 (1.5) -0.9 (0.8) 0.00001
WHR 0.88 0.87 (0.08) -0.01 (0.06) 0.31
(0.06)
Total cholesterol (mmol/L) 5.5 (0.9) 5.2 (1.1) -0.3 (0.8) 0.037
LDL cholesterol (mmol/L) 3.4 (0.8) 3.2 (1.0) -0.2 (0.3) 0.033
HDL cholesterol (mmol/L) 1.5 (0.4) 1.3 (0.4) -0.2 (0.3) 0.18
Triglyceride (mmol/L) 1.3 (0.8) 1.4 (1.1) +0.1 (0.9) 0.50
Systolic blood pressure (mmHg) 121 (11) 116 (10) -5 (10) 0.021
Diastolic blood pressure (mm 80 (9) 80 (8) 0(3) 0.84H
Data mean (SD). n= 38
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Table 8-2 Dietary information from baseline (record one) and week twelve (record
two).
Nutrient value Baseline Week 12 Difference p
9980 (8833, 11283) 8109 (7206, 9267) -1660 (-3465, -209)
kJ 0.0001
kcal 2380 (2107, 2688) 1929 (1710, 2200) -408 (-833, -39) 0.0001
PIS ratio 0.54 (0.38, 0.65) 0.58 (0.47, 0.69) +0.08 (-0.08, +0.20) 0.09
Fat % energy 35.6 (33.2, 41.4) 28.6 (26.7,32.4) -6.1 (-9.8, -2.4) 0.0001
Saturated fat % 12.3 (10.9, 14.6) 9.4 (7.9, 11.4) -2.7 (-5.8, -1.3) 0.0001
energy
Polyunsaturated 6.3 (5.3, 7.7) 5.0 (4.0, 6.3) -0.8 (-2.1, 0.0) 0.004
fat % energy
Protein 0/0 14.4 (13.3, 16.2) 16.7 (15.0, 18.1) +2.3 (0.2, 3.6) 0.0001
energy
Carbohydrate 43.5 (37.9,48.0) 49.2 (44.3, 52.8) +3.7 (-1.1, +10.0) 0.001
% energy
Alcohol % 4.2 (2.4, 10.1) 4.6 (3.6, 8.6) 0.0 (-2.0, +2.2) 0.950energy (n = 35) (n = 35) (n = 35)
n-38
Data as median, 25 and 75 % inter-quartile ranges
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Table 8-3 Haemostatic and fibrinolytic measurements at baseline and week twelve
Baseline Week 12 Difference p
Haematocrit (%) 46 (3) 45 (3) -1 (3) 0.04
Plasma viscosity (m Pas) 1.25 (0.07) 1.24 (0.07) -0.01 0.44
(0.03)
Fibrinogen (gIL) 2.54 (0.59) 2.76 (0.74) +0.22 0.12
(0.82)
Factor VII activity (IU/dL) 108 (17) 105 (17) -3 (10) 0.19
PAl activity (% pool) 86 (39) 68 (30) -18 (16) 0.06
t-PA antigen (ug/ml.) 8.4 (3.8) 8.1 (3.5) -0.3 (2.9) 0.53
Data as mean (SO), n=38
262
Table 8-4 Relationships between changes in body mass index, waist circumference
and waist to hip ratio with changes in haemostatic and rheological measures
Change in haemostatic
factors
Change in
waist (cm)
Change in
WHR
Change in
BMI
(kg/m2)
Haematocrit (%) r= -0.006
p= 0.979
r =0.051
P = 0.809
r = -0.311
p = 0.130
Plasma viscosity (mPas) r= 0.083 r= 0.350 r = -0.174
p=0.698 p = 0.094 p = 0.416
Fibrinogen (gIL) r= -0.039 r= 0.242 r = 0.130
P = 0.835 P = 0.182 P = 0.477
r= 0.335 r = -0.120 r = -0.166
Factor VII activity (IU/dL) p= 0.053 P = 0.543 P = 0.231
PAl activity (% pool) r= -0.277 r = 0.122 r = -0.244
p = 0.161 P = 0.553 P = 0.231
t-PA antigen (~g/mL) r = -0.460 r = -0.019 r = -0.192
p = 0.016 p = 0.924 P = 0.338
Cholesterol (mmol/L) r= 0.344 r = 0.085 r = -0.172
p = 0.040 P = 0.616 P = 0.308
HDL cholesterol (mmol/L) r = -0.046 r = -0.072 r = 0.019
p =0.801 p = 0.687 p = 0.917
LDL cholesterol (mmol/L) r = 0.333 r = 0.132 r = -0.129
p = 0.058 p = 0.457 p = 0.468
Triglyceride (mmol/L) r -0.217 r=-0.114 r = -0.125
p =0.203 P = 0.501 p- 0.461
n=38
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Table 8-5 Relationships between plasma lipids and haemostatic and rheological
measures at baseline
Haemostatic Cholesterol LDL HDL Triglyceride
factors (mmollL) cholesterol cholesterol (mmollL)
(mmollL) (mmollL)
Haematocrit (%) r= 0.142 r = 0.313 r = 0.130 r = -0.085
p = 0.381 P = 0.072 p=0.445 p = 0.604
Plasma viscosity r = 0.445 r = 0.436 r = 0.313 r = 0.529
(mPas) p=0.004 p = 0.012 p=0.059 p = 0.0001
Fibrinogen (gIL) r=0.046 r = 0.020 r = -0.073 r= 0.252
p = 0.806 p = 0.918 p = 0.706 p = 0.172
Factor VII activity r = 0.219 r = 0.107 r = 0.056 r= 0.322
(lU/dL) p = 0.254 p = 0.611 p = 0.780 p = 0.088
PAl activity (% r = -0.286 r = -0.218 r = -0.244 r=0.117
pool) p = 0.166 p = 0.318 p = 0.250 p = 0.577
t-PA antigen r = 0.127 r = -0.201 r = -0.203 r = 0.088
(J,!g/mL) p = 0.529 p = 0.325 p = 0.320 p = 0.662
n=38
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Table 8-6 Relationships between plasma lipids and haemostatic and rheological
measures at week twelve
Haemostatic Cholesterol LDL HDL Triglyceride
factors (mmol/L) cholesterol cholesterol (mmol/L)
(mmol/L) (mmol/L)
Haematocrit (%) r = 0.029 r =0.158 r = -0.664 r=0.128
p = 0.890 P = 0.471 P = 0.0001 p = 0.543
Plasma viscosity r= 0.249 r= 0.295 r = -0.430 r = 0.469
(mPas) p = 0.241 p = 0.183 p= 0.04 p = 0.021
Fibrinogen (gIL) r = 0.356 r = 0.387 r= -0.243 r = 0.154
p = 0.046 P = 0.038 p = 0.188 p = 0.401
Factor VII activity r = 0.100 r = 0.059 r= 0.050 r = -0.041
(IU/dL) p = 0.607 p = 0.776 p = 0.800 p = 0.832
PAl activity (% r = 0.218 r = -0.323 r= -0.050 r = 0.288
pool) p= 0.284 p = 0.123 p = 0.814 p = 0.154
t-PA antigen ------r = 0.454 r = 0.459 r= -0.223 r = 0.330
(J-lg/mL) p = 0.017 p = 0.016 p = 0.264 p = 0.092
n=38
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Table 8-7 Relationships between changes in plasma lipids and changes in
haemostatic and rheological measures
Change in Change in Change in Change in Change in
haemostatic cholesterol LDL HDL triglyceride
factors (mmollL) cholesterol cholesterol (mmollL)
(mmollL) (mmollL)
Haematocrit (%) r= 0.209 r =0.237 r= 0.016 r = -0.237
P = 0.328 P = 0.288 p= 0.945 P = 0.265
Plasma viscosity r = 0.129 r = 0.144 r= -0.035 r= 0.207
(mPas) p = 0.556 P = 0.533 p=0.881 p = 0.342
Fibrinogen (gIL) r = 0.016 r = -0.015 r = -0.189 r = 0.225
p= 0.932 p= 0.939 P = 0.335 P = 0.224
Factor VII activity r= 0.041 r = -0.049 r = 0.141 r = -0.008
(lU/dL) p = 0.838 P = 0.819 P = 0.512 P = 0.968
PAl activity (% r = -0.534 r = -0.549 r = -0.215 r = 0.234
pool) p= 0.006 p= 0.007 P = 0.325 P = 0.260
t-PA antigen r= -0.230 r = -0.287 r = -0.157 r = -0.232
(llg/mL) p=0.248 p = 0.155 P = 0.443 p = 0.244
0-38
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Figure 8-1 Relationship between changes in factor VII activity and body mass index
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Plate 8-1 British Petroleum Refinery, Grangemouth
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Chapter 9 The effects of moderate weight loss on haemostatic
and rheological factors and plasma lipids in all subjects who
participated in the present studies
9.1 Introduction and hypotheses
A BM! 25.0-30.0 kg/m', BM! > 30.0 kg/m', obesity and a BM! at the top of the healthy
range (BM! 22.5-25.0 kg/m') are all established as increasing ll-ID risk (Lew and
Garfinkel, 1979, Manson et al, 1990, Colditz et al, 1995). The earlier chapters have
described the effects from the same dietary intervention for weight loss in these three
different weight catagories. The outcome measures were established ll-ID risk factors
relating to haemostasis, rheology and plasma lipids. This chapter firstly examined the
effects from dietary intervention and weight change on IHD risk factors for all subjects
considered as a single group. Secondly, it sought any differences in IHD risk factors and
success in achieving weight loss between the groups.
There were five research questions to be answered:
1) Does the subject group diagnosed with angina show raised IHD risk factors in
comparison to those of the other subject groups at baseline?
2) Does the angina group achieve greater weight losses and changes in IHD risk factors,
haemostatic and rheological measures and plasma lipids, compared with the other subject
groups after intervention?
The remaining questions concern the three subject groups considered as one.
3) Does a dietary intervention incorporating an energy deficit approach to weight loss
(600 kcal per day) achieve losses of close to the theoretical 0.5 kg per week?
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4) Does weight loss following a dietary intervention to lower total energy intake and
change dietary composition in line with current dietary targets, improve haemostatic and
rheological risk factors for llID across a wide BM! range?
5) Does weight loss following a dietary intervention to lower total energy intake and
change dietary composition in line with current dietary targets, improve plasma lipid
concentrations across a wide BM! range?
9.2 Methods
The data concerning the subjects from each group (chapter 6, 7 and 8) were merged and
analysed in two ways. Firstly, one way analysis of variance was used to determine any
differences between the groups in their body weight and llID risk factors at baseline.
Mann Whitney or Student's t-tests were used to examine any differences between the
groups. These same approaches were used to examine if any changes achieved in body
weight and llID measurements after dietary intervention were significantly different
according to group. The second analysis in all subjects used Students t-test to test for ay
changes between body weight and BM! and llID risk factors after dietary intervention.
Any relationships between changes in body weight or BM!, and llID risk factors were
examined by correlation analysis and linear regression analysis. The regression analyses
were completed to evaluate the effects of age, sex, study group and presence of disease on
any changes in the outcome measures of interest.
9.3 Results
A total of 132 subjects (69 women, 63 men) completed the weight loss interventions. The
overweight/obese subjects numbered 45,36 women and 9 men with a body weight range
of 86.6 -153.2 kg. The overweight/obese subjects with angina group numbered 49, 27
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men and 22 women, with a body weight range of 68.8 - 114.0 kg. The close to healthy
weight group numbered 38,31 men and 7 women, with a body weight range of 57.8 - 91.0
kg.
The laboratory data were incomplete for all 132 subjects, due either to insufficient assay
sample, or lost samples. The number of analyses for each llID risk factor are given in the
relevant table.
The characteristics of each study group at baseline are given in table 9.1. There were
significant differences in age, with the angina group significantly older than the other two
groups (p<0.05). The overweight group had a higher mean body weight and BM! than the
angina or close to healthy weight groups (p<0.05), with the latter group having the a lower
WHR (p<0.01). Plasma total and LDL cholesterol concentrations were highest in the
angina subjects, and lowest in the close to healthy BM! subjects (p<0.01). Surprisingly,
the haematocrit was highest in the close to healthy BM! subjects and lowest in the
overweight group (p<0.01). Plasma viscosity, fibrinogen, PAl activity, t-PA antigen and
were lowest in the close to healthy weight group. Factor VII activity, HDL cholesterol
and triglyceride concentrations did not differ significantly according to group.
The changes in body weight, BM! and the llID risk factors according to group are shown
in table 9.2. Weight loss was significantly greater in the overweight (4.8%) than the
healthy weight subjects (3.3%) p=0.0026. The angina subjects were not significantly
different in their weight loss compared to either group. There was no change according to
group in WHR or plasma lipids, total, HDL, LDL or HDL cholesterol or triglyceride
concentrations. There were no significant differences in the changes in the llID risk
factors after intervention according to study group (table 9.2).
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Since there were no differences between the groups in changes in haemostatic and
rheological factors, there were examined as a single group. The characteristics at
baseline, post-intervention and changes in anthropometric and urn measurements for all
subjects are given in table 9.3. The RCA is not included as it was not measured in all of
the angina group or in any of the close to healthy weight subjects. The range of baseline
body weight was 57.8 to 150.2 kg. There was a significant (4.2%) fall in body weight and
BMI (p=0.00001). This represented an average weekly weight loss of 0.3 kg, which
represented 60% of the target value. Total cholesterol (6.7%, p=O.OOOOI),LDL (5.0%,
p=0.015) and HDL cholesterol (7.1%, p=0.028), fell significantly, whilst triglyceride
remained unchanged. Mean factor VU activity was significantly reduced (-5.1%) in all
subjects (p=0.0011), and fibrinogen concentrations rose (+3.2%, p=O.042).
The relationships between the changes in body weight and urn risk factors examined by
Pearson's correlation analyses are shown in table 9.4. There was a significant
relationships between changes in body weight and factor VU activity (p=O.OOI,figure
9.1), total cholesterol, (p=0.026, figure 9.2), and LDL cholesterol (p=O.OI5, figure 9.3).
Regression analysis showed no influence of age, sex, study group or BMI on these
changes. The change in BMI as a covariate in the regression analysis was a significant
influence on the changes in factor VII activity (p=O.003), total (p=O.03) and LDL
cholesterol (p=0.004) after dietary intervention.
9.4 Discussion
The three subject groups recruited to this series of studies were compared in terms of their
nm risk factors. The first research question was whether the subject group with angina,
would show higher nm risk factors compared to the other two groups at baseline. The
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results for llID risk factors were highest in those with angina, which proved the research
question. However, the question whether the angina subjects would achieve the greatest
weight losses and in turn the greatest falls in llID risk factors was unproven. The failure
of the presence of llID to improve dietary compliance of the angina group and exceed that
in the other groups, without a diagnosis of llID, could reflect many factors. It seemed
important that the diagnoses of angina were not new, and therefore the impetus often
associated with a new diagnosis was not apparent. A future study examining newly
diagnosed angina patients and their compliance with dietary advice would be interesting
to try and evaluate this effect. The greater age of the angina group was likely to have
contributed both to their increased llID risk and possibly, their difficulty in achieving
good dietary compliance.
The overall weight loss of all subjects was 60% of the target suggesting that the
individualised energy deficit approach to weight loss has promise for the wider
application in weight management. It was interesting to note that the overweight subjects
with the highest mean BMI lost the greatest amount of body weight whereas the healthy
weight subjects lost the least. This latter group has been rarely exposed to prescriptive
dietary advice and therefore the results were the most difficult to predict. However, the
fact that these subjects, with a desire to lower their body weight, were the leanest at
baseline, made it less easy to predict their compliance with prescriptive dietary advice.
The results in terms of weight loss support the theory that, in the short term, the greater
body weight ensures the greatest weight loss.
As all participants were volunteers and therefore motivated to take part in the study, it was
expected that the weight loss would have been closer to the calculated 6.0 kg.
Considering the effect of dietary advice in all subjects as one group, the 60% target weight
loss was only moderately encouraging. In a routine clinical setting the weight loss results
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following this approach may be less, with routine patients rather than volunteers being
advised, and perhaps being insufficient to result in any measurable health benefits.
The differences in body weight loss between study groups in terms of target weight, 75%
(overweight), 58% (angina) and 43% (close to healthy weight), provide some support in
these subject groups for the use of the 600 kcal energy deficit approach to weight loss.
The results from the present studies have proven research questions four and five with
significant reductions noted in llID risk factors after weight loss. These findings
supported the role of moderate weight loss in improving some plasma lipids, haemostatic
and rheological risk factors.
9.S Conclusion
The 600 kcal energy deficit dietary approach to weight loss, currently favoured in the
SIGN guidelines (SIGN, 1996), resulted in 60% of target weight loss being achieved.
This appears, from available clinical data, to be at least as effective as other dietary
approaches to weight loss currently used in clinical practice. The present results showed
that close to 5% weight loss reduced llID risk. However, it was surprising that the
presence of nm did not improve dietary compliance in comparison to healthy subjects.
These studies support the further testing of this approach to weight management in
clinical practice.
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Table 9-1 Anthropometric and IHD risk factor measures at baseline according to
study group
Overweight Angina Healthy p
weight
Age (years) 43.6 (10A)a,b 60.3 (6.5t 41.6 (8.5)b 0.0001
BM! (kg/m2) * 34.9 (6.l) a 29.3 (4.1) b 25.3 (lA) C 0.0001
Weight (kg) * 93.5 (19.3)a 81.6 (11.7) b 77.9 (8.l)C 0.0001
Waist to hip ratio 0.99 (0.05) a,b 1.00 (0.06) a 0.88 (0.06) b 0.0001
Total cholesterol (mmolll) 5.8 (l.l)a,b 6.3 (LIt 5.5 (0.9)b 0.005
LDL cholesterol (mmolll) 3.8 (1.1)a,b 4.6 (0.9) a 304 (0.8) b 0.001
HDL cholesterol (mmolll) 1.3 (0.5) a 1.3 (0.3) a 1.5 (0.4) a 0.232
Triglyceride (mmolll) lA (0.6) a 1.8 (0.8) a 1.3 (0.8) C 0.089
Haematocrit (%) * 43 (4)a 45 (5) b 46 (3)C 0.008
Plasma viscosity (mPas) 1.31 (0.07) a 1.30 (0.08) a,b 1.25 (0.07)b 0.0001
Fibrinogen (gIL) * 3.3 (0.9) a 3.3 (0.9)b 2.5 (O.S)C 0.001
Factor VII activity (IU/dL) 115 (2) a 120 (23) a 108(17)a 0.092
PAl activity (% pool) * 147 (62) a 134 (75)b 86 (39)C 0.0001
t-PA antigen (~g/mL) * 9.2 (5.l) a 10.9 (3.2)b 804 (3.8) C 0.006
~i~ificantly different from each other when superscripts differ (t-test, or ...
indicates Mann Whitney test), Data as mean (SD), n= 132
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Table 9-2 Changes in anthropometric and IHD risk factors measures after
intervention according to study group
Overweight Angina Healthy p
weight
Weight (kg) -4.5 (2.9) a -3.5 (2.6) a, b -2.6 (2.6)b 0.008
BMI (kg/m2) -1.7 (1.1)a -1.2 (0.9) a, b -0.9 (0.8) b 0.008
Waist to hip ratio -0.1 (0.1) a -0.01 (0.06) a -0.01 (0.06)a 0.458
Total cholesterol (mmol/l) -0.4 (0.8) a -0.4 (0.8) a -0.3 (0.8) a 0.713
LDL cholesterol (mmol/l) -0.2 (0.9) a -0.3 (0.6) a -0.2 (0.3) a 0.490
HDL cholesterol (mmol/l) -0.1 (0.5) a -0.1 (0.6) a -0.1 (0.9) a 0.714
Triglyceride (mmol/l) 0.0 (0.4) a -0.1 (0.9) a 0.0 (OJ) a 0.722
Haematocrit (%) o (4)a -0.5 (6)a -1 (3)a 0.332
Plasma viscosity (mPas) -0.02 (0.07) a -0.01 (0.2) a -0.01 (0.03)a 0.455
Fibrinogen (gil) -0.4 (1.4) a +0.2 (OJ)a +0.2 (0.8) a 0.334
Factor VII activity (IU/dL) -7 (17) a -5 (20) a -3 (10) a 0.334
PAl activity (% pool) -7(59)a -11 (72) a -18 (16) a 0.500
t-PA antigen (llg/mL) -0.4 (3.4) a -0.3 (2.8) a -0.3 (2.9) a 0.669
Significantly different from each other when superscripts differ (t-test)
Data as mean (SD), n= 132
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Table 9-3 Characteristics of all subjects who completed the study at baseline and
week twelve
n Baseline Week 12 Change p
Weight (kg) 132 84.5 (15.4) 80.9 (14.8) -3.6 (2.8) 0.00001
BMI (kg/m2) 132 30.0 (5.9) 28.8 (5.6) -1.2 (1.0) 0.00001
Waist to hip ratio 132 0.93 (0.07) 0.92 (0.09) -0.01 (0.06) 0.12
Total cholesterol (mmolll) 109 5.9 (1.1) 5.5 (1.1) -0.4 (0.8) 0.00001
LDL cholesterol (mmolll) 84 4.0 (1.0) 3.8 (0.9) -0.2 (0.8) 0.015
HDL cholesterol (mmolll) 86 1.4 (0.4) 1.3 (0.4) -0.1 (0.4) 0.028
Triglyceride (mmolll) 105 1.4 (0.7) 1.5 (1.0) +0.1 (0.9) 0.37
Haematocrit (%) 110 45 (4) 44 (3) -1 (4) 0.46
Plasma viscosity (mPas) 103 1.28 (0.08) 1.27 (0.08) -0.01 (0.07) 0.56
Fibrinogen (gil) 114 3.1 (0.9) 3.2 (0.8) +0.1 (0.8) 0.042
Factor VII activity (IU/dL) 109 116 (21) 110 (20) -6 (20) 0.011
PAl activity (% pool) 106 122 (65) 115 (63) -7 (49) 0.18
t-PA antigen (J.lg/mL) 99 9.5 (3.9) 8.8 (3.5) -0.7 (3.3) 0.056
n=132
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Table 9-4 Relationships between changes in haemostatic and rheological factors
plasma lipids and weight change
Change in risk factor Correlation
coefficient
Total cholesterol (mmollL) r=0.213
p=0.026
HDL cholesterol (mmollL) r=O.IlI
p=0.307
LDL cholesterol (mmollL) r=0.264
p=0.015
Triglyceride (mmollL) r=-0.027
p=0.784
Haematocrit (%) r=-0.059
p=0.539
Plasma viscosity (mPas) r= -0.038
p=0.705
Change in fibrinogen (gil) r= 0.005
p= 0.960
Factor VII activity (lU/dL) r= 0.310
p=O.OOI
PAl activity (% pool) r= 0.078
p= 0.430
t-PA antigen (~g/mL) r= 0.134
p= 0.185
n=132
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Figure 9-1 Changes in body weight and factor VII activity
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Figure 9-2 Changes in body weight and total cholesterol concentrations
2.5
~ 2.0- 1.50
i 1.00.5-0 0.0
~ -0.5~til
(l) -1.0-.s -1.5
0
.S -2.0
(l) -2.5
§ -3.0
...s::: -3.5U -4.0
•r=O.213
p=0.026 •
•• • I. I
• '" •••• I•• lA··. If •••• ,-------.-~.-.--r~~~.-l,'---. I· I
• • It.:iI • •• ."" ••• I.. .. ~
• •• I
• I
I
I
I
I
• •
-5 -3 -2 -1 o-4 1
Change inBMI (kg'm2)
n= 109
280
Figure 9-3 Changes in body weight and LDL cholesterol concentrations
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Chapter 10 The effects of moderate weight loss on serum
dehydroepiandosterone sulphate concentrations in overweight
subjects with angina pectoris and in those with body mass
index close to 25 kg/ml
10.1 Introduction and hypotheses
Intentional weight loss in the overweight offers real benefits in terms of mortality
(Williamson et al, 1995) and morbidity (Goldstein, 1992). The effects of weight loss in
older subjects with established ischaemic disease and elevated coronary risk have been
less rigorously examined, although Williamson et al (1995) suggested a benefit in women
with existing obesity related disorders.
Androgens are increasingly identified as key components of the insulin resistance
"metabolic syndrome", with particular reference to PCOS (Nestler et ai, 1988). A role
has been proposed for DHEAS, the major adrenal androgen, in the prevention of
atherosclerosis. DHEAS has been postulated as the possible link between
hyperinsulinaemia and obesity (Nestler et al, 1992). Recent evidence suggests that
DHEAS concentrations exert multiple anti-atherogenic effects and that hyperinsulinaemia
may reduce serum DHEAS concentrations by decreasing production and enhancing
clearance. Lower DHEAS concentrations are found in those with elevated coronary risk
and the overweight (Barrett-Connor et al, 1986, Nestler et al, 1989, Nestler et al, 1992).
Men who survived MI have also been shown to have reduced serum DHEAS
concentrations in comparison with healthy matched controls (Slowinska-Srzednicka et ai,
1989, Mitchell et ai, 1994). In women, a prospective study failed to find any relationship
between DHEAS concentrations and llID (Barrett-Connor and Goodman-Gruen, 1995).
Some improvements have been reported in DHEAS concentrations with weight loss, in
subjects with a mean age of 40 years of both sexes (Leenen et al. 1994, Jakubowicz et ai,
282
1995) but not older subjects with known llID. The present studies used dietary advice
which reflected the present recommended dietary composition (COMA, 1991) together
with a moderate daily energy restriction to investigate the effects of weight loss in angina
subjects on serum DHEAS concentrations, urinary steroid metabolites and insulin
concentrations. Although the effect of considerable amounts of weight loss on circulating
DHEAS concentrations in healthy but overweight subjects has now been studied (Leenen
et al, 1994), no information is available as to the effect of moderate weight loss alone. In
the present study a dietetic led approach was used to reduce body weight in healthy
subjects who were above their own preferred body weight, but with a BM! close to the
reference range (18.5-25.0 kg/m').
The hypotheses for this work was that weight loss would increase plasma DHEAS
concentrations, thus reducing llID risk. There were three research questions related to
DHEAS and urinary steroid metabolites for these studies.
1) What is the effect of moderate weight loss on circulating DHEAS concentrations in
overweight elderly subject with angina pectoris?
2) What is the effect of moderate weight loss on the principal urinary steroid metabolites?
3) What is the effect of weight loss on circulating DHEAS concentrations in a group of
subjects close to healthy weight?
It was proposed that moderate weight loss may be beneficial in terms of both DHEAS
concentrations and IHD risk in younger subjects, prior to the onset of the age related
reductions in serum DHEAS.
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10.2 Methods
10.2.1 Study design and statistical approaches
The study design was a single stranded study, according to the reasons given in chapter 4.
The sample size that was required to complete these studies was 57 subjects. The
biological data were normally distributed as determined from a distribution plot and were
analysed using paired Student's t tests. The dietary data showed a skewed distribution and
were analysed using a paired Wilcoxon test. Pearson's correlation analysis was carried
out to investigate any relationships between changes in body weight, or BM! and
percentage body fat and DHEAS and insulin concentrations and plasma lipid
measurements.
10.2.2 Subjects
Fifty four overweight angina subjects (31 men) with a BM! > 26 kg/nr' who had received
a medical diagnosis of angina pectoris were recruited (chapter 7). Fifty one healthy
subjects were recruited to a worksite intervention (chapter 8). The details of the physical
measurements made and the dietary interventions given to all subjects have already been
described (chapters 5, 7-8).
10.2.3 Venesection and laboratory methods
Fasting blood was sampled at baseline and post-intervention (week 12) for all subjects.
Total serum concentrations of DHEAS concentrations were determined using a
radioimmunoassay kit (leN Biomedicals, High Wycombe, Bucks., UK). Insulin assays
were determined using an "in house" immunoradiometric assay. Both of these methods
have already been described (chapter 5). For the angina subjects, complete volume 24
hour urine collections were made and urinary steroid profiles were conducted on 10 mL
aliquots. The gas chromatography/mass spectrometry method used was based on that of
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Shackleton (Shackleton, 1985) using a Fisons MD 800 G C mass spectrometer. The inter-
and intra-assay CV's were < 15% and <10%, respectively for all of the major urinary
steroid metabolites measured. The androgen (aetiocholanolone and androsterone) and
glucocorticoid metabolites, tetrahydrocortisone, tetrahydrocortisol, and allo-
tetrahydrocortisone, were quantified. Each set of pre- and post-treatment measurements
were assayed in the same batch.
10.3 Results
10.3.1 Angina subjects
Thirteen subjects failed to complete the protocol (9 men, 4 women). Data describing the
characteristics of the 41 subjects (21 men) who completed the study are described (table
10.1). There were no significant differences between the sexes for age (p=0.76) although
men were significantly heavier than women with mean BMI's of 30.5 (SD 4.7) vs. 27.4
(SD 2.9) kglm2 (p=0.013). Percentage body fat was significantly higher in women than
men (p=0.0001). At baseline no significant differences were seen in the biochemical
measurements according to gender, and therefore the subjects were analysed as a single
group. A significant relationship was observed between age and DHEAS concentrations
(p=0.009, figure 10.1). No significant associations between either BMI or percentage
body fat were observed for baseline DHEAS concentrations, principle urinary steroid
metabolites or plasma insulin. No significant relationship between DHEAS and BM! was
noted (p=0.279, figure 10.2). The urinary steroid metabolites did not significantly change
after intervention (table 10.2).
10.3.2 Effects of weight loss in angina subjects
Mean weight change over 12 weeks was similar at -3.3 in men and women, range -11.1 to
+1.7 kg in the angina study. There was a significant fall in plasma insulin in women (13.1
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to 9.7 mUlL, p=0.023) (table 10.1). At baseline, there were few significant associations
from correlations between biochemical measures, BMI, waist circumference or WHR.
The exceptions were the associations between BMI and the urinary metabolites
tetrahydrocortisone and the total of allo-tetrahydrocortisol, tetrahydrocortisol,
tetrahydrocortisone and tetrahydrocortisol (table 10.3). At week 12 these same
relationships were seen, and additional relationships between BMI and urinary
andosterone and 5 alpha tetrahydrocortisol (table lOA). There were no associations
between the measures of greatest interest in this study, plasma insulin and serum DHEAS
concentrations, at baseline (r=-0.055, p=0.769), week 12 (r=0.073, p=0.696) or the
changes (r=-0.062, p=0.702).
After intervention there were no associations between changes in BMI and changes in
serumDHEAS and urinary steroid metabolites.
10.3.3 Healthy subjects
Amongst the healthy subjects 13 subjects failed to complete the protocol. The
characteristics of the remaining 31 subjects are shown (table 10.6). Women had
substantially lower serum DHEAS concentrations, which were substantially lower than
those of men, mean 404 (SD 3.5) vs. 8.7 (SD 4.6) umol/L, Due to their small numbers,
women were discarded from the analysis. The mean weight loss for the male subjects was
2.9 (SD 2.7) range -9.8 - +2.10 kg (table 10.6). There were no significant relationships
between age or baseline BM! and serum DHEAS concentrations, except between BMI
and plasma insulin concentrations post-intervention (r=0.030, p=0.873, figure 10.3,
r=0.0l3, p=0.947, figure lOA).
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10.3.4 Effects of weight loss in healthy subjects
The characteristics at baseline and week 12 and the changes in physical and biochemical
measures are shown (table 10.6). Post-intervention there was no change in serum
DHEAS or plasma insulin after intervention. Percentage body fat, BMI or serum DHEAS
concentrations showed no significant associations at baseline or post-intervention (table
10.7-10.9). Insulin was the exception and BMI at baseline and post-intervention. At
week 12 plasma insulin concentration was significantly related to waist circumference
(r=0.323, p=0.045, table 10.8). There were no associations with BMI, waist and WHR
and changes in serum DHEAS and plasma insulin concentrations post-intervention (table
10.9). In particular, there were no significant associations between changes in insulin and
serum DHEAS concentrations.
10.3.5 Healthy subjects and angina subjects
In order to examine the relationships between body weight, weight change, percentage
body fat and serum DHEAS and insulin the healthy subjects and those with angina were
combined into a single group of 72 subjects with a wider ranges of age, BM! and weight
losses.
10.3.6 Effects of weight loss in healthy subjects and angina subjects
The physical and biochemical measurements for all subjects are shown (table 10.10). No
significant changes in serum DHEAS or plasma insulin were observed. At baseline
significant correlations were found between age, BMI, WHR and serum DHEAS and
plasma insulin concentrations (table 10.11). Post-intervention these relationships were
maintained, with the exception ofWHR (table 10.12). At each measurement occasion, no
relationship between serum DHEAS and plasma insulin was observed, and no significant
relationships were seen between the changes pre- and post-intervention. After
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intervention there were no significant associations between changes in BMI, body weight
or percentage body fat and changes in serum DHEAS or insulin concentrations.
The data were examined for correlations between BMI, and WHR, at baseline and week
12 and significant relationships were found (table 10.11-10.13). At baseline plasma
insulin and serum DHEAS concentrations were significantly correlated with BMI, and
WHR, and there were similar relationships at week 12. However, no significant
relationships were seen between the changes in BMI, WHR and serum DHEAS and
plasma insulin (table 10.13).
The relationships between age and serum DHEAS are shown (r=-0.578, p=O.OOOI,figure
10.5, and between serum DHEAS and BMI before and after intervention (FO.264,
p=0.026, figure 10.6, ) and r=-0.313, p=0.008, figure 10.7). The positive relationships
between insulin and BMI before and after intervention are shown (r=0.285, p=0.016,
figure 9.8, FO.310, p=O.Oll, figure 9.9).
10.4 Discussion
DHEAS has been proposed as a potential anti-obesity agent (Berdanier et ai, 1993) based
mainly on studies confounded by age. The theoretical benefits of increasing serum
DHEAS concentrations in terms of combating the effects of ageing (Morales et al, 1994),
reducing the risk for nm and the possible role as an anti-obesity agent has led to DHEAS
supplementation studies (Herbert, 1995). However, the results from these studies are
equivocal. Supplementation of DHEAS has led to the development of a highly
androgenic state and insulin resistance in post-menopausal women when given at 1600
mg per day for 28 days (Mortola and Yen, 1990). In contrast, DHEAS supplementation in
men at 50 mg per day for 6 months lowered LDL cholesterol concentrations and reduced
body fat (Nestler et ai, 1988). Another study found no anti-obesity effects with DHEAS
supplementation (Usiskin et al, 1990). The side effects of supplementation remain
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unknown and therefore any supplementation with steroid hormones must be approached
with caution. Therefore the act of losing weight as a potential mechanism of raising
endogenous DHEAS appears attractive.
The hypotheses for the present studies was that body weight loss would increase plasma
DHEAS concentrations, thus reducing llID risk. The first research question for these
studies was to examine whether moderate weight loss would effect serum DHEAS
concentrations in overweight, elderly subjects with angina pectoris. Three reports have
suggested an increase in serum DHEAS concentrations with substantial weight loss in the
overweight, (Leenen et aI, 1994, Crave et aI, 1995, Jakubowicz et al, 1995). All three
studies recruited subjects aged close to a mean age of forty years who were free of
cardiovascular disease. A 1000 kcal dietary plan was used in a study of overweight men
and pre-menopausal women and aged below 51 years (Leenen et aI, 1994). These
subjects had a higher BM! than those in the present study (range 28-38 kg/m2) and a 14%
weight loss (12-13 kg) resulted in acute increases in serum DHEAS concentrations of
36% and 32% in women and men and a corresponding 45% and a 35% reduction in
insulin concentrations in women and men respectively. Another study achieved 4.9 kg
(5.8%) weight loss in hyperinsulinaemic pre-menopausal hirsute women using a
conventional dietary approach of 1500 kcal daily (Crave et al, 1995). This increased
subjects serum DHEAS concentrations by 15-20% and decreased their plasma insulin
concentrations by 15-20 %. The third study recruited both men and pre-menopausal
women and achieved a 10% weight loss using a 1000-1400 kcal per day conventional
dietary regimen. Men showed significant elevations (125%) in serum DHEAS
concentrations although no such changes were observed in women. The authors were
unable to explain these sex specific effects on serum DHEAS as both men and women
showed significant falls in insulin concentrations after weight loss (Jakubowicz et ai,
1995). The results from these three studies were promising as to the potential benefits of .
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moderate weight loss on increasing serum DHEAS and lowering plasma insulin
concentrations. However, the older subjects in the present study were probably
approaching their lowest adrenal production rate (DePretti et al, 1978). The ability of
older persons to increase or alter their steroid hormone production rate or their metabolic
clearance rate is uncertain (Kurtz et al, 1987).
Inmen high serum DHEAS concentrations have been related to a central fat distribution,
while low serum DHEAS concentrations have been related to hyperinsulinaemia (Herranz
et al, 1995). This finding was also shown in pre-menopausal women (Williams et aI,
1993). A review has suggested that insulin had helped to lower serum DHEAS by
inhibiting the production, rather than the clearance of serum DHEAS and related steroids
(Nestler et aI, 1991). A significant inverse correlation was found between BM! and
DHEA (not DHEAS) concentrations in a study of morbidly obese pre-menopausal
women (mean BM! 41.8 (SD 10.3) kg/m2 (De Pergola et al, 1991) and between increasing
visceral fat and increasing serum DHEAS concentrations (De Pergola et aI, 1994). The
results of the present study failed to confirm either a relationships between serum DHEAS
and insulin, or between plasma insulin and serum DHEAS concentrations and body fat
percentage pre-intervention. The lack of association between changes in insulin and
changes in serum DHEAS are contrary to other results (Leenen et al, 1994, Crave et al,
1995, Jakubowicz et al, 1995) and may reflect the rather modest degree of overweight in
our subjects, and the fact that they were not selected on the basis of hyperinsulinaemia.
This is despite the care taken in providing an accurate dietary prescription derived using
measured REE. The use of hyperinsulinaemi a as a selection criteria was most pertinent to
the comparison with the findings of the Crave study (Crave et al, 1995). Their population
was both obese and hirsute indicating the presence of insulin resistance unlike that in the
study population. The weight loss of 4.9 kg (5.9% body weight) was very close to that
achieved in this present study. However, the subjects in the present study were not
290
selected on the criteria ofhyperinsulinaemia. The other study of weight loss (Jakubowicz
et aI, 1995) included subjects who were not insulin resistant but who had achieved an
11% body weight loss, greater than that achieved in this study.
From theoretical considerations a lower fat intake could enhance insulin sensitivity and
therefore in older subjects increase serum DHEAS (Ward et al, 1994). However, a mixed
omnivorous diet has been shown to have no important influence on serum DHEAS in
comparison with a vegetarian diet (Hill and Wynder, 1979). In view of this finding seems
unlikely that the relatively low fat intake achieved in the present study (30% v 34%
energy) would have had any major effects. Another study in pre-menopausal women
which sought to examine the relationship between dietary lipid and adrenal hormones
found a significant positive relationship between the level of dietary fat and serum
DHEAS concentrations. An inverse relationship was seen with serum DHEAS and
plasma insulin concentrations (Bhathena et aI, 1989).
To gain a greater insight into how any change in body weight may have influenced the
metabolism of steroids, urinary steroid metabolites were measured, in accordance with the
second research question. Would moderate weight loss effect the principle urinary steroid
metabolites? The principal urinary excretion of steroid metabolites (androsterone,
aetiocholanolone, tetrahydrocortisol, tetrahydrocortisone and allo- tetrahydrocortisol)
were unaffected by dietary intervention and weight loss within this study. The other
studies which have examined the effect of weight loss, mentioned in this chapter did not
include these urinary measurements (Leenen et al, 1994, Crave et al, 1995, Jakubowicz et
al, 1995). An early study (Hendrikx et al, 1968) reported a fall in the excretion of serum
DHEAS and metabolites with slimming over a 14 day period. Plasma insulin
concentrations are known to increase both conjugation and excretion of steroids (Nestler
et al, 1993). However, there are difficulties with requesting volunteers to make 24 hour
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urinary collections. The value of any laboratory measurements depend on the
completeness of the 24 hour urine collections as the results are expressed by urine
volume. It has been established using para-amino benzoic acid that twenty four hour
collections are often incomplete (Bingham and Cummings, 1985). Primarily, as urine
collections require a large amount of subject co-operation, and are awkward to carry out
and ensure no urine has been discarded. The angina subjects were an elderly group, and
their age may have compounded these difficulties. The finding that there was no change
in urinary steroids after weight loss was not unexpected. Difficulties in obtaining
complete 24 hour urine collections may have masked any small differences before and
after intervention, given the moderate degree of weight loss which had failed to affect
either serum DHEAS or plasma insulin concentrations.
The third research question for this study was whether moderate weight loss in subjects
who were not "elderly", (prior the onset of major age related falls), would increase serum
DHEAS. As the healthy subjects had both close to healthy BM! and serum DHEAS
concentrations within the reference ranges (Orentreich et al, 1984) the failure of moderate
weight loss to affect both serum DHEAS and plasma insulin was perhaps not surprising.
Once more, the subjects were primarily chosen on BM! criteria and not because of the
presence of insulin resistance or any particular other metabolic criteria. The findings for
the study on healthy weight subjects found serum DHEAS values within the accepted
reference ranges 2-9 J..lmollL. The increase in the serum DHEAS values in the healthy
subject group, 42.4 (SD 8.0) years compared with the angina group given their greater age
61.3 (SD 6.5) years was expected.
The dietary change in the healthy weight subjects was similar to that reported by the
angina group, with a reduction in dietary fat intake from 36.4 to 28.6%. It was expected
that a lower dietary fat intake would influence and even decrease insulin sensitivity, and
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that as a consequence of this serum DHEAS concentrations would increase. However the
moderate weight loss achieved in this study was insufficient to affect changes in plasma
insulin or serum DHEAS concentrations. Even considering these weight losses, the
subjects did not seem to be insulin resistant, given the relatively crude assessment
method, fasting insulin, that was used. The more precise methodology to assess insulin
sensitivity involving euglycaemic clamps (Bonora et al, 1989) was outside the practical
limitations of this work. The results from both subjects groups (healthy and angina
subjects) were consistent and showed that plasma insulin concentrations were unaltered
by moderate weight loss.
This study confirmed several relationships. These included BMI, body weight and
percentage body fat inversely with DHEAS and positively with insulin concentrations
(Leenen et ai, 1994). Itwas of interest to consider aU subjects as one group for the second
analyses. This was valid given the almost identical approaches in terms of recruitment
and dietary intervention. These analyses shed light on the failure of the healthy group to
show any significant negative relationship with age and serum DHEAS concentrations.
Considerable evidence exists to support the faU in adrenal steroid production with
increasing age (DePretti et ai, 1978). It seems most likely that this established
relationship of age and serum DHEAS did not become apparent in the healthy group, as
the group only represented a narrow age range where all participants were of employable
age. The relationship between age and serum DHEAS concentrations was very significant
when all subjects were considered as one group. These findings were in agreement with
the majority of the literature (Orentreich et ai, 1984). The significant relationship
between serum DHEAS and BM! could have been due to the confounding influence of
age. The subjects were older in the angina group and they were also more overweight.
The healthy SUbjectswere also younger and slimmer. As age has been established as the
principle factor that affects the production of adrenal steroids, the influence of age but not
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BM!, was probably the most influential factor. In addition, the other established positive
relationship, that of age with plasma insulin, was also seen.
10.5 Conclusions
This study indicates no important effects of moderate weight loss on serum DHEAS and
plasma insulin concentrations in older overweight subjects in younger healthy and non
overweight, subjects of employable age. Expected relationships between age and DHEAS
and between the three measures of body composition and these biochemical measures
were seen when the two groups were considered as one.
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Table 10-1 Characteristics of angina subjects at baseline and week twelve
Baseline Difference pWeek 12
Age (years) 61.3 (6.5)
Weight (kg) SO.S(12.1)
BMI (kg/m2) 29.1 (4.2)
% Body Fat * 34.5 (6.2)
Waist circumference (cm) 104 (10)
WHR 1.00 (0.05)
Serum DHEAS (umol/L) 2.6 (1.9)
Plasma insulin (mUlL) 13.3 (S.2)
77.5 (11.7) -3.3 (2.3) 0.00001
27.9 (4.1) -1.2 (O.S) 0.00001
33.7 (5.5) -O.S(3.5) 0.11
101 (11) -3.0 (4.3) 0.0004
0.99 (O.OS) -0.01 (0.06) 0.97
2.5 (1.6) -0.1 (0.9) 0.35
12.0 (9.0) -1.3 (7.9) 0.15
Data as mean (SD), n=41
* assessed by the method of Lean et al (1996)
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Table 10-2 Serum and urinary hormonal concentrations at baseline and week twelve
for angina subjects
n Baseline Week 12 Difference p
Urinary 22 773 (510) 858 (456) +85 (357) 0.86
androsterone
(ug/24 hours)
Urinary 22 678 (401) 729 (383) +51 (387) 0.73
aetiocholanolone
(llg/24 hours)
Urinary 22 0.95 (0.35) 1.03 (0.48) +0.08 (0.35) 0.64
androsterone I
aetiocholanolone
ratio (1lg/24hours)
UrinaryTHF 21 2075 (864) 2261 (802) +186 (950) 0.81
(1lg/24hours)
Urinary Allo- THF 21 2105 (1076) 2260 (1178) +155 (876) 0.79
(llg/24 hours)
Urinary 21 3563 (1120) 3922 (1399) +359 (1514) 0.85
tetrahydrocortisone
(llg/24 hours)
Total urinary 22 1451 (857) 1587 (788) +136 (715) 0.28
androsterone
aetiocholanolone
(1lg/24hours)
Total urinary THF 20 7710 (2597) 8552 (2941) +842 (3146) 0.31Allo-THF and THE
_{J::!g/24hours}
Data as mean (SO). Numbers vary for the values for urinary metabolites and
reflect the number of urinary collections made by subjects at baseline and week 12
THF = tetrahydrocortisol, THE = tetrahydrocortisone
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Table 10-3 Relationships between baseline dehydroepiandosterone sulphate, insulin,
urinary steroid metabolites, body mass index, waist circumference and
waist to hip ratio for angina subjects
n BMI Waist WHR
(kg/m2) circumferen
ce ~cm}
Age (years) 41 r =-0.260 r = -0.141 r = 0.150
P =0.109 P = 0.386 P = 0.355
Serum DHEAS (umol/L) 41 r = 0.162 r = -0.072 r = -0.153
p =0.328 p = 0.659 p = 0.346
Plasma insulin (mUlL) 41 r = 0.192 r = 0.158 r = 0.284
p = 0.247 p = 0.329 p = 0.070
Urinary androsterone 22 r= 0.252 r = -0.068 r = 0.059
(Jlg/24 hours) p = 0.226 p = 0.753 p = 0.785
Urinary aetiocholanolone 22 r = 0.232 r = -0.007 r= 0.269
(Jlg/24 hours) p = 0.263 P = 0.975 P = 0.204
Urinary androsterone / 22 r=0.171 r = -0.114 r = -0.229
aetiocholanolone ratio p = 0.440 P = 0.605 p = 0.293
~g!~4 hou!!l
.~~-.---UrinaryTHF 21 r = 0.212 r = 0.165 r=0.312
(Jlg/24 hours) p = 0.329 P = 0.441 p= 0.138
Urinary Allo-THF (Jlg/24 hours)
._-----_.
21 r = 0.373 r = 0.048 r = 0.066
p =0.079 p = 0.823 p = 0.759
Urinary THE (Jlg/24 hours) -21 r = 0.492 r= 0.245 r= 0.339
p = 0.016 p= 0.259 p = 0.1l3
Total urinary aetiocholanolone 22 r= 0.260 r= -0.044 r = 0.160
and androsterone (Jlg/24 hours) p = 0.214 p= 0.840 P = 0.456
Total urinary THF Allo-THF and 20 r = 0.430 r = 0.182 r= 0.265
THE (Jlg/24 hours) p = 0.042 P = 0.406 p = 0.221
Numbers vary for the values for urinary metabolites and reflect the number of
urinary collections made by subjects at baseline
THF = tetrahydrocortisol, THE = tetrahydrocortisone
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Table 10-4 Relationships at week twelve between dehydroepiandosterone sulphate,
insulin, urinary steroid metabolites, body mass index, waist circumference
and waist to hip ratio for angina subjects
n BMI (kg/m2) Waist WHR
circumference (cm)
SerumDHEAS 41 r = 0.082 r = -0.027 r = -0.022
(umol/L) p = 0.614 P = 0.614 P = 0.891
Plasma insulin 41 r = 0.107 r = 0.145 r = 0.139
(mUlL) p = 0.512 p = 0.512 p = 0.391
Urinary 22 r = 0.475 r=0.177 r = -0.005
androsterone p = 0.025 P = 0.430 p = 0.983
(~g/24 hours)
Urinary 22 r = 0.300 r= 0.262 r = 0.091
aetiocholanolone p = 0.175 P = 0.238 P = 0.687
(~g/24 hours)
Urinary 22 r=0.316 r = -0.027 r = -0.132
androsterone / p = 0.188 P = 0.914 P = 0.591
aetiocholanolone
ratio (~g/24 hours)
UrinaryTHF 21 r = 0.335 r = 0.111 r = 0.123
(~g/24 hours) p = 0.137 p = 0.632 P = 0.597
Urinary Allo-THF 21 r = 0.448 r = 0.028 r = -0.073
(~g/24 hours) p= 0.04 p= 0.903 P = 0.755
Urinary THE 21 r= 0.549 r = 0.239 r = -0.034
(~g/24 hours) p=0.0008 p = 0.284 P = 0.882
Total urinary 22 r = 0.421 r = 0.230 r = 0.041
aetiocholanolone and p = 0.051 p= 0.303 P = 0.855androsterone
(~gl24 hours)
Total urinary THF 20 r= 0.520 r = 0.150 r= 0.009
Allo-THF and THE p = 0.016 P = 0.516 p= 0.967(~g/24 hours)
N~bers vary for the values for urinary metabolites and reflect the number of
unnary collections made by subjects
THF = tetrahydrocortisol, THE = tetrahydrocortisone
298
Table 10-5 Relationships after weight loss between changes in
dehydroepiandosterone sulphate, insulin, urinary steroid metabolites, body
mass index, waist circumference and waist to hip ratio for angina subjects
n BMI Waist WHR
(kg/m2) circumference
(cm)
Serum DHEAS (J.lmollL) 41 r = 0.149 r = 0.082 r= 0.029
p = 0.358 p = 0.616 p = 0.859
Plasma insulin (mUlL) 41 r=0.116 r = -0.055 r = 0.003
p = 0.478 P = 0.736 p = 0.702
Urinary androsterone 22 r = -0.087 r = 0.128 r = 0.021
()lg/24 hours) p = 0.722 P = 0.603 p = 0.931
Urinary aetiocholanolone 22 r = -0.098 r= 0.092 r= 0.045
()lg/24 hours) p = 0.690 p=0.707 p = 0.853
Urinary androsterone / 22 r = 0.180 r = -0.032 r = -0.041
aetiocholanolone ratio p = 0.461 p= 0.895 P = 0.869
()lg/24 hours)
Urinary THF (J.lg/24hours) 21 r = 0.125 r= -0.062 r= -0.059
p=0.621 p= 0.808 P = 0.815
Urinary Allo-THF 21 r = 0.088 r= 0.062 r = 0.037
(llg/24 hours) p = 0.704 P = 0.788 p = 0.874
Urinary THE (llg/24 hours) 21 r = -0.092 r= -0.086 r = -0.090
p=0.717 P = 0.735 p = 0.721
Total urinary 22 r = -0.064 r= 0.153 r = 0.069
aetiocholanolone and p=0.778 p = 0.100 p = 0.760
androsterone (J.lg/24hours)
Total urinary THF Allo- ---_20 r= 0.072 r= 0.007 r = 0.001
THFandTHE p = 0.764 P = 0.850 P = 0.996
(J.lg/24hours)
Numbers vary for the values for urinary metabolites and reflect the number of
urinary collections made by subjects
THF = tetrahydrocortisol, THE = tetrahydrocortisone
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Table 10-6 Characteristics of healthy subjects at baseline and week twelve
Baseline Week12 Difference p
Age (years) 42.4 (8.0)
Weight (kg) 80.6 (5.5) 77.7 (5.9) -2.9 (2.7) 0.00001
BMI (kglm1) 25.4 (1.4) 24.5 (1.4) -0.9 (0.8) 0.00001
0/0 body fat 26.5 (7.0) 23.1 (4.8) -3.56 (3.2) 0.0003
Waist 88.6 (7.6) 85.5 (7.6) -3.1 (4.5) 0.0003
WHR 0.90 (0.05) 0.88 (0.07) -0.02 (0.07) 0.38
Plasma insulin (mUlL)
8.7 (4.6)
8.6 (7.6)
8.3 (4.2) -0.4 (4.4)
8.1 (7.9) -0.5 (9.4)
0.65Serum DHEAS (umel/L)
0.78
Data mean (SD), n=31
Table 10-7 Relationships between baseline dehydroepiandosterone sulphate, insulin,
body mass index, waist circumference and waist to hip ratio for healthy
subjects
BMI Waist circumference WHR Serum
(kg/m1) (cm) DHEAS
Serum
(IlmollL)
FO.013 r= 0.209 r = 0.108
DHEAS p=0.947 p = 0.267 p = 0.569
(IlmollL)
Plasma FO.311 r=0.246 r= 0.205 r = -0.055
insulin p=0.048 p = 0.121 p = 0.198 p = 0.769
(mUlL)
n=31
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Table 10-8 Relationships at week twelve between dehydroepiandosterone sulphate,
insulin, body mass index, waist circumference and waist hip ratio for
healthy subjects
BMI(kg/m1) Waist circumference WHR Serum
(cm) DHEAS
~~mollL}
SerumDHEAS r = -0.193 r = 0.173 r = 0.307
(umol/L) p = 0.306 p = 0.370 p = 0.105
Plasma insulin r = 0.415 r = 0.323 r = 0.234 r = -0.055
(mUlL) p = 0.007 p = 0.045 p = 0.151 p = 0.769
n=31
Table 10-9 Relationships between changes in dehydroepiandosterone sulphate,
insulin, body mass index and waist circumference in healthy subjects
BMI Waist circumference WHR Serum
(kg/m2) (cm) DHEAS
~~mollL)
SerumDHEAS r- -0.097 r = -0.036 r = 0.215
(pmol/L) p= 0.542 p= 0.824 P = 0.183
Plasma insulin r=0.137 r = 0.033
,._----_ .._----_
r=0.1l8 r = -0.107
(mUlL) p= 0.426 P = 0.853 P = 0.505 P = 0.566
n=31
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Table 10-10 Characteristics of healthy subjects and angina subjects combined at
baseline and week twelve
Baseline Week 12 Difference p
Age (years) 51.0 (11.9)
BMI (kg/m2) 27.7 (3.8) 26.6 (3.6) -1.1 (0.9) 0.00001
Body weight (kg) 81.2 (9.6) 77.9 (9.4) -3.3 (2.6) 0.00001
Body fat (%) 30.6 (7.2) 28.6 (7.8) -2.0 (3.8) 0.00001
Waist (cm) 96.9 (11.6) 94.5 (12.1) 2.4 (4.4) 0.00001
WHR 0.94 (0.1) 0.93 (0.1) 0.01 (0.06) 0.19
DHEAS (umol/L) 4.9 (4.3) 4.8 (3.9) -0.1 (2.7) 0.65
Insulin (mUlL) 11. (8.1) 10.1 (8.6) -0.9 (8.5) 0.35
Data mean (SD), 0=72
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Table 10-11 Relationships at baseline between dehydroepiandosterone sulphate,
insulin, body mass index, waist and waist hip ratio in healthy subjects and
angina subjects combined
Age BMI Waist WHR DHEAS
(years) (kg/m2) (cm) {~mollL}
DHEAS r=-0.578 r=-0.264 r=-0.371 r=-0.434
(JlmollL) p=O.OOOI p=0.026 p=0.001 p=0.001
Plasma r=0.228 r=0.285 r=0.328 r=0.374 r=-0.180
insulin p=0.046 p=0.016 p=0.002 p=0.0001 p=0.132
(mUlL)
n=72
Table 10-12 Relationships at week twelve between dehydroepiandosterone sulphate,
insulin, body mass index, waist and waist hip ratio in healthy subjects and
angina subjects combined
BMI Waist WHR
DHEAS r=-0.306 r=-0.419 r=0.029
(umol/L) p=0.007 p=0.0001 p=0.805
Plasma r=0.252 r=0.390 r=0.396
insulin p=0.021 p=O.OOOl p=0.0001
(mUlL)
DHEAS
(JlmollL)
r=-0.180
p=0.132
n=72
303
Table 10-13 Relationships between changes in dehydroepiandosterone sulphate,
insulin, body mass index, waist and waist to hip ratio in healthy subjects and
angina subjects combined
BMI Waist WHR
DHEAS (Jlmol/L) r=-0.046 r=0.046 r=0.056
p=0.698 p=0.699 p=0.636
Plasma insulin (mUlL) r=0.155 r=0.086 r=0.172
p=0.161 p=0.444 p=0.124
DHEAS
(JlmollL)
r=-0.090
p=0.456
n=72
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Figure 10-1Relationship between dehydroepiandosterone sulphate concentrations
and age in angina subjects
10
r=O.381 •
,-.. p=O.OO9-...._ •- ••
~
'-' 5V)
~
0
~
(1)
V) 0
40 50 60 70 80
Age (years)
n=41
305
Figure 10-2Relationships at baseline between dehydroepiandosterone sulphate
concentrations and body mass index in angina subjects
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Figure 10-3Relationship between dehydroepiandosterone sulphate concentrations
and age in healthy subjects
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Figure 10-4Relationships at baseline between dehydroepiandosterone sulphate
concentrations and body mass index in healthy subjects
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Figure 10-5Relationships between dehydroepiandosterone sulphate concentrations
and age in healthy subjects and angina subjects combined
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Figure 10-6 Relationships at baseline between dehydroepiandosterone sulphate
concentrations and body mass index in healthy subjects and angina subjects
combined
•
20 - • r=O.578--- p=O.OO<)1~
0
! ••10 - •
~
••• • •. . .: ......_ '.' .. • •
• • '. ----- •......=._ ....
0 • / I. ,a .• I •• •' .. '..' . .'.. •
~
o - ., . • • •
~
I
22
I
32
Baseline BM (kg'm2)
I
42
n=72
310
Figure 10-7Relationships at baseline between insulin concentrations and body mass
index in healthy subjects and angina subjects combined
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Figure 10-8 Relationships at week twelve between dehydroepiandosterone sulphate
concentrations and body mass index in healthy subjects and angina subjects
combined
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Figure 10-9Relationships at week twelve between plasma insulin concentrations and
body mass index in healthy subjects and angina subjects combined
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Chapter 11 Final discussion and recommendations for further
work
11.1 Introduction and review
This programme of PhD research was initiated in September 1992. Since then, the
publication of a number of studies, by workers outside this Glasgow laboratory have
addressed several of the original issues considered in this thesis. These include the effects
of dietary change and weight loss on haematological and rheological factors. Hence, the
findings of the present studies within this thesis can be discussed in the context of more
recent research.
The present studies have compared the effect of similar individualised dietary
interventions, in three different subject groups, with the IHD risk factor measurements the
principle end points. The study design aimed to evaluate the effects of a practical dietetic
intervention for weight loss in free living subjects. Despite the different settings from
which subjects were sought, the protocols and nutrition targets remained the same, namely
dietary change and weight loss, and meaningful inter-study comparisons were possible.
This design did not allow the examination of the effects of specific nutrient consumption
on the chosen IHD risk factors, because of the difficulties inherent in attempts to quantify
nutrient intakes in the context of obesity and weight loss.
In general, all volunteers were "healthier" than the general population and included very
few smokers. All subjects' risk factors were within the laboratory reference ranges, with
the exception of hyperlipidaemia. This is frequently a feature of health concerned
individuals who tend to volunteer for research.
The results of all three studies have shown that the prescription of a 600 kcal daily energy
deficit diet and the resulting weight loss were important in reducing the measured indices
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of blood coagulation. In answering the research question, "does dietary intervention to
lower total energy intake and change dietary composition in line with current dietary
targets improve haemostatic and rheological risk factors for IHD?" the results showed
some risk factor improvements although there were few differences between studies on
different BMI categories.
In comparison with a conventional hospital base for clinical research, the work-site setting
(chapter 8) illustrated a large number of benefits both to the study investigators and
subjects. The advent of e-mail allowed easy contact, on an individual basis, to a large
employee population. Details of the recruitment requirements were sent to each
employee's mailbox, and the enthusiastic response may have reflected this individualised
approach. Secondly, the work-site population was fresh to the notion of volunteering to
become part of a study, whereas this was a much more common occurrence in the hospital
setting. By granting one hour weekly to attend the study appointments, without loss of
salary, the employer actively encouraged staff participation as part of health promotion,
and further work has been initiated.
11.1.1Whole blood and plasma viscosity
After weight loss, plasma and whole blood viscosities remained unchanged in all studies.
These fmdings, that moderate weight loss does not lower plasma viscosity, were in
agreement with those present in the literature (Ernst et al, 1989, Craverie et al, 1990,
Tozzi et ai, 1994). However, the literature reported that only large amounts of weight loss
(15-20 kg) significantly influenced viscosity (Parenti et al, 1987) and moderate weight
loss of around 7.0 kg was insufficient (Craveri et al, 1990). Little evidence remains
available for the effect of weight loss on WBV, which remained unchanged in the present
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studies. The present studies were under-powered for WBV, and therefore the influence of
~ errors remained a possibility.
11.1.2 Red cell aggregation
The results of the overweight and angina studies showed RCA was significantly reduced
with weight loss. These results, which concur with Ernst and Matrai, 1987, Poggi et ai,
1994, are amongst the few reports showing that moderate weight loss can improve RCA.
The RCA measures were not made in the close to healthy weight subjects due to practical
limitations, but the comparison with the two other subject groups would have been of
interest. Inter-study comparisons with published data were also impossible (Ernst and
Matrai, 1987, Poggi et ai, 1994) as the method of RCA measurement differed between
studies. The available data suggest that RCA becomes elevated in the overweight, but
that moderate weight loss can be beneficial in improving measures.
11.1.3 Fibrinogen
The stability of plasma fibrinogen despite weight loss in each study did not support the
hypothesis that moderate weight loss could lower plasma fibrinogen. Although these
present findings were in agreement with the majority of the literature (Hughes et ai, 1984,
Craveri et ai, 1990, Palareti et ai, 1994, Ditschuneit et ai, 1995, Craveri et ai, 1992,
Gelmini et ai, 1989, Folsom et ai, 1993, Anderson et ai, 1995, Ernst et ai, 1989 and
Mehrabian et ai, 1990), the studies were under powered with respect to fibrinogen and ~
errors may have been present. However, the present results and those from the literature
support the interpretations of the review article by Ernst (1993). This article reported that
that weight loss, in any amount failed to significantly lower plasma fibrinogen
concentrations. The reasons why weight loss has such small effects on plasma fibrinogen
are unclear, given the strong epidemiological relationships between increasing BMI and
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plasma fibrinogen. In conclusion, moderate weight loss appears to have no significant
effect on plasma fibrinogen concentrations.
11.1.4 Factor VII activity
The healthy overweight and angina studies both showed a significant fall in factor vn
activity after moderate weight loss. In contrast, the close to healthy weight subjects
showed no significant change in factor vn activity after weight loss. Two influential
factors for the latter result are likely to have been initial plasma concentrations within the
healthy range, and insufficient weight loss. However, greater weight losses than achieved
in the present studies may have improved factor vn activity, even in this healthy group.
In conclusion, the present findings support the value of weight management in reducing
lliD risk in overweight and angina subjects.
11.1.5 Plasminogen activator inhibitor activity and tissue plasminogen activator
antigen
In the present studies, moderate weight loss failed to change the fibrinolytic indices
significantly. Research elsewhere has confirmed the effect of greater weight loss in
reducing both PAl activity and t-PA antigen. The present studies were just sufficiently
powered with respect to both PAl activity and t-PA antigen, with an associated risk of ~
errors, particularly in the study of healthy weight subjects. However, sub-group analysis
found lowered PAl activity after moderate weight loss in overweight women, overall
fmdings from all the present studies confirm that moderate weight loss does not improve
fibrinolytic indices. Once more the lower than expected overall weight loss may have
offered a partial explanation for these findings.
11.1.6 Lipids
Lower plasma total and LDL and an unchanged HDL cholesterol concentrations were
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consistent results of moderate weight loss in the present studies. The failure of weight
loss to lower LDL cholesterol in this study of overweight subjects was surprising, with no
obvious explanation, other than insufficient weight loss. However, when all subjects from
the three studies were considered as a group, LDL concentrations significantly fell. This
reduction is in agreement with the majority of the literature (Leighton et aI, 1990,
Bremner et ai, 1994, Litchenstein et ai, 1994).
The failure of HDL cholesterol concentration to increase after weight loss was in contrast
with expectations, and other findings from the literature (MacMahon et ai, 1985, Bremner
et aI, 1994). However, shorter term studies, e.g. sixteen weeks duration, showed falls in
HDL cholesterol, which reflect the acute effects of weight loss (Litchenstein et aI, 1994).
This is likely to have been either a significant fall in HDL concentrations, or them
remaining the same, as was the case in the present studies. Often weight loss confounds
the results of short term studies (less than 4 months), and can even leads of an elevation in
plasma cholesterol known as the "transient hypercholesterolaemia of weight loss"
(phinney et al, 1991). However, when weight losses are maintained an improvement in
plasma cholesterol fractions, usually to below the pre-weight loss concentrations, is
frequently seen (Phinney et al, 1991).
Research studies have shown that weight loss favours reductions in plasma triglyceride
concentrations, in contrast to the present findings (Stewart et al, 1990). The stability of
plasma triglyceride and the lack of any positive correlations with factor VII activity were
in contrast to the evidence to support such a relationship in hypertriglyceridaemic subjects
(Miller et aI, 1991, Meade et aI, 1993). The present results probably reflected the
relatively low concentrations of all indices, within their reference ranges. The finding that
changes in haemostatic, rheological factors and plasma lipids were unrelated to moderate
weight loss has supported the current theory concerning the two systems relationship.
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11.1.7 Dehydroepiandosterone sulphate and insulin
The concentrations of DHEAS and insulin are both known to be affected by BM!. A rise
in insulin concentrations and a fall in DHEAS concentrations have been observed with
increasing BMI. The failure of moderate weight loss to change either of these measures in
the present studies has rejected the study hypothesis that reducing body weight in
overweight and close to healthy weight subjects would lead to increases in OHEAS.
These results may be explained by having insufficient weight loss in both of these groups.
The greater age of the angina patients reflected their lowered OHEAS concentrations
(DePretti et al, 1978). These lowered concentrations were probably influential in the
failure of weight loss to effect changes in OHEAS, possibly increasing the susceptibility
of angina subjects to further development of ischaemic disease.
11.2 Effectiveness of methods of dietary assessment and intervention
11.2.1 The energy deficit approach to weight loss
The present studies provided an opportunity to implement the 600 kcal daily energy
deficit approach in three different BMI categories. These comparisons are new, the only
other evidence being an audit where the energy deficit approach was shown to be more
effective than a 1200 kcal diet (Frost et al, 1991). Other evidence from the placebo arm
of anti-obesity medication studies support the findings of Frost et al, 1991, (Orent and van
der Veen, 1993).
It was proposed that the presence of a diagnosis of angina would improve the compliance
of subjects with a dietary regimen and to favour increased weight loss. However, the
results did not support the value of an established diagnosis in improving dietary
compliance. A possible explanation was that these health-conscious volunteers had
already made appropriate dietary modifications. This is similarly postulated to explain
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poor results in NIDDM patients (Ha and Lean, unpublished). However, the similar
weight loss between different study groups challenges this hypothesis. The study of
weight loss in healthy subjects was perhaps the most interesting and novel aspect of this
work with a less predictable outcome. The similar weight losses observed probably
reflected a similar degree of dietary compliance between groups. These results following
a quantitative approach in volunteers with a desire to reduce body weight appeared not to
be significantly influenced by BMI.
11.3Overall conclusions: practical lessons and ideas for further work
The results of these studies suggest that moderate weight loss has value in the
management of the risk of llID by reducing factor VII activity, RCA, total and LDL
cholesterol. The approach that was used in this present work has now been adopted into
the current guidelines for the management of overweight in Scotland (SIGN, 1996).
Epidemiological studies have described some elevated haemostatic indices as important
risk factors for llID. Overweight and obesity have been associated with raised levels of
these measurements. In the present work the moderate weight loss that was achieved was
below that planned for, and this may explain why only factor VII activity, RCA, total and
LDL cholesterol showed significant falls. However, the fact that the majority of the
measures of IHD risk factors at baseline were within their laboratory reference ranges may
also have contributed to their stability after weight loss.
Longer-term studies would allow greater insight into the effectiveness of the 600 kcal
daily energy deficit approach. The effect of increasing and maintaining these reductions
in body weight on the specific IHD indices would also be of great interest.
A number of practical methodological insights have resulted from the completion of this
work. With the advantage of hindsight, these would have modified the way the present
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work was carried out. In general, all dietary intervention studies are very reliant on the
good will and commitment of participants. In addition, although dietary studies appear
time consuming, in practice, completion time seems to exceed all conservative
predictions. Although three different methods were used, recruitment was a major issue
always taking longer to complete than envisaged. The use of the popular press for
recruitment in the angina study was a quick, and almost too effective, method, which met
with an excellent telephone response. On the other hand these were a highly health
conscious group, looking with hope to benefit from any advances in the care of those with
angina. In contrast, e-mail recruitment in the work-site setting was a more effective
method, not reliant on the help of others. The work-site setting using e-mail recruitment
would have been ideally suited as an approach for the overweight study.
A number of possible research projects have resulted from the studies presented in this
thesis, which are summarised in the following four questions.
1. A controlled study of the effects of weight loss on the reported frequency of chest pain
observed in angina subjects.
2. A comparison and longer term follow-up of a 600 kcal daily energy deficit diet versus a
low energy diet plan using a randomised, controlled experimental design, together with a
long term follow-up.
3. The investigation of the influence of increased age on the ability of volunteers to
achieve intentional weight loss.
4. The effect of weight loss and weight maintenance on the stability of haemostatic,
rheological and lipid risk factors for IHD.
In conclusion, the work in this thesis confirms the value of moderate weight loss in
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achieving improvements in risk factors for llID. The value of a 600 kcal deficit diet,
which was effective in achieving these moderate weight losses, was demonstrated. Good
counter arguments could be made to support the use of a VLCD approach together with a
weight maintenance programme (Wing et ai, 1994). However, the results from a
comprehensive follow up of the participants over time would have been of interest.
The potential value of the 600 kcal daily energy deficit approach has been illustrated,
especially given the encouraging comparison across three different study groups. Further
studies over a longer period of time would be of interest to try to increase weight loss and
examine any effects of measures of health status, and llID risk factors. However, as
already discussed in chapter 9, these results represent fmdings in health conscious
volunteers. Frost et al (1991) used the routine clinical setting for their encouraging
weight loss results for the 600 kcal energy deficit approach. A positive viewpoint on the
broadly similar weight loss response in all groups to the 600 kcal energy deficit diet
suggests a wide application across populations.
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Appendix 2 Flow chart showing the daily 600 kcal energy deficit approach to weight
loss: designing the energy content of a diet for weight loss at 0.5 - 1.0 kg per week
Method
1 Weight, Age, sex
Estimated basal metabolic rate (BMR)
WHO, 1986
Multiply by "activity factor to obtain
estimated 24 hour energy expenditure
I Subtract 600 kcal for prescription
[ Round to nearest 100 kcal/day
Total energy prescription for weight
reduction
Exam Ie 1 Exam le 2
80 kg, 45
ears, female
100 kg, 45
ears, male
12038 kcal 11505 kcal
12649 kcal 11957 kcal
-600 kcal I -600 keal
I 2048 keal I 1347 keal
12000 k ea1 11400 k ea1
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Appendix 3 Healthy eating dietary advice plan
The Healthy Eating Plan
Designed by
Department of Human Nutrition
University of Glasgow
Food intake plans
This eating plan has been designed for you and the amounts of foods are based on your
needs related to your age, sex and level of activity. Do try not to eat less than the healthy
eating plan for you. When you are hungry, do not just give up, but fill up on foods from
the bread or fruit exchange lists. Try to plan your meals ahead and use a shopping list
when buying food to make your shopping in line with the healthy eating plan.
Good ideas
• Eat fish three times weekly, tuna, sardines in sandwiches, or fish such as cod or kippers.
• Choose skimmed or semi- skimmed milk
• Eat at least three fresh fruit, one pure fruit juice and two large helpings of vegetables
daily
• Grill or bake instead of frying foods
• Avoid eating pies, sausages or pates
• Use polyunsaturated margarine or low fat spreads, or no spread
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Bread exchanges
All amounts shown contain approximately 100 kcal, with valuable protein, carbohydrate,
vitamins and minerals as well as being low in saturated fat.
Bread
WhiteBread
Wholemeal bread
Wholemeal! white soft roll
Pitta bread
Crisp breads
Cereal
Weetabix
Cooked porridge made with water
Whole grain or other cereal
(e.g. frosties, Cornflakes, Rice
Krispies, Ricicles, Sugar Puffs,
Special K)
Unsweetened Muesli
Other foods
Mushy peas
Baked beans
Potatoes boiled or baked
Pasta (Cooked)
Brown rice cooked
White rice cooked
Vegetable soup
Biscuits (rich tea, osbourne)
Oven chips (low fat)
One bread exchanee
1 slice
1 slice
1 slice
Ih
2
1 biscuit
5-6 tablespoons
5 tablespoons
~ tablespoons
5 tablespoons
5 tablespoons
2 egg sized
5 tablespoons
3 tablespoons
3 tablespoons
3!4large can
2
10 chips
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Meat exchanges
All contain around 120 kcal, with important minerals such as iron and calcium and a
range of vitamins. Use the exchanges to choose alternatives to red meat as a focus to your
meals.
Meat Corned beef 2 thin slices
Cooked lean ham 3 slices
Cooked lean mince (turkey) 3 tablespoons
Cooked lean stewing steak 3 tablespoons
Cooked lean pork 3 tablespoons
Grilled lean bacon (back) 2 -3 rashers
Bolognese sauce (turkey mince) 4 tablespoons
Chilli (turkey mince, 4 tablespoons
or vegetable, or soya) 5 tablespoons
Shepherds pie 5 tablespoons
Chicken Cooked chicken/turkey breast 4-5 slices
Chicken casserole 1 cupful
Fish Choose fish at least three times
weekly.
1 small tinTuna fish (drained) in brine
3/4 small tinSalmon tinned
Sardines in tomato saucelbrine 3 sardines
Mackerel, kippers herring 1hmedium fillet
Grilled/poached haddock! cod 1hmedium fillet
Grilled/poached plaice/sole 1hmedium fillet
Fish fingers grilled 3
Fish pie 5-6 tbs.
Eggs Eggs 1
Cheese Cheddar cheese 30g (1 oz)
Reduced fat cheddar 60g (2 oz)
Low fat cheese spread 40g (1 112oz)
Edamlbrie 30g (1 oz)
Cottage cheese 100g (3 112 OZ)
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Fruit exchanges
All contain around 70 kcal, little fat, some fibre and plenty of vitamins. Regularly eating
fruit is especially important if you smoke. You should try to take only 1 fruit exchange as
pure fruit juice, and the remainder as the whole fruit, which contain many other important
protective dietary factors.
Eat fruit at least three times daily.
Fruit juice 1wine glass
(unsweetened)
Apple 1
Orange 1
Peach 1
Tangerine 2
Pear 1
Pineapple 1 larye slice
Grapes smal bunch (12)
Plums 2
Banana 1
Small bowl fresh fruit salad
Tinned fruit in natural juice 1 small tin of fruit canned
e.g.: Mandarin oranges in fruit juice
Pears
Peaches
Fruit cocktail
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Convenience food exchanges: Many represent the use of bread plus meat exchanges
Only use these items occasionalrYJ_the J are eX_Q_ensiveand not good value.
Birds Eye Bread Meat Exchan_g_e
exchange
Gravy and roast chicken.
1
1200g
1 pkt 1 plus
1 pkt
1 pkt
one 1 plus
lone 1plus
1
one 1_Q_lus
lOOg 1 plus
lOOg 1plus
1
Beef curry and rice
Chicken and mushroom
casserole
1
Mince beef with
~egetables
and gravy
Chicken and mushroom
I pancake
Cheese and ham pancake
1
1
1
Minced beef pancake 1
Potato waffle, grilled
Heinz
Baked beans with pork
sausages
Macaroni cheese
1
1
1
Ravioli in tomato sauce
Spaghetti in tomato sauce IOOg
Spaghetti bolognese
Marks & Snencer
Lasagne
Chilli con came
Beef stew with dumplings
Braised beef with
vegetables
lOOg Iplus
lOOg lplus
lOOg 1plus
lOOg 1plus
lOOg 1 plus
lOOg 1
1
1
1
1
1
Braised steak lOOg I
Haddock momay lOOg 1
Fish lasagne 1IOOg 1plus
Fish pie 1IOOg 1plus
Cod in parsley sauce IOOg 1
Ocean pie 1lOOg 1_plus
Seafood pasta IlOOg I plus
Chicken supreme 1lOOg 1plus
Chicken and potato bake 1IOOg 1__Q_lus
Chicken and chilli sauce lOOg I
Chicken chasseur lOOg 1
Sweet and sour chicken IOOg I
Findus French bread pizza one
cheese and tomato
1 plus 1 plus
332
IDEAS FOR MEALS
Breakfasts: these are often different at weekends to weekdays, and here are some ideas
for alternatives to a fried breakfast.
• 4 tbs. cereal, 125 mL semi- skim milk, 1 slice bread toasted, 1 tsp. jam or marmalade
= 2 Bread exchanges and milk from allowance
• 2 Slices bread toasted, 30g Cheddar type cheese
= 2 Bread exchanges 1 Meat exchange
• 1 soft roll, 2-3 rashers grilled lean bacon
= 2 Bread exchanges, 1 Meat exchange
• 4 -5 tbs. cooked porridge, 2 crisp-breads, 1 tsp. jam or marmalade
= 2 Bread exchanges, 1 Meat exchange
• 1 small tub cottage cheese, 1 toasted roll
= 2 Bread exchanges, 1 Meat exchange
• 2 slices bread toasted, 1 boiled egg
= 2 Bread exchanges 1 Meat exchange
• 1 small tin baked beans, 2 slices of toast
= 3 Bread exchanges
IDEAS FOR MEALS
Lunches
• Healthy option!: 100g cottage cheese with a filling if preferred, 4 crisp breads, 1 Orange
= 2 Bread exchange, 1 Meat exchange, and 1 Fruit exchange
• 100g cottage cheese, 1 medium baked potato, 1 tablespoon pasta sauce
= 2 Bread exchanges 1 Meat exchange
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• 1 tbs. pasta sauce, lOOg cottage cheese, lOOg baked potato, 1 banana
= 1Meat exchange, 2 Bread exchanges, 1 Fruit exchange
• lOOg tuna in brine (drained), jacket potato (lOOg), mixed salad
= 1 Meat exchange, 2 Bread exchanges
• 3 sardines in tomato sauce, 2 slices white bread, 1 apple
= 3 Bread exchanges, 1 Meat exchange
• 2 -3 rashers lean grilled bacon, 2 slices wholemeal bread, 1 diet yoghurt
= 1 Meat exchange, 2 Bread exchange and milk from allowance
• 1 bowl Scotch Broth, 2 crisp breads, 1OOgtinned mandarin oranges
= 1 Meat exchange, 2 Bread exchanges, 1 Fruit exchange
IDEAS FOR MEALS
Evening meals
• 5 tbs. spaghetti in tomato sauce, 1 grilled haddock fillet, assorted veg, 1 slice bread
= 1 Meat exchange, 2 Bread exchange
• 2 egg sized boiled potatoes, 3 grilled fish fingers, fresh carrots
= 1 Meat exchange, 1 Bread exchange
• 1 small tin baked beans, 1 slice toast, 1 poached egg, 1 apple
= 2 Bread exchange, 1 Meat exchange, 1 Fruit exchange
• 5 tbs. Shepherds pie, assorted veg (free foods), 1 wholemeal roll, 4 tablespoons fruit
jelly
with milk from allowance
= 1 Meat exchange, 3 Bread exchange, from milk allowance
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• 4 tbs. Chilli, 6 tbs. cooked white rice, 1 diet fromage frais
= 1Meat exchange, 2 Bread exchanges, 1 Fruit exchange
• 1 bowl vegetable broth, 3 tbs.l50g roast lean pork, 2 egg sized potatoes,
assorted vegetables, 1 small banana
= 2 Bread exchanges, 1Meat exchange, 1 Fruit exchange
.2-3 lean bacon rashers, 2 tbs. mashed potato, 5 tbs. mushy peas, 1 fresh fruit
=1 Meat exchange, 2 Bread exchanges, 1 Fruit exchange
FOODS TO AVOID FOR WEIGHT GAIN
Sugary Foods -Syrup treacle, lemon curd, sweets, chocolates, cakes, pastries. Most
puddings and ice creams, except those included in the any of the exchange lists.
Fatty Foods - Dripping, lard, cooking fat, cooking oils and all fried foods. Potatoes
cooked in fat e.g. chips, crisps, saute, roast and stovies.
Cream, cream cheese, pate, fatty meats, salted or coated nuts. Rich sauces and thick
gravies.
Salad cream and mayonnaise.
Buttery rolls (rowies), sausage rolls, pies and bridies.
Drinks - Drinking chocolate, cocoa, Horlicks, Ovaltine and other malted drinks.
Fruit drinks, squashes and fizzy drinks containing sugar.
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ALCOHOL
Most alcoholic drinks are high in calories. Also, it is easy to drink quite a lot, without
realising how much alcohol you are having. To help to control your weight it is important
to limit your alcohol intake.
You are allowed a maximum of 6 units of alcohol per week.
1 unit of alcohol is equivalent to:
1 pub measure of spirits - whisky, gin, vodka with a mixer, 1 Ihpint beer, lager, cider.
1 small glass red/white wine, liqueurs, excepting creamy ones
UNRESTRICTED FOODS
Remember to try and avoid nibbling between meals. But if you feel you are going to, try
to choose something from the snack or free foods list.
Drinks
Black coffee, tea, herb tea, Bovril, Oxo, Marmite, tomato juice, soda water, Perrier water
and "Low calorie" drinks, e.g. Diet Cola, Diet Lilt, Reduced Cal, Sugar free squashes.
Vegetables and salads
Dress with vinegar, herbs, or oil free dressing. Avoid oil and mayonnaise. Cucumber,
cress, lettuce, radish, tomato, pickled onion, asparagus, broccoli, cabbage, carrot,
cauliflower, celery, courgette, endive, kale, leeks, marrow, mushrooms (boiled not fried),
onion, spinach, Swede, sprouts, green beans, turnip, beetroot, parsley, peppers.
Fresh fruit
Fresh grapefruit, rhubarb, gooseberries, strawberries, raspberries, black currants
(sweetened with artificial sweetener), lemon, lime, melon.
Seasoning
Make your meals more interesting!
Spices, herbs, pepper, mustard, lemon juice, vinegar, mint, Worcestershire sauce, gravy
browning, tomato puree.
HELPFUL HINTS: EATING OUT
1.Extend your pre meal drink with low calorie drinks e.g. lemonade, tonic or soda water.
2. Mineral water is very popular, drink it neat or mix it with wine to make it go further.
3. Save calories by choosing a starter such as tomato juice, a slice of melon or soup.
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4. Have a fair sized portion for you main course, but avoid chips, rich sauces, pastry and
fried foods. Ask for extra vegetables.
5. Have second helpings of vegetables or potatoes if you are still hungry.
6. Move straight to coffee, with milk or black. Send back cream and ask for milk.
7. Eat slowly and enjoy your food.
TEMPTATION
All people following a healthy diet have good days when eating healthily seems easy.
There are also days when it may seems almost impossible to follow this eating plan.
1. Have a hot drink - tea, coffee, beef or vegetable extract.
2. Always have on hand some vegetable nibbles, carrots, celery or pickled onions.
3. Occupy yourself with hobbies, sewing, knitting, gardening or just go out for walks.
4. Put health at the top of your agenda, - it's just not worth sacrificing your long term goal
for a few minutes enjoyment.
CHECKLIST
1. Have managed to eat all the exchanges on your diet
2. Have managed to eat all the five portions of fruit and vegetables?
NAME
ADDRESS
SUBJECT NUMBER .
BASELINE WEIGHT
DATE
DESIRED WEIGHT
WEIGHT Metric Imperial
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3.11200 kcal diet prescription
The Healthy Diet 12
Daily allowances
250 mL semi skimmed milk
(100 mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
6 x bread exchange
2 x meat exchange
3 x fruit exchange
1 x wine glass fruit juice (125 mL)
Polyunsaturated spread: 20g or 2 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or
109 sunflower margarine
Suggested meal plan. Remember try to take all the exchanges
Breakfast
Supper
1 x glass of fresh fruit juice
1 x bread exchange
Spread jam or marmalade
Tea / coffee
Tea / Coffee or low calorie drink
2 x bread exchange
1 x meat exchange
Salad / vegetable
1 x fruit exchange
Tea / Coffee or low calorie drink
Tea / Coffee or low calorie drink
1 x meat exchange
2 x bread exchange
Salad / vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
Mid-Morning
Lunch
Mid afternoon
Evening meal
Exchanges kcal kJ fat g pufa g mufag sfa g cho g prot g
3 Fruits 156 652 / / / / 39.6 1.5
1 Fruit juice 45 188 I / / / 11.0 0.6
6 Bread 563 2355 9.6 3.6 2.4 3.0 102.0
2Meat 240 1004 12.6 1.6 4.5 5.1 5.0 13.6
109 pufa 71 297 7.8 4.1 2.6 1.6 I /
Margarine
250mL 115 481 4.0 / 1.2 2.5 12.5 8.25SSkim milk
Total nut. 1190 4979 34.0 9.3 10.8 12.1 170 60.4% energy 25.7 7.0 8.1 9.1 53.6 20.3
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3.2 1300 kcal diet prescription
The Healthy Diet 13
Daily allowances
250 mL pint semi skimmed milk
(lOO mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
7 x bread exchange
2 x meat exchange
3 x fruit exchange
1 x wine glass fruit juice (125 mL)
Polyunsaturated spread: 20g or 2 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or
sunflower margarine 109 e.g. flora, vitalite or sunflower margarine
Suggested meal plan. Remember try to take all the exchanges
Breakfast
Supper
1x glass of fresh fruit juice
2 x bread exchange
Spread jam or marmalade
Tea / coffee
Tea / Coffee or low calorie drink
2 x bread exchange
1 x meat exchange
Salad / vegetable
1 x fruit exchange
Tea / Coffee or low calorie drink
Tea / Coffee or low calorie drink
1 x meat exchange
2 x bread exchange
Salad / vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
Mid-Morning
Lunch
Mid afternoon
Evening meal
Exchanges kcal kJ fat g pufag mufag sfa g cho z prot g
3 Fruits 156 652 / / / / 39.6 1.5
1 Fruit juice 45 188 / / / / 11.0 0.6
7 Bread 657 2747 14.6 4.2 2.8 3.5 119.3 27.0
2Meat 240 1004 12.6 1.6 4.5 5.1 5.0 13.6
109 pufa 71 297 7.8 4.1 2.6 1.6 / /Margarine
250mL 115 481 4.0 / 1.2 2.5 12.5 8.25SSkim milk
Total nut. 1284 5369 39.0 9.9 11.2 12.6 187.4 64.3% energy 27.3 6.9 7.8 8.8 54.7 20.0
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3.31400 kcal diet prescription
The Healthy Diet 14
Daily allowances
250 mL semi skimmed milk.
(lOOmL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
7 x bread exchange
2 x meat exchange
3 x fruit exchange
2 x wine glass fruit juice (125 mL)
Polyunsaturated spread: 40g or 3 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or 20g sunflower margarine e.g. flora,
vitalite or 16g
(11/2 tablespoons sunflower oil)
Suggested meal plan. Remember try to take all the exchanges
Breakfast 1 x glass of fresh fruit juice
2 x bread exchange
Spread jam or marmalade
Tea / coffee
Tea / Coffee or low calorie drinkMid-Morning
Lunch
Supper
2 x bread exchange
1 x meat exchange
Salad / vegetable
1 x fruit exchange
Tea / Coffee or low calorie drink
Tea / Coffee or low calorie drink
1 x meat exchange
2 x bread exchange
Salad / vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
1 x fruit juice
Mid afternoon
Evening meal
Exchanges kcal kJ fat g pufag mufag sfa g cho g prot g
3 Fruits 156 652 I / / / 39.6 1.5
2 Fruit juice 90 376 / / / / 22.0 1.2
7 Bread 657 2747 14.6 4.2 2.8 3.5 119.3 27.0
2Meat 240 1004 12.6 1.6 4.5 5.1 5.0 13.6
20gpufa 142 594 15.6 8.1 2.6 3.2 / /
Margarine
250mL 115 481 4.0 / 1.2 2.5 12.5 8.25
SSkim milk
Total nut. 1400 5857 46.8 13.9 11.2 14.2 198.4 64.9
% energy 30.0 8.9 7.2 9.1 53.0 18.5
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3.4 1500 kcal diet prescription
The Healthy Diet 15
Daily allowances
250 mL semi skimmed milk.
(lOO mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
7 x Bread exchange
3 x meat exchange
3 x fruit exchange
2 x wine glass fruit juice (125 mL)
Polyunsaturated spread: 30g or 2 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or
15 g sunflower margarine, e.g. flora, vitalite. or I2g sunflower oil (l tablespoon)
Suggested meal plan. Remember try to take all the exchanges
Breakfast
Supper
1 x glass of fresh fruit juice
2 x bread exchange
Spread jam or marmalade
Teal coffee
Tea I Coffee or low calorie drink
2 x bread exchange
1 x meat exchange
Salad I vegetable
1 x fruit exchange
Tea I Coffee or low calorie drink
Tea I Coffee or low calorie drink
2 x meat exchange
2 x bread exchange
Salad I vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
1 x fruit juice
Mid-Morning
Lunch
Mid afternoon
Evening meal
Exchanges kcal kJ fat g pufa g mufag sfa g chog prot g
3 Fruits 156 652 / I I I 39.6 1.5
2 Fruit juice 90 376 I I I I 22.0 1.27 Bread 657 2747 14.6 4.2 2.8 3.5 119.3 27.03 Meat 360 1506 18.8 2.4 6.8 7.6 7.5 40.7I5g pufa 106.5 445.6 11.7 6.1 1.9 2.4 I IMargarine
250mL 115 481 4.0 I 1.2 2.5 12.5 8.25SSkim milk
Total nut. 1484 6211 49.1 12.7 12.8 16.0 201.0 78.6% energy 29.7 7.7 7.7 9.7 51.0 21.1
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3.5 1600 kcal diet prescription
The Healthy Diet 16
Daily allowances
250 mL semi skimmed milk.
(100 mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
8 x Bread exchange
3 x meat exchange
3 x fruit exchange
2 x wine glass fruit juice (125 mL)
Polyunsaturated spread: 40g or 4 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or
20g sunflower margarine, vitalite or flora or 16g (1 1/2 tablespoons) sunflower oil.
Suggested meal plan. Remember try to take all the exchanges
Breakfast 1 x glass of fresh fruit juice
2 x bread exchange
Spread jam or marmalade
Tea / coffee
Tea / Coffee or low calorie drinkMid-Morning
Lunch
Supper
2 x bread exchange
1 x meat exchange
Salad / vegetable
1 x fruit exchange
Tea I Coffee or low calorie drink
Tea I Coffee or low calorie drink
2 x meat exchange
3 x bread exchange
Salad / vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
1 x fruit juice
Mid afternoon
Evening meal
Exchanges kcal kJ fat g pufa g mufag sfa g cho g prot g
3 Fruits 156 652 I I / / 39.6 1.5
2 Fruit juice 90 376 I I I I 22.0 1.2
8 Bread 750 3138 12.8 4.8 3.2 4.0 136.4 30.4
3 Meat 360 1506 18.8 2.4 6.8 7.6 7.5 40.7
20gpufa 142 594 15.6 8.1 2.6 3.2 I /
Margarine
250mL 115 481 4.0 I 1.2 2.5 12.5 8.25SSkim milk
Total nut. 1613 6748 51.2 15.3 13.8 17.3 218 82.0
% energy 28.5 8.5 7.6 9.6 50.6 20.3
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3.6 1700 kcal diet prescription
The Healthy Diet 17
Daily allowances
250 mL semi skimmed milk.
(100 mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
9 x Bread exchange
3 x meat exchange
3 x fruit exchange
2 x glass fruit juice
Polyunsaturated spread: 40g or 2 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or
20g sunflower margarine, flora, vitalite, or 16g 11/2 tablespoons sunflower oil.
Suggested meal plan.
Breakfast
Mid-Morning
Lunch
Mid afternoon
Evening meal
Supper
Remember try to take all the exchanges
1 x glass of fresh fruit juice
2 x bread exchange
Spread jam or marmalade
Teal coffee
Tea I Coffee or low calorie drink
3 x bread exchange
1 x meat exchange
Salad I vegetable
1 x fruit exchange
Tea I Coffee or low calorie drink
Tea I Coffee or low calorie drink
2 x meat exchange
3 x bread exchange
Salad I vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
1 x fruit juice
Exchanges kcal kJ fat g pufa g mufag sfa g cho g prot g
3 Fruits 156 652 I I I I 39.6 1.5
2 Fruit juice 90 376 I I I I 22.0 1.2
9 Bread 844 3253 14.4 5.4 3.6 4.5 153.4 34.2
3 Meat 360 1506 18.8 2.4 6.8 7.6 7.5 40.7
20gpufa 142 594 15.6 8.1 2.6 3.2 I IMargarine
250mL 115 481 4.0 I 1.2 2.5 12.5 8.25SSkim milk
Total nut. 1707 7142 52.8 15.9 14.2 17.8 235 85.8% energy 27.8 8.3 7.4 9.3 51.6 20.1
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3.7 1800 kcal diet prescription
The Healthy Diet 18
Daily allowances
300mL semi skimmed milk.
(lOO mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
9 x Bread exchange
3 x meat exchange
3 x fruit exchange
3 x wine glass pure unsweetened fruit juice
Polyunsaturated spread: 50g or 5 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or
25g sunflower margarine, flora or vitalite, or 20g sunflower oil (2 tablespoons).
Suggested meal plan.
Breakfast
Mid-Morning
Lunch
Mid afternoon
Evening meal
Supper
Remember try to take all the exchanges
2 x glass of fresh fruit juice
2 x bread exchange
Spread jam or marmalade
Tea I coffee
Tea I Coffee or low calorie drink
3 x bread exchange
1 x meat exchange
Salad I vegetable
1 x fruit exchange
Tea I Coffee or low calorie drink
Tea I Coffee or low calorie drink
2 x meat exchange
3 x bread exchange
Salad I vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
1 x fruit juice
Exchanges kcal kJ fat g pufa g mufag sfa g cho g prot g
3 Fruits 156 652 I I I I 39.6 1.5
3 Fruit juice 135 565 I I I I 33.0 1.8
9 Bread 844 3253 14.4 5.4 3.6 4.5 153.4 34.23 Meat 360 1506 18.8 2.4 6.8 7.6 7.5 40.725g pufa 177 741 19.5 10.1 3.3 4.0 I IMargarine
300mL 138 577 4.8 I 1,4 3.0 15.0 9.9SSkim milk
Total nut. 1810 7573 57.5 17.9 15.1 19.1 248.5 88.1% energy 28.5 8.9 7.5 9,4 51.0 18.2
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3.8 1900 kcal diet prescription
The Healthy Diet 19
Daily allowances
325 mL semi skimmed milk.
(lOOmL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
lOx Bread exchange
3 x meat exchange
3 x fruit exchange
3 x glass fruit juice
Polyunsaturated spread: 50g, 5 scrapes (e.g. sunflower spread, flora lite, vitalite lite) or
25g sunflower margarine or 20g 2 tablespoons sunflower oil.
Suggested meal plan. Remember try to take all the exchanges
Breakfast 2 x glass of fresh fruit juice
3 x bread exchange
Spread jam or marmalade
Tea / coffee
Tea / Coffee or low calorie drinkMid-Morning
Lunch
Supper
3 x bread exchange
1 x meat exchange
Salad / vegetable
1 x fruit exchange
Tea / Coffee or low calorie drink
Tea / Coffee or low calorie drink
2 x meat exchange
3 x bread exchange
Salad / vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
1 x glass fruit juice
Mid afternoon
Evening meal
Exchanges kcal kJ fat g pufag mufa g sfa g cho g _prot_g
3 Fruits 156 652 / / / / 39.6 1.5
3 Fruit juice 135 565 / / / / 33.0 1.8
10 Bread 938 3924 16.1 6.0 4.0 5.0 170.5 38.0
3 Meat 360 1506 18.8 2.4 6.8 7.6 7.5 40.7
25 gpufa 177 741 19.5 10.1 3.3 4.0 / /Margarine
325mL 149 623 5.2 / 1.4 3.25 16.25 10.6SSkim milk
Total nut. 1915 8012 59.6 18.5 15.5 19.9 266.8 92.6% energy 28.0 8.6 7.2 9.3 52.0 19.3
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3.9 2000 kcal diet prescription
The Healthy Diet 20
Daily allowances
325 mL semi skimmed milk.
(lOOmL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
11x Bread exchange
3 x meat exchange
3 x fruit exchange
3 x glass fruit juice
Polyunsaturated spread: 50g, 5 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or
25 g sunflower margarine e.g. flora, vitalite or 20 g sunflower oil. (2 tablespoons)
Suggested meal plan. Remember try to take all the exchanges
Breakfast 2 x glass of fresh fruit juice
3 x bread exchange
Spread jam or marmalade
Tea I coffee
Tea I Coffee or low calorie drinkMid-Morning
Lunch
Supper
3 x bread exchange
1 x meat exchange
Salad I vegetable
1x fruit exchange
Tea I Coffee or low calorie drink
Tea I Coffee or low calorie drink
2 x meat exchange
4 x bread exchange
Salad I vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
1 x fruit juice
Mid afternoon
Evening meal
Exchanges kcal kJ fat g pufa g mufag sfa g cho g prot g
3 Fruits 156 652 I I I I 39.6 1.53 Fruit juice 135 565 I I I I 33.0 1.811 Bread 1032 4317 17.5 6.6 4.4 5.5 187.6 41.83 Meat 360 1506 18.8 2.4 6.8 7.6 7.5 40.725gpufa 177 741 19.5 10.1 3.3 4.0 / /Margarine
325mL 149 623 5.2 / 1.4 3.25 16.25 10.6SSkim milk
Total nut. 2009 8406 61.3 19.1 15.9 20.4 283.9 96.4% energy 27.0 8.5 7.1 9.1 52.9 19.1
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3.10 2100 kcal diet prescription
The Healthy Diet 21
Daily allowances
325 mL semi skimmed milk.
(lOO mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
11 x Bread exchange
4 x meat exchange
3 x fruit exchange
3 x glass fruit juice
Polyunsaturated spread: 50g or 5 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or
25 g sunflower margarine e.g. flora, vitalite or 20 g sunflower oil.
Suggested meal plan.
Breakfast
Mid-Morning
Lunch
Mid afternoon
Evening meal
Supper
Remember try to take all the exchanges
2 x glass of fresh fruit juice
3 x bread exchange
Spread jam or marmalade
Teal coffee
Tea I Coffee or low calorie drink
3 x bread exchange
2 x meat exchange
Salad I vegetable
1 x fruit exchange
Tea I Coffee or low calorie drink
Tea I Coffee or low calorie drink
2 x meat exchange
4 x bread exchange
Salad I vegetable
1 x fruit exchange
1 x bread exchange
1 x fruit exchange
1 x fruit juice
Exchanges kcal kJ fat g pufa g mufag sfa g cho g prot g
3 Fruits 156 652 I I I I 39.6 1.5
3 Fruit juice 135 565 I I I I 33.0 1.8
11 Bread 1032 4317 17.5 6.6 4.4 5.5 187.6 41.8
4Meat 482 2017 25.0 3.2 9.1 10.1 10.0 54.2
25 g pufa 177 741 19.5 10.1 3.3 4.0 I IMargarine
300mL 138 577 4.8 I 1.4 3.0 15.0 9.9SSkim milk
Total nut. 2120 8869 67.1 19.9 31.4 22.6 285.0 109.2% energy 28.4 8.4 13.3 9.5 50.4 20.6
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3.11 2200 kcal diet prescription
The Healthy Diet 22
Daily allowances
325 mL semi skimmed milk.
(lOOmL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
12 x Bread exchange
4 x meat exchange
3 x fruit exchange
3 x wine glass fruit juice
Polyunsaturated spread: 50g or 5 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or 25g sunflower margarine e.g. flora or
vitalite or 20g sunflower oil.
Suggested meal plan. Remember try to take all the exchanges
Breakfast 2 x glass of fresh fruit juice
3 x bread exchange
Spread jam or marmalade
Tea I coffee
Tea I Coffee or low calorie drinkMid-Morning
Lunch
Supper
3 x bread exchange
2 x meat exchange
Salad I vegetable
1 x fruit exchange
Tea I Coffee or low calorie drink
Tea / Coffee or low calorie drink
2 x meat exchange
4 x bread exchange
Salad I vegetable
1 x fruit exchange
1 x fruit juice
2 x bread exchange
1 x fruit exchange
1 x fruit juice
Mid afternoon
Evening meal
]Exchanges kcal kJ fat g pufa _g_ mufag sfa g cho g protg
3 fruits 156 652 I / I I 39.6 1.5
3 Fruit juice 135 565 I I I I 33.0 1.8
12 Bread 1126 4711 19.3 7.2 4.8 6.0 204.6 45.6
4Meat 482 2017 25.0 3.2 9.1 10.1 10.0 54.2
25g pufa 177 741 19.5 10.1 3.3 4.0 I I
Margarine
325mL 149 623 5.2 I 1.4 3.25 16.25 10.6SSkim milk
Total nut. 2225 9309 69.0 20.5 18.6 23.4 303.4 113.7% energy 27.9 8.2 7.5 9.4 51.0 20.4
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3.12 2300 kcal diet prescription
The Healthy Diet 23
Daily allowances
325 mL semi skimmed milk.
(100 mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
12x Bread exchange
4 x meat exchange
3 x fruit exchange
3 x wine glass fruit juice
Polyunsaturated spread: 60g or 6 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or 30g sunflower margarine e.g. flora,
sunflower margarine, vitalite or 25g sunflower oil.
Suggested meal plan.
Breakfast
Mid-Morning
Lunch
Mid afternoon
Evening meal
Supper
Remember try to take all the exchanges
2 x glass of fresh fruit juice
3 x bread exchange
Spread jam or marmalade
Teal coffee
Tea I Coffee or low calorie drink
3 x bread exchange
2 x meat exchange
Salad I vegetable
1x fruit exchange
Tea I Coffee or low calorie drink
Tea I Coffee or low calorie drink
2 x meat exchange
4 x bread exchange
Salad I vegetable
1 x fruit exchange
1 x fruit juice
2 x bread exchange
1 x fruit exchange
1 x fruit juice
Exchanges kcal kJ fat g pufa g mufag sfa g cho g prot g
3 Fruits 156 652 I I I I 39.6 1.5
3 Fruit juice 135 565 I I I I 33.0 1.812Bread 1126 4711 19.3 7.2 4.8 6.0 204.6 45.64Meat 482 2017 25.0 3.2 9.1 10.1 10.0 54.230 g pufa 212 887 23.4 12.1 3.9 4.8 I IMargarine
375mL 172.5 721 6.0 I 1.8 3.8 18.8 12.4SSkim milk
Total nut. 2283 9553 73.7 22.5 19.6 24.7 306 126.1% energy 29.0 8.8 7.7 9.7 50.2 22.0
349
3.13 2400 kcal diet prescription
The Healthy Diet 24
Daily allowances
350 mL semi skimmed milk.
(lOO mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
13x Bread exchange
4 x meat exchange
4 x fruit exchange
3 x wine glass fruit juice
Polyunsaturated spread: 60g or 6 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or 30g sunflower margarine e.g. flora or
vitalite or 25g sunflower oil.
Suggested meal plan.
Breakfast
Mid-Morning
Lunch
Mid afternoon
Evening meal
Supper
Remember try to take all the exchanges
2 x glass of fresh fruit juice
4 x bread exchange
Spread jam or marmalade
Tea / coffee
Tea / Coffee or low calorie drink
3 x bread exchange
2 x meat exchange
Salad / vegetable
2 x fruit exchange
Tea / Coffee or low calorie drink
Tea / Coffee or low calorie drink
2 x meat exchange
4 x bread exchange
Salad / vegetable
1 x fruit exchange
1 x fruit juice
2 x bread exchange
1 x fruit exchange
1 x fruit juice
Exchanges kcal kJ fat g pufag mufag sfa g cho g prot_g
3 Fruits 156 652 I I I I 39.6 1.5
3 Fruit juice 135 565 / I / I 33.0 1.8
13 Bread 1219 5100 20.9 7.8 5.2 6.5 221.6 49.4
4Meat 482 2017 25.0 3.2 9.1 10.1 10.0 54.2
30 gpufa 212 887 23.4 12.1 3.9 4.8 / /Margarine
350mL 161 673 5.6 / 1.6 3.5 17.5 11.55SSkim milk
Total nut. 2365 9894 74.9 23.1 19.8 24.9 334.9 118.9
% energy 27.8 8.6 7.3 9.2 51.9 19.6
350
3.142500 kcal diet prescription
The Healthy Diet 25
Daily allowances
325 mL semi skimmed milk.
(100 mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
14 x Bread exchange
4 x meat exchange
4 x fruit exchange
3 x wine glass fruit juice
Polyunsaturated spread: 60g or 6 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or 30g sunflower margarine e.g. flora or
vitalite or 25 g sunflower oil.
Suggested meal plan. Remember try to take all the exchanges
Breakfast 2 x glass of fresh fruit juice
4 x bread exchange
Spread jam or marmalade
Tea / coffee
Tea / Coffee or low calorie drinkMid-Morning
Lunch
Supper
4 x bread exchange
2 x meat exchange
Salad / vegetable
2 x fruit exchange
1 x fruit juice
Tea / Coffee or low calorie drink
Tea / Coffee or low calorie drink
2 x meat exchange
4 x bread exchange
Salad / vegetable
1 x fruit exchange
1 x fruit juice
2 x bread exchange
2 x fruit exchange
1 x fruit juice
Mid afternoon
Evening meal
Exchanges kcal kJ fat g pufa g mufa g sfa g cho g prot g
4 Fruits 208 870 / / / / 52.8 2.0
3 Fruit juice 135 565 / / / / 33.0 1.8
14 Bread 1312 5489 22.5 8.4 5.6 7.0 238.6 53.2
4Meat 482 2017 25.0 3.2 9.1 10.1 10.0 54.2
30g pufa 212 887 23.4 12.1 3.9 4.8 / /
Margarine
325 mL 149 623 5.2 / 1.4 3.25 16.25 10.6
SSkim milk
Total nut. 2498 10451 76.1 23.7 20.0 25.2 350.6 121.6
% energy 27.4 8.5 7.2 9.0 52.6 19.4
351
3.15 2600 kcal diet prescription
The Healthy Diet 26
Daily allowances
500 mL semi skimmed milk.
(100 mL of milk can be taken as a diet, natural yoghurt or as a diet fromage frais)
14 x Bread exchange
4 x meat exchange
4 x fruit exchange
3 x wine glass fruit juice
Polyunsaturated spread: 60g or 6 scrapes
(e.g. sunflower spread, flora lite, vitalite lite) or 30 sunflower margarine e.g. flora or
vitalite or 25g sunflower oil.
Suggested meal plan.
Breakfast
Mid-Morning
Lunch
Mid afternoon
Evening meal
Supper
Remember try to take all the exchanges
1 x glass of fresh fruit juice
4 x bread exchange
Spread jam or marmalade
Tea / coffee
Tea / Coffee or low calorie drink
4 x bread exchange
2 x meat exchange
Salad / vegetable
1 x fruit exchange
Tea / Coffee or low calorie drink
Tea / Coffee or low calorie drink
2 x meat exchange
4 x bread exchange
Salad / vegetable
1 x fruit exchange
1 x fruit juice
2 x bread exchange
1 x fruit exchange
1 x fruit juice
Exchanges kcal kJ fat g pufa g mufag sfa g cho g prot g
4 Fruits 208 870 / / / / 52.8 2.0
3 Fruit juice 135 565 / / / / 33.0 1.8
14 Bread 1312 5489 22.5 8.4 5.6 7.0 238.6 53.2
4Meat 482 2017 25.0 3.2 9.1 10.1 10.0 54.2
30g pufa 212 887 23.4 12.1 3.9 4.8 / /
Margarine
500 mL 230 962 78.9 23.7 20.9 26.9 25.0 16.5
SSkim milk
Total nut. 2283 10790 78.9 23.7 20.9 26.9 359.4 127.8
% energy 31.1 ? 9.3 8.2 10.6 59.0? 22.3?
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University wants angina volunteers
PEOPLE who suffer from angina are being asked to volunteer
for a Glasgow University project to find out if a healthy diet
would make them feel better. Research scientist Catherine
Hankey said yesterday: "We are looking for all shapes and
sizes, so both slim and overweight people will be welcome.
Whatever their size, we'll devise a diet for them. Our volunteers
will also find out how much of their weight is muscle and
how much is fat." After evaluating their diet by computer, Ms
Hankey will provide the volunteers with individually designed
diets for a 12-week period. Angina sufferers who can
help should contact Ms Hankey on 0141 3044686
THE HERALD, September 151993
J
Uolunteers
sought for
heart study
GLASGOW University wants to hear from angina
sufferers.
They are all needed for a special project into diet being
carried out in the Department of Human Nutrition.
Researcher Catherine Hankey and Professor Mike
Lean say a lot of research ,- _
has been done on foods
which increase the risk of
heart disease.
But they add that little
is known about the bene-
fits of a healthy diet and
any effect it may have on
clotting or thrombosis.
Catherine believes a
healthy diet would help
angina sufferers but she
needs the facts to back
her up.
She will evaluate vol-
unteers' current diet and
provide them with an in-
dividually designed diet.
During that time theywill
have to visit Glasgow
Royal Infirmary,
Anyone who can help
should contact Catherine
on3044686.
EVENING TIMES
September 14 1993
Appeal for
angina study
volunteers
ADIET specialist at Glasgow
University is looking for an-
gina sufferers to help her re-
search the complaint.
Catherine Hankey, of the
Department of Human
Nutrition, wants 50-70
volunteers for the 12-week
project.
"There has been a lot of
research done on foods
which might increase the
risk of heart disease - by
narrowing the arteries for
example," she said. "But
little is known about the
benefits of a healthy diet and
any effect it may have on the
rate of blood clotting or
thrombosis. "
Ms Hankey will ask the
volunteers to record every-
thing they eat for four days and
will then draw up individual
diets for them.
"We are looking for
people of all shapes and
sizes," said Ms Hankey,
who can be contacted on
0141-3044686.
THE SCOTSMAN
September 15 1993
Diet for
medical
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Fancy a real hearty diet?
UNIVERSITY researcher
Catherine Hankey is on
the look-out for angina
sufferers.
Because she wants to know
what they eat!
Angina is a chest pain
sparked off by the heart not get-
ting enough blood or oxygen.
It's a major contributor to
Scotland's grim annual heart
death toll.
we'll devise a diet for them," said
Catherine.
The volunteers will also have
the chance to find out just how
. much of their weight is muscle
factors such as smoking and and how much is actually fat.
obesity. Common sense suggests Itdoesn't matter if volunteers
that ahealthy dietwould improve are already on drug treatment for
matters. angina.
But Catherine wants to look
closer at what angina sufferers IMPROVE
actually tuck into. The programme is NOT suitable
After evaluating their diet by for people already on a special
computer, she will provide them diet or involved in other research.
with individually-designed diets "I'm sure that many sufferers
for a 12-week period. would like to do their bit to help
Thisdietwillbecalculatedon scientists know more about
the basis of age, weight and sex. angina," said Catherine.
The research team is hoping to "If the new diets improve their
find up to 70 volunteers. condition, so much the better."
"We're laking for all shapes Catherine can be contacted on
and sizes. Whatever their size, 041-3044686.
By MIKE RITCHIE
Health Correspondent
There's been a lot of research
onfoodswhichmight increase the
risk of heart disease - by narrow-
ing the arteries, for example.
But little is known about the
benefits of a healthy diet or the
effect it could have on the rate
of blood-clotting or thrombosis.
Angina can be sparked off by
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